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Summary of the Ph. D. thesis “New multicomponent 
reactions for the synthesis of pyridine derivatives as 
potential anti-neurodegenerative agents” 
1. Introduction 
Pyridine and its partially saturated derivatives are among the most important 
nitrogen heterocycles found in natural products and show a broad range of 
applications widespread in so many different fields of chemistry. Above all, these 
scaffold are of particular interest in medicinal chemistry, being present in many 
marketed drugs. Thus, the pyridine and, specially, the 1,4-dihydropyridine (1,4-
DHP) moieties, due to their pharmacological versatility, can be defined as 
“privileged scaffolds” (i.e. molecular structures which show the ability to interact 
with different groups of therapeutic targets). 
In an attempt to improve synthetic access to this important structural motif (and, 
more generally, to all heterocycles), in the last decades multicomponent reactions 
(MCR) have appeared as a powerful alternative to other methods. 
Multicomponent reactions can be defined as convergent reactions where three or 
more reagents are combined in such a way that the final product retains significant 
portions of all starting materials, allowing the creation of several bonds and 
consequently providing an elevated molecular complexity in a single operation. 
This methodology has emerged as one of the most promising technologies that 
allow fulfilling some of the modern requirements of organic chemistry that go 
beyond the traditional ones such as reactivity and selectivity and that are focused 
on economic and environmental concerns. Besides their green character 
associated to the reduction in the number of isolation and purification stages, the 
use of multicomponent procedures is very attractive for the generation of libraries 
for drug discovery projects due to their modular nature. 
2. Objectives 
Within the general framework of the development of multicomponent reactions 
for the synthesis of pharmacologically relevant dihydropyridines and pyridines, 
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we have pursued the following specific objectives:  
1. Development of a new approach to pyridine derivatives, based on a double 
elimination process on 1-dimethylamino-6-ethoxytetrahydropyridines 
generated through a Lewis-acid catalyzed four-component reaction. 
2. Development of a new multicomponent route to 4,6-diarylpyridine 
frameworks and study of the conditions required for the reaction to afford 
dihydropyridines or pyridines.  
3.  In view of the fact that some classical 1,4-dihydropyridines have shown 
good neuroprotective activities that can not be exploited therapeutically 
because of their cardiovascular effects, we also planned the study of 4,6-
diaryl-1,4-dihydropyridines as neuroprotectors, considering that do not 
satisfy the well-known structure-activity relationships of vasodilator 
dihydropyridines. 
4.  Synthesis of fused dihydropyridines and their pyrane oxygen 
heteroanalogues via a Hantzsch-like three-component reaction and their 
subsequent study as neuroprotectors via inhibition of GSK3β.  
5.  Multicomponent synthesis of hybrid structures related to nimodipine and the 
benzothiazepine derivative CGP-37157 (a blocker of the mitochondrial 
Na+/Ca2+ exchanger) as potential anti-Alzheimer compounds aimed at 
stabilizing neuronal and mitochondrial calcium cycling by a multitarget 
approach. Similarly, the synthesis and study of hybrids of a CGP-37157 aza 
analogue and lipoic acid, a well-known antioxidant able to cross the blood-
brain barrier, were planned. 
6.  Finally, during a 3-month period at Georg-August Universität of Göttingen 
(Professor Ackermann’s group) as part of the requirements for the European 
Mention to the Ph. D. title, a new Ru(II)-catalyzed oxidative C-H 
alkenylation of arylsulfonamides was planned.  
3. Results and discussion  
The main results obtained are summarized below:  
• We have developed a new indium trichloride-catalyzed four-component 
reaction between dimethylhydrazine, β-dicarbonyl compounds, acrolein 
and ethanol. This reaction allowed the formation of 6-ethoxy-1,4,5,6-
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tetrahydropyridine derivatives one C-C, two C-N and one C-O bonds, 
furnishing the heterocyclic framework from very simple open-chain 
precursors via a formal aza [3+3] cycloaddition. These compounds were 
subsequently converted into 2,3-disubstituted pyridines by a double 
elimination reaction and, interestingly, the whole sequence can be 
performed without the need for purifying any intermediate. 
 
 
 
• A library of 4,6-diaryl-1,4-dihydropyridines was generated by a the three-
component reaction between β-dicarbonyl compounds, chalcones and 
ammonium acetate in refluxing ethanol, in the presence of a catalytic 
amount of cerium(IV) ammonium nitrate. These compounds were shown 
to provide neuroprotection against calcium overload and oxidative stress 
models, evaluated on neuroblastoma cells. 
 
 
 
• Interestingly, a small variation of the previous three-component reaction 
(i.e. the use of β-ketoamides as the β-dicarbonyl compound), under similar 
conditions (CAN as catalyst in refluxing ethanol), directly afforded 
aromatic compounds that can be regarded as nicotinamide analogues via a 
3CR-air oxidation sequence. This formal [3+3] aza-annulation leads to the 
formation of one C−C and two C−N bonds in a single synthetic operation 
and involves up to five individual steps.  
O
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• We also performed the synthesis of fused dihydropyridines and their 
oxygen heteroanalogues via a Hantzsch-like three-component reaction 
between malononitrile, aromatic aldehydes and C5-functionalized 
pyrazoles.  
 
 
 
• We synthesized a hybrid of an aza analogue of CGP-37157 and 
nimodipine via a multicomponent approach and also via a convergent 
strategy. Moreover, the synthesis of a hybrid of CGP-37157 aza analogue 
and the antioxidant lipoic acid was performed. 
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• A new ruthenium-catalyzed oxidative C-H bond alkenylation on aryl 
sulfonamides was developed. 
 
 
4. Conclusions  
1. We developed three different multicomponent protocols for the synthesis 
of the pyridine moiety and its fused related derivative. These 
methodologies allow a rapid and efficient access to densely functionalized 
pyridines, facilitating the generation of compound libraries of great 
significance in many areas of medicinal chemistry and drug discovery. 
2. We identified a class of 4,6-diaryl-1,4-dihydropyridines showed improved 
selectivity towards Cav1.3 neuronal calcium channels with regards to 
previously studied dihydropyridines and behave as neuroprotective agents 
against ischemic injury.  
3. Pyrano[2,3-c]pyrazoles and dihydropyrazolo[3,4-b]pyridines were 
rationally designed as inhibitors of GSK3β, an important anti-Alzheimer 
target, and synthesized using multicomponent strategies. These 
compounds are currently under pharmacological evaluation. 
4. We developed different strategies for the synthesis of various hybrid 
compounds containing as pharmacophoric moieties a CGP-37157 aza 
analogue, nimodipine and lipoic acid. These compounds were designed as 
multitarget anti-neurodegenerative agents acting on neuronal calcium 
regulation and as antioxidants, and are being tested against Alzheimer’s 
disease.  
5. With the development of a new direct C-H functionalization of 
sulfonamide derivatives, we have paved the way for the fast synthesis of 
new types of compounds containing this pharmacophore, which is of 
critical importance in many areas of medicinal chemistry. 
 
H
SO2NHR2
R1
H CO2R
2
Ru(II) cat
oxidant
SO2NHR2
R1
CO2R2
+
C-H functionalization
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Resumen de la tesis	  doctoral “Nuevas reacciones 
multicomponente para la síntesis de derivados de 
piridina como agentes antineurodegenerativos 
potenciales” 
1. Introducción 
La piridina y sus derivados parcialmente saturados figuran entre los heterociclos 
más habituales en la naturaleza y presentan una amplia gama de aplicaciones en 
todos los campos de la Química. En concreto, estos esqueletos son de especial 
interés en Química Farmacéutica, y están presentes en un gran número de 
fármacos. La piridina y, sobre todo, la 1,4-dihidropiridina (1,4-DHP), presentan 
una elevada versatilidad farmacológica que permite clasificarlas como 
“estructuras privilegiadas”, es decir, estructuras capaces de interaccionar con 
diferentes familias de dianas terapéuticas.  
En un intento de mejorar el acceso sintético a estos motivos estructurales (y, en 
general, a todo tipo de heterociclos), durante las últimas décadas se han 
desarrollado métodos basados en el empleo de reacciones multicomponente 
(MCR) como alternativa a los procedimientos tradicionales. Las reacciones 
multicomponente se pueden definir como procesos convergentes en los que se 
combinan tres o más reactivos de tal manera que el producto final contiene 
fragmentos significativos de todos ellos, de modo que se generan varios enlaces 
en una sola operación. Esta metodología ha surgido como una de las más 
prometedoras para satisfacer los exigentes requisitos actuales para los métodos de 
síntesis orgánica, que van más allá de los tradicionales de reactividad y 
selectividad para considerar también aspectos económicos y medioambientales. 
Además de pertenecer al ámbito de la Química Verde por permitir disminuir el 
número de etapas de aislamiento y purificación, las reacciones multicomponente 
son muy atractivas para la generación de quimiotecas para el descubrimiento de 
fármacos a causa de su carácter modular. 
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2. Objetivos 
Dentro del marco general del desarrollo de reacciones multicomponente para la 
síntesis de dihidropiridinas y piridinas de relevancia farmacológica, nuestros 
objetivos específicos han sido:  
1. Desarrollo de un nuevo método para el acceso a derivados de piridina basado 
en un proceso de doble eliminación a partir de 1-dimetilamino-6-etoxi-
1,4,5,6-tetrahidropiridinas, sintetizadas a través de una reacción 
multicomponente catalizada por ácidos de Lewis. 
2. Desarrollo de una nueva ruta multicomponente hacia 4,6-diarilpiridinas o sus 
1,4-dihidro derivados, con estudio de las condiciones requeridas para obtener  
ambos tipos de productos.  
3. A la vista de que algunas 1,4-dihidropiridinas clásicas han mostrado Buena 
actividad neurorotectora que no puede explotarse a causa de sus efectos 
cardiovasculares, hemos planeado el estudio de las of 4,6-diaril-1,4-
dihidropiridinas como agentes neuroprotectores, ya que estos compuestos no 
cumplen algunas de las relaciones estructura-actividad de las dihidropiridinas 
vasodilatadoras. 
4. Síntesis de heterociclos fusionados derivados de dihidropiridina y pirano a 
través de reacciones multicomponente de tipo Hantzsch, así como su estudio 
como agentes neuroprotectores por inhibición de GSK3β.  
5. Síntesis multicomponente de estructuras híbridas referibles a nimodipino y 
CGP-37157 (un inhibidor del intercambiador mitocondrial Na+/Ca2+) como 
agentes anti-Alzheimer potenciales por estabilización de los niveles 
neuronales y mitocondriales de calcio a través de una aproximación 
multidiana. También se planificó la síntesis de estructuras híbridas formadas 
por un aza análogo de CGP-37157 y el ácido lipoico, un conocido agente 
antioxidante capaz de atravesar la barrera hematoencefálica 
6. Por últipo, durante una estancia de tres meses en la Georg-August Universität 
de Göttingen (grupo del professor Ackermann), como parte de los requisitos 
para la Mención Europea al título de doctor, se planeó una nueva 
alquenilación C-H oxidativa de arilsulfonamidas catalizada por especies de 
Ru(II). 
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3. Resultados y discusión  
Los principales resultados obtenidos pueden resumirse como sigue:  
• Hemos desarrollado una nueva reacción en cuatro componentes, catalizada 
por tricloruro de indio, entre dimetilhidrazina, compuestos β-
dicarbonílicos, acroleína y etanol. Esta reacción condujo a la formación de 
derivados de 1-dimetilamino-6-etoxi-1,4,5,6-tetrahidropiridina mediante la 
formación de enlaces C-C (1), C-N (2) y C-O (1), proporcionando el 
heterociclo deseado a partir de precursores acíclicos muy sencillos, a 
través de una cicloadición formal de tipo aza [3+3]. Estos compuestos se 
transformaron después en piridinas 2,3-disustituidas a través de una 
reacción de eliminación doble. Es interesante resaltar que la secuencia 
completa se llevó a cabo si necesidad de purificar ningún intermedio.  
 
• Se ha sintetizado una quimioteca de 4,6-diaril-1,4-dihidropiridinas 
mediante una reacción tricomponente entre compuestos β-dicarbonílicos, 
chalconas y acetato amónico en etanol a reflujo, en presencia de una 
cantidad catalítica de nitrato cérico amónico. Estos compuestos fueron 
neuroprotectores en situaciones de sobrecarga de calcio y en modelos de 
stress oxidativo en células de neuroblastoma. 
 
Una pequeña variación de la reacción anterior (usando β-cetoamidas como 
el componente β-dicarbonílico), en condiciones similares (CAN como 
catalizador en etanol a reflujo), proporcionó directamente compuestos 
aromáticos que pueden considerarse análogos de nicotinamida, a través de 
una secuencia 3CR-oxidación. Esta anelación formal aza [3+3] conduce a 
la formación de un enlace C−C y dos	  enlaces C−N en una única operación 
O
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sintética que comprende cinco etapas individuales.  
 
• Hemos llevado a cabo la síntesis de heterociclos fusionados derivados de 
dihidropiridina y su heteroanálogo oxigenado, el pirano, a través de 
reacciones tricomponente de tipo Hantzsch entre malononitrilo, aldehídos 
aromáticos y pirazoles funcionalizados en C5.  
 
• Hemos sintetizado un compuesto híbrido formado por un aza análogo de 
CGP-37157 y por nimodipino, empleando tanto un proceso 
multicomponente como una estrategia convergente. También se ha logrado 
la síntesis de un híbrido del  aza análogo de CGP-37157 y el ácido lipoico. 
 
 
 
• Se ha desarrollado una nueva alquenilación C-H de arilsulfonamidas, 
catalizada por rutenio. 
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4. Conclusiones  
1. Hemos desarrollado tres protocolos multicomponente para la síntesis de 
esqueletos de piridina y sus derivados de fusión con pirazol. Estas 
metodologías permiten un acceso rápido y eficiente a piridinas altamente 
funcionalizadas, permitiendo la generación de quimiotecas de gran 
significación en muchos campos de la Química Farmacéutica y el 
descubrimiento de fármacos. 
2. Hemos demostrado que las 4,6-diaril-1,4-dihidropiridinas presentan una 
selectividad mejorada respecto a canales de calcio neuronal Cav1.3 en 
comparación con las dihidropiridinas previamente conocidas. Estos 
compuestos se comportan como agentes neuroprotectores frente a fenómenos 
isquémicos. 
3. Se han diseñado derivados de pirano[2,3-c]pyrazol y dihidropirazolo[3,4-
b]piridina como inhibidores de GSK3b, una importante diana anti-Alzheimer, 
y se han sintetizado empleando estrategias multicomponentes. Estos 
compuestos están actualmente en evaluación farmacológica. 
4. Hemos desarrollado varias estrategias para la síntesis de compuestos híbridos 
que contienen como farmacóforos un aza análogo de CGP-37157, nimodipino 
y ácido lipoico. Estos compuestos se habían diseñado como agentes anti-
neurodegenerativos multidiana, dirigidos a la regulación del calcio neuronal y 
como antioxidantes, y están siendo evaluados frente a la enfermedad de 
Alzheimer. 
5. Con el desarrollo de un nuevo método de funcionalización C-H directa de 
sulfonamidas, hemos preparado el camino para la síntesis de nuevos tipos de 
compuestos portadores de este farmacóforo, de importancia crucial en	  
Química Farmacéutica. 
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1.1 MULTICOMPONENT REACTIONS AND THEIR CURRENT 
RELEVANCE 
In recent years synthetic organic chemistry, in spite of an awesome evolution 
process, has reached the awareness that only a small part of the extremely vast 
chemical space has been discovered.1 The increasingly urgent necessity to extend 
our knowledge of this chemical space has identified one of the major current 
challenges of organic synthesis as the aptitude of being able to readily create 
molecular diversity and complexity. 2  Thus contemporary organic synthesis, 
beyond being driven by traditional concepts such as reactivity and selectivity, is 
also focused on economic and environmental concerns. These groundbreaking 
requirements are at the basis of the concept of the ideal synthesis (Figure 1.1)3 and 
can be summarized as follows: 
 
1.- Ability to generate high molecular diversity and complexity.  
2.- Use of simple and readily available starting materials. 
3.- Experimental simplicity, leading to the possibility of automation.  
4.- Low environmental impact (use of environmentally friendly solvents, atom 
economy, low use of energy). 
                                                
1 (a) Reymond, J.‐L.; Ruddigkeit, L.; Blum L. C.; van Deursen R. WIREs Comput Mol Sci 2012, 2, 
717-733; (b) Ruddigkeit, L.; van Deursen R.; Blum L. C.; Reymond, J.‐L. J. Chem. Inf. Model. 
2012, 52, 2864−2875. 
2 Some reviews on diversity-oriented organic synthesis: (a) Schreiber, S. L. Science 2000, 287, 
1964-1969; (b) Spring, D. R. Org. Biomol. Chem. 2003, 1, 3867-3870; (c) Burke, M. D.; Berger, E. 
M.; Schreiber, M. L. Science 2003, 302, 613-618; (d) Burke, M. D.; Schreiber, S. L. Angew. Chem., 
Int. Ed. 2004, 43, 46-58; (e) Tan, D. S. Nature Chem. Biol. 2005, 1, 74-84; (f) Wessjohann, L. A.; 
Ruijter, E. Top. Curr. Chem. 2005, 243, 137-184; (g) Spandl, R. J.; Bender, A.; Spring, D. R. Org. 
Biomol. Chem. 2008, 6, 1149-1158; (h) Galloway, W. R. J. D.; Isidro-Llobet, A.; Spring, D. R. Nat. 
Commun. 2010, 1, art n°80; (i) O’Connor, C. J.; Beckmann, H. S. G.; Spring, D. R. Chem. Soc. Rev. 
2012, 41, 4444-4456. 
3 Wender, P. A.; Miller, B. L. Nature 2009, 460, 197-201. 
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Figure 1.1 
 
In the view of achieving a better knowledge and exploration of the chemical 
space, the first of these necessities has emerged as particularly important and the 
development of processes that allow the creation of several bonds, providing 
consequently an elevated molecular complexity in a single operation, has become 
one of the more attractive goals of organic synthesis.4 In this context, during the 
last decades, multicomponent reactions (MCRs) have got a renewed attention 
from the organic chemists, emerging as one of the most promising technologies 
towards achieving this end.5 
 
Multicomponent reactions can be defined as convergent reactions where three or 
more reagents are combined in such a way that the final product retains significant 
portions of all starting materials.6,7,8 Ideally, they allow the simultaneous addition 
                                                
4 For	   reviews	  of	  multibond	   forming	   reactions	   as	   a	   pathway	   towards	   eco-­‐compatible	   chemistry,	  
see:	  (a)	  Coquerel, Y.; Boddaert, T.; Presset, M.; Mailhol, D.; Rodriguez, J. Ideas in Chemistry and 
Molecular Sciences, in Advances in Synthetic Chemistry; Pignataro, B., Ed.; Wiley-VCH: Weinheim, 
Germany, 2010; Vol. 1, Chapter 9, 187−202; (b)	   Bonne,	   D.;	   Constantieux,	   T.;	   Coquerel,	   Y.;	  
Rodriguez,	   J.	   Chem.	   Eur.	   J.	   2013,	   19,	   2218	   –	   2231.	   (c)	   For	   a	   Special	   Issue	   on	   this	   topic,	   see:	  
Menéndez,	  J.	  C.	  (ed.),	  Curr.	  Org.	  Chem.	  2013,	  17,	  issue	  18,	  1919-­‐2064. 
5 Some	   reviews	  on	  multicomponent	   reactions	   for the generation of molecular complexity and 
diversity: (a) Biggs-Houck, J. E.; Younai, A.; Shaw, J. T. Curr. Opin. Chem. Biol. 2010, 14, 371-382; 
(b) Ruijter, E.; Scheffelaar, R.; Orru, R. V. A. Angew.	   Chem.,	   Int.	   Ed.	   2011,	   50,	   6234-­‐6246; (c) 
Eckert, H.; Molecules 2012, 17, 1074-1102; (d) van der Heijden, G.; Ruijter, E.; Orru, R. V. A. 
Synlett 2013, 24, 666-685; (e) Brauch, S.; van Berkel, S. S.; Westermann, B. Chem. Soc. Rev. 
2013, 42, 4948-4962. 
6  For monographs on multicomponent reactions, see: (a) Zhu, J.; Bienaymé, H. (eds.), 
Multicomponent Reactions. Wiley-VCH, 2005. (b) Zhu, J.; Wang, Q.; Wang, M. (eds.), 
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of all reagents, which then combine orderly under the same reaction conditions to 
afford the final products without isolating intermediates. However, in order to 
avoid side reactions, very often it is necessary to add the reagents consecutively, 
and in these cases they are described as sequential multicomponent reactions.  
Despite the centuries-old history of MCRs (the firstly known MCRs such as the 
classical Strecker,9 Hantzsch10 and Biginelli11 reactions were described during the 
second half of the XIX century), their development and application in medicinal 
chemistry have experienced an explosive growth only recently because of their 
perfect adaptability to the creation of libraries with a high degree of structural 
diversity.12 As a consequence, the development of new multicomponent reactions 
is a significant part of the research work currently carried out in and drug 
discovery programs.13 
                                                                                                                                 
Multicomponent Reactions in Organic Synthesis. Wiley-VCH, 2014. (c) Herrera, R. P.; Marques-
López, E. Multicomponent Reactions: Concepts and Applications for Design and Synthesis. 
Wiley-VCH, 2015. 
7 Some general reviews on multicomponent reactions, with special emphasis on the use of 
isonitriles in (a-d, g, m): (a) Dömling, A.; Ugi, I. Angew. Chem., Int. Ed. 2000, 39, 3168-3210; (b) 
Ugi, A. Pure Appl. Chem. 2001, 73, 187-191; (c) Ugi, A. Molecules 2003, 8, 53-66; (d) Zhu, J. Eur. 
J. Org. Chem. 2003, 1133-1144; (e) Orru, R. V. A.; de Greef, M. Synthesis 2003, 1471-1499; (f) 
Tejedor, D.; González-Cruz, D.; Santos-Expósito, A.; Marrero-Tellado, J. J.; de Armas, P.; García-
Tellado, F. Chem. Eur. J. 2005, 11, 3502-3510; (g) Dömling, A. Chem. Rev. 2006, 106, 17-89; (h) 
Liéby-Muller, F.; Simon, C.; Constantieux, T.; Rodriguez, J. QSAR Comb. Sci. 2006, 25, 432-438; 
(i) Tejedor, D.; García-Tellado, F. Chem. Soc. Rev. 2007, 36, 484-491; (j) Touré, B. B.; Hall, D. G. 
Chem. Rev. 2009, 109, 4439-4486; (k) Sunderhaus, J. D.; Martin, S. F. Chem. Eur. J. 2009, 15, 
1300-1308; (l) Singh, M.S.; Chowdhury, S. RSC Adv. 2012, 2, 4547-4592; (m) Koopmanschap, 
G.; Ruijter, E.; Orru, R. V. A. Beilstein J Org Chem. 2014, 10, 544–598; (n) Cloc, R.; Ruijter, E.; 
Orru, R. V. A. Green Chem. 2014, 16, 2958-2975.	  
8 Reviews on asymmetric multicomponent reactions: (a) Ramón, D. J.; Yus, M. Angew. Chem., 
Int. Ed. 2005, 44, 1602-1634. (b) Guo, H.; Ma, J. Angew. Chem., Int. Ed. 2006, 45, 354-366; (c) 
Guillena, G.; Ramón, D. J.; Yus, M. Tetrahedron: Asymmetry 2007, 18, 693-700; (d) Bonne, D.; 
Coquerel, Y.; Constantieux, T.; Rodriguez, J. Tetrahedron: Asymmetry 2010, 21, 1085-1109; (e) 
Bonne, D.; Coquerel, Y.; Constantieux, T.; Rodriguez, J. en Targets in Heterocyclic Systems - 
Chemistry and Properties, Vol. 15, Eds.: Attanasi, O. A.; Spinelli, D. Societá Chimica Italiana, 
Roma, 2011, p. 140-163; (f) Yu, J.; Shi, F.; Gong, L.-Z. Acc. Chem. Res. 2011, 44, 1156-1171; (g) 
de Graaff, C.; Ruijter E.; Orru, R. V. A. Chem. Soc. Rev. 2012, 41, 3969-4009. 
9 Strecker, A. Liebigs Ann. 1850, 75, 27–45. 
10 Hantzsch, A. Chem. Ber. 1881, 14, 1637-1638. 
11 Biginelli, P. Chem. Ber. 1891, 24, 1317–1319.  
12 Review on the impact of molecular complexity on the discovery of new lead compounds in 
drug research: Hann, M. M.; Leach, A. R. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864. 
13 Reviews on the applications of multicomponent reactions in drug discovery: (a) Tietze, L. F.; 
Modi, A. Med. Res. Rev. 2000, 20, 304-322; (b) Weber, L. Curr. Med. Chem. 2002, 9, 2085-2093 
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Scheme 1.1: The first multicomponent reactions described in the literature 
 
Nowadays the best-studied multicomponent reactions are those involving the use 
of isonitriles as one of the components, the so-called IMCRs (isocyanide-based 
multicomponent reactions).7a-d,g,m Most IMCRs are focused on the construction of 
peptide-like structures and can be referred to two classical reactions described 
firstly by Passerini14 and Ugi,15 shown in Scheme 1.2. Their extensive use is owed 
to different reasons: first of all to chemical ones, because of their particular 
versatility derived from the presence of the isonitrile group. In fact this group 
shows a special reactivity bearing a carbon atom that can behave as a nucleophile 
and an electrophile and also taking part in radical reactions, conferring acidity to 
                                                                                                                                 
(c) Hulme, C.; Gore, V. Curr. Med. Chem. 2003, 10, 51-80; (d) Ulaczyk-Lesanko, A.; Hall, D. G. 
Curr. Opin. Chem. Biol. 2005, 9, 266-276; (e) Slobbe, P.; Ruijter E.; Orru, R. V. A. Med. Chem. 
Commun. 2012, 3, 1189-1218; (f) Dömling, A.; Wang, W.; Wang, K. Chem. Rev. 2012, 112, 3083-
3135; (g) Ruijter E.; Orru, R. V. A. Drug Discov. Today: Technol. 2013, 10, e15-e20. 
14 Passerini, M. Gazz. Chim. Ital. 1921, 51, 126–129.  
15 Ugi, I.; Meyr, R.; Fetzer U.; Steinbrückner, C. Angew. Chem. 1959, 71, 386.  
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its a protons and having affinity for many metals. Moreover their exceptionally 
elevated atom economy (a measure of the conversion efficiency of all the atoms 
involved in the reaction and superior to 90% for both these MCRs) makes these 
reactions very attractive from an environmental and economical point of view. 
 
 
Scheme 1.2: The two classical isocyanide-based multicomponent reactions 
 
Bearing in mind that more than 60% of drug molecules are heterocycles, it is 
surprising that multicomponent reactions leading directly to heterocyclic 
frameworks have not received closer attention.16 In this context, the present thesis 
deals with the application of multicomponent strategies to the synthesis of 
functionalized polyheterocyclic frameworks (with a special consideration for the 
pyridine nucleus), in order to identify new small molecules17 with potential 
pharmacological activity.18  
                                                
16 For selected reviews of the synthesis of heterocycles using multicomponent reactions as key 
steps, see: (a) Sapi, J.; Laronze, J.-Y. Arkivoc 2004 (vii) 208-222; (b) D’Souza, D. M.; Mueller, T. J. 
J. Chem. Soc. Rev. 2007, 36, 1095-1108; (c) Isambert, N.; Lavilla, R. Chem. Eur. J. 2008, 14, 8444-
8454; (d) Sunderhaus, J. D.; Martin, S.-F. Chem. Eur. J. 2009, 15, 1300-1308; (e) Jiang, B.; Rajale, 
T.; Wever, W.; Tu, S.-J.; Li, G. Chem. Asian J. 2010, 5, 2318-2335. (f) Estévez, V.; Villacampa, M.; 
Menéndez, J. C. Chem. Soc. Rev. 2010, 39, 4402-4421. (g) Estévez, V.; Villacampa, M.; 
Menéndez, J. C. Chem. Soc. Rev. 2014, 43, 4633-4657. (h) For a monograph, see: Ruijter, E.;. 
Orru, R. V. A. Synthesis of heterocycles via multicomponent reactions, vols. 1 and 2, Springer 
Verlag, 2010 (Topics in Heterocyclic Chemistry series, volumes 23 and 25). 
17 For some reviews on the importance of small molecules in medicinal chemistry see: (a) 
Schreiber, S. L. Chem. Eng. News. 2003, 81, 51-61; (b) Stockwell, B. R. Nature 2004, 432, 846-
854; (c) Spring, D. R. Chem. Soc. Rev. 2005, 34, 472-482; (d) Schreiber, S. L. Proc. Natl. Acad. Sci. 
U.S.A. 2011, 108, 6699-6702. 
18 For some reviews on the biological importance of extending the exploration of chemical 
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1.2 RELEVANCE OF THE PYRIDINE NUCLEUS AND ITS DERIVATIVES 
The pyridine nucleus was described for the first time by the Scottish chemist 
Anderson in 1846 during some experiments carried out studying the pyrolysis of 
bones. From this process he could separate “a colorless liquid with unpleasant 
odor” from which he initially isolated picoline (the first known pyridine base) and 
at a later stage pyridine itself. Owing to its flammability, Anderson gave to this 
substance the name we still use, deriving from the Greek πυρ (pyr) that means fire 
and from the suffix -idine that was used for all aromatic bases.19 Some years later 
Körner (1869) and Dewar (1871) independently proposed the correct structure of 
pyridine, describing it as the mono-aza-analogue of benzene. Since its 
identification, this nucleus became one of the most investigated aromatic 
compounds and nowadays it has widespread applications in various chemical 
fields, from supramolecular20 to coordination chemistry21 as well as in polymers 
science 22  and in organic chemistry being part of various organo- 23  and 
organometallic catalysts.24 However the most attractive aspect of this nucleus is 
related to its noteworthy biological importance. The first pyridine-based natural 
compound come to the fore was niacin (already known as vitamin B3 or nicotinic 
acid), when, in the 1930s, it was identified as an efficient compound to cure 
pellagra, one of the most common life-threatening diseases known at that period 
and characterized by dementia and dermatitis.25 At the turn of 20th century, 
beyond niacin, other pyridines such as nicotine, nicotinamide and the oxido-
reductive NAD-NADH coenzymes had already identified and described. To date 
                                                                                                                                 
space, see: (a) Dobson, C. M. Nature 2004, 432, 824-828; (b) Lipinski, C.; Hopkins, A. Nature 
2004, 432, 855-861; (c) Bon, R. S.; Waldmann, H. Acc. Chem. Res. 2010, 43, 1103-1114; (d) 
Reymond, J.-L.; Awale, M. ACS Chem. Neurosci. 2012, 3, 649-657. 
19 Anderson, T. Liebigs Ann. 1846, 60, 86-103. 
20 (a) Kozhevnikov, V. N.; Kozhevnikov, D. N.; Nikitina, T. V.; Rusinov, V. L.; Chupakhin, O. L.; 
Zabel, M.; König, B. J. Org Chem. 2003, 68, 2882-2888; (b) Hofmeier, H.; Schubert, U. S. Chem. 
Commun. 2005, 2423-2432; (c) Šmejkal, T.; Breit, B. Angew. Chem., Int. Ed. 2008, 47, 311-315. 
21 (a) Halcrow, M. A. Coord. Chem. Rev. 2005, 249, 2880-2908; (b) de Ruiter, G.; Lahav, M; van 
der Boom, M. E. Acc. Chem. Res. 2014, 47, 3407-3416. 
22 Raje, V. P.; Bhat, R. P.; Samant, S. D. Synlett 2006, 2676-2678. 
23 (a) Fu, G. C. Acc. Chem. Res. 2004, 37, 542-547; (b) De Rycke, N.; Couty, F.; David, O. R. P. 
Chem. Eur. J. 2011, 17, 12852-12871.  
24 (a) Shibatomi, K.; Muto, T.; Sumikawa, Y.; Narayama, A.; Iwasa, S. Synlett 2009, 241-244; (b) 
Lin, S.; Lu, X. Org. Lett. 2010, 12, 2536-2539.  
25 Elvehjem, C. A.; Madden, R. J.; Strong, F. M.; Woolley, D. W. J. Biol. Chem. 1938, 123, 137-149. 
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many other natural compounds containing a pyridine nucleus are known and 
studied for their interesting biological activity and their potential pharmacological 
effects (Figure 1.2)26 
 
 
Figure 1.2 
 
                                                
26 (a) Epibatidine: Daly, J. W.; Garraffo, H. M.; Spande, T. F.; Decker, M. W.; Sullivan J. P.; 
Williams, M. Nat. Prod. Rep. 2000, 17, 131-135; (b) Kedarcidin: Leet, J. E.; Schroeder, D. R.; 
Langley, D. R.; Colson, K. L.; Huang, S.; Klohr, S. E.; Lee, M. S.; Golik, J.; Hofstead, S. J.; Doyle, T. 
W.; Matson, J. A. J. Am. Chem. Soc. 1993, 115, 8432–8443; (c) Rhexifoline: M. R. Roby and F. R. 
Stermitz, J. Nat. Prod. 1984, 47, 846-853 (d) Ilicifoliunines A: Santos, V. A. F. F. M.; Regasini, L. 
O.; Nogueira, C. R.; Passerini, G. D.; Marinez, I.; Bolzani, V. S.; Graminha, M. A.; Cicarelli, R. M. B.; 
Furlan, M. J. Nat. Prod. 2012, 75, 991-995; (e) Alkaloid isolated from A. chinense: Zhang, Y.; Liu, 
Y.-B.; Li, Y.; Ma, S.-G.; Li, L.; Qu, J.; Zhang, D.; Chen, X.-G.; Jiang, J.-D.; Yu, S.-S. J. Nat. Prod. 2013, 
76, 1058–1063; (f) Clivimine: Ieven, M; Vlietinck, A. J.; Vanden Berghe, D. A.; Totte, J. J. Nat. 
Prod. 1982, 45, 564-573. 
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Also in the fields of medicinal chemistry and drug discovery various compounds 
containing the pyridine ring show numerous interesting pharmacological activities 
such as anti-inflammatory, 27  antiasthmatic, 28 antiretroviral, 29  antihistaminic, 30 
anticancer,31 antiulcer32 and antidiabetic ones.33 
 
 
Figure 1.3 
 
Finally it is worth mentioning that pyridine compounds are also important in the 
agrochemical field, showing different activities such as insecticide34, herbicide35 
                                                
27 Duffy, C. D.; Maderna, P.; McCarthy, C.; Loscher, C. E.; Godson, C.; Guiry, P. J. ChemMedChem 
2010, 5, 517-522. 
28 Buckley, G. M.; Cooper, N.; Davenport, R. J.; Dyke, H. J.; Galleway, F. P.; Gowers, L.; Haughan, 
A. F.; Kendall, H. J.; Lowe, C.; Montana, J. G.; Oxford, J.; Peake, J. C.; Picken, C. L.; Richard, M. D.; 
Sabin, V.; Sharpe, A.; Warneck, J. B. H. Bioorg. Med. Chem. Lett. 2002, 12, 509-512. 
29 Balzarini, J.; Stevens, M.; De Clercq, E.; Schols, D.; Pannecouque, C. J. Antimicrob. Chemother. 
2005, 55, 135-138. 
30 Bachert, C. Clin. Ther. 2009, 31, 921-944. 
31 Ou, S.-H. I. Drug Des. Dev. Ther. 2011, 5, 471-485. 
32 Saccar, C. L. Expert. Opin. Drug Metab. Toxicol. 2009, 5, 1113-1124. 
33 Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, 
C. A.; Smith, S. A.; Thurlby, P. L. J. Med. Chem. 1994, 37, 3977–3985. 
34 Zhang, W.; Chen, Y.; Chen, W.; Liu, Z.; Li, Z. J. Agric. Food Chem. 2010, 58, 6296-6299.  
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and fungicide36 (Figure 3). 
 
 
Figure 1.4 
 
The biological interest and the extensive synthetic utility of the pyridine scaffold 
has led to the development of a large number of methods for its synthesis, which 
have been reviewed recently.37 Several multicomponent procedures are included 
among these synthetic methodologies38 and in the next Section we will mention 
the most frequently employed strategies for building the pyridine ring. 
  
                                                                                                                                 
35 Xie, Y.; Chi, H.-W.; Guan, A.-Y.; Liu, C.-L.; Ma, H.-J.; Cui, D.-L. J. Agric. Food Chem. 2014, 62, 
12491-12496. 
36 Yan, X.; Qin, W.; Sun, L.; Qi, S.; Yang, D.; Qin, Z.; Yuan, H. J. Agric. Food Chem. 2010, 58, 2720-
2725. 
37 (a) Henry, G. D. Tetrahedron 2004, 60, 6043-6061; (b) Hill, M. D. Chem. Eur. J. 2010, 16, 
12052-12062. 
38 Allais, C.; Grassot, J.-M.; Rodriguez, J.; Constantieux, T. Chem. Rev. 2014, 114, 10829-10868. 
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1.3 STRATEGIES FOR THE SYNTHESIS OF PYRIDINE DERIVATIVES: AN 
OVERVIEW 
The present section is a brief overview on the strategies for the synthesis of 
pyridine derivatives. As in our opinion the best option to describe the various 
methodologies is organizing them by the typology of the ring-disconnection (as 
demonstrated by Henry in his excellent review),37a there is no question that the 
most efficient way to obtain highly functionalized pyridines is to disconnect the 
ring in the maximum number of fragments. For this reason and having in mind the 
objective of the present thesis, we will focus especially on multicomponent 
strategies for pyridine synthesis. 
1.3.1 Synthetic methodologies not based on multicomponent 
reactions 
The [5+1] approach is the simplest disconnection in the pyridine synthesis. 
Although the general procedure is represented by the condensation of 1,5-
dicarbonyl compounds with ammonia (Scheme 1.3A), there are several variations 
reported in the literature based on the use of differently conjugated unsaturated 
compounds (Scheme 1.3B).39  
 
 
Scheme 1.3: The two-component [5+1] approach to pyridine 
 
                                                
39 For examples of pyridine synthesis based on the [5+1] approach, see: (a) Perveev, F. Y.; 
Koshmina, N. V. Russ. J. Org. Chem. 1968, 4, 167-186; (b) Hu, J.; Zhang, Q.; Yuan, H.; Liu, Q. J. 
Org. Chem. 2008, 73, 2442–2445; (c) Huang, P.; Zhang, R.; Liang, Y.; Dong, D. Org. Lett. 2012, 
14, 5196-5199. 
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The [4+2] disconnection is one of the most widely applied in azaheterocycle 
synthesis and, differently from the previous strategy, is usually based on a 
cycloaddition process where the nitrogen could be part of either the 4-atom or the 
2-atom reactant. Among the various approaches of this typology, the normal-40 
and the inverse-41 electron demand hetero-Diels-Alder cycloadditions represent a 
powerful strategy for pyridine synthesis (Scheme 1.4A). Transition metal-
catalyzed processes are also valuable strategies to the formation of the pyridine 
ring by coupling azadienes and 2-carbon components (Scheme 1.4B).42 
 
 
Scheme 1.4: The two-component [4+2] approach to pyridine 
 
The last kind of two-component approach to the pyridine synthesis is based on the 
[3+3] disconnection. The most popular strategy for this kind of approach is the 
condensation between 1,3-dicarbonyl compounds and β-enamines (Scheme 
1.5A).43 A variation of this kind of strategy is the Bohlmann-Rahtz pyridine 
                                                
40 For examples of pyridine synthesis based on [4+2] normal electron demand Diels-Alder 
reactions, see: (a) Villacampa, M; Pérez, J. M.; Avendaño, C.; Menéndez J. C. Tetrahedron, 1994, 
50, 10047-10054; (b) Boger, D. L.; Ichikawa, S.; Jiang, H. J. Am. Chem. Soc. 2000, 122, 12169-
12173; (c) Barluenga, J.; Fernández-Rodríguez, M. A.; García-García, P.; Aguilar, E. J. Am. Chem. 
Soc. 2008, 130, 2764-2765; (d)  Lu, J.-Y.; Arndt, H.-D. J. Org. Chem. 2007, 72, 4205-4212; (e) Lu, 
 J.-Y.; Keith, J. A.; Shen, W.-Z.; Schürmann, M.; Preut, H.; Jacob, T.; Arndt, H.-D. J. Am. Chem. Soc. 
2008, 130,  13219-13221. 
41 For examples of pyridine synthesis based on [4+2] inverse electron demand Diels-Alder 
reaction, see: (a) Pabst, G. R.; Schmid, K.; Sauer, J. Tetrahedron Lett. 1998, 39,  6691-6694; (b) 
Linder, I.; Gerhard, M.; Schefzig, L.; Andrä, M.; Bentz, C.; Reissig, H.-U.; Zimmer, R. Eur. J. Org. 
Chem. 2011, 6070-6077; (c) E. D. Anderson and D. L. Boger, J. Am. Chem. Soc. 2011,  133, 
12285-12292.  
42 For examples of pyridine synthesis based on [4+2] metal-catalyzed cycloadditions, see: (a) 
Roesch, K. R.; Larock, R. C. J. Org. Chem. 2002, 67, 86-94; (b) Too, P. C.; Wang Y.-F.; Chiba, S. 
Org. Lett. 2010, 12, 5688-5691; (c) Hyster; T. K.; Rovis, T. Chem. Commun. 2011, 47, 11846-
11848; (d) Neely, J. M.; Rovis, T. J. Am. Chem. Soc. 2013, 135, 66-69. 
43 For examples of pyridine synthesis based on [3+3] condensations, see: (a) Henecke, H. Chem. 
Ber. 1949, 82, 36-41; (b) Stork, G.; Ohashi, M.; Kamachi, H.; Kakisawa, H. J. Org. Chem. 1971, 36, 
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synthesis44 based on the reaction between conjugated ethynylcarbonyl compounds 
and β-enamines (Scheme 1.5B).45 
 
 
Scheme 1.5: The two-component [3+3] approach to pyridine 
 
Before moving to focus on the multicomponent strategies for the pyridine 
synthesis, we consider appropriate to make a brief description of the [2+2+2] 
disconnection that, in our opinion, is borderline between this and the next section. 
Generally this approach is based on the reaction of cycloaddition between two 
alkyne components and a nitrile in the presence of various transition metal 
catalysts.46 However, although at first sight this kind of approach could be 
considered as a multicomponent strategy, it is usually carried on as a linear 
process employing diynes and nitriles or alkynyl nitriles and alkynes (Scheme 
1.6A).47 In this manner it is possible to overcome the regioselectivity problems 
derived from the use of three different two-atom fragments in a one-pot fashion 
and that could theoretically generate a large number of very similar products 
(Scheme 1.6B).48  
 
                                                                                                                                 
2784–2786; (c) Yamaguchi, Y.; Katsuyama, I.; Funabiki, K.; Matsui, M.; Shibata, K. J. Heterocyclic 
Chem. 1998, 35, 805-810; (d) Sagitullina, G. P.; Garkushenko, A. K.; Dushek, M. A.; Poendaev, N. 
V.; Sagitullin, R. S. Chem. Heterocycl. Compd. 2011, 46, 1250-1254. 
44 Bohlmann, F; Rahtz, D. Chem. Ber. 1957, 90, 2265-2272. 
45 The Bohlmann-Rahtz pyridine synthesis has been reviewed: Bagley, M. C.; Glover, C.; Merritt, 
E. A. Synlett 2007, 2459−2482. 
46 (a)	   For	   a	   general	   overview	   of	   transition-­‐metal-­‐catalyzed	   reactions	   in	   heterocyclic	   synthesis	  
including	  pyridines,	  see:	  Nakamura,	  I.;	  Yamamoto,	  Y.	  Chem.	  Rev.	  2004,	  104,	  2127-­‐2198;	  (b)	  For	  a	  
specific	   review	   of	  metal-­‐mediated	   [2+2+2]	   cycloaddition	   reactions,	   see:	   Domínguez,	   G.;	   Pérez-­‐
Castells,	   J.	   Chem.	   Soc.	   Rev.	   2011,	   40,	   3430-­‐3444;	   (c)	   For	   a	   specific	   review	   of	   metal-­‐mediated	  
[2+2+2]	  pyridine	  synthesis,	  see:	  Varela,	  J.	  A.;	  Saá,	  C.	  Chem.	  Rev.	  2003,	  103,	  3787-­‐3801. 
47 Varela,	  J.	  A.;	  Castedo,	  L;	  Saá,	  C.	  J.	  Org.	  Chem.	  1997,	  62,	  4189-­‐4192. 
48 Brandli, C.; Ward, T. R. J. Comb. Chem. 2000, 2, 1–42.  
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Scheme 1.6: The [2+2+2] approach to pyridine synthesis 
 
1.3.2 Synthetic methodologies based on multicomponent reactions 
As the present thesis deals with multicomponent reaction for the synthesis of 
pyridine derivatives, we will next focus on this kind of approach, highlighting the 
various typologies of disconnections described in the literature. 
1.3.2.1 Approaches based on the [3+2+1] disconnection 
The multicomponent version of the Bohlmann-Rahtz synthesis is one of the 
simplest approaches based on the [3+2+1] disconnection. Described firstly at the 
beginning of the millennium, this strategy is based on the formation in situ of the 
β-enamine component by the condensation between an ammonia analogue and an 
enolizable carbonyl compound (Scheme 1.7).49  
 
                                                
49 For examples of pyridine syntheses based on the multicomponent version of the Bohlmann-
Rahtz synthesis, see: (a) Bagley, M. C.; Dale, J. W.; Bower, J. Chem. Commun. 2002, 1682-1683; 
(b) X. Xiong, M. C. Bagley, K. Chapaneri, Tetrahedron Lett. 2004, 45, 6121-6124; (c) Aulakh, V. 
S.; Ciufolini, M. A. J. Am. Chem. Soc. 2011, 133, 5900-5904; (d) Zhang, L.-J.; Wu, Q.; Sun, J.; Yan, 
C.-G. Beilstein, J. Org. Chem. 2013, 9, 846-851. 
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Scheme 1.7: The [3+2+1] multicomponent version of the Bohlmann-Rahtz pyridine synthesis 
developed by Bagley’s group49b 
 
The same in situ formation of the β-enamine is used also in the strategy centered 
on the Michael addition, a comparable methodology based on the reaction of this 
β-enamine with a α,β-unsaturated carbonyl compound. This methodology 
generally affords tetrasubstituted pyridines and allows the use of various 
typologies of Michael acceptors and of enolizable carbonyl compounds. 50 
It is worth reminding that, whereas the Bohlmann-Rahtz reaction affords directly 
the fully unsaturated pyridine nucleus, the Michael addition-initiated [3+2+1] 
approach needs a final step of aromatization that usually occurs in a sequential 
manner, after the formation of the heterocycle, and in the same reactions 
conditions employed for the multicomponent protocol (Scheme 1.8).  
 
 
Scheme 1.8: The [3+2+1] Michael addition-based multicomponent strategy for pyridine 
synthesis developed by Rodriguez’s group50d 
 
The major drawbacks of this strategy are represented by the requirement to use β-
unsubstituted aldehydes and ketones, probably because of the reversibility of the 
Michael addition with hindered substrates; the use of activated Michael acceptors 
                                                
50 For examples of multicomponent pyridine syntheses based on the Michael addition strategy, 
see: (a) Katritzky, A. R.; Abdel-Fattah, A. A. A.; Tymoshenko, D. O.; Essawy, S. A. Synthesis 1999, 
2114-2118; (b) Al-Saleh, B.; Abdelkhalik, M. M.; Eltoukhy, A. M.; Elnagdi, M. H. J. Heterocycl. 
Chem. 2002, 39, 1035-1038; (c) Kantevari, S.; Chary, M. V.; Vuppalapati, S. V. N.; Lingaiah, N. J. 
Heterocycl. Chem. 2008, 45, 1099-1102; (d) Liéby-Muller, F.; Allais, C.; Constantieux, T.; 
Rodriguez, J. Chem. Commun. 2008, 4207-4209; (e) Allais, C.; Constantieux, T.; Rodriguez, J. 
Chem. Eur. J. 2009, 15,  12945-12948; (f) Allais, C.; Liéby-Muller, F.; Constantieux, T.; Rodriguez, 
J. Eur. J. Org. Chem. 2013, 19, 4131-4145; (g) Raja, A. V. P.; Tenti, G.; Perumal, S.; Menéndez, J. 
C. Chem. Commun. 2014, 50, 12270-12272. 
R1O
R3
OR4
NH4OAc
EtOH
reflux, 24 h N R1R4
R2
O O
R2
R3
+
R1O
R2
O
R4 O
R3
+
NH4OAC, 4Å MS
PhCH3, 110 °C, 24 h N R1R4
O
R2R
3
N
H
R1R4
O
R2R
3
in situ 
oxidation
1. Introduction	   39 
 
 
with enhanced electrophilicity represents a way to circumvent the problem.51 
 
A conceptually comparable approach to the Michael addition-based process is 
represented by the Kröhnke pyridine synthesis. Described firstly in 1961, this 
methodology is based on the reaction between a α,β-unsaturated carbonyl 
compound, a α-pyridinium methyl ketone salt and ammonium acetate as the 
source of the nitrogen atom.52 The reaction usually provides access to pyridines 
bearing up to four substituents and it is particularly useful for the synthesis of 
polyaryl derivatives. Initially described as a sequential process, to date different 
variations in a one-pot multi step fashion have been described (Scheme 1.8),53 
including one methodology based on a [2+2+1+1] disconnection characterized by 
the in situ formation of the α,β-unsaturated carbonyl derivative.54 
 
  
Scheme 1.9: The [3+2+1] one-pot Kröhnke pyridine synthesis described by Lee53e 
 
Finally a more limited approach to pyridine that exploits the [3+2+1] 
disconnection is the strategy involving the use of Mannich bases as starting 
materials (Scheme 1.1). 55  In the most exploited version of this reaction a 
protonated Mannich base is reacted with an enolizable carbonyl derivative in the 
presence of ammonium acetate as ammonia source (Scheme 1.9). Although 
mostly employed in the synthesis of fused pyridine systems, in the last years 
several approaches to non-polycyclic pyridines based on this method have been 
                                                
51 Allais, C.; Constantieux, T.; Rodriguez, J. Chem. Eur. J. 2009, 15, 12945-12948.  
52 Zecher, W.; Kröhnke, F. Chem. Ber. 1961, 94, 690-697. 
53 For examples of the Kröhnke pyridine synthesis, see: (a) Constable, E. C.; Lewis, J. Polyhedron 
1982, 1, 303-306; (b) Neve, F.; Crispini, A.; Campagna, S. Inorg. Chem. 1997, 36, 6150-6156; (c) 
Katritzky, A. R.; Abdel-Fattah, A. A. A.; Tymoshenko, D. O.; Essawy, S. A. Synthesis 1999, 2114-
2118; (d) Zhao, L.-X.; Moon, Y.-S.; Basnet, A.; Kim, E.; Jahng, Y.; Park, J. G.; Jeong, T. C.; Cho, W.-
J.; Choi, S.-U.; Lee, C. O.; Lee, S.-Y.; Lee, C.-S.; Lee, E.-S. Bioorg. Med. Chem. Lett. 2004, 14, 1333-
1337; (e) Basnet, A.; Thapa, P.; Karki, R.; Na, Y.; Jahng, Y.; Jeong, B.-S.; Jeong, T. C.; Lee, C.-S.; 
Lee, E.-S. Bioorg. Med. Chem. 2007, 15, 4351-4359.  
54 Yan, C.-G.; Cai, X.-M.; Wang, Q.-F.; Wang, T.-Y.; Zheng, M. Org. Biomol. Chem. 2007, 5, 945-
951.  
55 Mannich, C.; Krösche, W. Arch. Pharm. (Weinheim) 1912, 250, 647-667.  
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described.56 
 
 
Scheme 1.10: The [3+2+1] multicomponent strategy for pyridine synthesis from Mannich bases 
developed by Risch56b 
 
1.3.2.2 Approaches based on the [2+2+1+1] disconnection 
At the beginning of the 20th century the Russian chemist Chichibabin described a 
pseudo-four-component synthesis of the pyridine ring based on the [2+2+1+1] 
approach from the reaction between 3 equiv of an enolizable aldehyde and 1 equiv 
of ammonia (Scheme 1.10A).57 The low yield, harsh conditions and numerous 
byproducts left this protocol in the oblivion till at the end of 1940s Frank and 
Steven carried out various experiments in an attempt to better understand the 
reaction. During their mechanistic studies they used plausible intermediates of the 
reaction, such as α,β-unsaturated carbonyl compounds generated from the 
condensation of two equiv of the enolizable carbonyl derivative, reaching 
surprisingly the formation of an unexpected pattern of substitution in the pyridine 
ring (a 2,4,6-trisubstitution instead of the 2,3,5-trisubstitution depicted by 
Chichibabin). Pointing at the reversible nature of the aldol condensation, they 
envisioned a reaction pathway going through the formation of a 1,5-dicarbonyl 
compound with the final step of ring closure by the intervention of the ammonia 
source (Figure 1.10B).58  
 
                                                
56 For examples of multicomponent pyridine synthesis based on the Mannich reaction, see: (a) 
Sielemann, D.; Keuper, R.; Risch, N. Eur. J. Org. Chem. 2000, 543-548; (b) Winter, A.; Risch, N. 
Synthesis 2003, 2667 -2670; (c) Jemmezi, F.; Chtiba, S.; Khiari, J. J. Heterocycl. Chem. 2013, 50, 
206-208.  
57 Chichibabin, A. E. J. Russ. Phys. Chem. Soc. 1906, 37, 1229-1231. 
58 Frank, R. L.; Seven, R. P. J. Am. Chem. Soc. 1949, 71, 2629-2635. 
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Scheme 1.11 
 
These mechanistic studies allowed to overcome some of the limitations of the 
original protocol and from that moment most of the variations derived from this 
pyridine synthesis are directed to the formation of the 2,4,6-trisubstituted pyridine 
(known as Kröhnke pyridines, as mentioned in the previous section) from the 
reaction between an ammonia source, a non-enolizable aldehyde and two 
equivalent of an enolizable ketone (Scheme 1.11).59 
 
 
Scheme 1.12 The [2+2+1+1] Chichibabin reaction-based pseudo-four-component strategy for 
pyridine synthesis developed by Penta59d 
 
                                                
59 For examples of pyridine synthesis based on variations to the Chichibabin synthesis, see: (a) 
Tu, S.; Jia, R.; Jiang, B.; Zhang, J.; Zhang, Y.; Yao, C.; Ji, S. Tetrahedron 2007, 63, 381-388;  (b) 
Rong, L.; Han, H.; Wang, S.; Zhuang, Q. Synth. Commun. 2008, 38, 1808-1814; (c) Li, J.; He, P.; 
Yu, C. Tetrahedron 2012, 68, 4138-4144; (d) Penta, S.; Vedula, R. R. J. Heterocycl. Chem. 2013, 
50, 859-862.  
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An interesting variation of this synthetic strategy is represented by the 
replacement of one of the equivalents of the enolizable ketone by malononitrile; 
in this case we can properly consider this [2+2+1+1] approach as a real four-
component variation of the Chichibabin pyridine synthesis (Scheme 1.12).60 
 
 
Scheme 1.13: The [2+2+1+1] Chichibabin reaction-based four-component strategy for pyridine 
synthesis developed by Pagadala60d 
 
The last [2+2+1+1] approach we are going to describe in this section is probably 
one of the most common methods for the construction of the pyridine nucleus: the 
Hantzsch reaction. As already mentioned in the paragraph 1.1, this 
multicomponent reaction was one of the first described in the literature10 and 
allows the formation of a 1,4-dihydropyridine (DHP) derivative by a pseudo-four-
component reaction between an aldehyde, a source of ammonia and two equiv of 
a β-dicarbonyl compound (Scheme 1.1). The oxidation of DHP into pyridine has 
been thoroughly investigated and it is usually performed with well-known 
oxidizing agents, 61  including some environmentally friendly protocols that 
involve O2 as oxidant. 62  Although in most cases this oxidation is usually 
                                                
60 For examples of pyridine synthesis based on variations to the Chichibabin synthesis involving 
malononitrile, see: (a) Kambe, S.; Saito, K.; Sakurai, A.; Midorikawa, H. Synthesis 1980, 366-368; 
(b) Shi, F.; Tu, S. J.; Fang, F.; Li, T. J. Arkivoc 2005, 137-142; (c) Mungra, D. C.; Patel, M. P.; Patel, 
R. G. Arkivoc 2009, 64-74; (d) Pagadala, R.; Maddila, S.; Moodley, V.; van Zyl, W. E.; 
Jonnalagadda, S. B. Tetrahedron Lett. 2014, 55, 4006-4010. 
61 For examples of dihydropyridine oxidation into pyridine, see: (a) Yadav, J. S.; Reddy, B. V. S.; 
Basak, A. K.; Baishya, G.; Narsaiah, A.V.  Synthesis, 2006, 451–454; (b) Ghorbani-Choghamarani, 
A.; Nikoorazm, M.; Goudarziafshar, H.; Shiri, L.; Chenani, Z. Bull. Korean Chem. Soc. 2009, 30, 
972-974; (c) Liao, X.; Lin, W.; Lu, J.; Wang, C. Tetrahedron Lett. 2010, 51, 3859-3861; (d) Jia, X.; 
Yu, L.; Huo, C.; Wang, Y.; Liu, J.; Wang, X. Tetrahedron Lett. 2014, 55, 264-266; (e) Sanchez, L. 
M.; Sathicq, A. G.; Baronetti, G. T.; Thomas, H. J.; Romanelli, G. P. Catal. Lett. 2014, 44, 172-180; 
(f) Saikh, F.; De, R.; Ghosh, S. Tetrahedron Lett. 2014, 55, 6171-6174. 
62 For examples of dihydropyridine oxidation into pyridine employing O2 as oxidant, see: (a) 
Ortiz, M. E.; Nuñez-Vergara, L. J.; Camargo, C.; Squella, J. A. Pharm. Res. 2004, 21, 428-435; (b) 
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performed in a sequential manner, 63  in the literature we can find also 
multicomponent procedures focused on affording the pyridine derivative in a one-
pot fashion (Scheme 1.13).64  
 
 
Scheme 1.14: The combinatorial study developed by Cotterill employing the [2+2+1+1] 
approach of the Hantzsch dihydropyridine synthesis64a 
 
As partially shown in the scheme 1.13, the major limitation of the original 
protocol is the absence of regioselectivity of the process when two different β-
dicarbonyl compounds are employed, namely when we move from a pseudo-four-
component reaction to a real four-component reaction. To overcome this 
drawback, the more efficient strategy is to form previously the intermediates that 
are supposed to take part in the Hantzsch reaction, such as a Knoevenagel adduct 
between one of the β-dicarbonyl compound and the aldehyde, or the β-enaminone 
intermediate derived from the reaction between the ammonia source and one of 
the β-dicarbonyl compound. This methodology, known as “modified three-
component Hantzsch approach”, allows the control of the regioselectivity of the 
reaction and it usually employed in the generation of non-symmetrical 1,4-DHPs 
                                                                                                                                 
Han, B.; Kiu, Z.; Liu, Q.; Yang, L.; Liu, Z.-L.; Yu, W. Tetrahedron 2006, 62, 2492-2496; (c) Shen, L.; 
Cao, S.; Wu, J.; Zhang, J.; Li, H.; Liu, N.; Qian, X. Green Chem. 2009, 11, 1414-1420; (d) Abdel-
Mohsen, H. T.; Conrad, J.; Beifuss, U. Green Chem. 2012, 14, 2686-2690; (e) Wei, X.; Wang, L.; 
Jia, W.; Du, S.; Wu, L.; Liu, Q. Chin. J. Chem. 2014, 32, 1245-1250. 
63 (a) Xia, J. J.; Wang, G. W. Synthesis 2005, 2379-2383; (b)  Das Sharma, S.; Hazarika, P.; 
Konwar, D. Catal. Commun. 2008, 9, 709-714. 
64 (a) Cotterill, I. C.; Usyatinsky, A. Y.; Arnold, J. M.; Clark, D. S.; Dordick, J. S.; Michels, P. C.; 
Khmelnitsky, Y. L. Tetrahedron Lett. 1998, 39, 1117-1120; (b) De Paolis, O.; Baffoe, J.; Landge, 
S.; Török, B. Synthesis 2008, 3423-3428; (c) Shen, L.; Cao, S.; Wu, J.J.; Zhang, J.; Li, H.; Liu, N. J.; 
Qian, X. H. Green Chem. 2009 11, 1414-1420; (d) Mirza-Aghayan, M.; Asadi, F.; Boukherroub, R. 
Monatsh. Chem. 2014, 145, 1919-1924. 
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(where the adjective non-symmetrical indicates the presence of two different ester 
groups at C-3 and C-5 of the DHP, scheme 1.14).65 
 
 
Scheme 1.15: Regioselectivity in the Hantzsch dihydropyridine synthesis. 
 
Despite its strategic limitations, the Hantzsch synthesis has been and still is one of 
the most employed strategies, especially in medicinal chemistry because it allows 
a straightforward access to the 1,4-dihydropyridine nucleus that is present in 
many marketed drugs.66 Indeed, due to their pharmacological versatility, 1,4-
DHPs can be defined as “privileged scaffold”, namely, as defined firstly by 
Evans,67 molecular structures which show the ability to interact with different 
                                                
65  (a) Andersen, K. H.; Nordlander, M.; Westerlund, R. C. U.S. Patent 5856346, 1999; 
(b) Dondoni A, Massi A, Aldhoun M J Org. Chem. 2007, 72, 7677-7687; (c) Vishnu, N. R.; 
Puruschottam, J. A.; Kumar, S. S. Eur. Patent EP 2386544, 2011. 
66 (a) Ioan, P.; Carosati, E.; Micucci, M.; Cruciani, G.; Broccatelli, F.; Zhorov, B. S.; Chiarini, A.; 
Budriesi, R. Curr. Med. Chem. 2011, 18, 4901-4922; (b) Carosati, E.; Ioan, P.; Micucci, M.; 
Broccatelli, F.; Cruciani, G.; Zhorov, B. S.; Chiarini, A.; Budriesi, R. Curr. Med. Chem. 2012, 19, 
4306-4323.  
67 Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, 
G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; 
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groups of pharmacological receptor. Owing to this intriguing characteristic, the 
use of this kind of structures for drug discovery is very attractive.68 
 
The therapeutic use of dihydropyridines should be improved by their asymmetric 
synthesis, considering that the absolute configuration of the stereogenic C-4 atom 
of chiral DHPs has a significant role on their pharmaceutical profiles. Despite its 
long history, only in the last decade have diastereoselective and enantioselective 
versions of the Hantzsch reaction been reported. Thus, in the course of work 
aimed at the synthesis of C-glycosylated analogues of medicinally relevant DHPs, 
Dondoni and co-workers studied conventional Hantzsch reactions having aldoses 
as substrates, and found that they proceeded only with modest 
diastereoselectivities (de < 50%). Further research showed that the use of (S)- or 
(R)-Pro as organocatalysts led to highly diastereoselective Hantzsch reactions 
from methyl acetoacetate, its β-enaminone and sugar-derived aldehydes obtained 
from agarose (Scheme 1.16). 
 
 
Scheme 1.16. A diastereoselective Hantzsch reaction leading to C-glycosylated 1,4-
dihydropyridines 
 
                                                                                                                                 
Kunkel, K. A.; Springer, J. P.; Hirshfield, J. J. Med. Chem. 1988, 31, 2235-2246 
68 For the importance of privileged scaffolds in medicinal chemistry and drug discovery, see: (a) 
Costantino, L.; Barlocco, D. Curr. Med. Chem. 2006, 13, 65-85; (b) Welsch, M. E.; Snyder, S. A.; 
Stockwell, B. R. Curr. Opin. Chem. Biol. 2010, 14, 347-361. 
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Mechanistically, this transformation was proposed to start by the formation of an 
enaminone from the β-ketoester and L-Pro, followed by a Knoevenagel reaction 
with the heterocyclic aldehyde and subsequent hydrolysis. A Michael addition of 
the β-ketoester enaminone to the Knoevenagel product followed by a final 
cyclocondensation with loss of a molecule of water would explain the isolation of 
the final dihydropyridine (Scheme 1.16).69 
 
Enantioselective versions of the Hantzsch reaction have also been reported. As 
shown in Scheme 1.17, the reaction between dimedone, ethyl acetoacetate, 
ammonium acetate and aromatic aldehydes in the presence of a chiral BINOL-
phosphoric acid catalyst gave dihydropyridines in good to excellent yields and in 
enantiomeric excesses above 94%, although the absolute configuration of the final 
products was not determined.70 
 
 
Scheme 1.17. Enantioselective Hantzsch reactions in the presence of a chiral Brønsted acid 
 
                                                
69 Ducatti, D. R. B.; Massi, A.; Noseda, M. D.; Duarte, M. E. R.; Dondoni, A. Org. Biom. Chem. 
2009, 7, 1980-1986. 
70 Evans, C. G.; Gestwicki, J. E. Org. Lett. 2011, 11, 2957-2959. 
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Within the general framework of the development of multicomponent reactions 
for the synthesis of pharmacologically relevant dihydropyridines and pyridines, 
we have pursued the following specific objectives: 
 
1.  Development of a new approach to pyridine derivatives, based on a double 
elimination process on a tetrahydropyridine derivative generated through a 
Lewis-acid catalysed four-component reaction between β-dicarbonyl 
compounds, dimethylhydrazine, acroleins and ethanol (Scheme 2.1). 
 
 
Scheme 2.1: New four-component reaction for the pyridine synthesis 
 
2.  Development of a new multicomponent route to 4,6-diarylpyridine 
frameworks from β-dicarbonyl compounds, chalcones and an ammonia 
source, and study of the conditions required for the reaction to afford 
dihydropyridines or pyridines (Scheme 2.2).  
 
 
Scheme 2.2: New three-component reaction for the synthesis of DHPs and pyridines 
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3.  Classical 1,4-dihydropyridines have shown good neuroprotective 
activities, which have not been exploited therapeutically because of their 
cardiovascular effects. In view of the fact that 4,6-diaryl-1,4-
dihydropyridines do not satisfy the well-known structure-activity 
relationships of vasodilator dihydropyridines, we also planned the study of 
the compounds mentioned in Objective 2 as neuroprotectors. 
 
 
Scheme 2.3: Structural variations between classical 1,4-DHPs (a) and our compounds (b) 
 
4.  Synthesis of fused dihydropyridines and their oxygen heteroanalogues via 
a Hantzsch-like three-component reaction between malononitrile, aromatic 
aldehydes and C5-functionalized pyrazoles, and their subsequent study as 
neuroprotectors via inhibition of GSK3β. 
 
 
Scheme 2.4: Design of bicyclic GSK3β inhibitors 
 
5.  Multicomponent synthesis of hybrid structures related to nimodipine and 
CGP-37157 as potential anti-Alzheimer compounds aimed at stabilizing 
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37157 aza analogue and lipoic acid, a well-known antioxidant able to cross 
the blood-brain barrier, were planned (Scheme 2.6).  
 
 
Scheme 2.5: Design and synthesis of hybrid multitarget neuronal calcium stabilizer 
 
Scheme 2.6: Design and synthesis of hybrid multitarget directed ligand with potential 
antioxidant properties 
 
6.  During a stay at Georg-August-Universität Göttingen (Professor 
Ackermann’s group) as part of the requirements for the European Mention 
to the Ph. D. title, a Ru(II)-catalyzed oxidative C-H alkenylation of 
arylsulfonamides was developed (Scheme 2.7).  
 
N
H
N
Cl
OH
Cl
O
Aza-analogue of 
CGP-37157
O
O
N
H
O
O
H3C CH3
NO2
CH3
CH3
H3CO
Nimodipine
N
HN
Cl
O
Cl
O
O
N
H
O
O
H3C CH3
NO2
CH3
CH3
Hybrid Multitarget Calcium 
Stabilizer
1,4-DHP: 
Calcium channel 
blocker
NCXmito inhibitor
N
H
N
Cl
OH
Cl
O
Aza-analogue of 
CGP-37157 (153) Lipoic acid
Hybrid Multitarget Directed 
Ligand
Antioxidant
NCXmito inhibitor
N
H
N
Cl
O
OCl
O
S S
HO
O
S S
52  2. Objectives 
 
 
 
Scheme 2.7: Development of a new Ru(II)-catalyzed oxidative C-H alkenylation of 
arylsulfonamides 
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3.1 SYNTHESIS OF PYRIDINE DERIVATIVES VIA A NEW FOUR-
COMPONENT REACTION 
3.1.1 Introduction  
In an attempt to find an innovative pathway for the synthesis of the pyridine motif 
and related heterocycles, the initial purpose of our work was to extend the range 
of the applications of a previous four-component protocol developed by our own 
group and that consisted in a mild, high-yielding synthesis of tetrahydropyridines 
from a,b-unsaturated aldehydes, amines, 1,3-dicarbonyl compounds and alcohols. 
The reaction, catalyzed by cerium(IV) ammonium nitrate (CAN) acting as a 
Lewis acid, takes place under mild reaction conditions and shows a high 
efficiency, allowing the generation of four bonds (two C-N, one C-O and one C-
C) in a single operation (Scheme 3.1).71  
 
 
Scheme 3.1: Reaction scheme followed in our previous project. 
 
Previous work also made clear the importance of the use of CAN as a Lewis acid, 
able to promote the initial reaction between the amine and the 1,3-dicarbonyl 
components to give the corresponding β-enaminones, and expediting their 
subsequent Michael addition to the α,β–unsaturated aldehydes (Scheme 3.2). 
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Scheme 3.2: Mechanistic rationale proposed for the four-component reaction leading to 
tetrahydropyridine compounds. 
 
3.1.2 Preliminary studies  
Our initial study was focused on the simplest possible approach to our goal: a 
multicomponent strategy similar to the one previously studied but using ammonia 
instead of primary amines as the source of nitrogen. In this way, we expected to 
obtain a N-unsubstituted tetrahydropyridine derivative that could then aromatize 
to pyridine via a sequential elimination/dehydrogenation process. A literature 
search revealed a pioneering work from Hoelderich’s group based on a similar 
reaction between β-ketoesters, ammonium acetate and acrolein catalyzed by 
zeolites, which employed very harsh reaction conditions (reactions carried out in 
gas phase and at high temperatures) and afforded the corresponding pyridines in 
moderate yield.72 Furthermore, we found in the literature two examples of a 
similar reaction between β-ketoesters, ammonium acetate and acrolein yielding 
the corresponding pyridines after an aromatization process in the presence of 
sulphur, but in very poor yield (17 and 26%).73  
Unfortunately, when we employed our usual CAN-catalyzed conditions in the 
reaction between ammonium acetate, ethyl acetoacetate and acrolein in ethanol, 
no cyclized derivative was detected. We decided to assay different catalysts, 
                                                
72 Hoelderich, W.; Goetz, N. U.S. Patent US4960894, 1990. 
73 Roy, P.J.; Dufresne, C.; Lachance, N.; Leclerc, J.P.; Boisvert, M.; Wang, Z.; Leblanc, Y. Synthesis 
2005, 2751-2757. 
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discovering that the reaction carried out in the presence of 10% InCl3 was strongly 
exothermic and afforded pyridine derivative 1 as the only product, albeit in a 
moderate 30% yield, together with recovered ethyl acetoacetate (Scheme 3.3).  
 
 
Scheme 3.3: Initial study for the multicomponent pyridine synthesis 
 
Although we initially postulated that the first step of the process was the 
formation of the β-enaminone, it is worth emphasizing that this reaction was 
found not to proceed via this intermediate, since it did not occur when ethyl 3-	  
aminocrotonate was employed as the starting material. Therefore, we assumed 
that our reaction followed a different synthetic pathway that starts with a Michael 
addition of the ketoester to the unsaturated aldehyde to give a 1,5-dicarbonyl 
compound, followed by its oxidative cyclodehydration with ammonia (Scheme 
3.4). 
 
 
Scheme 3.4: Supposed synthetic pathway for our initial multicomponent reaction 
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Since this approach to pyridines was already known in the literature,74 we did not 
further pursue the preparation of pyridines by this route. 
With this result in hand, we decided to explore as the next possible approach, the 
substitution of the primary amine by a compound with a nucleophilic nitrogen 
linked to a good leaving group in order to achieve the pyridine synthesis by 
combination of the MCR with a double elimination. O-Methyl- and O-
benzylhydroxylamine were our first choices as the source of the pyridine nitrogen 
atom but, unfortunately, the sequential four-component reaction between these 
starting materials, ethyl acetoacetate, acrolein and ethanol in the presence of 
catalytic amounts of CAN in acetonitrile solution was not successful. Indeed, by 
employing the previously established conditions for the case of primary amines, 
we were able to recover only mixtures of the E and Z oxime derivatives (5a), 
without finding any trace of the expected tetrahydropyridine derivatives (Scheme 
3.5).  
 
 
Scheme 3.5: Use of O-benzylhydroxylamine as the source of the pyridine nitrogen atom 
 
It is important to remark that the NMR spectra of these compounds did not show 
significant signals that could be ascribed to the corresponding enamine 
tautomer,75 which was assumed to be the reactive species according to the above-
mentioned precedent from our group. Even so, we carried on the reaction between 
O-benzylhydroxylamine and ethyl acetoacetate in the presence of various Lewis 
acids at different concentrations, in the hope that the formation of even only traces 
of the enamine tautomer could trigger the reaction with acrolein, displacing the 
                                                
74 (a) Liéby-Muller, F.; Allais, C.; Constantieux, T.; Rodriguez, J. Chem. Commun. 2008, 4207-
4209. (b) Allais, C.; Constantieux, T.; Rodriguez, J. Chem. Eur. J. 2009, 15, 12945-12948. (c) 
Allais, C.; Liéby-Muller, F.; Rodriguez, J.; Constantieux, T. Eur. J. Org. Chem. 2013, 4131-4145. 
75 Ahlbrecht, H.; Henk, H. Chem. Ber. 1976, 109, 1516-1529. 
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equilibria towards the desired products. Despite the different Lewis acids, the 
various catalyst amounts and the different reaction times employed, our attempts 
were unsuccessful and this forced us to accept the lack of reactivity of the oxime 
intermediates, and prompted us to search for alternative reagents as source of the 
pyridine nitrogen. 
Thus we turned our attention to 1,1-dimethylhydrazine, because it combined	  the 
nucleophilic character of a free NH2 group with the presence of a dimethylamino 
unit as a leaving group. In addition, hydrazones derived from 1,3-dicarbonyl 
compounds had previously been described to exist as mixtures of imino and 
enamino tautomers.76 Based on our previous experience with the hydroxylamine 
derivatives, on this occasion we started our study by conducting the reaction 
between 1,1-dimethylhydrazine and ethyl acetoacetate in acetonitrile in the 
presence of a catalytic amount of CAN (5 mol%). After stirring at room 
temperature for 15 minutes the reaction was complete, and afforded the desired 
product as a mixture of an enamine and a combination of Z- and E-hydrazone 
tautomers in 2:1 ratio, which was considered promising for our purpose (Scheme 
3.6). Before starting with the four-component process, we focused our attention 
on evaluating the effect of the catalyst in this model reaction, assaying several 
different Lewis acids under room temperature conditions. As shown in Table 3.1, 
all catalysts assayed were found to give excellent results (entries 1-4), specially 
indium trichloride (entry 2), which proved to be marginally better than our initial 
choice (CAN) and cheaper than both triflates; for this reason and in view of our 
previous experience with this reagent, InCl3 was chosen for subsequent studies.  
 
 
Scheme 3.6: Use of 1,1-dimethylhydrazine as the source of the pyridine nitrogen atom 
 
As an additional refinement, we successfully replaced the acetonitrile solvent by 
                                                
76 Ahlbrecht, H.; Henk, H. Chem. Ber. 1975, 108, 1659-1681. 
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the less toxic and inexpensive ethanol, which was anyway required as one of the 
reagents involved in the MCR process (entry 5). 
 
Table 3.1. Lewis acid-catalyzed reaction between 1,1-dimethylhydrazine and ethyl 
acetoacetate. 
Entry Lewis acid Solvent Yield (%) 
1 CAN (5 mol%) CH3CN 92 
2 InCl3 (10 mol%) CH3CN 96 
3 Yb(OTf)3 (5 mol%) CH3CN 96 
4 Sc(OTf)3 (5 mol%) CH3CN 96 
5 InCl3 (10 mol%) EtOH 98 
 
Consequently we applied the optimal conditions to our designed sequential four-
component reaction and, since at this stage we were primarily interested in the 
synthesis of tetrahydropyridine derivatives, we started our study of the 
multicomponent process by mixing 1,1-dimethylhydrazine and ethyl acetoacetate 
in ethanol in the presence of a catalytic amount of InCl3 (10 mol%) followed, after 
15 minutes, by the addition of acrolein, the simplest α,β-unsaturated aldehyde. 
After stirring the reaction mixture at room temperature for 3 hours, we were 
pleased to discover that the desired 1-dimethylamino-6-ethoxy-1,4,5,6-
tetrahydropyridine derivative 9 was obtained in 90% yield (Scheme 3.7). 
 
 
Scheme 3.7: InCl3-catalyzed sequential four-component process leading to tetrahydropyridine 
derivative 9 
 
We next focused our attention on establishing the most favorable conditions for 
the two-step aromatization process required to complete the sequence leading to 
pyridine derivatives (Scheme 3.8). 
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Scheme 3.8: Study of the two-step aromatization process 
 
For this purpose, we carried out a series of experiments whose results are 
summarized in Table 3.2. After using initially the isolated and purified compound 
9 for these experiments, we subsequently verified that it was possible to start the 
aromatization from the crude reaction mixture resulting from the workup of the 
initial four-component reaction, and this became the routine protocol. Our first 
choice of reaction conditions was based on a previous study carried out in our 
group,77 which showed, on one hand, the possibility to tranform 1-alkyl analogues 
of 9 into 1-alkyl-1,4-dihydropyridines in excellent yields by reflux in a suspension 
of neutral, grade I alumina in acetonitrile, whereas on the other hand, revealed the 
instability of the 1-alkyl	  analogues of 9 in the presence of Brönsted acids.78 In our 
case, the use of neutral, grade I alumina in acetonitrile afforded the desired 
pyridine 1 as the major product, but its isolated yield was modest owing probably 
to its adsorption onto the alumina (entry 1). The same conditions were applied to 
the mixture from the four-component reaction, without any workup in order to 
minimize the number of purification steps, albeit with a poor result (entry 2). 
Subsequently, based on the existence of some literature precedent for the use of 
oxidizing reagents in the aromatization of compounds containing a 1-
dimethylamino-1,4-dihydropyridine structural fragment, 79  we attempted the 
                                                
77 (a) Maiti, S.; Menéndez, J. C. Synlett 2009, 14, 2249-2252; (b) Maiti, S.; Sridharan, V.; 
Menéndez, J. C. J. Comb. Chem. 2010, 12, 713–722. 
78  For literature precedent of the acid-promoted elimination of dimethylamine from 1-
dimethylamino-1,4-dihydropyridine systems, see: (a) Waldner, A. Helv. Chim. Acta 1988, 71, 
486-492; (b) Nebois, P.; Barret, R.; Fillion, H. Tetrahedron Lett. 1990, 31, 2569-2572; (c) 
Valderrama, J. A.; González, M. F.; Valderrama, C. Tetrahedron 1999, 55, 6039-6050; (d) 
Manzanaro, S.; Vicent, M. J.; Martín, M. J.; Salvador-Tormo, N.; Pérez, J. M.; Avendaño, C.; 
Menéndez, J. C.; de la Fuente, J. A. Bioorg. Med. Chem. 2004, 12, 6505–6515. 
79 (a) Pérez, J. M.; López-Alvarado, P.; Avendaño, C.; Menéndez, J. C. Tetrahedron Lett. 1998, 39, 
673-676; (b) Pérez, J. M.; López-Alvarado, P.; Pascual-Alfonso, E.; Avendaño, C.; Menéndez, J. 
C. Tetrahedron 2000, 56, 4575-4583. 
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reaction of compound 9 with iron trichloride,80 obtaining only complex mixtures 
(entry 3). Thermal elimination processes carried out under vacuum that led to the 
desired transformation were also known in the literature,81 but in our case they 
were not viable owing to volatility of our materials (entry 4). Finally, it was found 
that the best conditions to obtain the target compound involved reflux in toluene 
containing a 20% w/w suspension of Pd/C (10% wt) (entry 5). 
 
Table 3.2. Studies leading to the synthesis of pyridine derivative 1. 
Entry Conditions Solvent T (°C) 
Time 
(h) 
Product 
ratioa 
Isolated 
Yield (%)b 
1 Al2O3c CH3CN Reflux 48 10:1:0 33 
2 
Al2O3c and 
InCl3 (10 
mol%) 
EtOH Reflux 24 0:2:1 0 
3 FeCl3·6 H2O EtOH Reflux 24 -d dec.d 
4 
Vacuum  
(0.1 torr) 
- 110 2 - 0 
5 Pd/C PhCH3 Reflux 12 1:0:0 85 
a Pyridine (1): Dihydropyridine (10): Tetrahydropyridine (9) ratio calculated on the spectra of the 
reaction crude 
b Pyridine overall yield for the two-step process, after chromatographic purification 
c Neutral, grade I Al2O3 
d Complex mixture, probably due to a decomposition of the intermediates 
 
By interrupting the reaction before completion it was possible to isolate the 1,4-
dihydropyridine derivative 10, which was identified as the intermediate in the 
transformation of the tetrahydropyridine 9 into pyridine 1 by monitoring the 
reactions by TLC and 1H-NMR (Scheme 3.8). As a result of this initial study, we 
have managed to establish a protocol for the synthesis of pyridine derivatives 
lacking substituents at positions 4, 5, and 6, which implies the construction of the 
heterocyclic framework from acrolein, dimethylhydrazine and a 1,3-dicarbonyl 
compound with 10 mol% InCl3, in ethanol, and then aromatization by Pd/C in 
                                                
80 Hemanth Kumar, K.; Muralidharan D.; Perumal, P.T. Tetrahedron Lett. 2004, 45, 7903-7906. 
81 (a) Kitahara, Y.; Kubo, A. Heterocycles 1992, 34, 1089-1092; (b) Pérez, J. M.; Avendaño, C.; 
Menéndez, J. C. Tetrahedron Lett. 1997, 38, 4717-4720; (c) Pérez, J. M.; López-Alvarado, P.; 
Avendaño, C.; Menéndez, J. C. Tetrahedron 2000, 56, 1561-1567. 
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refluxing toluene. 
 
3.1.3 Evaluation of the scope of the new synthesis of pyridine 
derivatives 
3.1.3.1 Variations in the 1,3-dicarbonyl component 
The optimized reaction conditions derived from our preliminary studies were then 
applied to the reactions of acrolein and dimethylhydrazine with a variety	  of 1,3-
dicarbonyl compounds that allowed structural variations of the R1 and R2 
substituents (Scheme 3.9). 
 
 
Scheme 3.9: Synthesis of the pyridine derivatives 
 
As shown in Table 3.3, the scope of the reaction included the use of b-ketoesters 
(entries 1-10), b-ketothioesters (entry 11) and b-diketones, which could be either 
symmetrical (entry 12) or non-symmetrical (entries 13 and 14). In the latter case, 
the reaction was found to be completely regioselective in favor of the pyridine 
derivative obtained from the initial attack onto the less hindered carbonyl group. 
Regarding the scope of the method in terms of the R1 substituent, we verified that 
the reaction could tolerate several types of modifications (including the presence 
of functional groups), as shown by entries 2-8. 
 
Table 3.3. Scope and yields for the synthesis of the pyridine derivatives 
Entry Cmpd. R1 R2 Time (h)a Yield (%)b 
1 1 CH3 OEt 3/12 85 
2 11 Et OEt 3/12 74 
3 12 Pr OEt 3/12 76 
4 13 iPr OEt 4/9 68 
N R1
R2
O1. InCl3 (10 mol%)EtOH, rt
then workup
2. Pd/C (20% w/w)
PhCH3, reflux 1, 11-23
O
R1
R2
N
NH2 O
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+
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Entry Cmpd. R1 R2 Time (h)a Yield (%)b 
5 14 CH2StBuc OEt 5/12 58 
6 15 (CH2)2CH=CH2c OEt 5/12 57 
7 16 CH2COOEt OEt 4/30 82 
8 17 c OEt 4/36 70 
9 18 CH3 OtBu 4/15 62 
10 19 CH3 OAllyl 3/36 67 
11 20 CH3 StBu 5/15 76 
12 21 CH3 CH3 4/6 55 
13 22 CH3 Ph 4/9 60 
14 23 CH3 iBu 5/18 47 
a Reaction times for the MCR/double elimination sequence.  
b Overall yield after column chromatography. 
c For the preparation of the corresponding 1,3-dicarbonyl compounds (which are not 
commercially available), see the experimental part. 
 
3.1.3.2 Attempted variations in the Michael acceptor 
In order to extend the scope of our protocol, we tried as Michael acceptors α,β-
unsaturated aldehydes different from acrolein, such as crotonaldehyde and 
cinnamaldehyde, but all our attempts were unsuccessful, giving very complex 
mixtures. To understand and address this limitation to our protocol, we decided to 
resolve by chromatography, the reaction mixture coming from crotonaldehyde 
(Scheme 3.10) and we verified that its main component was compound 24. 
Moreover, we could isolate and identify compound 26 and, finally, we were able 
to isolate also a little percentage of the expected intermediate, although partially 
oxidized to the dihydropyridine stage (compound 25). 
 
 
Scheme 3.10: Study of the four-component reaction involving crotonaldehyde 
 
O
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Compound 24 was probably derived from a transimination reaction between the 
dimethylhydrazone of ethyl acetoacetate 6a (the initial intermediate) and 
crotonaldehyde and which was proposed to take place via a [2+2]	  
cycloaddition/retro [2+2] cycloaddition process. Compound 26, probably came 
from the aldol addition of ethyl acetoacetate to 24 (Scheme 3.11). 
 
 
Scheme 3.11: Mechanistic rationale proposed for the formation of side products during the 
four-component reaction involving crotonaldehyde. 
 
All attempts to modify the outcome of this reaction by using other Lewis acids 
(CAN, InCl3, Yb(OTf)3 and Sc(OTf)3) at different concentrations (5 and 10 
mol%), under various temperature conditions (0°C, room temperature and reflux) 
and in different solvents (ethanol and acetonitrile) were unsuccessful. Similar 
products were observed in the crude NMR spectra of the reaction starting from 
cinnamaldehyde, and methacrolein gave even more complex mixtures. 
3.1.3.3 Synthesis of fused pyridines 
We also examined briefly the application of our methodology to the synthesis	  of 
fused pyridine derivatives by employing cyclic 1,3-diketones as substrates 
(Scheme 3.12). As shown in Table 3.4, these reactions worked well, although they 
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were slower at both the MCR and elimination stages, and afforded derivatives of 
7,8-dihydroquinolin-5(6H)-one (entries 1 and 2) or 6,7,8,9-tetrahydro-5H-
cyclohepta[b]pyridine (entry 3). 
 
 
Scheme 3.12: Synthesis of fused pyridine derivatives via a sequence of a four-component 2-
ethoxy-1,2,3,4,6,7,8-octahydroquinoline synthesis and a double elimination process. 
 
Table 3.4. Scope and yields for the synthesis of the fused pyridine derivatives 
Entry Cmpd. n R Time (h)a Yield (%)b 
1 27 1 H 15/36 81 
2 28 1 CH3 15/40 78 
3 29 2 H 15/20 76 
a Reaction times for the MCR/double elimination sequence. 
b Overall yield after column chromatography. 
 
Finally, to extend our protocol to the synthesis of tricyclic derivatives, we 
investigated a reaction starting from β-tetralone in lieu of the β-dicarbonyl 
compound employed in other cases. Interestingly, although the reaction could be 
expected to afford linear or angular tricyclic systems, we verified that it showed a 
complete regioselectivity in favor of the angular derivative, since employing the 
usual protocol we obtained a mixture of the partially (IIa) and fully (30) oxidized 
products shown in Scheme 3.13. As depicted in this scheme, the observed 
regioselectivity can be explained by the higher conjugation of the enamine Ia that 
leads to the angular compound. 
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Scheme 3.13: Synthesis of the tricyclic derivative, employing β-tetralone as starting material. 
 
The separation and individual purifications of the components of the above 
mixture were difficult to achieve. Thus, in order to make the procedure more 
selective toward the isolation of a single product, we decided to submit the 
mixture of II and 30 to an oxidation with DDQ, which afforded the fully aromatic 
benzo[f]quinoline 30 as a single product in 53% overall yield from acyclic starting 
materials. 
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3.2 ADDITIONAL STUDIES ON THE STEP INVOLVING 
DIMETHYLAMINE ELIMINATION 
It is worth emphasizing that whereas palladium is a well-known reagent for 
dehydrogenation reactions,82 to the best of our knowledge, this is the first time 
that Pd/C has been employed in this type of aromatization, therefore we 
considered interesting to investigate its role. To this end, we studied the reaction 
leading to 21 in the absence of catalyst and in the presence of active charcoal 
(Scheme 3.14).  
 
 
Scheme 3.14: Study of the double elimination process 
 
Both reactions afforded the expected pyridine derivative without any significant 
change in the yield, but with a remarkable difference in the reaction time (Table 
3.5). These experiments suggest that activated carbon has a role in the 
aromatization process, probably by increasing the contact surface of the starting 
materials with oxygen owing to adsorption phenomena. Palladium also has a clear 
role, which is more difficult to explain at this stage, but can perhaps be linked to 
its ability to adsorb dimethylamine, 83  making our observed transformation 
mechanistically similar to the palladium-promoted dehydrogenation. 
 
 
 
                                                
82 For an example of its use in a pyridine synthesis related to the ones described here, see: Li, Y., 
Plesescu, M.; Prakash, S.R. J. Label. Compd. Radiopharm. 2006, 49, 789-799. 
83 For evidence for the adsorption of methylamine on palladium, see: Migone, R. A.; Meitzner, 
G.; Mykytka W. J. and Sinfelt, J. H. Catal. Lett. 1995, 31, 27-35. 
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Table 3.5. Dihydropyridine/pyridine ratios for the synthesis of 21 under several conditions a 
Entry Time (h) No catalyst 
Activated 
charcoal 
Pd-C 
1 6 2.3:1 1.4:1 0:1 
2 12 1:1.2 1:6.7 - 
3 18 1:2.4 0:1 - 
4 24 1:4 - - 
5 30 0:1 - - 
a Determined by 1H-NMR of the crude reaction products 
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4.1 INTRODUCTION 
Neurodegenerative diseases (NDDs) constitute a significant public health problem 
worldwide and, among these, cerebrovascular accidents represent one of the leading 
causes of death, neurological disability and cognitive impairment.84  
Thanks to the extensive studies carried out in the last years, a significant progress has 
been made in the understanding of the physiopathology of stroke, leading to the 
description of several pathological features that are common with other 
neurodegenerative disorders. These features include protein misfolding and 
aggregation, excitotoxicity, oxidative stress, and an ionic imbalance (especially with 
reference to Ca2+), which is associated with mitochondrial dysfunction.85 In the last 
decades, these concepts prompted the scientific community to consider 
neuroprotection as a useful instrument to prevent the onset and to combat the 
progression of neurodegenerative disorders; thus the development of molecules active 
as neuroprotective agents represents one of the main challenges of modern 
medicine.86 
During cerebral ischemia, oxygen and glucose deprivation induces a metabolic 
cascade that leads to neuronal death. One of the most significant consequences of 
these changes is the dysregulation of Ca2+ homeostasis that seems to play a key role 
in the molecular mechanism leading to brain damage. 87  In this context, the 
                                                
84 Jaffer, H.; Morris, V. B.; Stewart, D.; Labhasetwar, V. Drug Deliv. Transl. Res. 2011, 1, 409-419. 
85 (a) Jellinger, K. J. Neural Transm., Suppl. 2003, 101−144. (b) Szydlowska, K.; Tymianski, M. Cell 
Calcium 2010, 47, 122−129. 
86 (a) Auriel, E.; Bornstein, N. M. J. Cell. Mol. Med. 2010, 14, 2200−2202; (b) Yamashita, T.; Deguchi, 
K.; Sehara, Y.; Lukic-Panin, V.; Zhang, H.; Kamiya, T.; Abe, K. Neurochem. Res. 2009, 34, 707-710; (c) 
Ginserb, M. D. Neuropharmacol. 2008, 55, 363-389. 
87 (a) Mattson, M. P. Aging Cell 2007, 6, 337–350; (b) Zündorf, G.; Reiser, G.  Antioxid. Redox 
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stabilization of Ca2+ homeostasis by blocking neuronal voltage-gated calcium 
channels (VGCCs) could represent one important approach for post-ischemic 
neuroprotection in humans.88  
VGCCs are multimeric membrane proteins that play a critical role in many 
physiological functions in a variety of tissues.89 These proteins are usually classified 
into three broad groups (CaV1, CaV2 and CaV3) and different subtypes, depending on 
the pore-forming subunit. The members of the CaV1 family represent the most 
intensely studied channels and are classified in four diverse isoforms (CaV1.1-CaV1.4) 
that differ in their tissue distributions and physiological functions.90 CaV1.2 VGCCs 
are the major and most targeted isoform,91 found mainly in the cardiovascular system, 
where they control vascular tone, although they are also found in neurons. CaV1.3 
VGCCs have a tissue distribution similar to CaV1.2 VGCCs, but they are more 
neurospecific and are believed to have an important role in neuronal excitability.92 
Furthermore, recent studies 93  have demonstrated the implication of Ca2+ entry	  
through CaV1.3 VGCCs in the generation of oxidative stress underlying the 
pathogenesis of Parkinson’s disease. Therefore, selective antagonism of CaV1.3 
VGCCs is considered a potential neuroprotective strategy that could slow down 
neuronal loss in the early stages of Parkinson’s disease.94 
Among VGCCs blockers, 1,4-dihydropyridines (DHPs) can certainly be considered 
                                                                                                                                      
Signaling 2011, 14, 1275–1287. 
88 Gribkoff, V. K.; Winquist, R. J. Expert Opin. Invest. Drugs 2005, 14, 579−592. 
89 (a) Lipscombe, D.; Helton, T. D.; Xu, W. J. Neurophysiol. 2004, 92, 2633-2641; (b) Triggle, D. J. 
Curr Pharm Des 2006, 12, 443-457. 
90 Catterall, W. A.; Pérez-Reyes, E.; Snutch, T. P.; Striessnig, J. Pharmacol. Rev. 2005, 57, 411-425. 
91 Halling, D. B.; Aracena-Parks, P.; Hamilton, S. L. Sci STKE 2005, 2005, re15. 
92 Striessnig, J.; Koschak, A. Channels (Austin) 2008, 2, 233-251. 
93 (a) Chan, C. S.; Guzmán, J. N.; Ilijic, E.; Mercer, J. N.; Rick, C.; Tkatch, T.; Meredith, G. E.; Surmeier, 
D. J. Nature 2007, 447, 1081-1086; (b) Hurley, M. J.; Brandon, B.; Gentleman, S. M.; Dexter, D. T. 
Brain 2013, 136, 2077-2097. 
94 Kang, S.; Cooper, G.; Dunne, S. F.; Dusel, B.; Luan, C. H.; Surmeier, D. J.; Silverman, R. B. Nat. 
Commun. 2012, 3, 1146. 
4. 4,6-Diaryl-1,4-DHPs as neuroprotective agents	   75 
 
 
the most extensively studied due to their pharmacological versatility.95 Their broad 
therapeutical use as antihypertensive drugs has clearly shown positive effects in the 
prevention of stroke96 and in the literature there are several examples of DHPs 
showing neuroprotective properties.97 More interestingly, it is also known that high 
doses of DHPs, such as nifedipine, induce some beneficial brain effects such as 
amelioration of age-related working memory deficits among others. 98  Indeed, 
nifedipine binds both CaV1.2 and CaV1.3 isoforms, although it shows high selectivity 
towards CaV1.2, a characteristic that, together with its difficulty in going across the 
blood−brain barrier, is a key requirement for its use in cardiovascular therapy, but 
also prevents its use as a neuroprotective agent.98 Therefore, a major drawback that 
needs to be addressed in this area is the prevalence of vascular side effects of 
currently used DHPs. Thus, a renewed interest exists on the discovery and study of 
selective CaV1.3 L-type VGCCs in the context of efforts to find CaV1.3 L-type 
VGCCs-selective neuroprotective agents for	  neurodegenerative diseases.94,99 
Against this background, we decided to prepare and evaluate a library of 6-aryl-1,4-
dihydropyridines that, in contrast to other extensively studied families of DHPs, have 
received little attention in the medicinal chemistry literature. 100 Thus we have 
                                                
95 (a) Edraki, N.; Mehdipour, A. R.; Khoshneviszadeh, M.; Miri, R. Drug Discov Today 2009, 14, 1058-
1066; (b) Ioan, P.; Carosati, E.; Micucci, M.; Cruciani, G.; Broccatelli, F.; Zhorov, B. S.; Chiarini, A.; 
Budriesi, R. Curr Med Chem 2011, 18, 4901-4922. 
96 Chen, G. J.; Yang, S. PloS one 2013, 8 (3), e57854. 
97 (a) Yamagata, K.; Ichinose, S.; Tagami, M. Hypertens. Res. 2004, 27, 271–282; (b) Yagami, T.; 
Ueda, K.; Sakaeda, T.; Itoh, N.; Sakaguchi, G.; Okamura, N.; Hori, Y.; Fujimoto, M. Biochem. 
Pharmacol. 2004, 67, 1153–1165. (c) León, R.; de los Ríos, C.; Marco-Contelles, J.; López, M. G.; 
García, A. G.; Villarroya, M. Eur. J. Med. Chem. 2008, 43, 668–674.  
98 Striessnig, J.; Koschak, A.; Sinnegger-Brauns, M. J.; Hetzenauer, A.; Nguyen, N. K.; Busquet, P.; 
Pelster, G.; Singewald, N. Biochem. Soc. Trans. 2006, 34, 903-909. 
99 (a) Kang, S.; Cooper, G.; Dunne, S. F.; Luan, C. H.; Surmeier, D. J.; Silverman, R. B. J Med. Chem. 
2013, 56, 4786-4797; (b) Locatelli, A.; Cosconati, S.; Micucci, M.; Leoni, A.; Marinelli, L.; Bedini, A.; 
Ioan, P.; Spampinato, S. M.; Novellino, E.; Chiarini, A.; Budriesi, R. J Med. Chem. 2013, 56, 3866-
3877; (c) Chang, C. C.; Cao, S.; Kang, S.; Kai, L.; Tian, X.; Pandey, P.; Dunne, S. F.; Luan, C. H.; 
Surmeier, D. J.; Silverman, R. B. Bioorg. Med. Chem. 2010, 18, 3147-3158. 
100 (a) Roh, E. J.; Keller, J. M.; Olah, Z.; Iadarola, M. J.; Jacobson, K. A. Bioorg. Med. Chem. 2008, 16, 
9349-9358; (b) Jiang, J. L.; van Rhee, A. M.; Melman, N.; Ji, X.-D.; Jacobson, K. A. J. Med. Chem. 
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designed dihydropyridine derivatives with a substitution pattern that do not satisfy the 
well-known structure-activity relationships for vascular activity. In particular, the 
absence of a substituent at C-5 and the presence of an aryl group at C-6, were 
expected to lead to a reduced vascular activity, since it is known that an ester group at 
C-5 and a small alkyl or aminoalkyl substituent at C-6 are required for the vascular 
activity of DHPs. 101 It is pertinent to note here that the C-5 substituent is known to 
have an influence on the tissue selectivity of 1,4-dihydropyridines and also on the 
antagonistic/agonistic character of the DHPs (Figure 4.1).102  
 
 
Figure 4.1: Comparison between traditional DHPs with cardiovascular activity (a) and the DHPs 
studied in this Chapter (b)  
 
In an effort to contribute to the search for new neuroprotective agents for the 
treatment of neurodegenerative diseases and cerebral ischemia, we decided to 
evaluate the ability of these DHPs to prevent neuronal [Ca2+]c overload by blockade 
of L-type VGCCs, with special focus on any possible selective antagonism of CaV1.3 
VGCCs. Moreover, we also investigated their neuroprotective effect against oxidative 
stress in vitro, extending also the investigation of their biological activity by using 
pharmacological assays that reproduce the pathological conditions of an ischemic 
episode.  
                                                                                                                                      
1996, 39, 4667-4675; (c) Jiang, J. L.; van Rhee, A. M.; Chang, L.; Patchornik, A.; Ji, X.-D.; Evans, P.; 
Melman, N.; Jacobson, K. A. J. Med. Chem. 1997, 40, 2596-2608. 
101 van Rhee, A. M.; Jiang, J. L.; Melman, N.; Olah, M. E.; Stiles, G. L.; Jacobson, K. A. J. Med. Chem. 
1996, 39, 2980-2989 
102 Triggle, D. J. Cell. Mol. Neurobiol. 2003, 23, 293-303. 
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4.2 SYNTHESIS OF A LIBRARY OF 4,6-DIARYL-1,4-DIHYDROPYRIDINES  
4.2.1 Proposal and optimization of a reaction to obtain DHPs 
On the basis of our previous work, we planned the synthesis of this dihydropyridine 
library via a three-component reaction starting from β-dicarbonyl compounds, 
chalcone derivatives, and ammonium acetate as a source of ammonia. As this formal 
[3+3] aza-annulation was supposed to proceed by a Hantzsch-like mechanism 
involving the initial formation of a β-enaminone from the β-dicarbonyl compound 
and ammonia, followed by its Michael addition onto the chalcone derivative and a 
final cyclocondensation with loss of a molecule of water, we needed to find a catalyst 
able to promote all the steps of the process (Scheme 4.1). 
 
 
Scheme 4.1: Planned three-component synthesis of DHP derivatives 
 
Thus, we put our attention first in cerium (IV) ammonium nitrate (CAN) as catalyst103 
because of its low cost and toxicity, tolerance to moisture and, as described in the 
previous chapter, especially because of the experience in our	  group with this reagent 
as a Lewis acid catalyst.104 
                                                
103 For a review of the use of CAN as a catalyst in organic synthesis, see: Sridharan, V.; Menéndez, J. 
C. Chem. Rev. 2010, 110, 3805-3849.  
104 For selected examples, see: (a) Sridharan, V.; Avendaño, C.; Menéndez, J. C. Org. Lett. 2008, 10, 
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Thereafter we started a preliminary study of our CAN-protocol employing as a model 
the reaction between 1,3-diphenylprop-2-en-1-one (the simplest chalcone), ethyl 
acetoacetate as 1,3-dicarbonyl component and ammonium acetate (Scheme 4.2). 
 
 
Scheme 4.2: Optimization study for our three-component synthesis of DHP derivatives. 
 
Our first reaction was carried out in one-pot fashion employing 1 equiv of chalcone, 
1.2 equiv of ethyl acetoacetate and 3 equiv of ammonium acetate in the presence of a 
catalytic amount of CAN (5 mol%); ethanol was selected as solvent and the reaction 
was performed at room temperature for 20 h, affording only small amounts of the 
expected product 50 (Table 4.1, entry 1). When the temperature was increased to 
reflux conditions, we were pleased to observe that the reaction furnished the expected 
product albeit in a moderate yield (entry 2). Surprisingly, when the same reaction was 
carried out in absence of the catalyst, we could notice a slight improvement in the 
yield (entry 3), therefore we decided to repeat the reaction in presence of CAN in a 
two-component fashion, but employing the commercially available ethyl 3-	  
aminocrotonate as starting material, since this compound is the expected β-enamine 
intermediate formed from ethyl acetoacetate and the ammonium acetate (entry 4). In 
this case, the yield of the reaction was better, which supports the mechanistic 
proposal shown in the Scheme 4.1. Interestingly, the NMR spectra revealed that only 
                                                                                                                                      
4303-4306. (b) V. Sridharan, S. Maiti and J. C. Menéndez, Chem. Eur. J. 2009, 15, 4565-4572. (c) 
Sridharan, V.; Ribelles, P.; Ramos, M. T.; Menéndez, J. C. J. Org. Chem. 2009, 74, 5715-5718. (d) 
Sridharan, V.; Maiti, S.; Menéndez, J. C. J. Org. Chem. 2009, 74, 9365-9371. (e) Estévez, V.; 
Villacampa, M.; Menéndez, J. C. Chem. Commun. 2013, 49, 591-593. (f) Rocchi, D.; González, J. F.; 
Menéndez, J. C. Green Chem. 2013, 15, 511-517.  
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ethyl acetoacetate remained in the crude reaction product, indicating that CAN could 
promote not only the formation of the enamine, but also the backward reaction of the 
initial ethyl 3-aminocrotonate to ammonia and ethyl acetoacetate. 
By increasing the catalyst load to 10 mol%, it was possible to reduce the reaction 
time, avoiding the complete reversion of the formed enamine to the starting materials 
(entry 5). A considerable improvement of the yield was reached when an additional 
amount of ammonium acetate was added to the reaction mixture to drive forward the 
equilibrium of enaminone formation. Even after longer reaction times, a little amount 
of remaining enaminone was detected after the workup (entries 6 and 7).  
 
Table 4.1. Optimization study for our three-component synthesis of DHP derivatives. 
Entry 
Solvent 
(conc.)a,b 
Catalyst 
load 
T (°C) 
Time 
(h) 
Conversion 
(%)c 
EAA:enam. 
ratio 
1 EtOH (0.33 M) 5 mol% rt 20 Trace  
2 EtOH (0.33 M) 5 mol% Reflux 20 38 Only EAA 
3 EtOH (0.33 M) - Reflux 20 51 Only EAA 
4 EtOH (0.33 M) 5 mol% Reflux 20 45d Only EAAe 
5 EtOH (0.33 M) 10 mol% Reflux 4 22 1:1 
6 EtOH (0.33 M) 10 mol% Reflux 8 58 1:1.45 
7 EtOH (0.33 M) 10 mol% Reflux 24 93f 1:0.75 
8 EtOH (1.0 M) 10 mol% Reflux 4 78 1:0.88 
9 EtOH (1.0 M) - Reflux 4 58 1:0.55 
10 Neat - 80 °C 4 57 1:4.45 
11 EtOH (1.0 M) 10 mol% Reflux 8 95g 1:1.23 
a referred to chalcone 
b all experiments were carried out with 1:1.2:3 ratio of chalcone:ethyl acetoacetate: ammonium 
acetate 
c conversion calculated in 1H-NMR spectra of reaction crudes 
d commercial enaminone was used 
e CAN promotes also the reverse reaction of enamine intermediate to ethyl acetoacetate and 
ammonia 
f after 5h reflux additional 3 eq. of ammonium acetate were added 
g after 4h reflux additional 1.5 eq. of ammonium acetate were added 
 
In a further attempt to improve our protocol, we increased the concentration of the 
80 4. 4,6-Diaryl-1,4-DHPs as neuroprotective agents 
 
 
reagents in the reaction mixture, and the reaction times could be reduced without any 
significant change in the yield, whereas the presence of the catalyst was proved to be 
essential in these conditions (entries 8 and 9). Because of the improvement obtained 
by reducing the amount of solvent, we also tried the reaction in the absence of 
solvent, but the yield was only moderate (entry 10). Finally, by combining the more 
suitable results obtained in the previous experiments, we could define the optimal 
conditions to be reflux in ethanol in the presence of CAN (10%), and excess of 
ammonium acetate added in two portions (entry 11). 
 
4.2.2 Synthesis of the starting chalcones 31-49 
To synthesize the library of DHPs, chalcones with diferent substituents in both rings 
were required. For the synthesis of different chalcones we employed literature 
conditions, namely the classical base-catalyzed Claisen–Schmidt condensation 
reaction between aromatic aldehydes and acetophenone derivatives in alcoholic 
solution (Scheme 4.3).105 
 
 
Scheme 4.3: Synthesis of the starting chalcones 31-49 
 
Table 4.2. Scope of the synthesis of chalcones 31-49 
Entry Cmpd. R1 R2 R3 Yield (%) 
1 31 C6H5 H 4-MeC6H4 85 
2 32 4-MeC6H4 H C6H5 83 
3 33 4-MeC6H4 H 4-MeC6H4 81 
4 34 4-MeC6H4 H 4-BrC6H4 89 
                                                
105 (a) Attar, S.; O'Brien, Z.; Alhaddad, H.; Golden M. L.; Calderón-Urrea A., Bioorg. Med. Chem. 2011, 
19, 2055– 2073; (b) Lu, S.-M.; Bolm, C. Angew. Chem., Int. Ed. 2008, 47, 8920–8923. 
R1
O
R3R1
O
R2 H R
3
O
+
NaOH
EtOH:H2O, rt R2
31-47
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Entry Cmpd. R1 R2 R3 Yield (%) 
5 35 4-MeC6H4 H 2-NO2C6H4 74 
6 36 C6H5 H 4-MeOC6H4 86 
7 37 4-MeOC6H4 H 4-MeOC6H4 73 
8 38 4-ClC6H4 H C6H5 93 
9 39 4-ClC6H4 H 4-ClC6H4 95 
10 40 4-ClC6H4 H 3-MeOC6H4 79 
11 41 4-ClC6H4 H 2-NO2C6H4 61 
12 42 C6H5 H 4-NO2C6H4 53 
13 43 2-NO2C6H4 H 4-MeC6H4 85 
14 44 C6H5 H 2-thienyl 66 
15 45 4-MeC6H4 H 2-thienyl 62 
16 46 2-furyl H 4-MeC6H4 70 
17 47 C6H5 CH3 C6H5 65 
 
The same strategy was applicable to the synthesis of two known Michael acceptors 
with extended conjugation to the γ and δ positions (Scheme 4.4).106 
 
 
Scheme 4.4: Synthesis of Michael acceptors with extended conjugation 
 
4.2.3 Synthesis of 4,6-diaryl-1,4-dihydropyridine derivatives 
With the optimized conditions established in Section 4.2.1, we carried out the 
synthesis of a library of 6-aryl-1,4-dihydropyridine derivatives, starting with a variety 
of 1,3-dicarbonyl compounds and chalcones that allowed structural variations at R1, 
                                                
106 Pinto, D. C. G. A.; Silva, A. M. S.; Levai, A.; Cavaleiro, J. A. S.; Patonay, T.; Elguero, J. Eur. J. Org. 
Chem. 2000, 2593–2599. 
O
CH3 H
O
R
+
O
NaOH
MeOH 
rt, 20 h R
48 R = H (78%)
49 R = CH3 (75%)
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R2, R3 and R4 substituents (Scheme 4.5). 
 
 
Scheme 4.5: Three-component synthesis of 4,6-diaryl-1,4-DHPs 
 
This method allowed the preparation in good to excellent yields of the compounds 
summarized in Table 4.3, which bear small alkyl groups at C-2 (R1), and ester 
(entries 1-3, 6-8, 10 and 14-20), thioester (entries 4, 9, 11-13 and 21) or ketone group 
(entry 5) at C-3 from the dicarbonyl reagent. A variety of aryl (entries 1-18 and 20), 
heteroaryl (entry 19) or styryl (entry 21) substituents at C-4 (R3), no substitution at C-
5, and aryl (entries 1-19 and 21) or heteroaryl (entry 20) groups at C-6 come from the 
chalcone component, and exhibit electron-releasing and electron-withdrawing 
substituents in either of the two rings. 
 
Table 4.3. Scope and yield of the 4,6-diaryl-1,4-DHP multicomponent synthesis 
Entry Cmpd. R1 R2 R3 R4 Yield (%) 
1 50 CH3 OEt C6H5 C6H5 95 
2 51 C2H5 OEt C6H5 C6H5 92 
3 52 C3H7 OEt C6H5 C6H5 81 
4 53 CH3 StBu C6H5 C6H5 99 
5 54 CH3 CH3 C6H5 C6H5 56 
6 55 CH3 OEt C6H5 4-ClC6H4 71 
7 56 CH3 OEt 4-ClC6H4 4-ClC6H4 86 
8 57 CH3 OEt 4-MeOC6H4 C6H5 73 
9 58 CH3 StBu 4-MeOC6H4 C6H5 69 
10 59 CH3 OEt 3-MeOC6H4 4-ClC6H4 75 
R1
R2
O
R3
R4 O
O
NH4AcO
CAN (10 mol%)
EtOH, reflux, 8 h N
H
R4
R3
R1
O
R2
50-70
+
4. 4,6-Diaryl-1,4-DHPs as neuroprotective agents	   83 
 
 
Entry Cmpd. R1 R2 R3 R4 Yield (%) 
11 60 CH3 StBu 4-BrC6H4 4-MeC6H4 67 
12 61 CH3 StBu 4-MeC6H4 C6H5 99 
13 62 CH3 StBu 4-MeC6H4 4-MeC6H4 97 
14 63 CH3 OEt 4-MeC6H4 C6H5 94 
15 64 CH3 OAllyl C6H5 4-ClC6H4 78 
16 65 CH3 OEt 4-NO2C6H4 C6H5 96 
17 66 CH3 OEt 2-NO2C6H4 4-MeC6H4 78 
18 67 CH3 OEt 2-NO2C6H4 4-ClC6H4 62 
19 68 CH3 OEt 2-Thienyl 4-MeC6H4 57 
20 69 CH3 OEt 4-MeC6H4 2-Furyl 49 
21 70 CH3 StBu  C6H5 52 
 
Compound 70 (entry 21) was obtained together with the corresponding pyridine 
derivative resulting from its dehydrogenation, presumably motivated by the formation 
of a highly conjugated compound. This reaction, which is undesired when 
dihydropyridines are the goal, was not detected or just traces	   of the aromatic 
compounds were observed in some cases. 
In order to explore the influence of a higher rigidity on the activity and selectivity of 
our compounds, we also included in the library the hexahydroquinolines 71 and 72 by 
application of the CAN-catalyzed multicomponent protocol to 1,3-cyclohexanedione 
and dimedone (Scheme 4.6). 
 
 
Scheme 4.6: Three-component synthesis of fused DHP derivatives 
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4.3 BIOLOGICAL EVALUATION OF 4,6-DIARYL-1,4-DIHYDROPYRIDINES. 
The group of Dr. Rafael León in the Instituto Teófilo Hernando and Departamento de 
Farmacología y Terapeútica, Facultad de Medicina, Universidad Autońoma de 
Madrid, performed the biological assays that follow and the study of molecular 
modeling of nifedipine and compound 63. 
 
4.3.1 Neuronal VGCCs blockade in SH-SH5Y neuroblastoma cells 
As previously mentioned, DHPs are specific L-type VGCC blockers. Their activity 
and vascular selectivity require an ester function at C-5 and a small alkyl or 
aminoalkyl substituent at C-6.102 To assess the neuroprotective effect of these new 
compounds against [Ca2+] overload, we first studied whether they had any effect on 
the Ca2+ entry elicited by K+ promoted depolarization in SH-SY5Y human 
neuroblastoma cells. IC50 values for Ca2+ signal blockade data of newly obtained 
DHPs are collected in Table 4.4, using nifedipine as the reference drug. Most DHPs 
showed moderate to high potency to block neuronal L-type VGCCs, with IC50 values 
ranging from more than 100 µM (compound 62) to 2.8 µM (compound 72). 
Regarding SAR studies related to the ester functionality, ethyl ester derivatives were, 
in general, better VGCCs blockers than tert-butyl thioester derivatives. Thus, 
compound 63 (ethyl ester and C-4 p-Me-phenyl) was 2.7 times more potent than 61 
(thioester and C-4 p-Me-phenyl) and more than 4.8 times better than 62 (thioester and 
C-6, C-4 p-Me-phenyl). The lower Ca2+ channel blocking properties of thioester 
derivatives might be related to an increased steric hindrance originated by the high 
volume of the tert-butyl thioester group. As an exception, compound 58, a thioester 
derivative bearing a C-4 p-OMe-phenyl substituent, was slightly more potent than its 
parent ethyl ester derivative 57. On the other hand, compound 62, showing two p-Me-
phenyl groups at C-4 and C-6, showed the lowest potency, with an IC50 value 
above100 µM. Among ethyl ester derivatives, compound 52 was the most potent with 
an IC50 value of 9.9 µM. 
Regarding the effect of the substituents present at the dihydropyridine ring, 
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replacement of the methyl group at C-2 (50) by an ethyl (51) or propyl group (52) 
improved their blocking properties from 18.7 µM for compound 50 to 12.8 µM for 51 
and 9.9 µM for 52. Bicyclic derivatives 71 and 72, which can also be viewed as C-2 
modified analogues of 50, showed good potencies, especially compound 72, which 
blocked the Ca2+ signal induced by high potassium levels with an IC50 of 2.8  µM, 
being the most potent VGCCs blocker of the series and almost as potent as 
nifedipine. Its analogue 71, which shares the same tetrahydroquinolin-5-(1H)-one 
core but lacks the two methyl substituents at position 7, was 8.6 times less potent than 
72. 
 
Table 4.4. IC50 Values of compounds 50-72 calculated as blockade of [Ca2+]c increase elicited by 70 
mM K+ in SH-SY5Y cells 
Entry Cmpd. IC50 (µM)a  Entry Cmpd. IC50 (µM)a 
1 Nifedipine 1.35 ± 0.4  13 61 56.2 ± 6.4 
2 50 18.7 ± 6.6  14 62 >100 
3 51 12.8 ± 2.1  15 63 20.6 ± 2.1 
4 52 9.9 ± 2.6  16 64 18.5 ± 1.1 
5 53 95.8 ± 5.7  17 65 12.2 ± 1.4 
6 54 27.1 ± 3.4  18 66 44.1 ± 8.2 
7 55 9.3 ± 1.1  19 67 57.1 ± 6.6 
8 56 28.4 ± 3.2  20 68 14.9 ± 3.8 
9 57 29.8 ± 4.8  21 69 55.5 ± 5.4 
10 58 26.8 ± 3.7  22 70 63.1 ± 3.0 
11 59 15.1 ± 2.8  23 71 24.0 ± 6.4 
12 60 59.6 ± 9.1  24 72 2.8 ± 0.8 
a IC50 values were determined from dose−response curves (1−100 µM). Data are 
expressed as the mean ± SEM of three to six different cultures in triplicate. 
 
In terms of the substituents present at C-4 of the dihydropyridine ring, compounds 
bearing unsubstituted phenyl rings were generally better blockers than those having 
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rings possessing electron-donating or electron-withdrawing groups.  
Finally, comparing different substituents at position C-6, electron-withdrawing 
substituents derivatives were in general more potent VGCCs blockers than the 
corresponding phenyl derivatives. Also generally speaking, derivatives bearing a p-
Me-phenyl moiety were poorer blockers than phenyl derivatives. 
4.3.2 Functional assay: Cav1.2 and Cav1.3 IC50 determination and 
selectivity comparison 
As stated above, Cav1.2 L-type VGCCs are the major isoform (≈90%)107 expressed in 
cardiac myocytes, smooth muscle, and pancreas while Cav1.3 channels are more 
neuron-specific (cerebral cortex, hippocampus, basal ganglia, habenula, and 
thalamus) and are thought to serve predominantly as modulators in the neuronal 
system. Cav1.3 is connected to mitochondrial oxidative stress and increased 
vulnerability in SNC dopaminergic neurons.93a,108 
Because of our goal of reducing cardiovascular effects in neuroprotective DHPs, it 
was crucial to study the Cav1.3/ Cav1.2 L-type VGCCs selectivity of these C-5 
unsubstituted DHPs. SH-SY5Y neuroblastoma cells were used to study the blockade 
of Cav1.3 L-type VGCCs.109 Compounds 63, 70, and 72 were selected to calculate 
their IC50 values for Cav1.3 L-type VGCCs because of their Ca2+ blockade properties 
and their overall neuroprotective profile (see Tables 4.5 and 4.6). Compound 72 
showed the best IC50 to block Ca2+ entry through	  neuronal L-type VGCCs (IC50 = 
2.81 µM) displaying only half potency of that found for nifedipine (IC50 = 1.35 µM), a 
classical, highly potent L-type blocker of VGCCs. Compounds 63 and 70 were less 
potent, with IC50 values of 20.6 and 63.1 µM, respectively (Table 4.4). 
To calculate the Cav1.3/Cav1.2 selectivity ratio, we used the relaxation induced by 
                                                
107 Sinnegger-Brauns, M. J.; Huber, I. G.; Koschak, A.; Wild, C.; Obermair, G. J.; Einzinger, U.; Hoda, J. 
C.; Sartori, S. B.; Striessnig, J. Mol. Pharmacol. 2009, 75, 407-414. 
108 Guzmán, J. N.; Sánchez-Padilla, J.; Wokosin, D.; Kondapalli, J.; Ilijic, E.; Schumacker, P. T.; 
Surmeier, D. J. Nature 2010, 468 (7324), 696-700. 
109 Sousa, S.R.; Vetter,I.; Ragnarsson, L.; Lewis, R.J. PLoS One 2013, 8, e59293. 
4. 4,6-Diaryl-1,4-DHPs as neuroprotective agents	   87 
 
 
each compound in 70 mM K+ precontracted rat mesenteric resistance arteries. All 
DHPs induced concentration-dependent relaxation responses. As shown in Table 4.5, 
the relaxation induced by nifedipine was higher than that induced by 63, 70, and 72. 
Nifedipine blocked the Cav1.2 cardiovascular subtype more potently than neuronal 
channels by a factor of 950, showing a high selectivity for the Cav1.2 VGCC subtype 
(entry 1). On the contrary, our modifications in the DHP structure have resulted in a 
drastic decrease in their selectivity toward Cav1.2 cardiovascular subtype. Compound 
72, the most potent VGCCs blocker of the new family, showed the highest selectivity 
toward Cav1.2 subtype, since it was only 8.3 times more potent toward this subtype 
than for neuronal Cav1.3 (entry 4), a result that represents a Cav1.2/Cav1.3 selectivity 
more than 100 times lower than that of nifedipine. This reduction on selectivity was 
even higher for compounds 70 and 63, which were 306- and 500-fold less selective 
toward Cav1.2 subtype than the reference compound (entries 2 and 3). Similar results 
were obtained when U46619 was used as precontraction stimulus (data not shown). 
Thus, 63 and 70 have drastically improved their selectivity toward the Cav1.3 by 
lowering their potency toward the cardiovascular subtype while maintaining their 
activity in the neuronal subtype. The Cav1.3/Cav1.2 selectivity ratio achieved by these 
compounds represents a substantial improvement even over isradipine, which so far 
was the DHP with the highest relative affinity for Cav1.3 L-type VGCCs but which is 
still Cav1.2-selective.108  
 
Table 4.5. IC50 values for VGCC blockade by nifedipine and compounds 63, 70, and 72 
Entry Cmpd. 
Experimental IC50 (µM) 
Cav1.3/Cav1.2 Neuronal 
(SH-SY5Y) 
Cardiovascular 
(70 mM K+) 
1 nifedipine 1.35 0.00142 950.7 
2 63 20.6 10.6 1.9 
3 70 63.1 20.3 3.1 
4 72 2.81 0.34 8.3 
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4.3.3 Molecular modeling 
Docking calculations were performed to acquire deeper insights into the molecular 
basis for the interaction of these new C-5-unsubstituted DHPs with Cav1.2 L-type 
channels. Although the X-ray structure of the L-type VGCCs is not available, several 
models have been described in recent years, among which we have used the one 
developed by Zhorov et al. 110  The nomenclature used by these authors was 
maintained for a better understanding. Experimental mutagenesis results 111  and 
predicted interactions99b,110,112 have located the DHP binding site in the interface of 
domains III and IV of the pore-forming α1 subunit, in transmembrane segments IIS5, 
IIIIS6, IVS6, and IIIP. 
It is known that although potent DHP antagonists have H- bond acceptors at both the 
port and starboard sides and H-bond donors at the stern, elimination	  of the port side 
ester group does not abolish the channel-blocking effect of DHPs.113 We performed 
our docking calculations with nifedipine as a reference compound. As shown in 
Figure 4.2A, nifedipine shares a similar position as that found for (S)-nimodipine, in 
which the NH group (stern) H-bonds to Y3i10. Nifedipine also has a polar o-NO2 
group at the bowsprit that H-bonds to Y4i11 and this residue, in turn, H-bonds to the 
carboxymethyl ester moiety present at port side. 
Then we docked compound 63 using the previously optimized settings, constraining 
the calculations to the DHP binding region where, presumably, these new C-5-
                                                
110 Tikhonov, D. B.; Zhorov, B. S. J. Biol. Chem. 2009, 284, 19006−19017. 
111  (a) Wappl, E.; Mitterdorfer, J.; Glossmann, H.; Striessnig, J. J. Biol. Chem. 2001, 276, 
12730−12735. (b) Yamaguchi, S.; Okamura, Y.; Nagao, T.; Adachi-Akahane, S. J. Biol. Chem. 2000, 
275, 41504−41511. (c) Schuster, A.; Lacinova, L.; Klugbauer, N.; Ito, H.; Birnbaumer, L.; Hofmann, F. 
EMBO J. 1996, 15, 2365−2370. (d) Peterson, B. Z.; Johnson, B. D.; Hockerman, G. H.; Acheson, M.; 
Scheuer, T.; Catterall, W. A. J. Biol. Chem. 1997, 272, 18752−18758. 
112 (a) Zhorov, B. S.; Folkman, E. V.; Ananthanarayanan, V. S. Arch. Biochem. Biophys. 2001, 393, 
22−41. (b) Cosconati, S.; Marinelli, L.; Lavecchia, A.; Novellino, E. J. Med. Chem. 2007, 50, 
1504−1513. 
113 Goldmann, S.; Stoltefuß, J. 1,4-Dihydropyridines: Effects of Chirality and Conformation on Their 
Activity. In Dihydropyridines; Busse, W.-D., Garthoff, B., Seuter, F., Eds.; Springer: Berlin and 
Heidelberg, Germany, 1993; pp 24−35. 
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unsubstituted DHPs may interact. We docked the (S)-63 enantiomer because it leaves 
the unsubstituted configuration at the port side position, and as we mentioned before, 
this deletion does not abolish the antagonistic activity by itself. The (S)-63 
enantiomer presents a 2-methyl and ethyl 3-carboxylate groups at the starboard side 
and a bulky phenyl moiety at the port side, and more importantly, it lacks the second 
carboxylic ester functionality at the port side. Docking results of (S)-63 (Figure 4.2B) 
predict an orientation of the DHP core similar to that found for nifedipine but show a 
noticeably different interaction pattern. The inclusion of a bulky phenyl group 
increases the steric hindrance with F3p49, and therefore (S)-63 appears displaced 
toward the side entry of the DHP binding site formed by Met3i18, Met4i12, Thr3o16, and 
Ser4i9 (not shown). Thus, the phenyl moiety at the port side is partially accommodated 
in a hydrophobic pocked formed by Met3i19 and Phe3p49 and the core of DHP is 
slightly displaced away from the selectivity pore of the channel. The NH at the stern 
H-binds to Tyr3i10 and the carbonyl group at the starboard establish an H-bond to 
Gln3o18. 
 
 
Figure 4.2: Docking studies for (S)-nimodipine (A) and (S)-63 (B) 
 
Comparing both complexes, we can conclude that the absence of several H-bond 
interactions and the inclusion of a bulky group at port side are destabilizing the 
interaction between our C-5-unsubstituted DHPs and the CaV1.2 L-type VGCCs. 
These results, together with our experimental data, give some hints of the reason for 
the observed decrease in selectivity toward CaV1.2. 
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4.3.4 Evaluation of neuroprotective properties 
4.3.4.1 Neuroprotection in [Ca2+]c overload model 
A tight control of Ca2+ homeostasis by neurons is crucial for cell survival. In several 
NDDs, Ca2+ dysregulation is thought to be one of the main causes of 
neurodegeneration.114 Thus, drugs restoring the Ca2+ balance should indeed be a 
therapeutic alternative for the disease.115 
In line with these findings, a study of the neuroprotective profile of the C-5-	  
unsubstituted DHPs against [Ca2+]c overload and oxidative stress was performed. In 
this study we discovered an interesting potential neuroprotective activity of the novel 
compounds 50-72 on SH-SY5Y cells exposed for 24 h to a depolarizing 
concentration of K+, which induced [Ca2+]c overload and consequently cell death. 
Cells were co-incubated with drugs at 5 µM and high K+ (70 mM, hypertonic). 
Thereafter, MTT reduction was measured as a parameter of cell death.116 As shown in 
Table 4.6, all the synthesized DHPs have a similar protective activities ranged from 
22.1% (66, entry 19) to 40.1% (59, entry 12), and the best neuroprotection result was 
obtained with compound 68, which was able to prevent the death of 51% of cells 
(entry 21). In general, compounds bearing an ester functionality showed a higher 
neuroprotective profile compared to those bearing a thioester moiety or fused DHPs 
derivatives 71 and 72 (entries 24 and 25), the latter of which had a low 
neuroprotective activity. 
Taking into account compounds of monocyclic type studied, 68, bearing a 2-thienyl 
substituent at C-4, showed the best neuroprotective capability against [Ca2+]c 
overload (entry 21) and 66 showed the poorest profile (entry 19). Generally, 
                                                
114 (a) Marx, J. Science 2007, 318 (5849), 384-385; (b) Green, K. N.; LaFerla, F. M. Neuron 2008, 59, 
190-194. 
115 Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D. W.; Tarozzi, 
A.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I. R.; Melchiorre, C. J. Med. 
Chem. 2008, 51, 4381-4384. 
116 Maroto, R.; De la Fuente, M. T.; Artalejo, A. R.; Abad, F.; Lopez, M. G.; Garcia-Sancho, J.; Garcia, 
A. G. Eur. J. Pharmacol. 1994, 270, 331-339. 
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compounds bearing an electron-donating group were better neuroprotectants than 
those bearing an electron-withdrawing group. 
VGCCs blockers have been previously studied as neuroprotectant agents, and as a 
common feature, it has been widely reported that their potency as [Ca2+]c elevation 
blockers and the neuroprotective effect against Ca2+ overload are not usually well 
correlated.117 This characteristic is also present in our family of DHPs; i.e., compound 
72 showed the best Ca2+ signal blockade (79% blockade), but it showed a moderate 
activity as neuroprotectant in the [Ca2+]c overload	  model (entry 25). However, 68 
blocked 36% of the Ca2+ signal and protected 40% of cells (entry 21). Similar results 
were obtained for compounds 63 and 59, with 39% and 40% protection (entries 16 
and 12), respectively, which decreased only 43% and 48% the calcium increase 
elicited by 70 mM K+ (Table 4.4). These results led us to focus our attention on the 
possibility of an additional mechanism of action for our compounds, possibly related 
to their antioxidant action (see below). The correlation between Ca2+ influx through 
L-type VGCCs and increased mitochondrial oxidative stress has been recently 
reported.118 Furthermore, L-type antagonists reverted the oxidative stress measured in 
the cells.119 Therefore, the neuroprotective effect of our compounds against Ca2+ 
overload might be composed of VGCC blocker potency and antioxidant effect. The 
protective capabilities of these DHPs in an oxidative stress model are summarized in 
Table 4.6. 
  
                                                
117 (a) Marco-Contelles, J.; León, R.; de Los Ríos, C.; Guglietta, A.; Terencio, J.; López, M. G.; García, 
A. G.; Villarroya, M. J. Med. Chem. 2006, 49, 7607-7610; (b) Marco-Contelles, J.; León, R.; López, M. 
G.; García, A. G.; Villarroya, M. Eur. J. Med. Chem. 2006, 41, 1464-9; (c) León, R.; Marco-Contelles, J. 
Curr. Med. Chem. 2011, 18, 552-576. 
118Khaliq, Z. M.; Bean, B. P. J. Neurosci. 2010, 30, 7401-7413. 
119 Dryanovski, D. I.; Guzmán, J. N.; Xie, Z.; Galteri, D. J.; Volpicelli-Daley, L. A.; Lee, V. M.; Miller, R. 
J.; Schumacker, P. T.; Surmeier, D. J. J. Neurosci. 2013, 33, 10154-10164. 
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Table 4.6. Neuroprotection Exerted by Compounds 3a−u and 5a,b against Ca2+ Overload Induced 
by 70 mM K+ in SH- SY5Y Human Neuroblastoma Cellsa 
Entry Cmpd. 
K+ (70 mM co-incubation) 
% survival % protection 
 basal 100  
 70 mM K+ 52.1 ± 3.5###  
1 Nifedipine (5 µM) 62.9 ± 3.4* 20.0 
2 Nifedipine (0.3 µM) 58.7 ± 2.2* 15.8 
3 50 67.6 ± 3.1*** 34.6 
4 51 67.3 ± 2.3*** 31.4 
5 52 65.4 ± 3.3* 23.3 
6 53 68.0 ± 2.2*** 34.1 
7 54 67.4 ± 1.4*** 32.5 
8 55 69.4 ± 2.4*** 36.6 
9 56 65.1 ± 4.2* 24.8 
10 57 69.4 ± 3.6*** 34.1 
11 58 66.7 ± 2.9*** 31.3 
12 59 72.7 ± 2.9*** 40.1 
13 60 67.2 ± 3.3*** 34.5 
14 61 67.4 ± 1.9*** 30.4 
15 62 69.9 ± 2.4*** 36.2 
16 63 72.3 ± 3.6*** 39.8 
17 64 68.7 ± 2.5*** 29.8 
18 65 64.6 ± 4.3* 23.5 
19 66 62.9 ± 5.7* 22.1 
20 67 59.3 ± 5.5ns 13.7 
21 68 75.6 ± 2.1*** 50.7 
22 69 68.5 ± 3.7** 32.0 
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Entry Cmpd. 
K+ (70 mM co-incubation) 
% survival % protection 
23 70 69.0 ± 2.6*** 35.3 
24 71 66.4 ± 1.3*** 28.2 
25 72 64.0 ± 4.1* 21.4 
a Data are the mean ± SEM of at least five different cultures in triplicate. % protection was calculated 
considering MTT reduction by nontreated cells (basal) as 100% survival. % of toxicity was normalized 
for 70 mM K+ seen for each treatment and subtracted to 100. (***) p < 0.001. (**) p < 0.01. (*) p < 
0.05. ns = not significant with respect to 70 mM K+ treated cells. (###) p < 0.001 compared to basal 
conditions. All compounds were assayed at 5 µM. 
 
4.3.4.2 Neuroprotection in an oxidative stress model 
Oxidative stress has been widely regarded as a key mechanism of neuronal death in 
several NDDs. As a common feature, high concentrations of reactive	  oxygen species 
(ROS) are produced by abnormal pathological mitochondria.120 ROS oxidize lipids, 
causing membrane impairment and inducing cell death.121 Oxidation would also 
affect ribosomal functioning and reduce protein synthesis.122 Free radicals may also 
oxidize DNA and RNA, as shown by the detection of high levels of oxidized products 
in vulnerable neurons. 
Rotenone and oligomycin A block complexes I and V, respectively, of the 
mitochondrial electron transport chain, thus disrupting ATP synthesis.120 The mixture 
of rotenone plus oligomycin A (rot/olig) constitutes a good model of oxidative stress 
having its origin in mitochondria. Exposure to this combination induces 
neurotoxicity, and it has been widely used to evaluate potential protective drugs for 
                                                
120 Egea, J.; Rosa, A. O.; Cuadrado, A.; García, A. G.; López, M. G. J. Neurochem. 2007, 102, 1842-
1852. 
121 Butterfield, D. A.; Drake, J.; Pocernich, C.; Castegna, A. Trends Mol. Med. 2001, 7, 548-554. 
122 Honda, K.; Smith, M. A.; Zhu, X.; Baus, D.; Merrick, W. C.; Tartakoff, A. M.; Hattier, T.; Harris, P. L.; 
Siedlak, S. L.; Fujioka, H.; Liu, Q.; Moreira, P. I.; Miller, F. P.; Nunomura, A.; Shimohama, S.; Perry, G. 
J. Biol. Chem. 2005, 280, 20978-20986. 
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neurodegenerative diseases.123 
 
 
Figure 4.3: Molecular structure of rotenone and oligomycin A 
 
First, we were interested in assessing the potential antioxidant effect of compounds 
50-72 with a co-incubation protocol. C-5-unsubstituted DHPs were co-incubated for 
8 h at a concentration of 5 µM with the stressor, followed by a 16 h postincubation of 
drugs at the same concentration without the toxic stimuli. These experimental 
conditions were designed to study the potential neuroprotective effect of the tested 
compounds based on their antioxidant capabilities. Besides, as described in the 
Section 4.1, oxidative stress may be increased by [Ca2+]c overload;108 thus, in the co-
incubation model of oxidative stress, neuroprotection afforded by C-5-unsubstituted 
DHPs could be dependent on their VGCC antagonism properties. As summarized in 
Table 4.7, the tested compounds showed, in general, interesting neuroprotective 
effects, ranging from 32.5% of derivative 50 (entry 3) to 61.9% for 54 (entry 7), 
bearing an acetyl group instead of an ester or thioester substitution. Results from our 
compounds are compared with melatonin (0.3 µM) and nifedipine (5 µM), which 
were used as positive control and reference compound, respectively.  
In general, in a comparison of DHPs possessing the same substituents at positions 2, 
                                                
123 (a) Romero, A.; Egea, J.; García, A. G.; López, M. G. J. Pineal Res. 2010, 49, 141-148; (b) 
González-Muñoz, G. C.; Arce, M. P.; López, B.; Pérez, C.; Romero, A.; del Barrio, L.; Martín de 
Saavedra, M. D.; Egea, J.; León, R.; Villarroya, M.; López, M. G.; García, A. G.; Conde, S.; Rodríguez-
Franco, M. I. Eur. J. Med. Chem. 2011, 46, 2224-2235. 
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3, and 6, ethyl ester and ketone derivatives showed similar protection profiles 
indicating that both groups have similar participation on their antioxidant effect. For 
the ethyl ester family, derivatives bearing electron-withdrawing groups were less 
potent neuroprotectants than those with electron-donating groups. Thus, compounds 
65 (entry 18) and 66-67 (entries 19 and 20), having respectively 4-NO2 or 2-NO2 
groups, were the less active neuroprotectants in this model. On the other hand, 
methyl- and methoxyphenyl derivatives showed a protective effect over 40% in most 
cases, compound 63 (entry 16) being the best with a 53.3% protection. Compounds 
bearing a p-chlorophenyl moiety at the C-6 position showed similar protection values 
as those compounds lacking this substituent, i.e., compounds 57 (p-methoxyphenyl at 
C-4 and phenyl at C-6, entry 10) and 59 (m-methoxyphenyl at C-4 and p-
chlorophenyl at C-6, entry 12) with protection values of 46.2% and 47.8%, 
respectively. Regarding the C-2-substituent, an increase of its steric	   volume was 
associated with an improvement of their neuroprotective profile, with protection 
values of 32.5% (methyl, 50, entry 3), 32.8% (ethyl, 51, entry 4), and 42.9% (propyl, 
52, entry 5). A similar correlation was also observed for their antioxidant effect. 
Regarding thioester derivatives, all tested compounds showed statistically significant 
neuroprotection with values ranging from 39.6% (53, entry 6) to 57.9% (60, entry 
13). Compounds 70 (entry 23) and 60 (entry 13) afforded neuroprotective effects over 
50%. Finally, polycyclic derivatives 71 and 72 (entries 24 and 25) were also able to 
protect SH-SY5Y cells in a statistically significant manner. 
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Table 4.7 Neuroprotective effect of C-5-unsubstituted DHPs 50-72 derivatives (5 µM) on SH-SY5Y 
cells viability against toxicity induced by: (a) 8 h co-incubation of rot/olig mixture (30/10 µM) in 
presence of drugs, followed by 16 h post-incubation of drugs, or (b) 8 h incubation of rot/olig 
mixture without any drug, followed by 16 h post-incubation of drugs.a 
Entry Cmpd. 
8 h rot/olig co-incubation + 
16 h postincubation 
8 h rot/olig  + 
16 h postincubation 
% survival % protection % survival % protection 
 basal 100 - 100 - 
 RO 65.6 ± 1.3### - 70.6 ± 1.8### - 
1 Melatonine 82.5 ± 2.7*** 44.7 87.8 ± 3.9** 58.3 
2 Nifedipine 78.4 ± 2.9** 29.3 73.8 ± 2.4ns 11.7 
3 50 78.4 ± 3.4** 32.5 - - 
4 51 77.4 ± 5.9** 32.8 - - 
5 52 80.5 ± 2.9** 42.9 80.6 ± 3.3ns 34.8 
6 53 79.5 ± 6.0** 39.6 - - 
7 54 87.3 ± 3.1*** 61.9 76.7 ± 4.1ns 21.7 
8 55 82.7 ± 3.2*** 46.2 - - 
9 56 69.9 ± 3.9ns 11.9 - - 
10 57 81.3 ± 7.0** 46.2 83.5 ± 2.2* 42.0 
11 58 82.3 ± 3.9*** 45.7 81.8 ± 3.1ns 38.6 
12 59 81.9 ± 3.4** 47.8 76.6 ± 3.9ns 20.5 
13 60 85.7 ± 4.3*** 57.9 74.2 ± 5.1ns 12.3 
14 61 83.3 ± 4.2*** 49.4 83.4 ± 3.1* 43.3 
15 62 79.9 ± 2.9** 36.2 - - 
16 63 83.5 ± 5.3** 53.3 88.0 ± 2.6** 60.1 
17 64 79.7 ± 3.2* 41.5 84.3 ± 3.1* 44.1 
18 65 64.6 ± 1.5n.s - - - 
19 66 69.9 ± 2.2ns 11.7 - - 
20 67 60.0 ± 3.1ns - - - 
21 68 81.9 ± 4.0*** 45.3 77.5 ± 4.7ns 25.6 
22 69 78.0 ± 3.6* 36.6 79.9 ± 3.8ns 33.2 
23 70 83.7 ± 1.7*** 52.4 86.2 ± 1.2** 52.2 
24 71 74.6 ± 4.3n.s 26.9 - - 
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Entry Cmpd. 
8 h rot/olig co-incubation + 
16 h postincubation 
8 h rot/olig  + 
16 h postincubation 
% survival % protection % survival % protection 
25 72 80.3 ± 3.9** 39.8 - - 
aData are means ± SEM of between five and 7 different cultures in triplicate. % Protection was 
calculated considering MTT reduction by nontreated cells (basal) as 100 % survival, % of toxicity was 
normalized for rot/olig seen for each treatment and subtracted to 100. (***) p < 0.001 (**) p < 0.01 
and (*) p < 0.05, ns = not significant, with respect to rot/olig treated cells; (###) p < 0.001 compared to 
basal conditions. All compounds were assayed at 5 µM concentration. 
 
These encouraging results prompted us to study the compounds with the best overall 
neuroprotective profile on a second model of oxidative stress. A neuroprotective 
compound with potential therapeutic interest will be used clinically after neurons 
already have become vulnerable; for instance, diseases are diagnosed after neuronal 
damage has already been established.124 Because we wanted to simulate experimental 
conditions closer to the clinical situation, in search for compounds able to protect 
cells already exposed to oxidative stress, we employed a protocol that consisted of an 
8 h incubation	  period with the stressor, followed by a 16 h incubation period with the 
drug alone. We selected 11 DHPs to be tested in this postincubation oxidative stress 
model, and data are collected in Table 4.7. Melatonin (0.3 µM) and nifedipine (5 µM) 
were also tested as positive and reference compounds, respectively. Among all tested 
compounds, derivatives 57, 61, 63, 64, and 70 (respectively entries 10, 14, 16, 17 and 
23) demonstrated a neuroprotective effect after a 16 h postincubation in a statistically 
significant manner. Protection values were, in all cases, over 40%, ranging from 
43.3% of derivative 61 to the 60.1% protection afforded by compound 63. It is 
interesting to emphasize that nifedipine, which showed significant neuroprotection in 
the co-incubation stress model, lost its ability to protect in the postincubation model. 
This result may indicate that neuroprotection is not fully dependent on the Ca2+ signal 
blockade properties.  
 
                                                
124 Parada, E.; Egea, J.; Romero, A.; del Barrio, L.; García, A. G.; López, M. G. Free Radic. Biol. Med. 
2010, 49, 1815-1821. 
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4.3.4.3 Neuroprotection: oxygen-glucose deprivation of hippocampal slices. An 
acute model of ischemia/reperfusion 
Oxygen and glucose deprivation (OGD) is an acute model of the lesion produced by 
[Ca2+]c overload during the OGD period followed by free radical generation during 
the reoxygenation phase.125 In neurons, the OGD period depolarizes the membrane 
after mitochondrial failure. Depolarization induces substantial [Ca2+]c elevation and a 
massive glutamate liberation, leading to increased cytotoxicity. Among all the 
experimental models of neurotoxicity elicited by Ca2+ overload, glutamate-induced 
Ca2+ overload seems to be the most relevant from a pathogenic point of view and has 
been related to several neurodegenerative diseases and stroke.126 Additionally, recent 
observations	   have confirmed the influence of mitochondria-mediated cell Ca2+ 
regulation on glutamate-induced excitotoxicity.127 On the other hand, the functional 
impairment of mitochondria, promoted by the lack of oxygen, is increased when 
reoxygenation triggers a massive production of reactive oxygen species raised by the 
OGD-induced overwork of the NADPH oxidase (NOX) enzyme.128 
To further characterize the neuroprotective profile of compounds 63 and 70, we used 
this model, where toxicity depends on [Ca2+]c overload and oxidative stress. Rat 
hippocampal slices were subjected to 15 min OGD followed by 120 min 
reoxygenation (see protocol in Figure 4.4A), and cell viability was assessed by MTT 
reduction. Under these experimental conditions, slices were treated with 63 or 70 at 
increasing concentrations (1, 3, and 10 µM) and with nifedipine (10 µM) as a control. 
Considering cell viability in basal slices as 100%, OGD reduced cell viability by 
40%. 
Compounds 63 and 70 afforded maximum protection at 10 µM (45%, Figure 4.4B). 
Nifedipine (10 µM) treatment produced no significant protection, corroborating the 
                                                
125 Egea, J.; Rosa, A. O.; Sobrado, M.; Gandía, L.; López, M. G.; García, A. G. Neuroscience 2007, 145, 
866-872. 
126 Lau, A.; Tymianski, M. Pflugers Arch. 2010, 460, 525-542. 
127 Abramov, A. Y.; Duchen, M. R. Biochim. Biophys. Acta 2010, 1800, 297-304. 
128 Chen, H.; Yoshioka, H.; Kim, G. S.; Jung, J. E.; Okami, N.; Sakata, H.; Maier, C. M.; Narasimhan, P.; 
Goeders, C. E.; Chan, P. H. Antioxidants & redox signaling 2011, 14, 1505-1517. 
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results obtained in SH-SY5Y cells subjected to rot/oligo stress postincubation. 
 
 
Figure 4.4: Post-OGD treatment with 63 and 70 protects hippocampal slices against oxygen and 
glucose deprivation followed by reoxygenation. (A) Protocol used to elicit toxicity. Hippocampal 
slices were exposed for 15 min to OGD followed by 2 h in control solution (Reox). 63, 70 and 
nifedipine, when used, were present during the 2 h reox period. (B) Cell viability was measured by 
the MTT reduction activity. Values are expressed as the mean ± SEM of five independent 
experiments: (∗∗∗) p < 0.001, compared to the basal; (##) p < 0.01 with respect to OGD-treated 
slices.  
 
 
In summary our new class of C5-unsubstituted-C6-aryl-1,4-dihydropyridines has 
shown the ability to block Ca2+ entry after a depolarizing stimulus and, more 
interestingly, showed an improved CaV1.3/CaV1.2 selectivity when compared to 
classical dihydropyridines. Considering that the different functions of CaV1.2 and 
CaV1.3 L- type VGCCs seem to be involved in different pathological conditions, the 
improved selectivity of our DHPs, could be promising for the future development of 
new generations of more selective C5-unsubstituted 1,4-dihydropyridines. 
Moreover, since our DHPs protected neuroblastoma cells against [Ca2+]c overload 
and oxidative stress-induced toxicity, their selectivity ratio makes them highly 
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interesting for the treatment of neurological disorders where Ca2+ dyshomeostasis and 
high levels of oxidative stress have been demonstrated. Indeed their low potency 
toward the cardiovascular channel subtype makes them potentially safer than classical 
1,4-dihydropyridines as far as cardiovascular side effects are concerned. Interestingly, 
some compounds afforded good protection in a postincubation model, which better 
simulates	  the clinical condition, offering a therapeutic window of opportunity of great 
interest for patient recovery after a brain ischemic episode. Good activities were also 
found in acute ischemia/reperfusion (oxygen and glucose deprivation) models. Taken 
together, these compounds deserve further investigation on neurological disease 
animal models to confirm their good in vitro neuroprotective profile described here. 
 
 
  
 
 
 
 
 
 
 
 
 
5. One-Pot Access To a Library of Densely Substituted 
Nicotinamides Via a Three-Component Formal Aza 
[3+3] Cycloaddition 
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5.1 INTRODUCTION: BIOLOGICAL RELEVANCE OF NICOTINAMIDE 
DERIVATIVES 
Nicotinic acid derivatives and, especially, nicotinamides constitute one of the 
most important families of biologically relevant compounds containing a pyridine 
ring. They are members of the B-vitamin group and play a key role in many 
essential metabolic processes. The NAD/NADP coenzymes are nicotinamide 
derivatives, leading to many potential targets for interference with drugs (Figure 
5.1).129  
 
Figure 5.1: Biologically relevant nicotinamide derivatives 
 
Besides, a number of derivatives of nicotinamide have demonstrated 
pharmacological activity at other types of targets. Thus, nicorandil is an 
established drug acting as a selective activator of ATP-dependent potassium 
channel that is employed in the treatment of cardiac ischemia.130  
 
                                                
129 (a) Ávalos, J. L.; Bever, K. M.; Wolberger, C. Mol. Cell 2005, 17, 855-868. (b) Taylor, D. M.; 
Maxwell, M. M.; Luthi-Carter, R.; Kazantsev, A. G. Cell. Mol. Life Sci. 2008, 65, 4000-4018. 
130 Eeckhout, E. Eur. Heart J. 2003, 24, 1282−1284. 
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Figure 5.2: Examples of pharmacologically relevant nicotinamides 
 
Many other pharmacologically relevant nicotinamides have been described, 
including antiarrythmic compounds acting by inhibition of the sodium−calcium 
exchanger (NCX),131 anti-cancer compounds acting by inducing apoptosis132 or by 
inhibiting vascular endothelial growth factor (VEGF)-induced	   angiogenesis,133 
anxiolytic, and antidepressant activity associated to the inhibition of Type 5 
metabotropic glutamate receptors (mGluR5)134 and inhibitors of the gastric H+/K+ 
ATPase acting as antiulcer agents (Figure 5.2).135 Nicotinamide itself, in high 
doses, is a neuroprotective agent in in vitro models of cytotoxicity and in vivo in 
                                                
131 Kuramochi, T.; Kakefuda, A.; Yamada, H.; Tsukamoto, I.; Taguchi, T.; Sakamoto, S. Bioorg. 
Med. Chem. 2005, 13, 4022-4036. 
132 Cai, S. X.; Nguyen, B.; Jia, S.; Guastella, J.; Reddy, S.; Tseng, B.; Drewe, J.; Kasibhatla, S. J. Med. 
Chem. 2003, 46, 2474-2481. 
133 Choi, H. E.; Yoo, M. S.; Lee, J. H.; Kim, J. H.; Kim, J. H.; Lee, J. K.; Kim, G. I.; Park, Y.; Chi, Y. H.; 
Paik, S. H.; Lee, J. H. Bioorg. Med. Chem. 2011, 21, 6236−6241. 
134 Cleva, R. M; Foster Olive, M. Molecules 2011, 16, 2097−2106. 
135 Terauchi, H.; Tanitame, A.; Tada, K.; Nakamura, K.; Seto, Y.; Nishikawa, Y. J. Med. Chem. 
1997, 40, 313−321. 
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brain ischaemia,136 the mechanisms of this neuroprotection being complex and not 
well known.137 Furthermore, nicotinamide is involved in the aging process138 and 
is the physiological inhibitor of the sirtuins,139 a family of NAD+ dependent 
histone deacetylases that have emerged as potential therapeutic targets for 
treatment of pathologies including metabolic, cardiovascular and 
neurodegenerative diseases, and also cancer.140 
 
Considering the biological significance of these derivatives, we thought that it 
was important to have efficient and versatile synthetic routes to obtain these 
compounds. There are not many precedents in the literature, particularly as it 
relates to multicomponent reactions, thus we assumed that we could adapt our 
previous multicomponent protocol carried out for the synthesis of 1,4-
dihydropyridines to the synthesis of nicotinamide derivatives, simply by 
employing β-ketoamides as the 1,3-dicarbonyl components of the reaction. 
                                                
136 Słomka, M.; Ziemińska, E.; Salińska, E.; Lazarewicz, J. W. Folia Neuropathol. 2008; 46, 69-80. 
137 Maiese, K.; Chong, Z.Z. Trends Pharmacol. Sci. 2003, 24, 228-232. 
138 Xu, P.; Sauve, A.A. Mech. Ageing Dev. 2010, 131, 287–298.  
139 (a) Jackson, M. D.; Schmidt, M. T.; Oppenheimer, N. J.; Denu, J. M. J. Biol. Chem. 2003, 278, 
50985-50998; (b) Avalos, J. L.; Bever, K. M.; Wolberger, C. Mol. Cell 2005, 17, 855-868. 
140 (a) Michan, S.; Sinclair, D. Biochem. J. 2007, 404, 1-13; (b) Taylor, D. M.; Maxwell, M. M.; 
Luthi-Carter, R.; Kazantsev, A. G. Cell. Mol. Life Sci. 2008, 65, 4000-4018; (c) Horio, Y.; Hayashi, 
T.; Kuno, A.; Kunimoto, R. Clin. Sci. 2011, 121, 191-203; (d) Carafa, V.; Nebbioso, A.; Altucci, L. 
Front. Pharmacol. 2012, 3, 1-6. 
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5.2 SYNTHESIS OF NICOTINAMIDES BY A NEW MULTICOMPONENT 
REACTION 
5.2.1 Proposal and optimization of a multicomponent reaction to 
obtain nicotinamide derivatives 
Thereafter we started the study of the multicomponent process that would afford 
nicotinamide derivatives by examining the reaction between chalcone, 
acetoacetamide and ammonium acetate (Scheme 5.1 and Table 5.1). 
According to our previous experience, the first reaction was performed in 
refluxing ethanol and in the presence of ceric ammonium nitrate (entry 1). It 
provided a rather complex mixture from which we could isolate the desired 
compound 83, the expected dihydropyridine (DHP) and a small amount of 
another compound identified as the cyclohexenone derivative 104 by its 
spectroscopic data. The trans disposition of substituents was asigned taking into 
account the value of the coupling constant between the corresponding protons 
(J=8.9 Hz). The latter compound arises from the Robinson annulation between the 
chalcone and acetoacetamide without incorporation of ammonia, and its identity 
was unambiguously confirmed by its independent synthesis from chalcone and 
acetoacetamide in the presence of piperidine.141  
 
 
Scheme 5.1: Initial study for the three-component synthesis of nicotinamides 
 
As shown in Table 5.1, subsequent experiments showed that the use of a	  higher 
catalyst load (entry 2) or of a more concentrated solution (entry 3) did not greatly 
                                                
141 Rajanarendar, E.; Kalyan Rao, E.; Raju, S. Indian J. Chem. 2009, 48B, 749-753. 
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improve the results, whereas a longer reaction time (15 h) was found to be highly 
beneficial, leading almost exclusively to the target compound 83 (entry 4). A 
control experiment carried out under the same conditions but in the absence of 
catalyst also led to consumption of the starting materials and to the formation of 
83, but in this case a higher amount of the side product 104 was observed (entry 
5). Therefore, subsequent experiments were performed in the presence of 10 
mol% of CAN in the conditions of entry 4 which corresponds to the best yield of 
83. 
 
Table 5.1. Optimization study of the multicomponent reaction 
Entry 
Catalyst 
load a 
Solvent Temper. 
Time 
(h) 
DHP:83:104 
ratio b 
1 10 mol% EtOH Reflux 4 41:45:14 
2 20 mol% EtOH Reflux 4 30:55:15 
3 10 mol% EtOHc Reflux 4 40:48:12 
4 10 mol% EtOH Reflux 15 0:95:5 
5 - EtOH Reflux 15 0:76:24 
a all the experiments were carried out with 1:1:3 ratio of chalcone:β-
ketoamides:ammonium acetate and the catalyst load is referred to the limiting reagent. 
b conversion in crude 1H-NMR spectra  
c 2 M solution of the reagents (in all the other experiments, reagent concentration was 
1 M). 
 
5.2.2 Synthesis of the starting β-ketoamides 73-80 
Once established the optimal condition for our protocol, different chalcones and 
ketoamides were required to explore the scope of this methodology. We had some 
commercial chalcones, and others were available by aldol condensation as 
described in Section 4.2.2, so we proceeded to the preparation of an ample variety 
of β-ketoamides. To this end, we initially prepared the N-mono- and disubstituted 
acetoacetamides 73-77 by a	   procedure developed in our group based on the 
treatment of primary and secondary amines with 2,2,6-trimethyl-1,3-dioxin-4-one 
in the presence of sodium acetate, which leads to the formation of an intermediate 
mixed anhydride, and allows the use of milder temperature conditions than 
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alternative protocols (Scheme 5.2 and Table 5.2).142  
 
 
Scheme 5.2: Synthesis of the starting β-ketoamides 73-77 
 
Table 5.2. Scope and yield of the synthesis of β-ketoamides 73-77 
Entry Cmpd. Z Yield (%) 
1 73 
 
95 
2 74  95 
3 75  90 
4 76 
 
71 
5 77 
 
96 
 
In addition, β-oxoanilides 78-80 were also prepared by a literature method,143	  
based on the reaction between the corresponding β-ketoesters and the appropriate 
aniline in refluxing toluene. The reflux condenser was connected to a Dean-Stark 
trap to continuously remove the alcohol generated during the reaction (Scheme 
5.3). 
 
                                                
142 Sridharan, V.; Ruiz, M.; Menéndez, J.C. Synthesis 2010, 6, 1053-1057. 
143 Jendralla, H.; Baader, E.; Bartmann, W.; Beck, G.; Bergmann, A.; Granzer, E.; Kerekjarto, B. V.; 
Kesseler, K.; Krause, R.; Schubert, W.; Wess, G. J. Med. Chem. 1990, 33, 61-70. 
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Scheme 5.3: Synthesis of the starting β-oxoanilides 78-80 
 
5.2.3 Synthesis of nicotinamide derivatives 
With the optimimal reaction conditions in hand, we explored the scope of the 
method (Scheme 5.4 and Table 5.3). 
 
 
Scheme 5.4: Three-component synthesis of nicotinamides 83-103 
 
As shown in the Table 5.3 the reaction normally proceeded in good to excellent 
yields, and tolerated well the presence of either electron-withdrawing or electron-
releasing groups at the chalcone aromatic rings. Ortho-substitution at the R1 
substituent (entry 8, compound 90) led to a decrease in yield due to steric 
hindrance, but it had little effect on the other aromatic ring (substituent R3), as 
shown by the 85% yield obtained for compound 89 (entry 7). 
 
Table 5.3. Scope and yield of the synthesis of nicotinamides 83-103 
Entry Cmpd. R1 R2 R3 R4 Z 
Yield 
(%)a 
1 83 C6H5 H C6H5 CH3 NH2 92 
2 84 4-MeC6H4 H C6H5 CH3 NH2 95 
3 85 4-MeC6H4 H 4-MeC6H4 CH3 NH2 95 
4 86 C6H5 H 4-MeOC6H4 CH3 NH2 95 
5 87 4-MeOC6H4 H 4-MeOC6H4 CH3 NH2 73 
78 R = C2H5 (54%)
79 R = C3H7 (55%)
80 R = CH(CH3)2 (66%)
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O
83-103
R4
Z
O
O
R1 O
R3
NH4OAc
+
R3
R1
R2 R2CAN (10 mol%)
EtOH, reflux
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Entry Cmpd. R1 R2 R3 R4 Z 
Yield 
(%)a 
6 88 4-ClC6H4 H 4-ClC6H4 CH3 NH2 95 
7 89 4-ClC6H4 H 2-NO2C6H4 CH3 NH2 85 
8 90 2-NO2C6H4 H 4-MeC6H4 CH3 NH2 66 
9 91b C6H5 CH3 C6H5 CH3 NH2 20 
10 92 4-MeC6H4 H 4-MeC6H4 CH3 
 
83 
11 93 C6H5 H C6H5 CH3 NHPh 84 
12 94b,c C6H5 H C6H5 C2H5 NHPh 74 
13 95 C6H5 H C6H5 C3H7 NHPh 82 
14 96c C6H5 H C6H5 CH(CH3)2 NHPh 74 
15 97 C6H5 H C6H5 CH3  64 
16 98 C6H5 H C6H5 CH3  80 
17 99 C6H5 H C6H5 CH3  
67 
18 100 C6H5 H 2-thienyl CH3 NH2 70 
19 101 4-MeC6H4 H 2-thienyl CH3 NH2 72 
20 102 C6H5 H  CH3 NH2 74 
21 103 C6H5 H  CH3 NH2 68 
a isolated yield after crystallization or chromatography 
b experiments carried out with 1:2:3 ratio of chalcone:β-ketoamides:ammonium acetate (+1 
additional eq of ammonium acetate after 24 h) 
c experiments carried out at 50°C 
 
To prove the ability of the method to introduce further structural diversity in the 
nicotinamide derivatives, we examined also the preparation of compounds bearing 
substituents other than phenyl at the pyridine C-4 position by use of suitably 
modified chalcones. This way, we prepared compounds 100 and 101 (entries 18 
and 19), with a heterocyclic moiety at C-4, and 102 and 103 (entries 20 and 21), 
with a styryl chain.  
The main limitation of the method came from the presence of substituents 
N
H
N
O
N
N
N CH3
CH3
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different from hydrogen at R2 (entry 9, compound 91), which was clearly 
detrimental for yield and which could not be overcome in spite of having 
attempted many different conditions (finally we had to modify slightly the 
experimental procedure for this derivative). In particular, it was interesting to note 
that not even by raising the temperature nor by extending the reaction time, we 
were able to increase the conversion of the starting chalcone into the expected 
product. Instead, we could observe only its progressive degradation to the parent 
compounds propiophenone and benzaldehyde. On the other hand, while R4 was 
methyl in most cases due to a better accessibility of the starting materials, we 
verified that the presence of other substituents was also possible (entries 12-14, 
compounds 94-96). In some of these cases, it was necessary to change slightly the 
experimental conditions in order to avoid the formation of the side products 
coming from the Robinson annulation, as confirmed by the identification of the 
compound 105 obtained from the reaction between chalcone, ammonium acetate 
and N-phenyl-3-oxopentanamide in the standard conditions (Scheme 5.5).  
 
 
Scheme 5.5: Competition between the three-component nicotinamides synthesis and 
Robinson annulation 
 
Finally, the amide nitrogen could be unsubstituted (entries 1-9 and 18-21, 
compounds 83-91 and 100-103), monosubstituted with alkyl (entry 10, compound 
92) or aryl (entries 11-14, compounds 93-96) groups or disubstituted (entries 15-
17, compounds 97-99).  
It is worth underlining that the synthesis of compound 83 was already known in 
the literature and it was based on a related two-component reaction starting from 
N
H
O O
O
NH4AcO
+
N-phenyl-3-
oxopentanamide
Chalcone
Ammonium 
acetate
N
N
H
O
O
N
H
O
+
94 105
CAN (10 mol%)
EtOH, reflux
16 h CH3CH3
CH3
69         :       31
Ratio in the 1H-NMR spectra
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chalcone and 2-methylcrotonamide, giving however just a modest 36% yield.144 
5.2.4 Use of cyclic b-ketoamides for the synthesis of fused pyridine 
systems 
Finally, we also examined briefly the preparation of fused pyridines by 
employing, as the starting material, the β-ketolactams 81 and 82. These 
compounds were prepared following a literature procedure that involves the initial 
acylation of Meldrum’s acid with N-Boc-β-alanine in the presence of EDCI and 
DMAP, and subsequent cyclization to compound 81 in refluxing AcOEt.145 
Finally, removal of the N-Boc protecting group of 81 in acid	  conditions, afforded 
the β-ketolactam 82 (Scheme 5.6). 
 
 
Scheme 5.6: Synthesis of the starting β-ketolactams 81 and 82 
 
With the desired β-ketolactams in hand, we studied their reaction with chalcone 
and ammonium acetate in refluxing ethanol. As shown in Scheme 5.7, in this case 
the main products were the 1,6-naphthyridine derivatives 106-107, containing a 
fused dihydropyridine substructure, together with a small amount of the 
corresponding pyridine 108, only when R = H. 
 
                                                
144 Kato, T.; Noda, M. Chem. Pharm. Bull. 1976, 24, 1408−1410. 
145 Vanotti, E.; Amici, R.; Bargiotti, A.; Berthelsen, J.; Bosotti, R.; Ciavolella, A.; Cirla, A.; Cristiani, 
C.; D’Alessio, R.; Forte, B.; Isacchi, A.; Martina, K.; Menichincheri, M.; Molinari, A.; Montagnoli, 
A.; Orsini, P.; Pillan, A.; Roletto, F.; Scolaro, A.; Tibolla, M.; Valsasina, B.; Varasi, M.; Volpi, D.; 
Santocanale, C. J. Med. Chem. 2008, 51, 487−501. 
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Scheme 5.7: Three-component reaction between chalcones, ammonium acetate and β-
ketolactams 
  
N
O
O
N
H
N
O
106 R = Boc (70%)
107 R = H (74%)
O
NH4OAc
+
R
R
N
NH
O
+
108
(14%)
CAN (10 mol%)
EtOH, reflux
15 h
81 R = Boc
82 R = H
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5.3 MECHANISTIC PROPOSAL 
Before focusing the attention on the mechanistic proposal, it is interesting to note 
that a similar reaction involving the use of primary amines instead of ammonia 
has been found to give cyclohexene derivatives rather than the pyridines obtained 
in the present work. 146  Thus, the exquisite balance between the two 
chemodivergent pathways involving [3+3] and aza-[3+3] formal cycloadditions, 
respectively, seems to depend on the steric hindrance of the nitrogen of the N-
nucleophile (Scheme 5.8). 
 
 
Scheme 5.8: Chemodivergent pathways of slightly different three-component reactions 
 
Mechanistically, both reactions are proposed to start by the generation of an 
intermediate β-enaminone I via the CAN-catalyzed reaction between the starting 
primary amine or ammonia and the β-dicarbonyl compound. This assumption is 
based on two experimental facts:  
a) CAN catalysis is known to lead to the very fast formation of β-
enaminones;147  
b) control experiments carried out from an isolated enaminone (3-
aminocrotonamide) led to a result that was identical to that of our three-
component reactions.  
 
A Michael addition of I onto the enone fragment of chalcone should lead to 
intermediate II, which would be in tautomeric equilibrium with two enamine 
                                                
146 Sridharan, V.; Menéndez, J.C. Org. Lett. 2008, 10, 4303−4306. 
147 Sridharan, V.; Avendaño, C.; Menéndez, J. C. Synlett 2007, 881−884. 
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species III and IV. In the case R = H, the unhindered nitrogen atom is able to 
attack the opposing carbonyl as a nucleophile, leading to dihydropyridine V after 
loss of a molecule of water, in a Hantzsch-like process. On the other hand, for the 
more hindered cases where R is different from hydrogen, the reaction with the 
side chain carbonyl is slower because of steric hindrance and the system tends to 
evolve via the less stable, but also more reactive, intermediate IV, which affords 
the cyclohexene derivatives VI (Scheme 5.9). 
 
 
Scheme 5.9: Mechanistic proposal for our three-component reaction 
 
While dihydropyridines are normally reasonably stable, during the optimization 
studies we never observed compounds V as the only reaction products but as part 
of mixtures with pyridines 83-103, indicating that they are particularly prone to 
oxidation. Furthermore, as already demonstrated in the previous chapter, when an 
ester (Z = OAlk) or ketone (Z = Alk) derivative was employed as starting 
material, the same protocol generated a stable dihydropyridine, which shows that 
this ease of oxidation has to be attributed to the presence of the amide substituent. 
This behavior can be attributed to the very strong conjugation between the amide 
carbonyl and its nitrogen, which makes the carbonyl less prone to accept electron 
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density from the dihydropyridine nitrogen and hence makes the latter more 
electron-rich and the corresponding heterocycle more readily oxidizable. In the 
case of compounds 106 and 107, the more rigid structure must hamper 
dehydrogenation by facilitating conjugation of the dihydropyridine nitrogen with 
the lactam carbonyl. 
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6.1 ALZHEIMER’S DISEASE: AN OVERVIEW 
6.1.1 Ethiology and pathophysiology of Alzheimer’s disease 
First described in 1906, Alzheimer’s disease (AD) is the most common 
neurodegenerative disease,148 with an estimated prevalence of more than 44 
million people worldwide in 2013, a number that is expected to reach 75 million 
in 2030 and 135 million in 2050.149 After more than a century and despite of an 
extensive research, the causes of AD are still unknown and consequently the 
discovery of effective therapies remains a long-standing and crucial objective of 
modern medicine.150 
This devastating neurological disorder is characterized by the progressive 
impairment of cognitive functions, memory loss, altered behavior and neuronal 
death. The pathological hallmarks of AD are known and at morphological levels 
are characterized by the presence and accumulation of senile plaques formed by a 
β-amyloid peptide (Aβ), derived from the amyloid protein precursor (APP), and of 
intracellular neurofibrillary tangles (NFTs) composed of a hyperphosphorylated 
form of the microtubular protein tau. 
During the last thirty years various etiological hypothesis for AD have been 
formulated by studying the different histopathological lesions discovered	   in the 
brain of AD patients. The first remarkable pharmacological results in the 
treatment of AD have been achieved by the use of acetylcholinesterase inhibitors, 
based on the evident deficit of acetylcholine in the cholinergic system typical of 
the AD patients. Indeed, despite of its limitations, the cholinergic hypothesis has 
allowed the development of four of the five drugs currently approved for the 
                                                
148 Goedert, M.; Spillantini, M. G. Science 2006, 314, 777-781. 
149  Alzheimer’s Disease International. Global impact of dementia 2013; 2013; 
http://www.alz.co.uk/research/GlobalImpactDementia2013.pdf. 
150 Holtzman, D. M.; Morris John, C.; Goate, A. Sci. Trans. Medl. 2011, 77, 77sr1. 
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treatment of AD. Although the therapy with acetylcholinesterase inhibitors 
produces improvement in the patients’ cognitive abilities and in their quality of 
lives, this kind of treatment is just a palliative remedy considering that the 
neurodegenerative process does not stop. 151  Some years later, the amyloid 
hypothesis emerged as a new encouraging theory to explore, considering that the 
accumulation of amyloid plaques is characteristic in all AD patients. Since the 
eighties, the majority of the investigations carried on AD have been focused on 
drug development in the context of this hypothesis; nevertheless, the extended 
efforts made in searching for effective therapies focused on this target have 
repeatedly failed.152 The difficulty in finding effective therapies based on this 
hypothesis, together with other controversial aspects such as the unsolved 
dilemma of whether Aβ is one of the causes or one of the risk factors for AD, and 
the not so strong correlation between the presence of Aβ deposits and some 
clinical manifestations in AD patients, prompted the scientific community to 
investigate additional pharmacological targets. Thus, at the end of the past 
century, a new theory for AD etiology was postulated: the tau hypothesis, based 
on the aberration of a microtubule-associated protein (MAP) called tau that is 
particularly abundant in the CNS and whose main physiological function is the 
stabilization of the neuronal cytoskeleton.153  
6.1.2 Tau protein, NFTs and glycogen synthase kinase-3β (GSK-3β) 
In physiological conditions tau helps to regulate microtubule dynamics and	   to 
promote their stability; conversely, in the pathological state tau undergoes post-
translational modifications that result in its dissociation from microtubules. 
Among these modifications, the most important one is certainly the 
hyperphosphorylation of the protein that elicits the formation of filamentous 
inclusion and tau aggregation in NFTs that, together with the senile plaques, 
constitute the classical aberrant structures present in AD patients.154  
                                                
151 Birks J. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005593. DOI: 
10.1002/14651858.CD005593. 
152 Hardy, J.; Selkoe, D. J. Science, 2002, 297, 353-356. 
153 Giacobini, E.; Gold, G. Nat. Rev. Neurol. 2013; 9, 677-686. 
154 (a) Johnson, G. V. W.; Hartigan, J. A. J. Alzheimers Dis. 1999, 1, 329-351; (b) Avila, J. FEBS Lett. 
2006, 580, 2922-2927. 
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In recent years different studies reported a tight connection between the two 
characteristic pathological features present in AD patients,155 but if on one hand it 
seems clear that Aβ requires the presence of tau to induce neurodegeneration, on 
the other hand the existence of several taupathies (different from AD) that lack the 
Aβ component, suggested tau as a new tangible therapeutic target in 
neurodegenerative diseases.156 
Tau phosphorylation is regulated by a fine equilibrium between the activities of 
tau kinases and phosphatases; a disruption of the physiological stability toward 
the former ones, leads to a hyperphosphorylation of tau that decreases its 
flexibility and its affinity for microtubules determining the formation of NTFs and 
subsequently the neurodegeneration. Among the numerous kinases implicated in 
this post-translational control of tau, one of the most important and relevant is the 
glycogen synthase kinase-3β (GSK-3β).  
GSK-3β, together with GSK-3α, represents one of the two GSK-3 isoforms 
existing in mammalians; they are encoded by two different genes and are 
ubiquitously expressed, however they are not similar in terms of functionality, 
considering that neither can compensate the deficiency of the other one. Although 
the exact functional distinction has to be still exactly established, it is clear that 
their activities are modulated by insulin and Wnt signaling and that they regulate 
many cellular processes by	  controlling different signaling pathways; interestingly 
their dysregulations are involved in the development of cancer, diabetes, AD and 
bipolar disorders.157 
Recently, several data suggest that these kinases, and especially GSK-3β, play a 
pivotal role in the etiopathogenesis of AD, leading to the postulation of the GSK-3 
hypothesis of AD.158 More in detail, besides being directly involved in the 
hyperfosforilation of tau, GSK-3β has been proposed also as a molecular linker 
between Aβ and tau,159 and as a player in choline metabolism, having therefore a 
                                                
155 Ittner, L. M.; Götz, J. Nat. Rev. Neurosci. 2011, 12, 67-72. 
156 Himmelstein, D. S.; Ward, S. M.; Lancia, J. K.; Patterson, K. R.; Binder, L. I. Pharmacol. Ther. 
2012, 136, 8-22. 
157 For an overview see the review and the references inside: Beurel, E.; Grieco, S. F.; Jope, R. S.  
Pharmacol. Ther. 2015, 148, 114-131. 
158 (a) Hooper, C.; Killick, R.; Lovestone, S. J. Neurochem. 2008, 104, 1433-1439; (b) Medina, M.; 
Ávila, J. Expert Opin. Ther. Targets 2014, 18, 69-77. 
159 Llorens-Martin, M.; Jurado, J.; Hernández, F.; Ávila, J. Front. Mol. Neurosci. 2014, 7, 46.  
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role also in the mechanism leading to the alteration of the cholinergic system 
characteristic of AD.160 Moreover there is no doubt about an upregulation of 
GSK-3β in the brains of AD patients, highlighting the undoubted participation of 
this kinase in the progression of this neurodegenerative process.161 In addition, it 
has been also shown that GSK-3β is a key mediator of apoptosis, taking part 
therefore in the mechanism involved in the neuronal loss in AD.162  
For these reasons, in the last years, GSK-3β has emerged as a promising 
therapeutic target against AD and various taupathies.163 
6.1.3 Oxidative damage in AD and the Nrf2-ARE pathway  
In recent years an increasing body of evidence indicates that oxidative stress, 
besides increasing with the age, is clearly involved in the pathogenesis and 
evolution of a number of neurological disorders.164 This	  phenomenon arises from 
an imbalance between an excessive production of reactive oxygen and nitrogen 
species (ROS and RNS respectively) and antioxidant defenses. Although ROS 
generation is a physiological event that takes part in the normal functioning of the 
cytosolic signaling system, it has to be strictly controlled because an abnormally 
increased ROS production leads to irreparable cellular damages such as lipid 
peroxidation and to macromolecular oxidation processes involving proteins and 
nucleic acids. These phenomena are even more harmful in the brain, where the 
elevated energy demand, the high oxygen consumption, the high content of redox-
active transition metal ions such as Fe2+ and Cu+ (that exacerbate ROS production 
via the Fenton reaction)165 and the relative lack of antioxidant enzymes, make its 
tissues highly susceptible to the oxidative imbalances and extremely prone to 
                                                
160 Samadi, A.; Valderas, C.; de los Ríos, C.; Bastida, A.; Chioua, M.; González-Lafuente, L.; 
Colmena, I.; Gandía, L.; Romero, A.; del Barrio, L.; Martín-de-Saavedra, M. D.; López, M. G.; 
Villarroya, M.; Marco-Contelles, J. Bioorg. Med. Chem. 2011, 19, 122-133. 
161 Leroy, K.; Yilmaz, S.; Brion, J. P. Neuropathol. Appl. Neurobiol. 2007, 33, 43-55. 
162 Mines, M. A.; Beurel, E.; Jope, R. S. Int. J. Alzheimers Dis. 2011, 2011, 861072. 
163 Martín, L.; Latypova, X.; Wilson, C. M.; Magnaudeix, A.; Perrin, M.-L.; Yardina, C.; Terro, F. 
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permanent damages.166 In particular, it has been demonstrated that the oxidative 
stress derived from the initiation and the abnormal propagation of ROS generation 
plays a major role in the pathogenesis and the progression of AD.167 Moreover, in 
recent years, some studies suggest that the oxidative stress is not only a 
consequence of the primary AD cascade of events, but could be also involved in 
the initial onset of AD,168 even in the preliminary phase known as mild cognitive 
impairment (MCI), when the senile plaques and the neurofibrillary tangles are not 
yet so evident.169 Another interesting evidence is that oxidative	   stress and Aβ 
seem to be linked in a downward spiral, with oxidative stress exacerbating the Aβ 
toxicity while Aβ increases oxidative stress.170 
To counteract the harmful effects of ROS/RNS and stabilize the redox imbalance 
generated in the oxidative stress, cells employ an endogenous antioxidant defense 
system composed of numerous detoxifying enzymes. The nuclear factor erythroid 
2-related factor (Nrf2)/antioxidant response element (ARE) transcriptional 
pathway represents the primary sensor to oxidative stress and the most important 
mechanism to reduce the detrimental effects of oxidant species.171 Nrf2 is a 
cap’n’collar (CNC) basic-region leucine zipper transcription factor that, by 
                                                
166 (a) Chong, Z. Z.; Li, F.; Maiese, K. Prog. Neurobiol. 2005, 75, 207–246; (b) Dasuri, K.; Zhang, 
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binding to ARE (an enhancer element) in the nucleus, promotes the transcription 
of detoxifying phase II enzymes such as NADPH quinone oxidoreductase 1 
(NQO-1), glutathione peroxidase (GPX), glutathione transferase (GST), catalase, 
superoxide dismutase (SOD), N-acyltransferase (NAT) and heme oxygenase 1 
(HO-1).172 
Under basal condition, Nrf2 is located in the cytoplasm where it is negatively 
controlled by the kelch-like ECH-associated protein 1 (Keap1) that prevents Nrf2 
translocation to the nucleus and promotes its rapid degradation (half life ≈ 20 min) 
by the ubiquitin proteasome system (UPS).173 Under conditions of oxidative stress 
such as the presence of ROS, reactive electrophiles or ARE inducers, some highly 
reactive cysteine residues of Keap1 are alkylated or oxidized to cystine, 
generating aconformational change in Keap1 leading to the release of Nrf2 and to 
its rapid translocation to the nucleus. Once in the nucleus, Nrf2 forms a 
heterodimer with its partner small Maf protein and then binds to ARE in the 
promoter region of antioxidant genes, initiating their transcription (Figure 6.1).174  
 
 
Figure 6.1: Activation mechanism of Nrf2/ARE pathway 
  
                                                
172 Zhang, M.; An, C.; Gao, Y.; Leak, R. K.; Chen, J.; Zhang, F. Prog. Neurobiol. 2013, 100, 30-47. 
173 Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; O’Connor, T.; Yamamoto, M. Genes Cells 2003, 
8, 379-391. 
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6.1.4 Interference with the Nrf2-ARE pathway: A new potential 
therapeutic approach to AD treatment? 
In view of the tight connection between oxidative stress and the pathogenesis of 
AD, in recent years the Nrf2-ARE pathway has been extensively studied to 
evaluate if its eventual dysregulation could be involved in the evolution of this 
neurodegenerative disease.  
An interesting study published by Ramsey et al in 2007 revealed that, differently 
from normal age-matched controls, in hippocampal neurons of AD patients, Nrf2 
is predominantly cytoplasmic without being translocated into the nucleus. 
Interestingly, it was also demonstrated that there was no difference between the 
cytoplasmic levels of Nrf2 in AD patients and the age-matched control cases, 
suggesting that the nuclear deficit in AD was not a result of a generalized loss of 
Nrf2, but just a disruption of the mechanism of nuclear localization.175 Thus this 
study suggests that the Nrf2/ARE pathway is impaired in AD and that could be 
involved in the progression of the pathology. 
In this context, the role of Nrf2/ARE pathway as a valuable pharmacological 
target for the treatment of AD has been investigated.176 Recent in vitro studies 
have shown that the activation of Nrf2 has a protective effect against the toxicity 
induced by Aβ;177 furthermore, an in vivo experiment of an intrahippocampal 
release of the gene expressing Nrf2 has shown cognitive improvement in a mouse 
model of AD.178 In another recent and very interesting study it was also shown 
that the Nrf2 pathway takes part also in the reduction of levels of phosphorylated 
tau by inducing a mechanism of autophagy in neurons, suggesting therefore an 
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H.; Yamamoto, M.; Yla-Herttuala, S.; Levonen, A. L.; Koistinaho, J. Mol. Cell Neurosci. 2008, 39, 
302–313; (b) Lee, C.; Park, G. H.; Lee, S. R.; Jang, J. H. Oxid. Med. Cell. Longev. 2013, 2013, 
313510; (c) Karkkainen, V.; Pomeshchik, Y.; Savchenko, E.; Dhungana, H.; Kurronen, A.; 
Lehtonen, S.; Naumenko, N.; Tavi, P.; Levonen, A.-L.; Yamamoto, M.; Malm, T.; Magga, J.; 
Kanninen, K. M.; Koistinaho, J. Stem cells 2014, 32, 1904–1916. 
178 Kanninen, K.; Heikkinen, R.; Malm, T.; Rolova, T.; Kuhmonen, S.; Leinonen, H.; Yla-Herttuala, 
S.; Tanila, H.; Levonen, A.-L.; Koistinaho, M.; Koistinaho, J. Proc. Natl. Acad. Sci. USA 2009, 106, 
16505–16510  
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additional protective role against tau-induced toxicity.179 
6.1.5 Linking the Nrf2-ARE pathway to the activity of glycogen 
synthase kinase-3β in AD 
GSK-3β is a ubiquitous enzyme with prevalent brain distribution that has a critical 
central role in various signaling pathways 180  and, as already mentioned in 
Paragraph 6.1.2, its dysregulation is associated with multiple neuropathological 
mechanisms involved in AD. Interestingly, in the last decade it has been 
demonstrated that GSK-3β is also implicated in the regulation of Nrf2, thereby 
underscoring another possible connection with the pathological pathways leading 
to the AD.  
The activity of GSK-3β regulates in a negative manner the subcellular distribution 
of Nrf2, by promoting its cytosolic distribution through two different mechanism 
of control: (a) by fostering Nrf2 exclusion from the nucleus or (b) by preventing 
the translocation of Nrf2 to the nucleus. In a model of prolonged oxidative stress, 
that can simulate the pathological conditions in AD, the activation of GSK-3β 
results in the extrusion of Nrf2 from the nucleus; conversely, the inhibition of 
GSK-3β reverts the situation and promotes the nucleus accumulation of Nrf2 and 
the activation of the ARE transcription.181 Although the exclusion of Nrf2 from 
the nucleus was initially supposed to depend on its direct phosphorylation by 
GSK-3β, 182 it was later demonstrated that the Nrf2 phosphorylation is actually 
mediated by the tyrosine kinase Fyn that is, in turn, activated by GSK-3β.183 A 
very recent study has revealed that GSK-3β prevents the Nrf2 translocation to the 
nucleus also by phosphorylating Nrf2 when is located in the cytoplasm; in this 
                                                
179 Jo, C.; Gundemir, S.; Pritchard, S.; Jin, Y. N.; Rahman, I.; Johnson, G. V. W. Nat. Commun. 
2014, 5, 3496. 
180 Grimes, C. A.; Jope, R. S. Prog. Neurobiol. 2001, 65, 391-426. 
181 (a) Rojo A. I.; de Sagarra, M. R.; Cuadrado, A. J. Neurochem. 2008, 105, 192-202; (b) Rojo, A. 
I.; Rada, P.; Egea, J.; Rosa, A. O.; López, M. G.; Cuadrado, A. Mol. Cell. Neurosci. 2008, 39, 125–
132. 
182 Salazar, M.; Rojo, A. I.; Velasco, D.; De Sagarra, R. M.; Cuadrado, A. J. Biol. Chem. 2006, 281, 
14841–14851. 
183 (a) Jain, A. K.; Jaiswal, A. K. J. Biol. Chem. 2006, 281, 12132–12142; (b) Jain, A. K.; Jaiswal, A. 
K. J. Biol. Chem. 2007, 282, 16502-16510. 
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case the phosphorylation takes place on a degron of Nrf2, promoting its 
degradation by the proteasome.184   
The analysis of these data suggests, therefore, that an increased activation of 
GSK-3β results in a drop of the protective effects promoted by the Nrf2-	  ARE 
pathway; consequently the inhibition of GSK-3β could potentially represent a 
useful therapeutic strategy to restore the protective cellular response to the 
oxidative damage. 
6.2. GLYCOGEN SYNTHASE KINASE-3β INHIBITORS FOR THE 
TREATMENT OF ALZHEIMER’S DISEASE 
The increasing evidence that an overactivation of GSK-3β has a role in various 
pathological mechanisms involved in the progression of the AD, together with the 
consideration that our organism is not able to downregulate this kinase, has 
generated a lot of interest in the search for molecules that could have a therapeutic 
effect by downregulating GSK-3β and thus restoring its functionality to the 
physiological one.185 The validation of this theory seems to be supported by the 
promising results obtained in various animal AD models where the use of GSK-
3β inhibitors or the specific genetic knockdown of this kinase lead to an 
improvement of the cognitive impairments and to an attenuation of the 
neuropathology in the animal models. Moreover, these auspicious data in mouse 
models were supported by the evidence that epidemiological studies in human 
patients with bipolar disorders treated with lithium (the first GSK-3β inhibitor 
discovered),186 showed a reduced tendency to develop AD and a reduced rate of 
dementia if compared with bipolar patients treated with different drugs. 
Nevertheless, to date, apart from lithium, only a limited number of GSK-3β 
inhibitors has reached the clinical phase, and thus the development of new GSK-
3β inhibitors represents a very attractive goal in the treatment of AD.187 
                                                
184 Chowdhry, S.; Zhang, Y.; McMahon, M.; Sutherland, C.; Cuadrado, A.; Hayes, J. D. Oncogene 
2013, 32, 3765-3781. 
185 Martínez, A.; Gil, C.; Pérez, D. I. Int. J. Alzheimers Dis. 2011, 2011, 280502. 
186 Ryves, W. J.; Harwood A. J. Biochem. Biophys. Res. Comm. 2001, 280, 720-725. 
187 (a) Arfeen, M.; Bharatam, P. V. Curr. Pharm. Des. 2013, 19, 4755-4775; (b)King, M. K.; Pardo, 
M.; Cheng, Y.; Downey, K.; Jope, R. S.; Beurel, E. Pharmacol. Ther. 2014, 141, 1-12. 
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We can classify the various typologies of GSK-3β inhibitors in different 
categories, depending on the inhibition mechanism: (a) inhibition by metal (b) 
inhibition at the ATP binding site, (c) inhibition at the non-ATP binding site, (d) 
peptide like inhibitors.	   The inhibition by metal is strictly related to the 
competition between the metal and the Mg2+ ions that in many kinases are 
responsible for the binding of ATP in its pocket. Lithium represents the best-
known inhibitor of this category and its activity depends also on an indirect 
increase in the phosphorylation at Ser9. 
The ATP competitive inhibitors are surely the most extensively studied and are 
usually organized in two generations: the first one is composed prevalently by 
natural compounds like paullone188 and staurosporine189 (among others); on the 
other hand, the second generation is prevalently formed by small synthetic 
molecules resulting from numerous studies addressed to find, beyond inhibitory 
activity, also high selectivity for GSK-3β over other kinases. Many inhibitors 
belonging to the second generation show common structural features such as aryl-
substituted heterocyclic cores like heteroaryl-pyrazolo[3,4-b]pyridine, 190  3-(7-
azaindolyl)-4-arylmaleimides 191 , [1,3,4]-triazole, 192  heteroarylpyrazine, 193 
dipyrrolo- furopyrrolopyrazinones194 derivatives (Figure 6.2). 
 
                                                
188 Leost, M.; Schultz, C.; Link, A.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. 
L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; 
Meijer, L. Eur. J. Biochem. 2000, 267, 5983-5994.  
189 Toledo, L. M.; Lydon, N. B. Structure 1997, 5, 1551-1556.  
190 Witherington, J.; Bordas, V.; Gaiba, A.; Naylor, A.; Rawlings, A. D.; Slingsby, B. P.; Smith, D. G.; 
Takle, A. K.; Ward, R. W. Bioorg. Med. Chem. Lett. 2003, 13, 3059-3062.  
191 Zhang, H.-C.; Ye, H.; Conway, B. R.; Derian, C. K.; Addo, M. F.; Kuo, G.-H; Hecker, L. R.; Croll, 
D. R.; Li, J.; Westover, L.; Xu, J. Z.; Look, R.; Demarest, K. T.; Andrade-Gordon, P.; Damiano, B. P.; 
Maryanoff, B. E. Bioorg. Med. Chem. Lett. 2004, 14, 3245-3250.  
192 Olesen, P. H.; Sorensen, A. R.; Urso, B.; Kurtzhals, P.; Bowler, A. N.; Ehrbar, U.; Hansen, B. F. J. 
Med. Chem. 2003, 46, 3333-3341.  
193 Berg, s.; Bergh, M.; Hellberg, S.; Högdin, K.; Lo-Alfredsson, Y.; Söderman, P.; von Berg, S.; 
Weigelt, T.; Ormö, M.; Xue, Y.; Tucker, J.; Neelissen, J.; Jerning, E.; Nilsson, Y.; Bhat, R. J. Med. 
Chem. 2012, 55, 9107−9119 
194 Rochais, C.; Duc, N. V.; Lescot, E.; Sopkova-de Oliveira Santos, J.; Bureau, R.; Meijer, L.; 
Dallemagne, P.; Rault, S. Eur. J. Med. Chem. 2009, 44, 708-716.  
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Figure 6.2: Examples of ATP competitive inhibitors of GSK-3β 
 
The catalytic triad (see later) seems to be another valuable target for the inhibition 
of GSK-3β; inhibitors acting at this site are not ATP-competitive and prevent the 
proper orientation of the substrate in the substrate-binding site. To date a set of 
thiadiazole derivatives are the only reported inhibitors (Figure 6.3A),195 but the 
postulation of this kind of inhibition still needs to be verified. 
Peptide-like inhibitors also compete with substrate preventing its binding in 
catalytic site of the GSK-3β (Figure 6.3B). In the last decade some small peptides 
have shown interesting preclinical result, although their poor pharmacokinetic 
characteristics make their pharmacological development problematic.196 
                                                
195 (a) Martínez, A.; Alonso, M.; Castro, A.; Pérez, C.; Moreno, F. J. J. Med. Chem. 2002, 45, 1292-
1299; (b) Palomo, V.; Pérez, D. I.; Pérez, C.; Morales-García, J. A.; Soteras, I.; Alonso-Gil, S.; 
Encians, A.; Castro, A.; Campillo, N. E.; Pérez-Castillo, A.; Gil, C.; Martínez, A. J. Med. Chem. 
2012, 55, 1645-1661.   
196 (a) Plotkin, B.; Kaidanovich, O.; Talior, I.; Eldar-Finkelman, H. J. Pharmacol. Exp. Ther. 2003, 
305, 974-980; (b) Eldar-Finkelman, H.; Eisenstein, M. Curr. Pharm. Des. 2009, 15, 2463−2470. 
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Figure 6.3: Thiadiazoles not ATP-competitive inhibitors of GSK-3β (A) and peptide-like 
inhibitors of GSK-3β (B) 
 
Thus we decided to design a new family of compounds that shares some some 
structural features with some known GSK-3β inhibitors such as PP1-PP2197or 
PP3198 and whose synthesis could be achieved via a multicomponent process 
(Figure 6.4). 
 
 
Figure 6.4: Design of compounds sharing structural features with some known GSK-3β 
inhibitors 
 
                                                
197 (a) Kim, H.-J.; Choo, H.; Cho, Y. S.; No, K. T.; Pae, A. N. Bioorg. Med. Chem. 2008, 16,636-643; 
(b) Kohara, T.; Fukunaga, K.; Masatake, F.; Hanano, T.; Okabe, H. Patent U.S. 6977262B2.  
198 Chioua, M.; Samadi, A.; Soriano, E.; Lozach, O.; Meijer, L.; Marco-Contolles, J. Bioorg. Med. 
Chem. Lett. 2009, 19, 4566-4569. 
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In an attempt to achieve a better understanding of the possible interactions 
between our compounds and the residues located at the catalytic site of GSK-3β, 
we carried out also some molecular modeling studies. Before going into the 
details of the computationally-driven approach employed for the calculation of the 
affinity between our compounds and the binding site of GSK-3β, hereunder is 
reported a brief description of the structure of GSK-3β and of its regulation 
mechanism. 
 
In the last decade, the elucidation of the crystal structure of GSK-3β has allowed 
the use of structure-based drug design strategies for predicting the behavior of 
newly designed inhibitors of the kinase. GSK-3β is a homodimer and each 
monomer is composed of a small N-terminal lobe, formed prevalently of β-sheets, 
and of a C-terminal lobe constituted of α-helices and loops. Regarding the 
possible interaction with ligands, there are two interesting pockets: the catalytic 
domain (the ATP binding site), located between the two lobes and bordered by the 
glycine-rich loop, and a pocket formed by a catalytic triad (Arg96, Arg180 and 
Lys205), situated on the interface of the two lobes, in the activation loop of the 
kinase (residues 200-226) (Figure 6.5).199 
 
Figure 6.5: Ribbon representation of GSK-3β (a) and the pocket formed by the catalytic triad (b) 
 
                                                
199 (a) Dajani, R.; Frase, E.; Roe, S. M.; Young, N.; Good, V.; Dale, T. C.; Pearl, L. H. Cell 2001, 105, 
721-732; (b) ter Haar, E.; Coll, J. T.; Austen, D. A.; Hsiao, H.-M.; Swenson, L.; Jain, J. Nat. Struct. 
Biol. 2001, 8, 593-596. 
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Regarding the functionality of GSK-3β, there are two phosphorylation sites that 
regulate its activity: (a) Ser9, located at the N-terminal domain; when this residue 
is phosphorylated by Akt/PKB, the protein becomes inactivated due to blocked 
access of the substrate to the catalytic domain. (b) Tyr216, located in the 
activation loop, that moves out the binding site when phosphorylated, allowing 
the entrance of the substrate and increasing the activity of GSK-3β by >200-fold. 
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6.3 SYNTHESIS OF A LIBRARY OF 1,4-DIHYDROPYRANO[2,3-c] 
PYRAZOLE DERIVATIVES 
6.3.1 Initial study of the reaction 
The proposed retrosynthetic approach relied on the reaction between an aromatic 
aldehyde, malononitrile and a pyrazolone to build a pyridine ring. Interestingly, 
an article published in 2010 by Mohanmed and coworkers reported a 
multicomponent approach to our target pyrazolopyridine derivatives based on a 
protocol that, depending on the reaction conditions, led either to the 
pyranopyrazole or to the pyrazoloropyridine nucleus in chemodivergent fashion 
(Scheme 6.1).200 This approach was attractive for our purposes, since it allowed 
generating greater molecular diversity in an easy way. 
 
 
Scheme 6.1: The multicomponent approach to pyrazolopyridine reported by Mohanmed200 
 
Thus we started the study of the reaction employing 5-methylpyrazol-3-one 
(previously synthesized by condensation between hydrazine and ethyl 
acetoacetate), benzaldehyde and malononitrile as starting materials. We carried 
out the reaction under both conditions described in the published procedure in 
order to get the two target families of compounds, but unexpetedly, in both cases 
the reaction afforded the same product. After a spectroscopic analysis and a 
comparison with data described in literature,201 we could confirm that the product 
obtained was the	  pyranopyrazole 110 (Scheme 6.2). 
 
                                                
200 Mohamed, N. R.; Khaireldin, N. Y.; Fahnmy, A. F.; El-Sayed, A. A. Der Pharma Chem. 2010, 2, 
400-417. 
201 Lehmann, F.; Holm, M.; Laufer, S. J. Comb. Chem. 2008, 10, 364-367. 
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Scheme 6.2: Initial study of the three-component reaction 
 
6.3.2 Scope of the reaction 
As this kind of product represented one of our target molecules, we decided 
anyway to explore the scope of this reaction employing a variety of aromatic 
aldehydes that allowed structural variations at C-4. As in the initial model 
experiments, the use of ammonium acetate allowed a good yield (86%), better 
than the one obtained by using piperidine (64%) and, considering that this 
multicomponent protocol was already known in the literature, we decided to 
explore the scope of the reaction without any further optimization studies 
(Scheme 6.3 and Table 6.1). 
 
 
Scheme 6.3: Scope of the three-component synthesis of pyrano[2,3-c]pyrazoles 110-129 
 
As shown in the Table 6.1, the reaction normally proceeded in good to excellent 
yields, tolerating well the presence of either electron-withdrawing or electron-
releasing groups at the aldehyde aromatic ring. 
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Table 6.1. Yield and scope for the synthesis of pyrano[2,3-c]pyrazoles 110-129 
Entry Cmpd. Ar 
Yield 
(%) 
 
Entry Cmpd. Ar 
Yield 
(%) 
1 110 C6H5 86  11 120 2-MeC6H4 88 
2 111 2-ClC6H4 85  12 121 3-MeC6H4 84 
3 112 3-ClC6H4 77  13 122 4-MeC6H4 81a 
4 113 4-ClC6H4 88  14 123 2-MeOC6H4 87 
5 114 2-BrC6H4 82  15 124 3-MeOC6H4 83 
6 115 4-BrC6H4 92  16 125 4-MeOC6H4 71 
7 116 4-FC6H4 73  17 126 3-pyridyl 85 
8 117 2-NO2C6H4 94  18 127 4-pyridyl 84 
9 118 3-NO2C6H4 91  19 128 2-furyl 83 
10 119 4-NO2C6H4 93  20 129 2-thienyl 78 
a Reaction time: 1h 
 
As shown in the Table 6.1, the reaction normally proceeded in good to excellent 
yields, tolerating well the presence of either electron-withdrawing or electron-
releasing groups at the aldehyde aromatic ring. Under the standard reaction 
conditions, the reaction with 4-methylbenzaldehyde initially did not afford the 
expected product 122, but only a complex mixture of compounds that we were not 
able to purify. Thus, in an attempt to better understand the reason for this different 
conduct, we decided to investigate the reaction involving 4-methylbenzaldehyde 
in more detail (Scheme 6.4). In particular, we initially simplified the protocol by 
forming the previously the Knoevenagel adduct 131 between the aldehyde and 
malononitrile and submitting this compound to the subsequent reaction with 
pyrazolone 109. Also in this case, our standard conditions led to the same 
complex mixture obtained in the multicomponent process. We decided therefore 
to go ahead in this study by resorting to a further simplification of the protocol 
and we decided therefore to examine the cyclization process of the proposed	  
intermediate 133, synthesized according to a literature method.202 Interestingly, 
when we studied the ring closure of this intermediate under our standard 
conditions, we realized that the formation of the expected product was very fast, 
                                                
202 Elinson, M. N.; Nasybullin, R. F.; Nikishin, G. I. C. R. Chim. 2013, 16, 789-794. 
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being complete in 1 hour, while a complex mixture of compounds was obtained 
when the cyclization process of 133 was performed under our conditions for 5 
hours. In view of this outcome, we went back to repeat our three-component 
reaction employing a shorter time and we were pleased to notice that, by this 
simple modification, our protocol allowed the formation of the expected product 
122 (entry 13).  
 
 
Scheme 6.4: Study of the reaction involving 4-methylbenzaldehyde 
 
To introduce further structural diversity in the 1,4-dihydropyrano[2,3-c]pyrazole 
derivatives, we synthesized also compounds bearing heterocyclic moieties at the 
C-4 position (compounds 126-129, entries 17-20). Interestingly, the reaction 
involving pyridinecarboxaldehydes afforded two different kinds of products 
depending on the nitrogen position in the aromatic ring of the aldehyde. Thus, 
when 3- and 4-pyridinecarboxaldehydes were used as starting materials, the 
reaction afforded the corresponding expected 1,4-dihydropyrano[2,3-c]pyrazole 
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(compounds 126 and 127, entries 17-18); on the other hand, when the reaction 
was performed employing 2-pyridinecarboxaldehyde, we were isolated a 
different. After its spectroscopic analysis, we identified its structure as 134, which 
ensued from a competitive nucleophilic addition of the pyridine nitrogen onto one 
of the cyano groups of the dinitrile fragment (Scheme 6.5). We confirmed that this 
kind of reactivity is congruent with one described in a recent paper published by 
Li’s group where a one-pot multistep synthesis of 3-aminoindolizines is 
described.203 
 
 
Scheme 6.5: Study of the reaction involving 2-pyridinecarboxaldehyde 
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6.4 MECHANISTIC PROPOSAL 
Before undertaking the synthesis of the alternative 4,7-dihydropyrazolo[3,4-
b]pyridine derivatives, we decide to focus our attention on the reaction 
mechanism, in an attempt to elucidate the overall synthetic pathway leading to 
both the fused bicyclic structures, and how to manage it toward the synthesis of 
the desired compound. 
Our starting point in the mechanistic investigation was to consider compound 132 
as the inmediate precursor for the final ring closure, and therefore we chose to 
explore two possible sequential synthetic pathways leading to this key 
intermediate. Our first proposal (Scheme 6.6, pathway A) was based on the 
sequence of reactions already planned for the study of the synthesis of 122. Thus, 
we proceeded to the formation of the Knoevenagel adduct 130 starting from 
benzaldehyde and malononitrile under two different reaction conditions: in the 
presence of ammonium acetate in refluxing ethanol (our established conditions) 
and with piperidine in refluxing ethanol (the other conditions published by 
Mohanmed).200 Both reactions led to the expected intermediate 130 that 
subsequently was treated with the pyrazolone 109, under the two above-described 
conditions. In both cases, the desired product 110 was formed, validating the 
results obtained in the initial multicomponent study of our protocol (Paragraph 
6.3.1, Scheme 6.2). In order to corroborate the viability of this synthetic pathway, 
we also synthesized intermediate 132, which was subsequently submitted to the 
cyclization process under the two experimental conditions previously 
investigated. Also in this case, both conditions afforded the expected product 110, 
confirming the feasibility of the proposed synthetic sequence. 
Considering the nucleophilic character of C-4 of pyrazolone 109, we decided to 
investigate also its addition to the carbonyl group of the benzaldehyde as the 
primary event of the multicomponent process (Scheme 6.6, pathway B). Also in 
this case the reaction between 109 and benzaldehyde was carried out under both 
the experimental procedures employed in our mechanistic study; however, the 
formation of the	   Michael-like compound I did not occur in none of our 
experimental conditions, probably because this kind of reaction requires harsher 
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conditions (higher temperatures and longer reaction times).204  
In view of these results we are prone to consider pathway A as the most probable 
one for the formation of the 1,4-dihydropyrano[2,3-c]pyrazole nucleus. 
 
 
Scheme 6.6: Mechanistic study of the three-component reaction 
 
  
                                                
204 Ahmed, M; Sharma, R, Nagda, D. P.; Salvi, V. K.; Talesara, G. L. E-J. Chem. 2006, 3, 28-34. 
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6.5 SYNTHESIS OF A LIBRARY OF 4,7-DIHYDRO-1H-PYRAZOLO[3,4-
b]PYRIDINE DERIVATIVES 
6.5.1 Initial study of the reaction and optimization  
Our next goal was to achieve the multicomponent synthesis of 4,7-dihydro-1H-
pyrazolo[3,4-b]pyridine compounds. We reasoned that the easiest way to 
construct this bicyclic nucleus, was to convert the pyrazolone 109 into the 
corresponding pyrazolamine I, incorporating in this way the nitrogen required for 
the formation of the pyridine nucleus. It should be possible to achieve this goal 
simply by converting the carbonyl group into an enamine by reaction with an 
ammonia source (Scheme 6.7). This conversion, the same published in the above-
mentioned literature precedent,200 would have allowed reaching the attractive goal 
of chemodivergence, i.e., obtaining different products from the same starting 
materials under different experimental conditions. 
Considering ammonium salts to be the most practical ammonia sources for the 
conversion of a carbonyl group into an enamine, we decided to explore once again 
the reaction initially investigated, trying to force the conditions in order to get the 
desired transformation. Thus, to drive the reaction towards the formation of the 
nitrogen nucleus, we attempted the following modifications: (a) carrying out the 
multicomponent process in the presence of a large excess of ammonium acetate 
(10 equiv., Scheme 6.7, A); (b) performing the reaction in the presence of 4Å 
molecular sieves to assist the removal of water arising from the reaction between 
the carbonyl group and the ammonia (Scheme 6.7, B); (c) performing the reaction 
in a sequential manner (Scheme 6.7, C). Unfortunately all these attempts led again 
to the formation of the 1,4-dihydropyrano[2,3-c]pyrazole derivative 110, 
demonstrating how difficult was this apparently easy conversion. Finally, in a last 
effort to reach the required transformation, we tried to perform a reaction just 
between the pyrazolone 109 and a large excess of ammonium acetate (10 equiv.), 
again in the presence of 4Å molecular sieves and in refluxing ethanol (the	  
experimental conditions employed in our multicomponent process); 
disappointingly, not even in this case we were able to get the target pyrazolamine 
I (Scheme 6.7, D).  
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Scheme 6.7: Attempts for the conversion of pyrazolone 109 in its corresponding pyrazolamine I 
 
In view of these experimental evidences, we decided to move our attention to the 
direct use of the pyrazolamine I as starting material in the multicomponent 
process with benzaldehyde and malononitrile (Scheme 6.8).  
 
 
Scheme 6.8: Initial study of the three-component reaction involving the pyrazolamine I 
 
As shown in Table 6.2, the first attempts were performed simply by mixing the 
three starting materials in ethanol at different temperatures; as shown in entries 1-
4, heating was necessary to obtain compound 135, the best	  option being the use of 
refluxing ethanol for 16 hours (yield 27%, entry 4). In an attempt to improve the 
yield of the reaction we began to investigate the effect of different promoters. 
Initially, as we supposed that the formation of the dihydropyridine ring could be 
facilitated by a basic medium, we examined the action of different organic bases 
(entries 5-8) without getting any traces of the desired product. Mindful of the role 
of ammonium acetate in our precedent protocol, we decided to try the effect of 
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this salt as promoter. We were pleased to notice that the use of 1.0 equivalent of 
ammonium acetate could foster the formation of product 135, even though in a 
modest yield (18%, entry 9), and interestingly, when the reaction time was 
increased, a better yield could be achieved (entries 10-11). These results prompted 
us to study in more depth if the effect of this salt was related to any of its two 
ions. Thus we performed two reactions employing two salts, each one containing 
one of the ions of ammonium acetate: ammonium chloride and sodium acetate 
(entries 12-13). Remarkably these two experiments did not afford the expected 
product, revealing that the effect of the ammonium acetate was not depending on 
the nature of its singular ions, but on some other aspect. We thought therefore that 
the accelerating effect of this salt could be attributed to the in situ formation of 
acetic acid from partial hydrolysis of the salt. As shown in entries 14 and 15, 
investigating directly the effect of the acetic acid in the reaction, we were gratified 
to observe that we could get the formation of the desired product in similar yields 
to the ones obtained in the same conditions with ammonium acetate (16% and 
38% against 18% and 44%). Reducing the amount of acetic acid from 1.0 to 0.25 
equivalents was detrimental for the yield, denoting a better result when the 
promoter was used in stoichiometric quantity (entry 16). The complementary 
effect of the ammonium and the acetate was confirmed later in the experiment 
performed mixing two salts containing individually each one of both ions 
composing ammonium acetate (ammonium chloride and sodium acetate): in this 
case it was possible to detect the formation of the product 135, although it was 
impossible to calculate exactly the yield because of the co-precipitation of the 
NaCl formed during the purification	   process, which was not easy to remove 
owing to the high polarity of our compound (entry 17). Our next interest was 
focused on investigating other Brønsted acids as promoters: as shown by the 
entries 18-20, only benzoic acid was able to promote efficiently the reaction 
leading to the desired product 135 (entry 18). As benzoic acid appeared to afford a 
better yield than ammonium acetate in a comparable reaction time (5 hours), we 
tried to use the same promoter for longer times, resulting however in an overall 
reduction of the yield (compare entries 11 and 21). Also, a reduction in the 
amount of benzoic acid (from 1.0 to 0.25 equivalent) resulted in a corresponding 
drop in the yield (entry 22). As ammonium acetate emerged as the best promoter 
for our protocol, at a later stage we decided to investigate also the effect of the 
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solvent in the reaction, and ethanol revealed to be the best option (entries 9 and 
23-27).  
 
Table 6.2. Optimization study for synthesis of 4,7-dihydro-1H-pyrazolo[3,4-b]pyridines 
Entry Solv. Temp. 
Time 
(h) 
Promoter 
(equiv.) 
Yield 
(%) 
1 EtOH rt 16 - No 
2 EtOH 50 °C 5 - Trace 
3 EtOH Reflux 5 - Trace 
4 EtOH Reflux 16 - 27 
5 EtOH Reflux 5 Piper. (1.0) No 
6 EtOH Reflux 5 Pyr. (1.0) No 
7 EtOH Reflux 5 Et3N (1.0) No 
8 EtOH Reflux 5 Et2NH (1.0) No 
9 EtOH Reflux 5 NH4AcO (1.0) 18 
10 EtOH Reflux 8 NH4AcO (1.0) 24 
11 EtOH Reflux 16 NH4AcO (1.0) 44 
12 EtOH Reflux 5 NH4Cl (1.0) No 
13 EtOH Reflux 5 NaAcO (1.0) No 
14 EtOH Reflux 5 AcOH (1.0) 16 
15 EtOH Reflux 16 AcOH (1.0) 38 
16 EtOH Reflux 5 AcOH (0.25) 12 
17 EtOH Reflux 5 
NH4Cl (1.0) + 
NaAcO (1.0) 
60 a 
18 EtOH Reflux 5 PhCOOH (1.0) 30 
19 EtOH Reflux 5 PTSA (1.0) No 
20 EtOH Reflux 5 HCl conc. (1.0) No 
21 EtOH Reflux 16 PhCOOH (1.0) 35 
22 EtOH Reflux 16 PhCOOH (0.25) 21 
23 DMF 100 °C 5 NH4AcO (1.0) No 
24 Dioxane 100 °C 5 NH4AcO (1.0) 5 
25 CH3CN Reflux 5 NH4AcO (1.0) 19 
26 MeOH Reflux 5 NH4AcO (1.0) No 
27 THF Reflux 5 NH4AcO (1.0) 8 
28 EtOH Reflux 40 NH4AcO (1.0) 64 
29 EtOH Reflux 40 AcOH (1.0) 58 
a Contaminated with NaCl 
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Finally, two last experiments focused on the influence of the reaction time (entries 
28 and 29) showed that longer times resulted in improvement of the yields. After 
this exhaustive study, we decided to choose the reaction conditions reported in the 
entry 11 as the optimal ones, considering that the excessive extension in the 
reaction time was not compensated by the slight improvement in the yield. 
 
6.5.2 Scope of the reaction 
With the optimal reaction conditions in hand, we explored the scope of the 
reaction using different aromatic aldehydes (Scheme 6.9). As shown in Table 6.3, 
the reaction proceeded in moderate yields with aromatic aldehydes bearing 
electron-withdrawing substituents, and with pyridinecarbaldehydes. 
 
 
Scheme 6.9: Three-component synthesis of 4,7-dihydro-1H-pyrazolo[3,4-b]pyridines 
 
Table 6.3. Scope and yield of the synthesis of 4,7-dihydro-1H-pyrazolo[3,4-b]pyridines 
Entry Cmpd. Ar 
Yield 
(%) 
 
Entry Cmpd. Ar 
Yield 
(%) 
1 135 C6H5 44  7 141 4-FC6H4 36 
2 136 2-ClC6H4 34  8 142 3-NO2C6H4 40 
3 137 3-ClC6H4 39  9 143 4-NO2C6H4 35 
4 138 4-ClC6H4 48  10 144 3-pyridyl 49 
5 139 2-BrC6H4 32  11 145 4-pyridyl 52 
6 140 4-BrC6H4 51  12 146 2-thienyl 24a 
a: In this case, a 14% yield of the corresponding oxidized product 147 was also recovered  
 
When aromatic aldehydes with electron-rich rings were employed, we were able 
to isolate only low quantities of the fully oxidized pyrazolo[3,4-b]pyridine 
derivatives, showing a clear relationship between the electron density of the 
aldehyde aromatic ring and the ease of oxidation of the formed dihydropyridine 
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(Scheme 6.10 and Table 6.4). As previously mentioned, the reaction with 
tiophene-2-carbaldehyde affords a mixture of dihydro (146) and oxidized (147) 
derivatives.  
 
 
Scheme 6.10: Three-component reaction involving electron-rich aromatic aldehydes 
 
Table 6.4. Yield of some representative three-component reaction involving electron-rich 
aromatic aldehydes 
Entry Cmpd. Ar Yield (%) 
1 147 2-thienyl 14a 
2 148 2-furyl 8 
3 149 4-MeOC6H4 23 
a Together with 24% of the corresponding dihydro derivative 
 
Additional experiments were carried out in an effort to avoid the final 
dehydrogenation step. Unfortunately, when the reaction with p-
methoxybenzaldehyde was carried out at low temperature, no signals of the 
products in the crude NMR spectra were detected. Moreover, shortening the 
reaction time did not allow finding the dihydropyridine derivative in the reaction 
mixture, but only smaller amounts of the oxidized analogous, demonstrating that 
the higher electron density, apparently, facilitates the oxidation of the pyridine 
ring. 
 
All compounds obtained in this chapter are currently under study as GSK-3β 
inhibitors by the group of Prof. R. León (Instituto Teófilo Hernando and 
Pharmacology Department, Facultad de Medicina, Universidad Autónoma, 
Madrid).
CN
N N
CN
NH2
Ar
N
N
H
H3C
++N N
H
H3C
NH2
Ar
HO
NH4OAc
EtOH
reflux, 16 h
147-149
  
 
  
 
 
 
 
 
 
 
 
 
 
7. New Benzodiazepine-Dihydropyridine Hybrid 
Compounds As Potential Multi-Target-Directed 
Ligands For The Treatment Of Alzheimer’s Disease 
 
  
 
  
7. Design and synthesis of hybrids as MTDLs for the treatment of AD	   149 
 
 
 
 
 
 
7.1. CALCIUM, MITOCHONDRIA AND NEURODEGENERATION: AN 
OVERVIEW. 
As already mentioned in the introduction to Chapter 4, the increasingly alarming 
situation related to neurodegenerative disorders has stimulated considerable 
research efforts aimed at achieving a better understanding of these diseases. The 
extensive studies carried out in the last decades on the most common 
neurodegenerative disorders, namely Alzheimer's, Parkinson's and Huntington's 
diseases (AD, PD, HD, respectively) and multiple and amyotrophic lateral 
sclerosis (MS and ALS), have pointed out the multifactorial pathogenic character 
of these disorders that are caused by genetic, endogenous and environmental 
factors. Although each disease is determined by its etiology and characterized by 
its own molecular mechanism and different clinical manifestations, there are some 
general traits that can be considered to be common in these pathologies, including 
protein misfolding and aggregation, an increase of the free radical formation and 
of oxidative stress and a dysregulation of ionic homeostasis (especially of Ca2+), 
associated with a mitochondrial dysfunction.85 
In this context, continuing our research on neuroprotective agents able to combat 
the onset and the progression of such kinds of diseases, we focused again our 
attention on the alteration of Ca2+ homeostasis and on its relationship with 
mitochondrial dysfunctions. These two issues indeed seemed to be clearly 
implicated in the pathogenesis of different	   neurodegenerative illness205, from 
AD87a to PD206 including ALS207 and especially HD.208 
                                                
205 (a) Nicholls, D. G. Biochim. Biophys. Acta 2009, 1787, 1416-1424; (b) Calì, T.; Ottolini, D.; 
Brini, M. Cell Calcium 2012, 52, 73-85; (c) Duchen, M. R. Pflugers Arch. - Eur. J. Physiol. 2012, 
464, 111-121. 
206 (a) Schapira, A. H. V. Lancet Neurol. 2008, 7, 97-109; (b) Yao, Z.; Wood, N. W. Antiox. Redox 
Signal. 2009, 11, 2135-2149. 
207 (a) Von Lewinski, F.; Keller, B. U. Trends Neurosci. 2005, 28, 494-500; (b) Grosskreutz, J.; Van 
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Before going into detail, it is worth highlighting the importance of calcium as an 
universal second messenger that is able to control fundamental biosynthetic 
pathways implicated in the normal life of all eukaryotic cells and particularly in 
neurons, where it has a pivotal importance taking part in the transmission of 
depolarizing signals and contributing to the synaptic activity. To maintain their 
integrity and their functions, neurons have developed a fine-tuned control system 
of Ca2+ homeostasis based on structures that regulate its flux across the plasma 
membrane and that control its intracellular distribution. This system, ingeniously 
described as “calcium signaling toolkit” by Brini et al., 209 is fundamental for 
maintaining the neuronal functions, and it is clearly involved in neuronal survival. 
It is composed of different ion channels, exchangers and pumps variously 
distributed among the cellular and subcellular structures. (Figure 7.1) 
 
 
Figure 7.1: Neuronal calcium signaling toolkit.209 
 
                                                                                                                                 
Den Bosch, L.; Keller, B. U. Cell Calcium 2010, 47, 165-174. 
208 (a) Quintanilla, R.A.; Johnson, G. W. W. Brain Res. Bull. 2009, 80, 242-247; (b) Oliveira, J. M. 
A. J. Neurochem. 2010, 114, 1-12. 
209 Brini, M.; Calì, T.; Ottolini, D.; Carafoli, E. Cell. Mol. Life Sci. 2014, 71, 2787-2814. 
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Among the organelles and intracellular compartments that constitute one part of 
this “neuronal Ca2+ signaling toolkit”, mitochondria (together with endoplasmic 
reticulum) are certainly ones of the most important players. Although their active 
role in the cellular homeostasis of Ca2+ was supposed since the early 60s, with the 
proposal and later the demonstration of the chemiosmotic theory,210 only in recent 
years it was established how close is the connection between these two issues.211 
Thanks to their extended Ca2+ transport system, mitochondria can reproduce rapid 
changes of [Ca2+]m in response to the typical oscillations in [Ca2+]c, generating in 
this way specific metabolic responses such as the activation of the enzymes 
implicated in	   the cellular respiration and the related ATP production. Thus, 
mitochondria show a central role in controlling cytosolic Ca2+ fluctuations, in part 
by executing their physiological activity, but also acting as adjustable buffers of 
Ca2+ inside cells and tuning cytosolic Ca2+ signals in two principal ways: by 
acting, in a tight communication with the vicinal endoplasmic reticulum, as sinks 
able to shape the cytosolic Ca2+ transient and by removing Ca2+ from specific 
regions, known as Ca2+ microdomains, in the proximity of calcium channels and 
transporters.212 
In recent years the sophisticated mitochondrial transport system that allows this 
dynamic interaction between mitochondria and calcium, has received a 
pronounced attention and it has started to be extensively studied; although this 
system is still only partially known, it can be briefly described. As shown in 
Figure 7.2, to enter the mitochondrial matrix, Ca2+ has to cross two different 
phospholipid bilayers that constitute the outer and the inner mitochondrial 
membranes (OMM and IMM, respectively). Since the OMM does not represent 
an obstacle to ionic permeation because of the presence of abundant large 
                                                
210 For an interesting historical overview of the relationship between mitochondria and calcium 
see: Carafoli, E. Trends Biochem. Sci. 2003, 28, 175-181. 
211 (a) Duchen, M. R. J. Physiol. 2000, 529, 57-68; (b) Vandecasteele, G.; Szabadkai, G.; Rizzuto, 
R. IUBMB Life 2001, 52, 213-219; (c) Paul S. Brookes, P. S.; Yoon, Y.; Robotham, J. L. ; Anders, M. 
W.; Sheu, S.-S. Am. J. Physiol. Cell Physiol. 2004, 287, C817-C833; (d) Szabadkai, G.; Simoni, A. 
M.; Bianchi, K.; De Stefani, D.; Leo, S.; Wieckowski, M. R.; Rizzuto, R. Biochim. Biophys. Acta 
2006, 1763, 442-449; (e) Bernardi, P.; Rasola, A. Subcell. Biochem. 2007, 45, 481-506; (f) 
Rizzuto, R.; De Stefani, D.; Raffaello, A.; Mammucari, C. Nature Rev. Mol. Cell Biol. 2012, 13, 566-
578. 
212 Rizzuto, R.; Brini, M.; Murgia, M.; Pozzan, T. Science 1993, 262, 744-747. 
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conductance channels called voltage dependent anion channels (VDACs), the 
Ca2+ diffusion through the OMM is not considered as the limiting factor in the 
mitochondrial Ca2+ uptake. On the other hand, the ion impermeability of the IMM 
(which, owing to its greater extension than OMM, shows a compartmentalization 
into numerous internal foldings called cristae) hampers the entrance of Ca2+ in the 
mitochondrial matrix. In this case, the transmembrane flow of this cation takes 
place through two different systems: a mitochondrial uniporter (MCU) that allows 
an accumulation of Ca2+ down its electrochemical gradient (generated by the 
activity of the electron transport chain components localized in the IMM), and 
two exchangers with H+ and Na+ (called HCXmito and NCXmito, mostly expressed 
in nonexcitable and excitable cells, respectively) whose driving forces are the 
electrochemical gradients of the monovalent cations, allowing the	   extrusion of 
Ca2+ from the matrix.213 
 
 
Figure 7.2: The calcium mitochondrial transport system.205b 
 
                                                
213 Celsi, F.; Pizzo, P.; Brini, M.; Leo, S.; Fotino, C.; Pinton, P.; Rizzuto, R. Biochim. Biophys. Acta 
2009, 1787,335-344.  
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7.1.1 The mitochondrial sodium/calcium exchanger (NCXmito) 
The existence of a transporter able to extrude Ca2+ from the mitochondria was 
reported for the first time in the 1970s, when Carafoli’s group discovered that in 
heart mitochondria a massive Ca2+ uptake was counterbalanced by a subsequent 
extrusion of the same cation, through an exchanger triggered by the presence of 
Na+ in the extramitochondrial solution. 214 In the same study and in further 
experiments it was demonstrated that this exchanger was rather selective toward 
Ca2+ over other bivalent cations as Mg2+ and Mn2+, which were not transported, 
and slightly selective for Na+ (in this case Li+ can substitute this ion, whereas 
other monovalent cation as Cs+, K+ and Rb+ failed to activate the	  exchanger).215 
Since the beginning of its discovery, owing to the capacity to transport differently 
charged ions, various hypothesis about the electronic balance of this kind of 
transport were advanced, and only in recent years some studies finally provided 
the evidence for a stoichiometry of 3 Na+/ 1 Ca2+ per transport mediated by the 
NCXmito.216 Furthermore, it seems that the mystery concerning the molecular 
identity of this exchanger has been solved very recently, when it was reported that 
a member of the Na+/Ca2+ exchanger family (namely a Na+/Ca2+/Li+ exchanger 
called NCLX), localized in the IMM, shows an activity that matches the one of 
the putative NCXmito, suggesting that this could be the structure of the long-sought 
mitochondrial exchanger.217 
Thus, the awareness that NCXmito can influence Ca2+-dependent processes in 
neurons by taking part in the modulation of [Ca2+]m and [Ca2+]c, generated a rising 
interest in reaching a deeper understanding about the role of this exchanger in the 
neuronal physiology. Although our knowledge about the correlation between the 
NCXmito activity and the neuronal functionality is still limited, in recent years 
some studies have revealed that the NCXmito, besides being involved in the 
cytosolic oscillation of Ca2+ and Na+, takes part in the regulation of Ca2+ recycling 
                                                
214 Carafoli, E.; Tiozzo, R.; Lugli, G.; Crovetti, F.; Kratzing, C. J. Mol. Cell. Cardiol. 1974, 6, 361-
371.  
215 Crompton, M.; Capano, M.; Carafoli, E. Eur. J. Biochem. 1976, 69, 453-462. 
216 Dash, R.K.; Beard, D.A. J. Physiol. 2008, 586, 3267-3285. 
217 Palty, R.; Silverman, W. F.; Hershfinkel, M.; Caporale, T.; Sensi, S. L.; Parnis, J.; Nolte, C.; 
Fishman, D.; Shoshan-Barmatz, V.; Herrmann, S.; Khananshvili, D.; Sekler, I. Proc. Natl. Acad. Sci. 
U.S.A. 2010, 107, 436-441. 
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between mitochondria and endoplasmic reticulum, in the neurotransmitter release 
and in the synaptic plasticity.218 
The novelty of NCXmito and its physiological importance since its discovery, 
prompted the scientific community to search for a selective inhibitor to be used in 
physiological and pharmacological studies. Some benzothiazepine analogues, 
already known as Ca2+ channel blockers, were the first compounds described as 
NCXmito inhibitors; however, their multiple interactions with various receptors 
and proteins complicated the	   interpretation of these physiological studies.219 
Following a rational design strategy, the benzothiazepine derivative CGP-37157, 
namely 7-chloro-3,5-dihydro-5-phenyl-1H-4,1-benzothiazepin-2one, turned out as 
a promising inhibitor of NCXmito (Figure 7.3).220  
 
 
Figure 7.3: Molecular structure of the NCXmito inhibitor CGP-37157 
 
A subsequent full pharmacological characterization of this drug showed that in rat 
cardiomyocytes it could inhibit the Na+/Ca2+ exchanger in submicromolar 
concentration, without showing significantly relevant effects on other receptors as 
L-type Ca2+ channels, the plasma membrane Na+/Ca2+ exchanger (NCXplm) or the 
Na+/K+ ATPase.221 However, in recent years various studies questioned the 
initially hypothesized high selectivity of CGP-37157 for NCXmito; in particular it 
was shown that this benzothiazepine could also inhibit VGCCs,222 the NCXplm223 
                                                
218 Palty, R.; Hershfinkel, M.; Sekler, I. J. Biol. Chem. 2012, 287, 31650-31657. 
219 Palty, R.; Sekler, I. Cell Calcium 2012, 52, 9-15. 
220 Chiesi, M.; Schwaller, R.; Eichenberger, K. Biochem. Pharmacol. 1988, 37, 4399-4403. 
221 Cox, D. A.; Conforti, L.; Sperelakis, N.; Matlib, M. A. J. Cardiovasc. Pharmacol. 1993, 21 595-
599. 
222 Baron, K.T.; Thayer, S.A. Eur. J. Pharmacol. 1997, 340, 295-300. 
223 Czyz, A.; Kiedrowski, L. Biochem. Pharmacol. 2003, 66, 2409-2411. 
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or the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA),224 even at higher 
concentrations than the ones needed for NCXmito inhibition. 
 
7.1.2 The NCXmito and neurological diseases 
As in recent years an increasing body of evidence indicates that calcium 
dysregulation and mitochondrial alterations play a key role in neurodegenerative 
diseases, the question of whether NCXmito takes part in these mitochondrial 
impairments has become more and more relevant and	  pressing. Nevertheless, the 
role of NCXmito in neurodegenerative processes is still largely unexplored or 
controversial, and further investigations are needed to establish whether this 
exchanger could be considered as a new interesting pharmacological target in the 
research and development of new drugs to treat these diseases. 
There are few published studies focused on the investigation of the role of 
NCXmito and its eventual connection with neurological disorders. For example, as 
regards the brain ischemia, the modalities of participation of NCXmito in the 
genesis of the neuronal damage are unclear, and this is why the kind of necessary 
pharmacological intervention to combat this illness condition is still under debate. 
Based on different physiological theories found in literature, there are some 
evidences indicating that a greater beneficial effect is expected by blocking 
pharmacologically the exchanger, rather than by activating it.225  
The relationship among Alzheimer’s and Parkinson’s diseases and NCXmito is 
intriguing and still under debate. Thus, the manifestation of a concomitant 
mitochondrial dysfunction and calcium dysregulation in this disease is evident, 
but the role of NCXmito remains essentially uncharted.225 We will extend this 
discussion in the following Section. 
 
                                                
224 Nerumann, J. T.; Diaz-Sylvester, P. L.; Fleischer, S.; Copello, J. A. Mol. Pharmacol. 2011, 79, 
141-147. 
225 Castaldo, P.; Cataldi, M.; Magi, S.; Lariccia, V.; Arcangeli, S.; Amoroso, S. Prog. Neurobiol. 
2009, 87, 58-79. 
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7.1.3 Calcium dysregulation and Alzheimer’s disease 
Alzheimer’s disease is a devastating neurological disorder characterized by the 
progressive impairment of cognitive functions, memory loss, altered behavior and 
neuronal death. As mentioned in previous chapters, the pathological hallmarks of 
this disease are known and at morphological levels are characterized by the 
presence and accumulation of senile plaques formed by a peptide β-amyloid (Aβ), 
derived from the amyloid protein precursor (APP), and of intracellular 
neurofibrillary tangles composed of a hyperphosphorylated form of the 
microtubular protein tau.	  The majority of the investigations carried on AD have 
been focused on drug development in the context of the amyloid hypothesis, 
considering that the accumulation of amyloid plaques is characteristic in all AD 
patients. However, the extended efforts made in searching for effective therapies 
focused on this target have repeatedly failed; thus it has been necessary to 
investigate additional pharmacological targets to treat AD. In recent years a 
number of studies have increasingly pointed out the connection between Ca2+ and 
AD pathogenesis, leading to the formulation of a “calcium hypothesis” of AD.226 
Among the findings that generated this hypothesis we can enumerate the evidence 
that experiments performed with APP transgenic mice revealed abnormal high 
basal Ca2+ levels in neuritis located close to amyloid deposits.227 Very recently it 
has been also demonstrated that Aβ can modify the interconnections between ER 
and mitochondria, altering the Ca2+ regulation process mediated by these 
organelles.228 Moreover, Aβ oligomers may enhance Ca2+ entry in the cell by 
altering the permeability of the membrane or the sensitive of some ion 
channels. 229  Recent studies showed that also presenilins play a role in the 
dysregulation of Ca2+ homeostasis by altering the release of Ca2+ from the internal 
                                                
226 (a) LaFerla, F. M. Nat. Rev. Neurosci. 2002, 3, 862-872; (b) Bezprozvanny, I.; Mattson, M. P. 
Trends Neurosci. 2008, 31, 454-463; (c) Berridge, M. J. Pflugers Arch. 2010, 459, 441-449. 
227 Kuchibhotla, K. V.; Goldman, S. T.; Lattarulo, C. R.; Wu, H. Y.; Hyman, B. T.; Bacskai, B. J. 
Neuron 2008, 59, 214-225. 
228 Hedskog, L.; Pinho, C. M.; Filadi, R.; Ronnback, A.; Hertwig, L; Wiehager, B.; Larssen, P.; 
Gellhaar, S.; Sandebring, A.; Westerlund, M.; Graff, C.; Winblad, B.; Galter, D.; Behbahani, H.; 
Pizzo, P.; Glaser, E.; Ankarcrona, M. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 7916-7921. 
229 (a) Kawahara, M.; Kuroda, Y. Brain. Res. Bull. 2000, 53, 389–397. (b) Kagan B. L.; Hirakura, Y.; 
Azimov, R.; Azimova, R.; Lin, M. C. Peptides 2002, 23, 1311–1315. 
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deposits of ER, by forming new channels or by modifying the activity of 
structural ER channels.230 Recently, a novel voltage-gate ion channel	  CALHM1 
that promotes the Ca2+ intracellular influx has emerged as another ionic 
checkpoint altered in AD, leading to modification in Ca2+ homeostasis.231 
 
7.1.4 Multitarget calcium stabilizers: a new approach for Alzheimer’s 
disease?  
Considering that neurons are excitable cells in an unceasing state of potential 
triggering action, we decided to focus our attention on the fluctuations of 
intracellular and mitochondrial Ca2+ fluxes. Indeed, in neurons, the continuous 
Ca2+ influx from the extracellular space has to be adequately counterbalanced by a 
set of cellular responses based on a Ca2+ efflux through the plasma membrane, on 
the Ca2+ uptake mediated by intracellular organelles and on the buffering 
contribution provided by some cytoplasmic calcium binding proteins (CBP). The 
equilibrium between the physiological condition of neurons (i.e. the conversion of 
the Ca2+ signaling in the vital coupling between the mitochondrial respiration and 
ATP production or in the release of neurotransmitters) and the pathological 
situation (with a deficit of the mitochondrial bioenergetic contribution leading to a 
condition of susceptibility for neurons to enter in apoptosis and die) depends on 
the harmonious coordination of these Ca2+ circuits.  
The multifactorial nature of the aforementioned neurodegenerative diseases 
describes a complex physiopathological framework that is difficult to challenge 
with the classical pharmacological strategy based on the concept “a single 
molecule for a single target”. Thus, in recent years, the hypothesis of a compound 
                                                
230 (a) Stutzmann, G. E.; Caccamo, A.; LaFerla, F. M.; Parker, I. J. Neurosci. 2004, 24, 508-513; (b) 
Tu, H.; Nelson, O.; Bezprozvanny, A.; Wang, Z.; Lee, S. F.; Hao, Y. H.; Serneels, L.; De Strooper, B.; 
Yu, G.; Bezprozvanny, I. Cell 2006, 126, 981-993; (c) Nelson, O.; Tu, H.; Lei, T.; Bentahir, M.; de 
Strooper, B.; Bezprozvanny, I. J. Clin. Invest. 2007, 117, 1230-1239; (d) Green, K. N.; Demuro, A.; 
Akbari, Y.; Hitt, B. D.; Smith, I. F.; Parker, I.; LaFerla, F. M. J. Cell Biol. 2008, 181, 1107-1116. 
231 Dreses-Werringloer, U.; Lambert, J. C.; Vingtdeux, V.; Zhao, H.; Vais, H.; Siebert, A.; Jain, A.; 
Koppel, J.; Rovelet-Lecrux, A.; Hannequin, D.; Pasquier, F.; Galimberti, D.; Scarpini, E.; Mann, D.; 
Lendon, C.; Campion, D.; Amouyel, P.; Davies, P.; Foskett, J. K.; Campagne, F.; Marambaud, P. 
Cell 2008, 133, 1149-1161. 
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capable to interact with two or more targets assumed as responsible for the 
pathogenic mechanisms of a disease, has been receiving a growing attention. This 
strategy, conceptually similar to the multiple-medication therapy which has been 
successfully employed in	  the treatment of chronic and complex diseases such as 
cancer and AIDS, is known as “Multi-Target-Directed Ligands” (MTDLs) and is 
thought to be potentially effective in the treatment of neurodegenerative 
illnesses.232 Thus, we supposed that designing compounds that could act as 
multitarget calcium stabilizers of the neuronal Ca2+ fluxes could represent an 
interesting approach to the development of new molecules to be employed as 
neuroprotective agents.233 
In this context we decided to focus our attention on NCXmito to investigate how to 
maintain a functional and physiological mitochondrial calcium cycle and its fine 
equilibrium within the complex cellular calcium organization in neurons. To reach 
this goal it is necessary to know inside which limits we can modify the NCXmito 
activity in order to let the related [Ca2+]c changes remain within a critical set 
point, avoiding that a cytoprotective signal might turn into a cytotoxic one.234 In 
fact, mitigation of the efflux rate via the NCXmito could slightly increase the 
[Ca2+]m and possibly stimulate ATP synthesis, but a mitochondrial Ca2+ overload 
could be the signaling to produce the mitochondrial permeability transition pore 
(mPTP) that excessively increase the permeability of the mitochondrial 
membrane, leading the cell to the apoptotic process. In spite of this apparent 
paradoxical situation, the hypothesis that a controlled Ca2+ accumulation in the 
mitochondria could convert these organelles into useful Ca2+ sinks, promoting a 
possible neuroprotective role by removing Ca2+ excess from the cytosol, prompted 
us to look for a therapeutic application of the NCXmito inhibition in combination 
with a pharmacological intervention on another cellular Ca2+ checkpoint.233 
In the literature, the studies regarding the neuroprotective effect of CGP-37157 in 
                                                
232 For some selected reviews of the Multi-Target-Directed Ligands approach for the treatment 
of neurodegenerative disease, see: (a) Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; 
Tumiatti, V.; Recanatini, M.; Melchiorre, C. J. Med. Chem. 2008, 51, 347-372; (b) León, R.; 
García, A. G.; Marco-Contelles, J. Med. Res. Rev. 2013, 33, 139-189; (c) Trinches Dias, K. S.; 
Viegas, C. Jr. Curr. Neuropharmacol. 2014, 12, 239-255. 
233 Fernández-Morales, J. C.; Arranz-Tangarro, J. A.; Calvo-Gallardo, E.; Maroto, M; Padín, J. F.; 
García, A. G. ACS Chem. Neurosci. 2012, 3, 873-883. 
234 Koike, T.; Martin, D. P.; Johnson, E. M. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6421−6425. 
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a model of neuronal death, showed that this NCXmito inhibitor can slow down the 
mitochondrial futile Ca2+ ion recycling through the MCU and the NCXmito, 
leading to a partially delay or prevention of cell death and exerting a 
neuroprotective effect.235 It must be taken into account that CGP-37157 is able to 
block also other ionic channels and this aptitude could take part in eliciting 
neuroprotection in the studied model,235 also by modifying other cellular calcium 
circuits beyond the mitochondrial one. In view of these evidences, we think that 
the synthesis and the biological evaluation of a multitarget calcium stabilizer 
could lead to a better comprehension of the physiopathological mechanisms 
involved in the generation of neurotoxicity elicited by a disruption of the Ca2+ 
homeostasis.236 
  
                                                
235 (a) Nicolau, S. M.; de Diego, A. M.; Cortés, L.; Egea, J.; González, J. C.; Mosquera, M.; López, 
M. G.; Hernández-Guijo, J. M.; García, A. G. J. Pharmacol. Exp. Ther. 2009, 330, 844-854; (b) 
Nicolau, S. M.; Egea, J.; López, M. G.; García, A. G. Biochem. Biophys. Res. Commun. 2010, 400, 
140-144. 
236  We thank Dr. Antonio García (Instituto Teófilo Hernando and Departamento de 
Farmacología, Facultad de Medicina Universidad Autónoma de Madrid) for the ideas that led 
into this project and his valuable input.  
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7.2 RATIONAL DESIGN OF A MULTITARGET CALCIUM STABILIZER 
Against the aforementioned background, we wanted to design a multitarget 
calcium stabilizer that, combining different bioactive moieties, were capable to 
interact with different targets involved in the regulation of the cellular and 
mitochondrial calcium cycles and could potentially provide neuroprotective 
effects in vulnerable neurons. Our initial choice was based on the combination of 
a benzothiazepine system analogous to CGP-37157 to interact with the NCXmito, 
and a dihydropyridine derivative to target the L-type VGCCs: in this manner we 
planned to intervene directly in the modulation of both the cellular and 
mitochondrial calcium cycles. The resulting molecule should contain the 
pharmacophores for both activities, and we envisioned a hybrid structure by 
linking two structurally active fragments. The CGP-37157 molecule did not offer 
many options to establish a link with another molecule without affecting its 
activity. In this regard, it was very useful a study published in 2003, about the 
synthesis of a large number of benzothiazepines analogous to CGP-37157, as well 
as other heterocyclic analogues, evaluating their inhibitory activity of NCXmito in 
search of a potential therapeutic activity in diabetes treatment. 237 The authors 
accomplished a detailed structure-activity relationship (SAR) analysis that is 
summarized in Figure 7.4. 
 
 
Figure 7.4: SAR analysis of the CGP-37157 analogous. 
 
The SAR analysis provides information to make various considerations about the 
                                                
237 Pei, Y.; Lilly, M. J.; Owen, D. J.; D’Souza, L. J.; Tang, X. Q.; Yu, J.; Nazarbaghi, R.; Hunter, A.; 
Anderson, C. M.; Glasco, S.; Ede, N. J.; James, I. W.; Maitra, U.; Chandrasekaran, S.; Moos, W. H.; 
Ghosh, S. S. J. Org. Chem. 2003, 68, 92-103. 
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critical moieties of the benzothiazepine structure with respect to the NCXmito: 
 
• Regarding the fused phenyl ring, the peak activity is obtained when there 
is a chlorine atom in the position 7. Changing chlorine for hydrogen or 
nitro groups leads to decreased activity. 
• The NH group in position 1 is required for the activity, probably because it 
is involved as a H-bond donor; changing H for alkyl or acyl substituents 
leads to a loss of activity. 
• The carbonyl group in position 2 is not so critical and its reduction to 
methylene group leads only to a slight reduction of the activity. 
• The presence of a phenyl ring in position 5 is generally required for the 
activity on the NCXmito; moreover the nature of the substituents on the ring 
seems to be relevant, with the 2-Cl substitution showing the best results. 
When the chlorine atom is changed for a methyl group, the activity of the 
molecule slightly decreases and, considering the substitution pattern of a 
same substituent, it was clear that the activity decreases progressively 
when the substituent is moved from the ortho to the para position. Finally 
the switch from a phenyl ring to a heteroaromatic aryl group leads to a 
reduction of the activity. 
• The last critical point of the molecule is represented by the position 4: the 
substitution of the sulphur atom of CGP-37157 was investigated and 
interestingly, some derivatives bearing aminoalkyl chains exhibited a 
similar potency in blocking the NCXmito to that of the parent compound. 
This finding was very interesting for two reasons: on one hand this new 
substitution could increase the water solubility of the molecule (improving 
therefore one of the major weaknesses of CGP-37157) and, on the other 
hand, this kind of modification offered a possible connection point 
between the benzothiazepine structure and the dihydropyridine moiety. 
 
With this information, we chose as NCXmito blocker partner, a	  benzodiazepinone 
derivative having in the position 4 a nitrogen atom instead of the sulphur, and 
bearing on this nitrogen a 2-hydroxyethyl substituent (this derivative, hereafter 
called 153, shows an IC50 value of 7.9 µM compared to the IC50 value of 1.4 µM 
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of CGP-37157). In this manner we conceived that the two methylenic groups 
could act as the linker between the benzodiazepine moiety and the 
dihydropyridine group, whereas the OH could be used for the formation of an 
ester group with one of the carbonyl functions located at C-3 or C-5 of the DHP. 
It is worth emphasizing that the derivative similar to 153 with a OEt instead of 
OH showed a stronger inhibition of NCXmito (with an IC50 value of 3.2 µM), 
which was promising for our purpose to convert this same free OH in an ester 
group. 
Regarding the other component of our hybrid, we decided to choose nimodipine 
as the dihydropyridinic element due to its well-known behaviour as calcium 
channel blocker, and also because one of its ester groups has a structural 
similarity with the linker (Figure 7.5). 
 
 
Figure 7.5: Rational approach to the synthesis of the multitarget calcium stabilizer 156. 
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7.3 SYNTHESIS OF THE HYBRID BETWEEN THE AZA-ANALOGUE OF 
CGP-37157 AND NIMODIPINE 
7.3.1 Synthesis of the aza-analogue of CGP-37157 (153) 
Compound 153 was synthesized modifying the methodology described in the 
above-mentioned work about the benzothiazepine analogues of CGP-37157.237 
As illustrated in the Scheme 7.1, 2-amino-2’,5-dichlorobenzophenone was 
condensed with a large excess of ethanolamine in absence of solvent at 140 °C, in 
a sealed tube. The obtained imine 150 was subsequently reduced in quantitative 
yield using NaBH3(CN) in a mixture of methanol and acetic acid (100:1) at room 
temperature, to afford the β-hydroxyamine 151. Although CGP-37157  is chiral, it 
is only available in racemic form and therefore every published study regarding 
this compound is based on the use of racemic material238 and there is no 
information on whether the two enantiomers show different inhibition properties 
of NCXmito. Thus, at this stage we decided to carry out this reduction without 
stereochemical control and employ from this point the racemic form of the 
synthesized compounds. 
 
 
Scheme 7.1: Synthesis of compounds 150 and 151 
 
With diamine 151 in hand, we proceeded to the formation of the diazepinic ring 
by reacting compound 151 with an excess of bromoacetyl bromide in a one-pot 
multi step fashion, with the initial formation of the amidic bond between the 
primary amine and the acyl group at room temperature and the subsequent ring 
closure achieved by the addition of	  DIPEA and by increasing the temperature to 
50 °C. Against literature precedent,237 this experiment did not afford the expected 
                                                
238 Fitosa, I.; Visya, J.; Simonyi, M.; Hermansson, J. J. Chromat. A 1995, 709, 265-273. 
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aza-analogue of CGP-37157 153 with the free OH at the end of the alkyl chain 
because of its further reaction with another molecule of bromoacetyl bromide. 
Thus, we had subsequently to hydrolyze the initially obtained compound 152 by 
classical base-promoted saponification in alcoholic solution at room temperature 
to finally get the expected aza-analogue of CGP-37157 153 in an overall 47% 
yield (Scheme 7.2). 
 
 
Scheme 7.2: Synthesis of compounds 152 and 153 
 
7.3.2 Synthesis of the 153-nimodipine hybrid via a multicomponent 
process 
With the aza-analogue of CGP-37157 (compound 153) in hand, our next step was 
to obtain a hybrid with nimodipine. Based on our previous experience and 
considering that, as mentioned in Section 1.1, the dihydropyridine represents one 
of the first heterocycles synthesized through a multicomponent reaction,10 we 
thought that an elegant approach to reach our goal would be to synthesize the 
expected hybrid in a multicomponent fashion, according to the	  reaction planning 
depicted in Scheme 7.3. 
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Scheme 7.3: Retrosynthetic approach to the hybrid 156 via a multicomponent process 
 
As reported in Section 1.3.2.1, Hantzsch’s original protocol is a pseudo four-
component reaction based on a one-pot cyclocondensation of 1 equiv of an 
aldehyde, 2 equiv of a β-ketoester, and 1 equiv of ammonia or a synthetic 
equivalent to afford symmetrical 1,4-dihydropyridines. If non-symmetrical 1,4-
dihydropyridines (where the adjective non-symmetrical indicates the presence of 
two different ester groups at C-3 and C-5 of the DHP) are desired, as in our case, 
the classical Hantzsch four-component reaction has to be adapted in methodology, 
known as “modified three-component Hantzsch approach” (Scheme 1.14). 
Therefore, as depicted in Scheme 7.3, we prepared on one hand, the β-ketoester 
derived from acetoacetic acid and alcohol 153 and, on the other hand, we prepared 
the conjugated enone derived from the condensation between metha-
nitrobenzaldehyde and isopropyl acetoacetate. In this manner, by forming 
previously the bond between the aldehyde and one of the β-ketoesters and 
employing a modified three-component Hantzsch reaction, we could avoid the 
possible generation of symmetrical DHPs deriving from the Hantzsch (pseudo) 
four-component reaction. 
The synthesis of the β-ketoester derived from acetoacetic acid and alcohol 153 
was achieved by a known protocol in the literature, 239  based on the 
                                                
239 Chavan, S. P.; Subbarao, Y. T.; Dantale, S. W.; Sivappa, R. Synth. Commun. 2001, 31, 289-294. 
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transesterification of methyl acetoacetate with compound 153, in presence of the 
acidic ion exchange resin Amberlyst® 15 in refluxing toluene, affording 
compound 154 in a moderate yield. The use of a Dean-Stark trap facilitated the 
progress of the reaction by removing the methanol produced during the 
transesterification reaction (Scheme 7.4). 
 
 
Scheme 7.4: Synthesis of the β-ketoester 154 
 
The synthesis of the other component of our Hantzsch-like protocol was achieved 
by the classical conditions for the Knoevenagel condensation,240 employing 3-
nitrobenzaldehyde and isopropyl acetoacetate as reagents, in refluxing benzene 
and in the presence of catalytic amounts of piperidine and acetic acid. The 
corresponding conjugated enone was obtained in 81% yield. Also in this case, the 
use of a Dean-Stark trap facilitated the progress of the reaction by removing the 
water generated during the condensation (Scheme 7.5). 
 
 
Scheme 7.5: Synthesis of 155 via Knoevenagel condensation 
 
To obtain the desired hybrid 156 we performed the final three-component reaction 
between compounds 154, 155 and ammonium acetate, in refluxing ethanol. We 
were pleased to find out that our protocol afforded the desired compound in good 
                                                
240 Poindexter, G. S.; Temple, D. L. Patent GB 2158065 A, 1985. 
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yield (71%) and that the global yield for the entire synthetic pathway, from the 
initial acetophenone to the final hybrid, was satisfactory (16,5%) (Scheme 7.6). 
 
 
Scheme 7.6: Multicomponent synthesis of the hybrid 156 
 
We obtained compound 156 as a mixture of diastereomers that were impossible to 
separate using standard chromatography methodologies. Nevertheless, the 
pharmacological study of compound 156 will provide useful information on the 
feasibility of our multitarget approach.  
 
7.3.3 Convergent synthesis of the hybrid 156 
A future synthesis of 156 or related compounds in enantiomerically pure form 
could be initiated by an enantioselective Hantzsch reaction, but the methods 
known for this transformation are very scarce.241 Alternatively, a chiral resolution, 
which is the usual strategy employed for the preparation of optically active 
                                                
241 For a review of the stereoselective synthesis of the dihydropyridine ring see: Tenti, G; 
Ramos, M. T.; Menéndez, J. C., in Rodriguez, J.; Bonne, D. (eds.) Stereoselective Multiple Bond-
Forming Transformations in Organic Synthesis Chapter 3: “Six-membered heterocycles” Wiley-
VCH: Weinheim, Germany, 2015. 
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DHPs,242 could be planned. In preparatory work towards	   this goal, we also 
designed an alternative synthetic pathway that involved obtaining separately the 
benzodiazepine and the dihydropyridine rings and linking them in the last step. 
Although at this preliminary stage we have not proceeded to the separation of the 
enantiomers, this linear synthetic pathway could allow the resolution of the 
racemic dihydropyridine using well-established methods before the last coupling 
reaction with benzodiazepine 153 (Scheme 7.7). 
 
 
Scheme 7.7: Retrosynthetic approach to the linear synthesis of the hybryd 156 
 
The key step in the designed synthetic pathway is clearly the final coupling 
reaction and, bearing in mind the presence of a hydroxy group in benzodiazepine 
153, we thought that this step could be easily achieved through an esterification 
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1980, 28, 2809-2812; (b) Arhancet, G. B.; Woodard, S. S.; Dietz, J. D.; Garland, D. J.; Wagner, G. 
M.; Iyanar, K.; Collins, J. T.; Blinn, J. R.; Numann, R. E.; Hu, X.; Huang, H.-C. J. Med. Chem. 2010, 
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reaction involving the carboxylic acid of the adequate dihydropyridine. 
Thus, our first goal was the synthesis of a non-symmetrical 1,4-dihydropyridine 
dicarboxylate in which just one of its ester groups could be univocally hydrolyzed 
to carboxylic acid. Considering that nimodipine has an isopropyl ester group on 
one side of the molecule, we looked for another ester group that, after the 
formation of the DHP, could be easily converted into a carboxylic acid. After a 
literature search, our first choice was an allylic ester, which is known for the 
possibility to be selectively hydrolyzed even in the presence of other ester 
groups.243 Also in this case, the need to get a non-symmetrical dihydropyridine 
with different ester groups at C-3 and C-5 prompted us to carry out our first 
reaction by the Hantzsch-like three-component reaction similar to that one 
performed in the last step of our previous multicomponent protocol. Thus we 
obtained dihydropyridine 157 in good yield by reacting enone 155, allyl 
acetoacetate and ammonium acetate in refluxing ethanol (Scheme 7.8). 
 
 
Scheme 7.8: Synthesis of the 1,4-DHP 157 
 
With the DHP 157 in hand, we proceeded to the conversion of the allyl ester into 
a carboxylic acid employing the literature methodology for the deprotection of the 
allyloxycarbonyl (Aloc) group. After an initial unsuccessful attempt with 
Pd(OAc)2 and triphenylphosphine in the presence of triethylamine and formic 
acid, the conversion into carboxylic acid was achieved in acceptable yield 
employing morpholine and a catalytic amount of palladium tetrakis 
triphenylphosphine in anhydrous THF at room temperature (Scheme 7.9). 244 
                                                
243 (a) Kosugi, Y.; Hori, M.; Nagasaka, T. Heterocycles 1994, 39, 591-602; (b) Ohmori, K.; Ogawa, 
Y.; Obitsu, T.; Ishikawa, Y.; Nishiyama, S.; Yamamura, S. Angew. Chem. Int. Ed. 2000, 39, 2290-
2294; (c) Sarabia, F.; Chammaa, S. J. Org. Chem. 2005, 70, 7846-7857. 
244 Schmidt, D. R.; Kwon, O.; Schreiber, S. L. J. Comb. Chem. 2004, 6, 286-292. 
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Scheme 7.9: Palladium-catalyzed conversion of the allyl ester into carboxylic acid 
 
To avoid the use of costly palladium catalysts we decided to investigate also other 
possibilities to obtain compound 158. We found that also the 2-cyanoethyl ester 
could be selectively converted into carboxylic acid, employing mild conditions 
and without using expensive catalysts.245 Thus, the first step in this new synthetic 
pathway was the synthesis of the 2-cyanoethyl acetoacetate, that was carried out 
employing the procedure shown in Section 5.2.1 and developed in our group, 
based on the treatment of alcohols with 2,2,6-trimethyl-1,3-dioxin-4-one in the 
presence of sodium acetate. The expected β-ketoester was obtained in refluxing 
THF in 51% yield (Scheme 7.10). 
 
 
Scheme 7.10: synthesis of the 2-cyanoethyl acetoacetate 159 
 
We then proceeded to the synthesis of the corresponding dihydropyridine	  by the 
usual Hantzsch-like three-component reaction between the enone 155, 2-
cyanoethyl acetoacetate 159 and ammonium acetate in refluxing ethanol (Scheme 
7.11). 
                                                
245 (a) Ogawa, T.; Nakazato, A.; Tsuchida, K.; Hatayama, K. Chem. Pharm. Bull. 1993, 41, 108-
116; (b) Ogawa, T.; Hatayama, K.; Maeda, H.; Kita, Y. Chem. Pharm. Bull. 1994, 42, 1579-1589; 
(c) Bärfacker, L.; Kuhl, A.; Hillisch, A.; Grosser, R.; Figueroa-Pérez, S. Heckroth, H.; Nitsche, A.; 
Ergüden, J.-K.; Gielen-Haertwig, H.; Schlemmer, K.-H.; Mittendorf, J.; Paulsen, H.; Platzek, J.; 
Kolkhof P. Chem. Med. Chem. 2012, 7, 1385-1403. 
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Scheme 7.11: Synthesis of the 1,4-DHP 160 
 
Once we had access to the DHP 160 bearing the 2-cyanoethyl ester group, we 
could perform its selective conversion into the monocarboxylic acid 158 by a 
literature methodology,245b consisting in a reaction at room temperature in a 
mixture of dichloromethane and methanol and in the presence of sodium sulfide 
hydrate; the DHP 158 was obtained in good yield (Scheme 7.12). 
 
 
Scheme 7.12: Conversion of the 2-cyanoethyl ester into carboxylic acid  
 
Comparing similar steps (namely the DHP formation and its subsequent 
deprotection to carboxylic acid) of the two linear synthetic pathways (the first one 
through the intermediate 157, that we call A and the second one through the 
intermediate 160) to the common intermediate 158, we can see how similar is the 
two-step yield for both routes (44% and 36% respectively); we can affirm 
therefore, that the pathway B is an efficient and cheaper alternative to the more 
expensive route A (Scheme 7.13). 
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Scheme 7.13: Comparison between route A and B to 158 
 
With the mono acidic dihydropyridine derivative 158 in hand we could finally 
proceed to the study of the coupling step with the benzodiazepine 153 making use 
of an esterification reaction. To increase the reactivity of the carboxylic group of 
158 to facilitate its coupling with the hydroxy group of 153 we firstly attempted 
its conversion into an acyl chloride243a or a mixed anhydride derivative,246 but 
unfortunately, the coupling reactions with 153 did not afford the expected hybrid 
156, probably due to the steric hindrance exerted by the benzodiazepine moiety 
that could reduce the reactivity of the hydroxyl. Hence we decided to convert not 
only the carboxylic acid, but also the hydroxyl group into more reactive species. 
In particular, we transformed the OH group of 153 into a silylated alcohol by 
reaction with trimethylsilyl chloride in dichloromethane in the presence of	  
triethylamine (step I), and on the other hand, we transformed the carboxylic acid 
of 158 into the corresponding acyl chloride (step II) by reaction with thionyl 
                                                
246 Chang, C.-C.; Cao, S.; Kang, S.; Kai,L.; Tian, X.; Pandey, P.; Fernandez Dunne, S.; Luan, C.-H.; 
Surmeier, D. J.; Silverman, R. B. Bioorg. Med. Chem. 2010, 18, 3147-3158. 
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chloride in a mixture of dichloromethane and N,N’-dimethylformamide. The 
critical coupling reaction was carried out simply adding the intermediate obtained 
in step II into the reaction mixture coming from the step I, affording finally the 
expected hybrid 156 in good yield (54% overall three steps) (Scheme 7.14).247 
 
 
Scheme 7.14: Final coupling step between 153 and 158 for the synthesis of 156 
 
The hybrid obtained in this chapter is currently under study as calcium	  stabilizers 
in SH-SY5Y human neuroblastoma cells to assess its potential neuroprotective 
activity, by the group of Prof. R. León (Instituto Teófilo Hernando and 
Pharmacology Department, Facultad de Medicina, Universidad Autónoma, 
Madrid). 
 
  
                                                
247 Bandi, P. R.; Kura, R. R.; Rapolu, R. R.; Dasari, M. R.; Dandamudi, S. K. US Patent US 
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7.4 SYNTHESIS OF THE HYBRID BETWEEN COMPOUND 153 AND 
LIPOIC ACID 
As mentioned in the Paragraph 6.1.3, in recent years large experimental evidence 
has demonstrated that oxidative stress is another very important factor in tight 
connection with calcium homeostasis, pathological conditions of mitochondria 
and neurodegenerative diseases. 248  As the oxidative stress arises from an 
imbalance between an excessive production of reactive oxygen species (ROS) and 
antioxidant defenses, it is interesting to underline that among the intracellular 
organelles that can generate ROS, mitochondria are the most prolific, being 
responsible for more than 90% of ROS production. If on one hand the ROS 
generation is fundamental for the cell life, taking part in the cytosolic signaling 
system, on the other hand it has to be strictly controlled to avoid an excessive 
ROS production that leads to irreparable cellular damages such as those already 
mentioned in the Section 6.1.3.  
The high susceptibility of the brain to oxidative damage and the evidence that the 
abnormal propagation of ROS generation play a major role in the pathogenesis 
and the progression of AD (insertar referencia cruzada), it seems clear that 
molecules with antioxidant properties could represent an interesting tool to 
combat this kind of diseases.249 Thus, considering that calcium dysregulation, 
mitochondrial impairment and an oxidative stress increase are tightly connected in 
the pathogenesis of AD, we decided to extend the concept of multitarget 
neuroprotective agent, involving in our project also a molecule with antioxidant 
properties. A suitable candidate was lipoic acid (LA), a natural precursor for some 
mitochondrial enzymes, that has been suggested to have multiple anti-AD and, 
more in general, anti-dementia properties derived from its capability to increase	  
acetylcholine production, to chelate transition metals, to scavenge ROS increasing 
GSH levels and down-regulating the inflammatory process, and to induce the 
                                                
248 (a) Kume, T.; Katsuki, H.; Akaike, A. Biol. Pharm. Bull. 2004, 27, 964-967; (b) Chinopoulos, C.; 
Adam-Vizi, V. FEBS J. 2006, 273, 433–450; (c) Lin, M. T.; Beal, M. F. Nature 2006, 443, 787-795; 
(d) Yan, M. H.; Wang, X.; Zhu, X. Free Radic. Biol. Med. 2013, 62, 90-101. 
249 (a) Grundman, M.; Delaney, P. Proc. Nutr. Soc. 2002, 61, 191-202; (b) Casetta, I.; Govoni, V.; 
Granieri, E. Curr. Pharm. Des. 2005, 11, 2033-2052. 
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synthesis of antioxidant protective enzymes.250 
So, we proceeded to the rational design of a new potential multitarget-directed 
ligand by combining the benzodiazepine 153 and lipoic acid in order to act on the 
mitochondrial calcium homeostasis (by targeting the NCXmito) and on the harmful 
oxidative processes. Also in this case, the hydroxyl moiety of 153 and the 
carboxylic group of LA were the more evident option for the junction between the 
two molecules (Figure 7.6).  
 
 
Figure 7.6: Rational approach to the synthesis of the hybrids 161 and 162 
 
The conditions used to obtain 156 from 153 and 158 were not successful in this 
case, but the synthesis of the new hybrid 161 was achieved in good yield, using 
EDCI as coupling agent in the presence of DMAP, in dichloromethane at room 
temperature (Scheme 7.15).251  
 
 
Scheme 7.15: Synthesis of the hybrids 161 and 162 
 
                                                
250 Maczurek, A.; Hager, K.; Kenklies, M.; Sharman, M.; Martins, R.; Engel, J.; Carlson, D. A.; 
Münch, G. Adv. Drug Deliv. Rev. 2008, 60, 1463-1470. 
251 Bernini, R.; Crisante, F.; Merendino, N.; Molinari, R.; Soldatelli, M. C.; Velotti, F. Eur. J. Med. 
Chem. 2011, 46, 439-446. 
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Also in this case the final product was a mixture of diastereomers that was 
impossible to separate using the basic chromatography methodologies. To 
simplify the product mixture we also prepared the hybrid using the pure R-(+)-
enantiomer of the lipoic acid (hybrid 162), so that, 162 was obtained as a mixture 
of only two diastereomers. 
 
Also these two hybrids are currently under study as calcium stabilizers and 
antioxidant agents in SH-SY5Y human neuroblastoma cells to evaluate their 
potential neuroprotective activity, by the group of Prof. R. León (Instituto Teófilo 
Hernando and Pharmacology Department, Facultad de Medicina, Universidad 
Autónoma, Madrid). 
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8.1 INTRODUCTION 
8.1.1 The C-H functionalization strategy 
The increasingly urgent need for green and sustainable chemistry has led organic 
chemists to search new efficient strategies for the creation of carbon-carbon 
bonds; in the last years the possibility to get this kind of connection from the 
activation and functionalization of simple carbon-hydrogen bond has emerged, 
more and more, as a very interesting and challenging target in organic 
synthesis, 252  with interesting applications in medicinal chemistry and drug 
discovery.253 Coupling the oxidations of two unreactive C-H bonds to build a new 
C-C bond allows the use of simple reagents, a reduction in the number of steps of 
a synthetic pathway leading consequently to a general reduction of the waste 
products and to more economic procedures. Being thermodynamically 
unfavorable the simultaneous formation of a C-C bond and the loss of a H-H 
molecule, these transformations, known as dehydrogenative cross-coupling 
reaction, require the intervention of a sacrificial oxidant as the driving force of the 
process (Figure 8.1).254 
 
 
Figure 8.1: Dehydrogenative cross-coupling reaction 
 
                                                
252  (a) Bergman, R. G. Nature 2007, 446, 391-393; (b) Ackermann, L. Modern Arylation 
Methods, Wiley-VCH, Weinheim, 2009. 
253 (a) Wencel-Delord, J.; Glorius, F. Nat. Chem. 2013, 5, 369-375; (b) Ackermann, L.; Vicente, 
R.; Kapdi, A. Angew. Chem. Int. Ed. 2009, 48, 9792 – 9826 . 
254 For a review of the catalytic dehydrogenative cross-coupling reaction, see: Yeung, C. S.; 
Dong, V. M. Chem. Rev. 2011, 111, 1215-1292. 
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Although palladium remains the best known metal for this kind of 
transformations, other transition metal-catalyzed carbon-carbon bond formations 
have received great attention from synthetic chemists. 255  In particular 
ruthenium(II) complexes have emerged as an efficient, less expensive256 and 
equally effective alternative to palladium in the field of the C-H activation.257 
 
8.1.2 Carboxylated-assisted ruthenium-catalyzed C-H functionalization 
At the turn of 1990s, the innovative works of Lewis258 and Murai259 described for 
the first time the potential efficiency of ruthenium catalysts in the conversion of 
C-H bonds into C-C or C-Het bonds. Subsequently great efforts were made to 
discover more stable and more efficient ruthenium catalysts to be employed in 
new metal-catalyzed reactions,260 though the major progresses in ruthenium-
catalyzed C-H activation were achieved by the use of	   ruthenium complexes 
generated in situ in catalytic systems with modest robustness.261 
In recent years, in order to find more efficient and practical ruthenium catalytic 
systems, the Ackermann group deeply investigated various procedures based on 
this transition metal, for C-H bond functionalization. After an extensive 
investigation, they could achieve the formation of a robust and efficient ruthenium 
catalytic system that involves the use of carboxylated ligands as cocatalytic 
additives. The carboxylates are supposed to form the ruthenium catalytic complex 
in situ and are expected to act as basic bifunctional ligands generating a six-
membered transition state (Figure 8.2). 
                                                
255 Ackermann, L.; Vicente, R.; Kapdi, A. R. Angew. Chem. Int. Ed. 2009, 48, 9792-9826. 
256  April 2015, http://www.infomine.com/investment/precious-metals/: Prices of gold, 
platinum, rhodium, palladium, iridium and ruthenium: €1110, €1073, €1058, €709, €530 and 
€46 per troy ounce, respectively. 
257 For recent reviews on ruthenium-catalyzed C–H bond functionalization, see: (a) Ackermann, 
L. Pure Appl. Chem. 2010, 82, 1403–1413; (b) Arockiam, P. B.; Bruneau, C.; Dixneuf, P. H. Chem. 
Rev. 2012, 112, 5879-5918. 
258 Lewis, L. N.; Smith, J. F. J. Am. Chem. Soc. 1986, 108, 2728–2735. 
259 Murai, S.; Kakiuchi, F.; Sekine, S.; Tanaka, Y.; Kamatani, A.; Sonoda, M.; Chatani, N. Nature 
1993, 366, 529– 531. 
260 Oi, S.; Fukita, S.; Hirata, N.; Watanuki, N.; Miyano, S.; Inoue, Y. Org. Lett. 2001, 3, 2579−2581. 
261 Ackermann, L.; Vicente, R. Top. Curr. Chem. 2010, 292, 211−229.  
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Figure 8.2: (A) Formation of the biscarboxylated ruthenium complex;  
(B) Proposed transition state for base-assisted ruthenations. 
 
The subsequent exhaustive mechanistic studies of this catalytic system carried out 
in ruthenium-catalyzed directed arylations and alkylations, effectively highlighted 
the key role of the carboxylated additives in promoting the C-H functionalization 
(Scheme 8.1).262 
 
 
Scheme 8.1: Proposed mechanism for direct arylations and alkylations by carboxylate 
assistance 
 
                                                
262 Ackermann, L. Acc. Chem. Res. 2014, 47, 281–295. 
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8.1.3 Ruthenium-catalyzed directed oxidative alkenylation of arenes 
Among the various transformations that can be classified as dehydrogenative 
cross-coupling reactions, the direct oxidative alkenylation of arenes via a double 
C-H cleavage is an appealing tool for the synthesis of highly functionalized 
aromatic rings (Figure 8.3A). This process (firstly proposed by Fujiwara and 
Moritani)263 based on a direct two-fold C-H activation allows to overcome the 
formation of pre-functionalized starting materials, emerging as a more atom- and 
step-economical strategy than the classical Heck (also known as the Mizoroki–
Heck) reaction: the palladium-catalyzed alkenylation of	  aryl halides with alkenes 
(Figure 8.3B).264 
 
 
Figure 8.3: Strategies for alkenylation of arenes 
 
Also for this kind of transformation, various synthetic protocols catalyzed by 
palladium (and also by rhodium) are known,265 however the use of ruthenium 
catalysts for the C-H alkenylation of arenes emerged for the first time only at the 
beginning of millennium.266 The initial limitations observed in this pioneering 
work were successively overcame in recent years by the investigations carried out 
by different research groups, including those of Ackermann and Miura & Satoh, 
that have led to the identification of different ruthenium complexes, to the 
introduction and to the use of Lewis-basic directing groups in the arene, and to the 
                                                
263 Fujiwara, Y.; Moritani, I.; Matsuda, M. Tetrahedron 1968, 24, 4819-4824.  
264 (a) Mizoroki, T.; Mori, K.; Ozaki, A. Bull. Chem. Soc. Jap. 1971, 44, 581; (b) Heck, R. F.; Nolley, 
J. P. J. Org. Chem., 1972, 37, 2320–2322; c) Oestreich, M. The Mizoroki-Heck Reaction, Wiley, 
Weinheim, 2009.  
265 Zhou, L.; Lu, W. Chem. Eur. J. 2014, 20, 634–642. 
266 Weissman, H.; Song, X.; Milstein, D. J. Am. Chem. Soc. 2001, 123, 337-338.  
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employment of external oxidants and additives. This extensive study has allowed 
the direct oxidative alkenylation of arenes bearing whether electron-withdrawing 
or electron-donating groups and, notably, also of heteroaromatic rings.267 
  
                                                
267 Kozhushkov, S. I.; Ackermann, L. Chem. Sci. 2013, 4, 886-896. 
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8.2 RUTHENIUM(II)-CATALYZED OXIDATIVE C-H ALKENYLATIONS OF 
ARYL SULFONAMIDES 
This section of the present doctoral thesis was developed in the group of Prof. 
Ackermann at the Institut für Organische und Biomolekulare Chemie of the 
Georg-August Universität of Göttingen during a 3-month period in September-
December 2013. 
 
Despite the large variety of experiments focused on exploring the aptitudes the 
role of numerous directing groups for the ruthenium-catalyzed oxidative C-H 
functionalization of arenes, the investigation of C-H activation on aryl 
sulfonamides has remained almost unexplored. Thus, a literature search revealed 
that only some cases of C-H functionalization of sulfonamides based had been 
reported and were based on the use of very expensive transition-metal catalyst 
such as palladium268 and rhodium.269 The great interest toward this kind of 
derivatives stems from their pronounced pharmaceutical properties and their 
cardinal importance in medicinal chemistry and makes the possibility to directly 
functionalize the aryl sulfonamide moiety really attractive. This prompted 
Ackermann and his group to investigate the efficiency of its ruthenium catalytic 
system in the oxidative C-H olefination of aryl sulfonamides (Scheme 8.2). 
 
 
Scheme 8.2: The project proposal for the ruthenium-catalyzed oxidative C-H alkenylation of 
aryl sulfonamides  
 
An initial study of the reaction was conducted employing N-isopropyl-4-methyl 
benzenesulfonamide as starting material that was synthesized according to a 
known procedure, simply reacting the p-toluenesulfonyl chloride with 
isopropylamine in diethyl ether in the presence of triethylamine at room 
                                                
268 Dai, H.-X.; Stepan, A. F.; Plummer, M. S.; Zhang, Y.-H.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 
7222-7228. 
269 Pham, M. V.; Ye, B.; Cramer, N. Angew. Chem. Int. Ed. 2012, 51, 10610-10614. 
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temperature (Scheme 8.3).270 
 
 
Scheme 8.3: Synthesis of the starting material 163 
 
Our initial screening was carried out employing 163 and an excess of ethyl 
acrylate (3 equiv) as starting materials (Scheme 8.4). The catalytic system 
developed by the Ackermann group consists of the ruthenium catalyst [RuCl2(p-
cymene)]2, the sacrificial oxidant and an additive. The effect of different solvents 
at various temperatures tried for this initial study, are shown in Table 8.1.  
 
 
Scheme 8.4: Initial screening of the reaction conditions for the oxidative C-H alkenylation 
employing N-isopropyl-4-methyl benzenesulfonamide as starting material 
 
Unfortunately, as shown in the Table 8.1, despite the numerous reaction 
conditions tested, this initial screening did not afford the desired product, and only 
the starting material (in some experiments together with the dimer of the	  acrylate) 
was recovered in all the reactions. 
 
Table 8.1. Study of the catalytic reaction involving 163 as starting material 
Entry Solvent Oxidant Additive Temp. Time 
Product 
(Yield %)a 
1 DMA Cu(OAc)2·H2O AgSbF6 
120 °C, 
under N2 
18 h sm 
2 tAmOH Cu(OAc)2·H2O AgSbF6 
120 °C, 
under N2 
18 h sm (86%) 
                                                
270 Hamura, S.; Oda, T.; Shimizu, Y.; Matsubara, K.; Nagashima, H. J. Chem. Soc., Dalton Trans. 
2002, 1521-1527. 
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Entry Solvent Oxidant Additive Temp. Time 
Product 
(Yield %)a 
3 PhCH3 Cu(OAc)2·H2O AgSbF6 
120 °C, 
under N2 
18 h sm 
4 H2O Cu(OAc)2·H2O AgSbF6 
100 °C, 
under N2 
18 h sm (91%) 
5 DCE Cu(OAc)2·H2O AgSbF6 
100 °C, 
under N2 
18 h 
sm (93%) + 
da 
6 DME Cu(OAc)2·H2O AgSbF6 
100 °C, 
under N2 
16 h 
sm (83%) + 
da 
7 1,4-dioxane Cu(OAc)2·H2O AgSbF6 
100 °C, 
under N2 
16 h 
sm (81%) + 
da 
8 o-xylene Cu(OAc)2·H2O AgSbF6 
100 °C, 
under N2 
16 h sm 
9 NMP Cu(OAc)2·H2O AgSbF6 
100 °C, 
under N2 
16 h sm 
10 MeOH Cu(OAc)2·H2O AgSbF6 
80 °C, 
under N2 
16 h sm 
11 DCE AgOAc 
tBuLeu-
OH 
100 °C, 
under air 
16 h sm 
12 DCE AgOAc 
No 
additive 
100 °C, 
under air 
16 h sm 
13 DCE Cu(OAc)2·H2O 
No 
additive 
100 °C, 
under air 
16 h sm 
14 DCMb AgOAc 
tBuLeu-
OH 
80 °C, 
under air 
16 h sm (86%) 
a: sm = starting material (163); da = dimer of acrylate; 
b: Reaction conditions employed in C-H olefination Pd-catalyzed271 
 
Owing to the lack of reactivity of our benzenesulfonamide 163, we decided to 
move toward the use of a more acidic benzenesulfoanilide derived from 
pentafluoroaniline. Also in this case, the formation of the desired starting material 
165 was achieved according to a known literature procedure271 based on the 
reaction between the p-toluenesulfonyl chloride and pentafluoroaniline in 
                                                
271 Dai, H.-X.; Stepan, A. F.; Plummer, M. S.; Zhang, Y.-H.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 
7222-7228 
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refluxing pyridine in the presence of DMAP for 16 hours (Scheme 8.5). 
 
 
Scheme 8.5: Synthesis of the new starting material 
 
With this new benzenesulfoanilide in hand, we started again the study of the 
reaction conditions for the C-H alkenylation; we were pleased to realize that the 
new N-arylbenzenesulfonamide 165 did show a higher reactivity than 163, 
affording an encouraging mixture of new products (Scheme 8.6). 
 
 
Scheme 8.6: Screening of the reaction conditions for the oxidative C-H alkenylation using 165 
as starting material 
 
As shown in the Scheme 8.6 and in the Table 8.2, purifying the crude mixtures 
obtained in these reactions, we could isolate and identify two interesting products 
(168 and 169) obtained by the effective direct C-H ortho-alkenylation of the aryl 
sulfonamide 165. Notably these two products were both derived from the mono-
alkenylation of 165 but, interestingly, in some cases the alkenylated product 169 
underwent a chemoselective intramolecular aza-Michael reaction affording the 
cyclic compound 168 (entries 6-13). Moreover in some experiments it was also 
O2
S Cl +
H2NH3C
F
F
F
F
F
O2
S N
H
H3C
F
F
F
F
F
165 (38%)
DMAP, Pyr 
rt, then 80 °C
16 h
+ COOEt
solvent, temperature °C, time
[RuCl2(p-cymene)]2 (5 mol%)
Cu(OAc)2·H2O (2 eq.)
AgSbF6 (20 mol%)
O2
S N
H
H3C
F
F
F
F
F
mixture of products
Products:
O2
S N
H
H3C
F
F
F
F
F N
O2
S
F F
F
FF
EtOOC
H3C
COOEt
COOEt
169 DAP
165
N
O2
S
F F
F
FF
EtOOC
H3C
168
188 8. Ru(II)-catalyzed C-H activation of sulfonamides 
 
 
possible to detect (even if it was impossible to achieve its purification due to an 
identical polarity with 168) the presence of a small amount of compound DAP 
resulting from a double ortho-alkenylation reaction (entries 7-13).  
 
Table 8.2. Study of the catalytic reaction involving 165 as starting material 
Entry Solvent Conditions 
Time 
(h) 
Product (Yield %) 
sma 169 168 DAP 
1 DCE 
100 °C, 
under N2 
16 77 - - - 
2 DME 
100 °C, 
under N2 
16 72 12 - - 
3 
1,4-
dioxane 
100 °C, 
under N2 
16 68 9 - - 
4 tAmOH 
120 °C, 
under N2 
16 68 10 - - 
5 PhCH3 
120 °C, 
under N2 
16 85 - - - 
6 DMA 
120 °C, 
under N2 
16 50 19 5 - 
7 DMF 
120 °C, 
under N2 
16 9 31 6 9 
8 H2O 
120 °C, 
under N2 
16 15 26 15 5 
9 
DMF/H2O 
(1/5) 
120 °C, 
under N2 
20 22 37 15 11 
10 
DMF/H2O 
(1/10) 
120 °C, 
under N2 
20 23 38 17 9 
11 
DMF/H2O 
(1/10) 
120 °C, 
under air 
16 38 4 38 3 
12b 
DMF/H2O 
(1/10) 
120 °C, 
under N2 
16 12 46 12 23 
13b,c 
DMF/H2O 
(1/10) a 
120 °C, 
under N2 
16 13 37 12 7 
a: sm = 165 
b: Reactions carried out in the absence of any additive (AgSbF6); 
c: In this reaction 1,5 eq. of ethyl acrylate was employed 
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Among the numerous solvents tested (entries 1-8), DMF and water seemed to be 
the most suitable ones for a better conversion of the starting material 165 (entries 
7 and 8); therefore we decided to study the effect of the combination in different 
ratio of these two solvents. Commendably the two examined different 
combinations of DMF and H2O (entries 9 and 10) allowed the formation of the 
products in interesting yields; we decided to choose the	  mixture with ratio 1:10 
because of its easier handling during the workup. Considering the oxidative 
character of our reaction, we investigated also the effect of the air atmosphere 
instead of the usual nitrogen atmosphere and surprisingly the latter conditions 
gave better results. Finally, it is worth highlighting that, initially, based on our 
previous laboratory experience, the reactions were performed in presence of 
AgSbF6; nevertheless a better conversion of our starting material 165 was 
achieved in the absence of any additive (entries 12 and 13). After this screening, 
we decided therefore to choose the conditions reported in the entry 12 as our 
optimal ones.  
Nevertheless, the lack of selectivity of our reaction, with the formation of a 
mixture of the three products 168, 169 and DAP, represented a relevant problem 
that remained unsolved in these experimental conditions. We tried to overcome 
this obstacle by decreasing the amount of the alkenylating agent, but 
unfortunately, we could not avoid the formation of the di-olefinated product DAP 
(entry 13). Thus, to prevent the formation of this undesired mixture of products, 
we decided again to change our starting material, employing this time a meta-
substituted benzene sulfonamide in order to direct the alkenylation process toward 
the less hindered ortho-C-H bond of the aryl sulfonamide. We proceeded 
therefore to the synthesis of the 3-methyl-N-(pentafluorophenyl) 
benzenesulfonamide 167 employing the same reaction conditions used in the 
preparation of 165 (Scheme 8.7). 
 
 
Scheme 8.7: Synthesis of the new meta-substituted starting material 167 
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With the optimal conditions determined in the previous experiments, we started 
studying the effects of different oxidizing agents employing starting materials 165 
and 167. As shown in Scheme 8.8, the new compound 167 afforded a less 
complex mixture of products containing only the open 171 and the cyclized 
mono-olefinated compounds 170. 
 
 
Scheme 8.8: Screening of different oxidants for the oxidative C-H alkenylation 
 
Table 8.3. Screening of different oxidants for the oxidative C-H alkenylation 
Entry Oxidant 
Product (Yield %) 
Sm: 165 Sm: 167 
1 Cu(OAc)2·H2O 
sm (12%), 168 (12%) 
169 (46%), DAP (23%) 
sm (14%), 170 (21%) 
171 (52%) 
2 CuBr2 sm (74%) 168 (5%) sm (67%), 170 (7%) 
3 CuBr2/NaOAc sm (74%), 168 (5%) 
sm (48%), 170 (14%) 
171 (22%) 
4 AgOAc 
sm (48%), 168 (18%) 
169 (5%) 
sm (62%), 170 (6%) 
171 (7%) 
5 AgXa sm (72%), 168 (5%) sm (61%), 170 (12%) 
6 Benzoquinone No identified products 
No identified 
products 
7 PhI(OAc)2 sm (84%) sm (89%) 
a: AgNO3 was employed with sm = 165, whereas AgCl was used with sm = 167. 
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As expected, Cu(OAc)2·H2O proved to be effective among various sacrificial 
oxidants. Interestingly, also CuBr2 and AgNO3 or AgCl could be employed as 
oxidants, affording small amounts of the desired products, which could be 
increased if additional quantities of an acetate salt were present (entries 2-5), thus 
indicating the importance of the carboxylate assistance. Finally, whereas 
PhI(OAc)2 proved to be ineffective as terminal oxidant (entry 7), benzoquinone 
evidenced some role as a reagent, generating a complex reaction mixture that we 
could not purify but that did not contain the expected products (entry 8). 
In an attempt to improve the conversion of the starting material and to achieve the 
exclusive formation of the cyclized product 170 derived from the intramolecular 
aza-Michael addition of 171 in a one-pot fashion, we started a screening of 
different additives (Scheme 8.9). 
 
 
Scheme 8.9: Screening of different additives for the oxidative C-H alkenylation 
 
As shown in Table 8.4, different additives were tested (entries 2-6) and only 
AgSbF6 and KPF6 gave promising results (entries 5 and 6) with the latter one 
showing a slightly better conversion of 167 into the desired product 170. 
Unfortunately neither increasing the reaction time (entry 7), nor the additive load 
(entry 8), afforded the expected improvement in the yield of 170. As the key step 
for this conversion was the intramolecular aza-Michael cyclization of 171, we 
decided to examine also the reactivity of two Lewis acids that are usually 
employed in this kind of reactions; unfortunately, neither CAN nor FeCl3 could 
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promote the desired cyclization of 171 (entries 9 and 10). Finally we also 
investigated the effect of the AgSbF6 and KPF6 in pure DMF, but once again the 
reaction afforded the known mixture of 170 and 171. 
 
Table 8.4. Screening of different additives for the oxidative C-H alkenylation 
Entry Additive 
Add. load 
(mol %) 
Time 
(h) 
Products yield (%) 
sm (167) 170 171 
1 - - 16 14 21 52 
2 MesCOOH 20 16 29 25 40 
3 MesCOOK 20 16 19 25 29 
4 
N-Piv-
LeuOH 
20 16 19 35 30 
5 AgSbF6 20 16 18 28 39 
6 KPF6 20 16 20 30 31 
7 KPF6 20 20 12 30 43 
8 KPF6 30 16 15 22 49 
9 CAN 20 16 37 27 13 
10 FeCl3 20 16 20 20 56 
11 KPF6a 20 16 62 - 12 
12 AgSbF6a 20 16 62 - 19 
a: reaction carried out in DMF 
 
To finish, we decided to study the conversion of the isolated 171 into 170 by 
employing different reagents in reaction conditions similar to the ones used for 
the catalytic reaction (due to the small amount of the reactive employed and its 
low solubility in water, the ratio between H2O and DMF was slightly increased 
from 10/1 to 5/1 in favor of the second one) (Scheme 8.10). 
 
 
Scheme 8.10: Study of the conditions for the intramolecular aza-Michael cyclization of 171 
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As shown in the Table 8.5 all the examined reagents such as Brønsted acids (entry 
1) or bases (entry 2) and Lewis acids (entries 3-5) afforded, in these reaction 
conditions, a good to excellent conversion of 171 into 170, even though the 
reaction seems to proceed slowly (after 4 hours at 120 °C, the	   reaction was 
monitored by TLC and only a partial conversion of 171 into 170 was appreciable). 
 
Table 8.5. Use of different reagents for the intramolecular aza-Michael cyclization of 171 
Entry Reagent Conversiona 
1 PTSA 88% 
2 DBU 81% 
3 CAN 88% 
4 InCl3 93% 
5 BF3OEt2 89% 
a: calculated by H-NMR 
 
With these promising results in hand, we tried again to carry out the reaction in a 
one-pot fashion using as additives these reagents that had shown to promote the 
intramolecular aza-Michael reaction. The use of PTSA was avoided since, 
according to our laboratory experience in similar reaction conditions, it underwent 
the same kind of C-H activation as 167 (Scheme 8.11). 
 
 
Scheme 8.11: Attempts for a one-pot domino oxidative C-H alkenylation/aza-Michael reaction 
 
As shown in the Table 8.6, in the examined conditions none of the reagents 
employed seemed to promote efficiently the one-pot cyclization, being the major 
product the open monoolefinated 171. 
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Table 8.6 Study for a one-pot domino oxidative C-H alkenylation/aza-Michael reaction 
Entry Additive 
Products yield (%) 
sm (167) 170 171 
1 DBU 16 16 51 
2 CAN 37 27 13 
3 InCl3 26 26 48 
4 BF3OEt2 25 20 45 
 
In a further attempt to get exclusively the bicyclic product 170, we tried to do the 
reaction in a sequential manner, adding InCl3 to the mixture after the first 16 
hours of reaction, and leaving the whole at the same conditions for additional 8 
hours. Unfortunately, as shown in Scheme 8.12, once again, the reaction afforded 
the usual mixture of compounds 170 and 171. 
 
 
Scheme 8.12: Sequential catalytic reaction 
 
In a further attempt to develop a synthetic methodology that could afford only the 
cyclized product 170, we ran the reaction under the standard conditions without 
any additive and at 150 °C in a sealed tube. In this case, only 170 was isolated 
after column chromatography in a moderate yield (41% isolated), although with 
recovery of 45% of the starting material (Scheme 8.13). 
 
 
Scheme 8.13: Catalytic reaction performed at 150 °C in a sealed tube. 
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To reduce molecular complexity and facilitate the C-H activation on the ortho-
position of the sulfonamide group we decided to synthesize also the 2,4-
dimethylbenzenesulfonamide 166. According to a literature procedure,272  we 
initially prepared the sulfonylchloride 164 by reacting 2,4-
dimethylbenzenesulfonic acid with 2,4,6-trichloro-1,3,5-triazine in refluxing 
acetone in the presence of triethylamine; the obtained sulfonyl chloride 164 was 
then employed in the preparation of the corresponding pentafluoroanilide 
according to the previously described procedure (Scheme 8.14). 
 
 
Scheme 8.14: Synthesis of 2,4-dimethylbenzenesulfonamide 166 as starting material. 
 
The behavior of the 2,4-dimethylbenzenesulfonamide 166 was similar to that of 
167, and when it was employed as starting material in our standard condition, we 
were able to recover, also in this case in a moderate yield, only the cyclized 
product 173 together with recovered starting material (Scheme 8.15). 
Unfortunately, due to the identical polarity of the starting material and	  the final 
product, it was impossible to isolate and characterize the latter one. 
 
 
Scheme 8.15: Oxidative C-H alkenylation using 166 as starting material. 
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8.3 MECHANISTIC PROPOSAL 
Finally, to prove the importance of the free-NH of the benzenesulfonamides for 
directing the alkenylation on its ortho-position, the N-Me derived of 167 was 
prepared by a two-step procedure employing sodium hydride in anhydrous DMF 
to deprotonate the sulfonamide NH followed by the alkylation with methyl iodide, 
to afford compound 172.273   
 
 
Scheme 8.16: Use of a N-methylathed starting material 172 for the ruthenium-catalyzed 
alkenylation. 
 
As expected, in the optimal reaction conditions, this new starting material did not 
undergo the C-H activation process and the starting material could be recovered 
after the reaction, confirming the pivotal role of the free NH in the mechanism of 
the ruthenium-catalyzed alkenylation (Scheme 8.16). 
Based on previous mechanistic studies, as shown in the Scheme 8.17, the 
Ackermann group proposed a plausible catalytic cycle that initiates with a 
reversible cyclometalation by a cationic ruthenium(II) complex to deliver 
complex I. Then, the subsequent insertion of the alkene generates the 
ruthenacycle II, which by β-hydride elimination furnishes the desired product 
171. Reductive elimination gives rise to a ruthenium(0) species, which is finally 
re-oxidized by Cu(OAc)2. 
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Scheme 8.17: Mechanistic rationale for the oxidative alkenylation of aryl sulfonamide 
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9.1 GENERAL EXPERIMENTAL INFORMATION 
All air- and/or moisture-sensitive reactions were carried out under an argon 
atmosphere in oven-dried glassware. Solvents and reagents were transferred by 
syringe or via cannula through rubber septa. 
Solvents 
Solvents were dried and purified by standard procedures. “Petroleum ether” refers 
to the fraction of light petroleum ether boiling in the range 40-60 °C. 
Reagents 
All commercially available reagents employed (Panreac, Probus, Scharlau, Fluka, 
Aldrich, Alfa-Aesar) were used without further purification. 
Chromatography 
Analytical thin layer chromatography (TLC) was performed using commercially 
available aluminium-backed plates coated with silica gel Scharlau Cf 530 with 
fluorescent indicator and visualized under ultra-violet light lamp Camag UV-II (at 
254 and 366 nm). 
Flash column chromatography was carried out using silica gel SDS 60 ACC or 
Scharlau Ge 048 and the eluent indicated in each case. 
Automatic flash chromatography was performed in a Teledyne ISCO COMBI 
Flash Rf instrument using RediSep Rf silica columns (24 g and 40 g) or self 
packed silica cartridges. 
Melting Point 
Melting points were determined either using a Kofler-type heating platine 
microscope from Reicher, 723 Model, or in a Stuart Scientific apparatus, SMP3 
Model, and are uncorrected. 
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IR Spectroscopy 
Infrared spectra were recorded using two different kind of equipments: 
• a Perkin-Elmer FTIR Paragon-1000 spectrometer; samples were prepared 
in a film form, by evaporation of a few drops of sample solution over a 
sodium chloride or potassium bromide window. 
• an Agilent Cary630 FTIR spectrometer with a diamond ATR accessory for 
solid and liquid samples, requiring no sample preparation. 
NMR Spectroscopy 
1H and 13C nuclear magnetic resonance spectra were recorded at 250 and 500 
MHz in the following spectrometers: Bruker AV-250 (1H, 250 MHz; 13C, 63 
MHz) and Bruker AV-500 (1H, 500 MHz; 13C, 125 MHz). CDCl3 and MeOD 
were used as deuterated solvents and all chemical shifts are quoted in parts per 
million and reported as follows: chemical shift δ (ppm) (multiplicity, number of 
protons, coupling constant J (Hz), assignment). Coupling constants are given in 
Hertz and multiplicity of NMR signals indicated as s (singlet), br s (broad singlet), 
d (doblet), t (triplet), q (quartet), sext (sextet), hept (heptet), m (multiplet), dd 
(doblet of doblets), dt (doblet of triplets) and td (triplet of doblets). NMR 
chemical shifts pointed as * show that the assignment can be interchanged 
between two or more magnetic nuclei with similar chemical shifts. Spectral 
assignments were carried out using DEPT, COSY, NOESY, HMQC, and HMBC 
experiments. The numeration shown in the structures of every single product 
doesn’t correspond to the official IUPAC numeration; its only purpose is to make 
the NMR assignment easier to understand. 
Mass Spectrometry 
Gas chromatography mass spectra (GC-MS) were taken with different ionization 
methods, as Electronic Impact (EI) or Electrospray Ionization (ESI) in both the 
positive and negative ion mode were carried out by Unidad de Espectometría de 
Masas from Universidad Complutense Madrid (Spain). 
Elemental Analysis 
Cuantitative elemental analysis by combustion of carbon, hydrogen, nitrogen and 
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sulfur were carried out in Servicio de Microanálisis Elemental from Universidad 
Complutense (Madrid, Spain), using a Leco CHNS 932 Elemental Analyzer. 
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9.2 A NEW MULTICOMPONENT PROTOCOL FOR THE SYNTHESIS OF 
PYRIDINE DERIVATIVES  
9.2.1 Synthesis of starting β-ketoesters 1-3. 
9.2.1.1 Synthesis of β-ketoesters 1 and 2. 
 
 
 
Compound R 
2 Allyl 
3 
 
 
To a solution of LDA (2.3 equiv, 23 mmol), generated in situ from 
diisopropylamine and n-butyllithium in THF anhydrous at 0 °C for 30 min, ethyl 
acetoacetate (1 equiv, 10 mmol) was added. The reaction mixture was stirred for 
45 min, then the corresponding bromide derivative (1.3 equiv, 13 mmol) was 
added and the mixture was stirred for 2 hours at 0 °C. The mixture was quenched 
with saturated aqueous NH4Cl solution and allowed to warm to room temperature. 
The two phases were separated, and the aqueous phase was repeatedly extracted 
with ethyl acetate. The combined organic layers were washed with brine, dried 
with Na2SO4 and the solvent was evaporated under reduced pressure to give 
compounds 2 and 3. The crude product thus obtained was used in subsequent 
reactions with no further purification. 
  
H3C OEt
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Ethyl 3-oxohept-6-enoate (2) 
Prepared from ethyl acetoacetate (1.301 g, 10 mmol) and 
allyl bromide (1.573 g, 13 mmol). 
Yield: 1.545 g (91%). Pale yellow liquid. 
 
Data of 2: 
IR (NaCl) ν 1744 (C-3=O), 1718 (C-1=O), 1317 (C-O), 916 (C=CH2) cm-1. 
1H-NMR (CDCl3, 250 MHz) 1.28 (t, J = 7.12 Hz, 3H, OCH2CH3), 2.31-2.39 (m, 
2H, CH2-5), 2.60-2.75 (m, 2H, CH2-4), 3.47 (s, 2H, CH2-2), 4.20 (q, J = 7.12 Hz, 
2H, OCH2CH3), 4.97-5.08 (m, 2H, CH2-7), 5.72-5.84 (m, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 202.5 (C-3=O), 167.6 (C-1=O), 137.0 (CH-6), 
115.9 (CH2-7), 61.8 (OCH2CH3), 49.8 (CH2-2), 42.4 (CH2-4), 27.8 (CH2-5), 14.5 
(OCH2CH3) ppm. 
These data are consistent with those described in the literature.274 
      
Ethyl 5-(furan-2-yl)-3-oxopentanoate (3) 
Prepared from ethyl acetoacetate (1.301 g, 10 mmol) and 
2-(bromomethyl)furan (2.079 g, 13 mmol). 
Yield: 1.535 g (73%). Brown liquid. 
 
Data of 3: 
IR (NaCl) ν 1744 (C-3=O), 1717 (C-1=O), 1317 (C-O) cm-1; 
1H-NMR (CDCl3, 250 MHz) δ 1.30 (t, J = 7.12 Hz, 3H, OCH2CH3), 2.91-2.94 
(m, 4H, CH2-4 and CH2-5), 3.47 (s, 2H, CH2-2), 4.21 (q, J = 7.12 Hz, 2H, 
OCH2CH3), 6.03 (dd, J = 0.75, 3.13 Hz, 1H, CH-3’), 6.29 (dd, J = 1.85, 3.13 Hz, 
1H, CH-4’), 7.31 (dd, J = 0.75, 1.85 Hz, 1H, CH-5’) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 201.8 (C-3=O), 167.4 (C-1=O), 154.4 (C-2’), 
141.5 (CH-5’), 110.6 (CH-4’), 105.7 (CH-3’), 61.7 (OCH2CH3), 49.5 (CH2-2), 
41.3 (CH2-4), 22.2 (CH2-5), 14.4 (OCH2CH3) ppm. 
These data are consistent with those described in the literature.275 
       
                                                
274 Huckin, S. N.; Weiler, L. J. Am. Chem. Soc. 1974, 96, 1082-1087. 
275 Matsui, M.; LaForge, F. B.; Green, N.; Schechter, M. S. J. Am. Chem. Soc. 1952, 74, 2181-2182. 
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9.2.1.2 Synthesis of ethyl 4-(tert-butylthio)-3-oxobutanoate (4) 
 
 
 
A mixture of 2-methylpropane-2-thiol (1 equiv, 10 mmol), ethyl 4-chloro-3-
oxobutanoate (1 equiv, 10 mmol) and potassium carbonate (1.1 equiv, 11 mmol) 
was stirred, in the absence of any solvents, for 90 min. After completion of the 
reaction (checked by TLC), the mixture was diluted with CH2Cl2 (40 mL), 
washed with water (10 mL) and brine, and dried over anhydrous Na2SO4. The 
solvent was evaporated under reduced pressure, and the residue mixture was then 
purified by silica gel column chromatography using petroleum ether:ethyl acetate 
mixture (from 10:1 to 5:1, v/v) as eluent to give 1.725 g (79% yield) of 4 as a 
brown liquid. 
 
Data of 4: 
Elemental analysis calcd (%)for C10H8O3S: C 55.02, H 8.31, S 14.69; found: C 
54.78, H 8.30, S 14.85. 
IR (NaCl) ν 1735 (C-1=O), 1366 (C-1-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.24-1.34 (m, 12H, OCH2CH3 and SC(CH3)3), 
3.44 (s, 2H, CH2-2), 3.69 (s, 2H, CH2-4), 4.19 (q, J = 7.12 Hz, 2H, OCH2CH3) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 200.7 (C-3=O), 167.6 (C-1=O), 61.7 (OCH2CH3), 
46.8 (CH2-2), 44.0 (SC(CH3)3), 40.0 (CH2-4), 31.1 (SC(CH3)3), 14.4 (OCH2CH3) 
ppm. 
These data are consistent with those described in the literature.276 
      
  
                                                
276 Hutchinson, J. H.; Riendeau, D.; Brideau, C.; Chan, C.; Delorme, D.; Denis, D.; Falgueyret, J. P.; 
Fortin, R.; Guay, J. J. Med. Chem. 1993, 36, 2771-2787. 
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9.2.2 Synthesis of the oxime and the β-enaminones 5-8. 
 
 
 
Compound R1 R2 
5 OBn OEt 
6 NMe2 OEt 
7 NMe2 SC(CH3)3 
8 NMe2 Ph 
 
To a stirred solution of 1,1-dimethylhydrazine or the suitable O-substituted 
hydroxylamine (1 equiv, 1 mmol) and 1,3-dicarbonyl compounds (1 equiv, 1 
mmol) in ethanol or acetonitrile (1 mL) was added a Lewis acid (5 or 10 mol%) 
and stirring was continued for 30 min at room temperature. After completion of 
the reaction (checked by TLC), the mixture was diluted with CH2Cl2 (30 mL), 
washed with water followed by brine, dried over anhydrous Na2SO4, and the 
solvent was evaporated under reduced pressure. 
Data of representative compounds 5-8, and the experimental conditions employed 
for their synthesis are indicated below. 
  
NH2
R1 H3C R2
O O
+
Lewis acid
(5 or 10 mol%)
EtOH or CH3CN
rt, 30 min CH3
R2
O
NR
1 CH3
R2
O
HN
+
NMe2
6b-8b
(E+Z)
5a-8a
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(Z and E)-Ethyl 3-(benzyloxyimino)butanoate (5a) 
Prepared from O-benzylhydroxylamine (123 mg, 1 mmol), 
ethyl acetoacetate (130 mg, 1 mmol) and CAN (27 mg, 5 
mol%).  
Reaction time: 30 minutes.  
Yield: 222 mg (95%). Colorless viscous liquid. 
 
Data of 5a: 
1H-NMR (CDCl3, 250 MHz) two isomers δ 1.23-1.32 (m, 3H, OCH2CH3), 2.00 
and 2.01 (s, 3H, CH3-4), 3.24 and 3.40 (s, 2H, CH2-2), 4.12-4.24 (m, 2H, 
OCH2CH3), 5.12 and 5.15 (s, 2H, OCH2Ph), 7.29-7.40 (m, 5H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) two isomers δ 170.0 and 169.2 (C-1=O), 152.4 and 
151.3 (C-3=N), 138.4 and 138.3 (CAr), 128.75 and 128.72 (2xCHAr), 128.3 and 
128.2 (2xCHAr), 128.13 and 128.10 (CHAr), 76.0 and 75.9 (OCH2Ph), 61.4 and 
61.3 (OCH2CH3), 41.8 and 36.0 (CH2-2), 21.0 and 15.1 (CH3-4), 14.57 and 14.52 
(OCH2CH3) ppm. 
      
(Z and E)-Ethyl 3-(2,2-dimethylhydrazono)butanoate (6a) and ethyl 3-(2,2-
dimethylhydrazinyl)but-2-enoate (6b) 
Prepared from 1,1-dimethylhydrazine (60 mg, 1 
mmol), ethyl acetoacetate (130 mg, 1 mmol) and 
InCl3 (22 mg, 10 mol%).  
Reaction time: 30 minutes.  
Yield: 169 mg (98%). Pale yellow viscous liquid. 
 
Data of 6a and 6b: 
1H-NMR (CDCl3, 250 MHz) three isomers δ 1.19-1.28 (m, 3H, OCH2CH3 for 6a 
and 6b), 1.97 (s, 3H, CH3-4 for 6b), 1.99 and 2.01 (s, 3H, CH3-4 for 6a), 2.37 and 
2.45 (s, 6H, N(CH3)2 for 6a), 2.49 (s, 6H, N(CH3)2 for 6b), 3.22 and 3.48 (s, 2H,	  
CH2-2 for 6a), 4.01-4.15 (m, 2H, OCH2CH3 for 6a and 6b), 4.32 (s, 1H, CH-2 for 
6b), 8.88 (bs, 1H, NH for 6b) ppm. 
CH3
OEt
O
N
O
12
3
4
CH3
OEt
O
NMe2N CH3
EtO
O
HN
and
NMe2
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These data are consistent with those described in the literature.277 
      
(Z and E)-S-tert-butyl 3-(2,2-dimethylhydrazono)butanethioate (7a) and S-
tert-Butyl 3-(2,2-dimethylhydrazinyl)but-2-enethioate (7b) 
Prepared from 1,1-dimethylhydrazine (60 
mg, 1 mmol), S-tert-butyl 3-oxobutane 
thioate (174 mg, 1 mmol) and InCl3 (22 mg, 
10 mol%).  
Reaction time: 20 minutes.  
Yield: 210 mg (97%). Orange viscous liquid. 
 
Data of 7a and 7b: 
1H-NMR (CDCl3, 250 MHz) three isomers δ 1.47, 1.48 and 1.50 (s, 9H, S(CH3)3 
for 7a and 7b), 1.96 (s, 3H, CH3-4 for 7b), 2.02 and 2.08 (s, 3H, CH3-4 for 7a), 
2.42 and 2.50 (s, 6H, N(CH3)2 for 7a), 2.53 (s, 6H, N(CH3)2 for 7b), 3.40 and 3.72 
(s, 2H, CH2-2 for 7a), 4.77 (s, 1H, CH-2 for 7b), 9.65 (bs, 1H, NH for 7b) ppm. 
      
(Z and E)-3-(2,2-dimethylhydrazono)-1-phenylbutan-1-one (8a) and 3-(2,2-
Dimethylhydrazinyl)-1-phenylbut-2-en-1-one (8b) 
Prepared from 1,1-dimethylhydrazine (60 mg, 1 
mmol), 1-phenylbutane-1,3-dione (162 mg, 1 
mmol) and InCl3 (22 mg, 10 mol%).  
Reaction time: 30 minutes.  
Yield: 195 mg (96%). Pale yellow viscous liquid. 
 
Data of 8a and 8b: 
1H-NMR (CDCl3, 250 MHz) three isomers δ 2.20 (s, 3H, CH3-4 for 8b), 2.23 and 
2.33 (s, 3H, CH3-4 for 8a), 2.63 (s, 6H, N(CH3)2 for 8a and 8b), 3.85 (s, 2H, CH2-
2 for 8a), 5.59 (s, 1H, CH-2 for 8b), 7.29-7.47 (m, 3H, ArH for 8a and 8b), 7.85-
7.91 (m, 2H, ArH for 8a and 8b), 11.76 (bs, 1H, NH for 8b) ppm. 
                                                
277 Coqueret, X.; Bourelle-Wargnier, F.; Chuche, J. Tetrahedron 1986, 42, 2263-2273. 
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13C-NMR (CDCl3, 63 MHz) δ 188.0 (C-1=O), 165.1 (C-3), 140.4 (CAr), 130.9 
(CHAr), 128.5 (2xCHAr), 127.3 (2xCHAr), 90.4 (CH-2), 48.8 (N(CH3)2), 19.0  
(CH3-4) ppm. 
These data are consistent with those described in the literature.278 
      
  
                                                
278 Jones, W. D.; Schnettler, R. A.; Huber, E. W. J. Heterocyclic Chem. 1990, 27, 511-518. 
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9.2.3 Synthesis of pyridine derivatives 1, 11-23. General procedure 
 
 
 
Cmpd. R1 R2  Cmpd. R1 R2 
1 CH3 OEt  17  OEt 
11 Et OEt  18 CH3 OtBu 
12 Pr OEt  19 CH3 OAllyl 
13 iPr OEt  20 CH3 StBu 
14 CH2StBu OEt  21 CH3 CH3 
15 (CH2)2CH=CH2 OEt  22 CH3 Ph 
16 CH2COOEt OEt  23 CH3 iBu 
 
To a stirred solution of 1,1-dimethylhydrazine (1 equiv, 3 mmol) and the 
appropiate 1,3-dicarbonyl compound (1 equiv, 3 mmol) in ethanol (3 mL) was 
added InCl3 (10 mol%) and stirring was continued for 30 min at room 
temperature. Acrolein (1.2 equiv, 3.6 mmol) was then added and stirring was 
continued at the same conditions for the time period specified in the compound 
data sheet. After completion of the reaction (checked by NMR), the mixture was 
diluted with CH2Cl2 (20 mL), washed with water followed by brine,	  dried over 
anhydrous Na2SO4, and the solvent was evaporated under reduced pressure.  
The residue containing the tetrahydropyridine derivative was then dissolved in 
NEtO
N
CH3
OEt
O
CH3H3C
N R1
R2
O
1. InCl3 (10 mol%)
EtOH, rt
then workup
2. Pd/C (20% w/w)
PhCH3, reflux
Pd/C (20% w/w)
PhCH3, reflux
1, 11-23
O
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R2
N
NH2 O
O
H3C CH3
+
9
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N
CH3
OEt
O
CH3H3C
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InCl3 (10 mol%)
EtOH, rt
then workup
O
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toluene (10 mL), Palladium on Carbon 10 wt % loading (20% wt/crude) was 
added and the resulting mixture was heated under reflux for the time periods 
specified in the compound data sheet. After completion of the reaction (checked 
by TLC), the mixture was diluted with CH2Cl2 (20 mL) and filtered through 
Celite, which was then washed repeatedly with additional CH2Cl2 in 5 mL 
portions. The combined organic layers were concentrated to dryness and the 
residue was purified by silica gel column chromatography using petroleum 
ether:ethyl acetate mixtures as eluent to give pure compounds (1, 11-23).  
 
Data of compounds 1, 9, 10 and 11-23, and the experimental conditions employed 
for their synthesis are indicated below. 
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Ethyl 1-(dimethylamino)-6-ethoxy-2-methyl-1,4,5,6-tetrahydropyridine-3-
carboxylate (9) 
Isolated from the reaction among 1,1-dimethylhydrazine, ethyl 
acetoacetate and acrolein, without performing any further step 
of oxidation. 
Pale yellow viscous liquid. In the spectra there is also a low 
percentage of the dihydropyridine derivative 10 due to the oxidation of 9 during 
the chromatographic purification. 
Purification: n-hexane:ethyl acetate (from 20:1 to 10:1, v/v) 
 
Data of 9: 
1H-NMR (CDCl3, 250 MHz) δ 1.12-1.28 (m, 6H, 2xOCH2CH3), 1.99-2.95 (m, 
2H, CH2-5), 2.20-2.28 (m, 2H, CH2-4), 2.37 (s, 3H, C-2CH3), 2.39 (s, 3H, NCH3), 
2.55 (s, 3H, NCH3), 3.38-3.49 (m, 2H, C-6OCH2CH3), 4.00-4.07 (m, 2H, 
COOCH2CH3), 4.67 (bs 1H, CH-6) ppm. 
      
Ethyl 1-(dimethylamino)-2-methyl-1,4-dihydropyridine-3-carboxylate (10) 
Generated from the partial oxidation of 9.  
Pale yellow viscous liquid. 
Purification: n-hexane:ethyl acetate (from 20:1 to 10:1, v/v) 
 
Data of 10: 
1H-NMR (CDCl3, 250 MHz) δ 1.28 (t, J = 7.1, 3H, OCH2CH3), 2.38 (s, 3H, C-
2CH3), 2.53 (s, 6H, N(CH3)2), 3.11-3.13 (m, 2H, CH2-4), 4.15 (q, J =7.1 Hz, 2H, 
OCH2CH3), 4.92 (dt, J = 3.75, 8.2 Hz, 1H, CH-5), 6.05 (td, J= 1.5, 8.2 Hz, 1H, 
CH-6) ppm. 
      
Ethyl 2-methylnicotinate (1) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), ethyl 
acetoacetate(390 mg, 3 mmol) and acrolein (202 mg, 3.6 mmol).  
Reaction time: 3 h for the first step and 12 h for the second step.  
NEtO
N
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Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v) 
Yield: 420 mg (85%). Pale yellow viscous liquid. 
 
Data of 1: 
Elemental analysis calcd (%) for C9H11NO2: C 65.44, H 6.71, N 8.48; found: C 
65.18, H 6.81, N 8.29. 
IR (NaCl) ν: 1724 (C=O), 1585 (C=N), 1278 (C-O) cm-1 
1H-NMR (CDCl3, 250 MHz) δ 1.41 (t, J = 7.3 Hz, 3H, OCH2CH3), 2.86 (s, 3H, 
C-2CH3), 4.39 (q, J = 7.3 Hz, 2H, OCH2CH3), 7.22 (dd, J = 4.8, 7.85 Hz, 1H, 
CH-5), 8.20 (dd, J = 1.8, 7.85 Hz, 1H, CH-4), 8.62 (dd, J = 1.8, 4.8 Hz, 1H, CH-
6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 167.0 (C=O), 160.2 (C-2), 152.1 (CH-6), 138.8 
(CH-4), 126.1 (C-3), 121.3 (CH-5), 61.7 (OCH2CH3), 25.2 (C-2CH3), 14.7 
(OCH2CH3) ppm. 
      
Ethyl 2-ethylnicotinate (11) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), ethyl 3-
oxopentanoate (433 mg, 3 mmol) and acrolein (202 mg, 3.6 mmol).  
Reaction time: 3 h for the first step and 12 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v). 
Yield: 397 mg (74%). Pale yellow viscous liquid. 
 
Data of 11: 
Elemental analysis calcd (%) for C10H13NO2: C 67.02, H 7.31, N 7.82; found: C 
66.89, H 7.29, N 7.69. 
IR (NaCl) ν 1724 (C=O), 1584 (C=N), 1269 (C-O) cm-1 
1H-NMR (CDCl3, 250 MHz) δ 1.33 (t, J = 7.5 Hz, 3H, OCH2CH3), 1.42 (t, J = 
7.15	  Hz, 3H, C-2CH2CH3), 3.19 (q, J = 7.5 Hz, 2H, C-2CH2CH3), 4.40 (q, J = 
7.15 Hz, 2H, OCH2CH3), 7.22 (dd, J = 4.8, 7.87 Hz, 1H, CH-5), 8.16 (dd, J = 1.8, 
7.87 Hz, 1H, CH-4), 8.66 (dd, J = 1.8, 4.8 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 167.1 (C=O), 164.7 (C-2), 152.1 (CH-6), 138.7 
(CH-4), 125.9 (C-3), 121.1 (CH-5), 61.7 (OCH2CH3), 30.7 (C-2CH2CH3), 14.6 
(OCH2CH3), 14.3 (C-2CH2CH3) ppm. 
N
OEt
O
CH3
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Ethyl 2-propylnicotinate (12) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), ethyl 
butyrylacetate (475 mg, 3 mmol) and acrolein (202 mg, 3.6 mmol).  
Reaction time: 3 h for the first step and 12 h for the second step. 
Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v). 
Yield: 440 mg (76%). Pale yellow viscous liquid. 
 
Data of 12: 
Elemental analysis calcd (%) for C11H15NO2: C 68.37, H 7.82, N 7.25; found: C 
68.19, H 7.77, N 7.53. 
IR (NaCl) ν 1725 (C=O), 1584 (C=N), 1261 (C-O) cm-1 
1H-NMR (CDCl3, 250 MHz) δ 1.00 (t, J = 7.35 Hz, 3H, C-2CH2CH2CH3), 1.40 
(t, J = 7.15 Hz, 3H, OCH2CH3), 1.70-1.79 (m, 2H, C-2CH2CH2CH3), 3.10-3.16 
(m, 2H, C-2CH2CH2CH3), 4.38 (q, J = 7.15 Hz, 2H, OCH2CH3), 7.19 (dd, J = 4.8, 
7.87 Hz, 1H, CH-5), 8.14 (dd, J = 1.8, 7.87 Hz, 1H, CH-4), 8.64 (dd, J = 1.8, 4.8 
Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 167.2 (C=O), 163.6 (C-2), 152.0 (CH-6), 138.7 
(CH-4), 126.2 (C-3), 121.1 (CH-5), 61.7 (OCH2CH3), 39.4 (C-2CH2CH2CH3), 
23.7 (C-2CH2CH2CH3), 14.58 (OCH2CH3*), 14.54 (C-2CH2CH2CH3*) ppm. 
      
Ethyl 2-isopropylnicotinate (13) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), ethyl 
isobutyrylacetate (475 mg, 3 mmol) and acrolein (202 mg, 3.6 
mmol).  
Reaction time: 4 h for the first step and 9 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v). 
Yield: 395 mg (68%). Yellow viscous liquid. 
 
Data of 13: 
Elemental analysis calcd (%) for C11H15NO2: C 68.37, H 7.82, N 7.25, found: C 
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68.05, H 7.82, N 7.39. 
IR (NaCl) ν 1724 (C=O), 1585 (C=N), 1278 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.34 (d, J = 6.75 Hz, 6H, C-2CH(CH3)2), 1.43 (t, J 
= 7.15 Hz, 3H, OCH2CH3), 3.85 (sep, J = 6.75 Hz, 1H, C-2CH(CH3)2), 4.42 (q, J 
= 7.15 Hz, 2H, OCH2CH3), 7.20 (dd, J = 4.78, 7.88 Hz, 1H, CH-5), 8.06 (dd, J = 
1.88, 7.88 Hz, 1H, CH-4), 8.71 (dd, J = 1.88, 4.78 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 167.7 (C=O*), 167.5 (C-2*), 152.0 (CH-6), 138.2 
(CH-4), 126.1 (C-3), 120.9 (CH-5), 61.8 (OCH2CH3), 32.7 (C-2CH(CH3)2), 22.7 
(C-2CH(CH3)2), 14.6 (OCH2CH3) ppm. 
      
Ethyl 2-(tert-butylthiomethyl)nicotinate (14) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), ethyl 4-
(tert-butylthio)-3-oxobutanoate 3 (654 mg, 3 mmol) and acrolein 
(202 mg, 3.6 mmol). 
Reaction time: 5 h for the first step and 12 h for the second step.  
Purification: n-hexane:ethyl acetate (from 12:1 to 3:1, v/v). 
Yield: 440 mg (58%). Yellow viscous liquid. 
 
Data of 14: 
Elemental analysis calcd (%) for C13H19NO2S: C 61.63, H 7.56, N 5.53, S 12.66;	  
found: C 61.78, H 7.29, N 5.75, S 12.85. 
IR (NaCl) ν 1724 (C=O), 1570 (C=N), 1266 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.35 (s, 9H, SC(CH3)3), 1.43 (t, J = 7.15 Hz, 3H, 
OCH2CH3), 4.38 (s, 2H, C-2CH2S), 4.42 (q, J = 7.15 Hz, 2H, OCH2CH3), 7.26 
(dd, J = 4.85, 7.95 Hz, 1H, CH-5), 8.20 (dd, J = 1.78, 7.95 Hz, 1H, CH-4), 8.64 
(dd, J = 1.78, 4.85 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 166.7 (C=O), 161.0 (C-2), 151.9 (CH-6), 139.2 
(CH-4), 126.4 (C-3), 122.1 (CH-5), 62.0 (OCH2CH3), 43.4 (SC(CH3)3), 34.9 (C-
2CH2S), 31.3 (SC(CH3)3), 14.6 (OCH2CH3) ppm. 
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Ethyl 2-(but-3-enyl)nicotinate (15) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), ethyl 3-
oxohept-6-enoate 1 (510 mg, 3 mmol) and acrolein (202 mg, 3.6 
mmol). 
Reaction time: 5 h for the first step and 12 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v). 
Yield: 350 mg (57%). Yellow viscous liquid. 
 
Data of 15: 
Elemental analysis calcd (%) for C12H15NO2: C 70.22, H 7.37, N 6.82; found: C 
69.93, H 7.44, N 6.72. 
IR (NaCl) ν 1725 (C=O), 1584 (C=N), 1253 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) 1.43 (t, J = 7.15 Hz, 3H, OCH2CH3), 2.47-2.56 (m, 
2H, C-2CH2CH2), 3.25-3.31 (m, 2H, C-2CH2CH2), 4.41 (q, J = 7.15 Hz, 2H, 
OCH2CH3), 4.96-5.12 (m, 2H, CH2CH=CH2), 5.89-6.00 (m, 1H, CH2CH=CH2), 
7.24 (dd, J = 4.78, 7.88 Hz, 1H, CH-5), 8.18 (dd, J = 1.85, 7.88 Hz, 1H, CH-4), 
8.68 (dd, J = 1.85, 4.78 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 167.1 (C=O), 162.8 (C-2), 152.2 (CH-6), 138.9 
(CH-4), 138.4 (CH2CH=CH2), 126.3 (C-3), 121.3 (CH-5), 115.3 (CH2CH=CH2), 
61.8 (OCH2CH3), 36.8 (C-2CH2CH2), 34.3 (C-2CH2CH2), 14.7 (OCH2CH3) ppm. 
      
Ethyl 2-(2-ethoxy-2-oxoethyl)nicotinate (16) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), diethyl 3-
oxopentanedioate (606 mg, 3 mmol) and acrolein (202 mg, 3.6 
mmol). 
Reaction time: 4 h for the first step and 30 h for the second step.  
Purification: n-hexane:ethyl acetate (from 12:1 to 5:1, v/v). 
Yield: 584 mg (82%). Yellow viscous liquid. 
 
Data of 16: 
Elemental analysis calcd (%) for C12H15NO4: C 60.75, H 6.37, N 5.90; found: C 
60.60, H 6.44, N 6.03. 
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IR (NaCl) ν 1738 (C=O), 1722 (C=O), 1573 (C=N), 1270 (C-O), 1246 (C-O) cm-
1. 
1H-NMR (CDCl3, 250 MHz) δ 1.28 (t, J = 7.13 Hz, 3H, C-2CH2CO2CH2CH3), 
1.41 (t, J = 7.13 Hz, 3H, C-3CO2CH2CH3), 4.21 (q, J = 7.13 Hz, 2H, C-
2CH2CO2CH2CH3), 4.31 (s, 2H, C-2CH2CO2CH2CH3), 4.39 (q, J = 7.13 Hz, 2H, 
C-3CO2CH2CH3), 7.36 (dd, J = 4.83, 7.9 Hz, 1H, CH-5), 8.34 (dd, J = 1.75, 7.9 
Hz, 1H, CH-4), 8.71 (dd, J = 1.75, 4.83 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 170.7 (C-2CH2C=O), 166.0 (C-3C=O), 155.8 (C-
2), 152.0 (CH-6), 138.7 (CH-4), 126.2 (C-3), 122.2 (CH-5), 61.5 
(CH2CO2CH2CH3), 60.9 (C-3CO2CH2CH3), 43.9 (C-2CH2COOR), 14.2 
(2xOCH2CH3) ppm. 
      
Ethyl 2-[2-(furan-2-yl)ethyl]nicotinate (17) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), 5-
(furan-2-yl)-3-oxopentanoate 2 (630 mg, 3 mmol) and acrolein 
(202 mg, 3.6 mmol). 
Reaction time: 4 h for the first step and 36 h for the second step.  
Purification: n-hexane:ethyl acetate (from 12:1 to 5:1, v/v). 
Yield: 515 mg (70%). Yellow viscous liquid. 
 
Data of 17: 
Elemental analysis calcd (%) for C14H15NO3: C 68.56, H 6.16, N 5.71; found: C 
68.38, H 5.93, N 5.68. 
IR (NaCl) ν 1722 (C=O), 1569 (C=N), 1258 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.43 (t, J = 7.15 Hz, 3H, OCH2CH3), 3.09-3.16 
(m, 2H, C-2CH2CH2), 3.51-3.57 (m, 2H, C-2CH2CH2), 4.42 (q, J = 7.15 Hz, 2H, 
OCH2CH3), 6.04 (dd, J = 0.75, 3.13 Hz, 1H, CH-3’), 6.30 (dd, J = 1.85, 3.13 Hz, 
1H, CH-4’), 7.27 (dd, J = 4.8, 7.9 Hz, 1H, CH-5), 7.34 (dd, J = 0.75, 1.85 Hz, 1H, 
CH-5’), 8.21 (dd, J = 1.83, 7.9 Hz, 1H, CH-4), 8.70 (dd, J = 1.83, 4.8 Hz, 1H, 
CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 167.0 (C=O), 162.0 (C-2), 155.9 (C-2’), 152.2 
(CH-6), 141.3 (CH-5’), 138.9 (CH-4), 126.4 (C-3), 121.5 (CH-5), 110.5 (CH-4’), 
105.5 (CH-3’), 61.9 (OCH2CH3), 35.9 (C-2CH2CH2), 28.3 (C-2CH2CH2), 14.6 
N
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O
O 1'2'
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(OCH2CH3) ppm. 
      
tert-Butyl 2-methylnicotinate (18) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), tert-
butyl acetoacetate (475 mg, 3 mmol) and acrolein (202 mg, 3.6 
mmol). 
Reaction time: 4 h for the first step and 15 h for the second 
step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v). 
Yield: 359 mg (62%). Yellow viscous liquid. 
 
Data of 18: 
Elemental analysis calcd (%) for C11H15NO2: C 68.37, H 7.82, N 7.25; found: C 
68.12, H 7.72, N 7.36. 
IR (NaCl) ν 1721 (C=O), 1584 (C=N), 1287 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.62 (s, 9H, OC(CH3)3), 2.82 (s, 3H, C-2CH3), 
7.20 (dd, J = 4.8, 7.85 Hz, 1H, CH-5), 8.11 (dd, J = 1.8, 7.85 Hz, 1H, CH-4), 8.59 
(dd, J = 1.8, 4.8 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 166.5 (C=O), 159.5 (C-2), 151.6 (CH-6), 138.6 
(CH-4), 127.8 (C-3), 121.2 (CH-5), 82.4 (C(CH3)3), 28.6 (C(CH3)3), 25.2 (C-
2CH3) ppm. 
      
Allyl 2-methylnicotinate (19) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), allyl 
acetoacetate (426 mg, 3 mmol) and acrolein (202 mg, 3.6 
mmol). 
Reaction time: 3 h for the first step and 36 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v). 
Yield: 355 mg (67%). Yellow viscous liquid. 
 
Data of 19: 
N
O
O
CH3
CH3
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Elemental analysis calcd (%) for C10H11NO2: C 67.78, H 6.26, N 7.90; found: C 
67.56, H 6.63, N 8.10. 
IR (NaCl) ν 1726 (C=O), 1585 (C=N), 1275 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.88 (s, 3H, C-2CH3), 4.86 (dt, J = 1.28-5.75 Hz, 
2H, OCH2CH=CH2), 5.31-5.49 (m, 2H, OCH2CH=CH2), 5.99-6.12 (m, 1H, 
OCH2CH=CH2), 7.26 (dd, J = 4.85, 7.88 Hz, 1H, CH-5), 8.25 (dd, J = 1.78, 7.88 
Hz, 1H, CH-4), 8.65 (dd, J = 1.78, 4.85 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 166.6 (C=O), 160.4 (C-2), 152.3 (CH-6), 138.9 
(CH-4), 132.3 (OCH2CH=CH2), 125.8 (C-3), 121.3 (CH-5), 119.2 
(OCH2CH=CH2), 66.3 (OCH2CH=CH2), 25.3 (C-2CH3) ppm. 
      
S-tert-Butyl 2-methylpyridine-3-carbothioate (20) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), S-
tert-butyl 3-oxobutanethioate (523 mg, 3 mmol) and acrolein 
(202 mg, 3.6 mmol). 
Reaction time: 5 h for the first step and 15 h for the second 
step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 5:1, v/v). 
Yield: 477 mg (76%). Pale brown viscous liquid. 
 
Data of 20: 
Elemental analysis calcd (%) for C11H15NOS: C 63.12, H 7.22, N 6.69, S 15.32; 
found: C 62.95, H 5.65, N 7.51, S 15.29. 
IR (NaCl) ν 1662 (C=O), 1563 (C=N) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.59 (s, 9H, SC(CH3)3), 2.69 (s, 3H, C-2CH3), 
7.18 (dd, J = 4.9, 7.75 Hz, 1H, CH-5), 7.91 (dd, J = 1.6, 7.75 Hz, 1H, CH-4), 8.57 
(dd, J = 1.6, 4.9 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 195.1 (C=O), 156.3 (C-2), 151.3 (CH-6), 135.8 
(CH-4), 134.6 (C-3), 121.0 (CH-5), 49.6 (SC(CH3)3), 30.1(SC(CH3)3), 23.7 (C-
2CH3) ppm. 
      
N
S
O
CH3
CH3
CH3
CH3
9. Experimental section	   221 
 
 
1-(2-Methylpyridin-3-yl)ethanone (21) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), 
acetylacetone (300 mg, 3 mmol) and acrolein (202 mg, 3.6 mmol). 
Reaction time: 4 h for the first step and 6 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, v/v) 
Yield: 223 mg (55%). Pale yellow viscous liquid. 
 
Data of 21: 
Elemental analysis calcd (%) for C8H9NO: C 71.09, H 6.71, N 10.36; found: C 
70.86, H 6.97, N 10.49. 
IR (NaCl) ν 1689 (C=O), 1563 (C=N) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.60 (s, 3H, C-3COCH3), 2.76 (s, 3H, C-2CH3), 
7.25 (dd, J = 4.85, 7.85 Hz, 1H, CH-5), 7.98 (dd, J = 1.4, 7.85 Hz, 1H, CH-4), 
8.60 (dd, J = 1.4, 4.85 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 200.8 (C=O), 158.4 (C-2), 151.6 (CH-6), 137.1 
(CH-4), 133.2 (C-3), 121.2 (CH-5), 29.7 (C(O)CH3), 25.0 (C-2CH3) ppm. 
      
(2-Methylpyridin-3-yl)(phenyl)methanone (22) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), 
benzoylacetone (487 mg, 3 mmol) and acrolein (202 mg, 3.6 
mmol). 
Reaction time: 4 h for the first step and 9 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, v/v). 
Yield: 355 mg (60%). Pale yellow viscous liquid. 
 
Data of 22: 
Elemental analysis calcd (%) for C13H11NO: C 79.16, H 5.62, N 7.10; found: C 
78.98, H 5.84, N 7.10. 
IR (NaCl) ν 1666 (C=O), 1580 (C=N) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.56 (s, 3H, C-2CH3), 7.25 (dd, J = 4.9, 7.65 Hz, 
1H, CH-5), 7.47-7.53 (m, 2H, CH-3’ and CH-5’), 7.60-7.67 (m, 2H, CH-2’ and 
CH-6’), 7.78-7.82 (m, 2H, CH-4 and CH-4’), 8.66 (dd, J = 1.4, 4.9 Hz, 1H, CH-6) 
N
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ppm. 
13C-NMR (CDCl3, 63 MHz) δ 197.4 (C=O), 157.0 (C-2), 150.9 (CH-6), 137.3 
(CPh), 136.5 (CH-4), 134.4 (C-3), 134.2 (CH-4’), 130.4 (CH-2’ and CH-6’), 
129.2 (CH-3’ and CH-5’), 120.8 (CH-5), 23.7 (C-2CH3) ppm. 
      
3-Methyl-1-(2-methylpyridin-3-yl)butan-1-one (23) 
Prepared from 1,1-dimethylhydrazine (180 mg, 3 mmol), 6-
methylheptane-2,4-dione (426 mg, 3 mmol) and acrolein (202 
mg, 3.6 mmol). 
Reaction time: 5 h for the first step and 18 h for the second 
step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, v/v). 
Yield: 250 mg (47%). Pale yellow viscous liquid. 
 
Data of 23: 
Elemental analysis calcd (%) for C11H15NO: C 74.54, H 8.53, N 7.90; found: C 
74.35, H 8.48, N 7.76. 
IR (NaCl) ν 1689 (C=O), 1564 (C=N) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.01 (d, J = 6.9 Hz, 6H, CH2CH(CH3)2), 2.27 
(sep, J = 6.9 Hz, 1H, CH(CH3)2), 2.73 (s, 3H, C-2CH3), 2.79 (d, J = 6.9 Hz, 2H, 
CH2CH(CH3)2) 7.24 (dd, J = 4.85, 7.8 Hz, 1H, CH-5), 7.89 (dd, J = 1.7, 7.8 Hz, 
1H, CH-4), 8.61 (dd, J = 1.7, 4.85 Hz, 1H, CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 203.9 (C=O), 157.9 (C-2), 151.2 (CH-6), 136.2 
(CH-4), 134.2 (C-3), 121.2 (CH-5), 51.0 (CH2CH(CH3)2), 25.5 (CH2CH(CH3)2), 
24.6 (C-2CH3), 23.0 (CH2CH(CH3)2) ppm. 
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9.2.4 Study of the reaction involving crotonaldehyde 
 
 
 
To a stirred solution of 1,1-dimethylhydrazine (1 equiv, 3 mmol) and ethyl 
acetoacetate (1 equiv, 3 mmol) in ethanol (3 mL) was added InCl3 (10 mol%) and 
stirring was continued for 30 min at room temperature. Crotonaldehyde (1.2 
equiv, 3.6 mmol) was then added and stirring was continued under the same 
conditions for 3 hours. After completion of the reaction (checked by NMR), the 
mixture was diluted with CH2Cl2 (20 mL), washed with water followed by brine, 
dried over anhydrous Na2SO4 and then, the solvent was evaporated under reduced 
pressure.  
After workup, the residue was purified by silica gel column chromatography 
using a petroleum ether:ethyl acetate mixture (7:1, v/v) as eluent to give pure 
compounds 24-26. Characterization data for all compounds of this reaction 
follow. 
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rt, 3 hH3C CH3
+
CH3
O
N
H3C
NMe2
+ +N CH3
OEt
O
N
H3C CH3
CH3
O CH3
OEt
OCH3
N
NMe2
24 25 26
224 9. Experimental section 
 
 
2-(But-2-enylidene)-1,1-dimethylhydrazine (24) 
Conversion 46% 
Colorless viscous liquid 
 
 
 
Data of 24: 
1H-NMR (CDCl3, 250 MHz) δ 1.77-1.80 (dd, J = 1.5, 6.75 Hz, 3H, CH3-5), 2.79 
(s,	  6H, N(CH3)2), 5.72-5.86 (m, 1H, CH-3), 6.11-6.23 (m, 1H, CH-4), 6.97-7.01 
(d, J = 8.85 Hz, 1H, CH-2) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 137.0 (CH-2), 130.6 (CH-4*), 130.3 (CH-2*), 43.1 
and 43.0 (N(CH3)2), 18.5 (CH3-5) ppm. 
These data are consistent with those described in the literature.279 
      
Ethyl 1-(dimethylamino)-2,4-dimethyl-1,4-dihydropyridine-3-carboxylate 
(25) 
Conversion: 34% 
Pale yellow viscous liquid 
 
 
 
Data of 25: 
1H-NMR (CDCl3, 250 MHz) δ 0.96-0.99 (d, J = 6.5 Hz, 3H, C-4CH3) 1.25-1.30 
(t, J = 7.2, 3H, OCH2CH3), 2.40 (s, 3H, C-2CH3), 2.51 (s, 3H, NCH3), 2.56 (s, 
3H, NCH3), 3.30-3.40 (m, 1H, CH-4), 4.06-4.24 (q, J =7.2 Hz, 2H, OCH2CH3), 
4.98-5.03 (dd, J = 5.75, 7.8 Hz, 1H, CH-5), 6.14-6.17 (d, J = 7.8 Hz, 1H, CH-6) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 169.4 (C=O), 151.5 (C-2), 121.0 (CH-6), 110.58 
(CH-5), 99.9 (C-3), 59.4 (OCH2CH3), 45.1 (NCH3), 44.0 (NCH3), 28.5 (CH-4), 
25.0 (C-2CH3), 15.2 (C-4CH3*), 14.8 (OCH2CH3*) ppm. 
      
                                                
279 Waldner, A. Helv. Chim. Acta 1988, 71, 486-492. 
N
H3C
NMe2
1
23
45
N CH3
OEt
O
N
H3C CH3
CH3
1
2
34
5
6
9. Experimental section	   225 
 
 
Ethyl 2-acetyl-5-(2,2-dimethylhydrazono)-3-methylpentanoate (26) 
Conversion 20% 
Pale yellow viscous liquid 
 
 
Data of 26: 
1H-NMR (CDCl3, 250 MHz) (two diastereoisomer) δ 0.94-1.01 (d, J = 6.8 Hz, 
3H, C-3CH3) 1.22-1.31 (t, J = 7.2, 3H, OCH2CH3), 2.01-2.19 (m, 1H, CH-3), 2.25 
(s, 3H, CH3-2’), 2.31-2.61 (m, 2H, CH2-4), 2.74 (s, 6H, N(CH3)2), 3.34-3.44 (d, J 
= 8.2 Hz, 1H, CH-2), 4.12-4.24 (q, J =7.2 Hz, 2H, OCH2CH3), 6.53-6.59 (m, 1H, 
CH-5) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 203.5 and 203.4 (C-1’=O), 169.4 and 169.2 (C-
1=O), 136.1 and 136.0 (CH-5), 65.8 and 65.4 (CH-2), 61.7 and 61.6 (OCH2CH3), 
43.59 and 43.55 (N(CH3)2), 38.2 and 38.1 (CH2-4), 32.4 and 32.3 (CH3-2’), 30.6 
and 30.0 (CH-3), 17.6 and 17.4 (C-3CH3), 14.5 and 14.4 (OCH2CH3) ppm. 
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9.2.5 Synthesis of fused pyridine derivatives 27-29. General procedure 
 
 
 
Compound n R 
27 1 H 
28 1 CH3 
29 2 H 
 
To a stirred solution of 1,1-dimethylhydrazine (1 equiv, 2 mmol) and the 
corresponding cyclic 1,3-dicarbonyl compound (1 equiv, 2 mmol) in ethanol (2 
mL) was added InCl3 (10 mol%), and stirring was continued for 30 min at 50 °C. 
Acrolein (1.2 equiv, 2.4 mmol) was then added and stirring was continued under 
the same conditions overnight. After completion of the reaction, the mixture was 
diluted with CH2Cl2 (15 mL), washed with water followed by brine, dried over 
anhydrous Na2SO4, and the solvent was evaporated under reduced pressure.  
The residue containing the tetrahydropyridine derivatives was then dissolved in 
toluene (7 mL), Palladium on Carbon 10 wt % loading (20% wt/crude) was added, 
and the resulting mixture was heated under reflux for the time periods specified in 
the compound data sheet. After completion of the reaction (checked by TLC), the 
mixture was diluted with CH2Cl2 (20 mL) and filtered through Celite, which was 
then washed repeatedly with additional CH2Cl2 in 5 mL portions. The combined 
organic layers were concentrated to dryness and the residue was purified by silica 
gel column chromatography using petroleum ether:ethyl acetate mixtures as 
eluent to give pure compounds (27-29).  
 
Data of compounds 27-29, and the experimental conditions employed for their	  
synthesis are indicated below.  
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7,8-Dihydroquinolin-5(6H)-one (27) 
Prepared from 1,1-dimethylhydrazine (120 mg, 2 mmol), 1,3-
cyclohexanedione (224 mg, 2 mmol) and acrolein (134 mg, 2.4 
mmol).  
Reaction time: 15 h for the first step and 36 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 7:1, v/v) 
Yield: 238 mg (81%). Yellow viscous liquid. 
 
Data of 27: 
Elemental analysis calcd (%) for C9H9NO: C 73.45, H 6.16, N 9.52; found: C 
73.18, H 6.32, N 9.44. 
IR (NaCl) ν 1688 (C=O), 1583 (C=N) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.20-2.28 (m, 2H, CH2-7), 2.70-2.75 (m, 2H, CH2-
6), 3.19 (t, J = 6.2 Hz, 2H, CH2-8), 7.31 (dd, J = 4.78, 7.88 Hz, 1H, CH-3), 8.30 
(dd, J = 1.88, 7.88 Hz, 1H, CH-4), 8.70 (dd, J = 1.88, 4.78 Hz, 1H, CH-2) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 198.4 (C=O), 164.1 (C-8a), 153.9 (CH-2), 135.4 
(CH-4), 128.6 (C-4a), 122.7 (CH-3), 39.0 (CH2-6), 32.9 (CH2-8), 22.3 (CH2-7) 
ppm. 
      
7,7-Dimethyl-7,8-dihydroquinolin-5(6H)-one (28) 
Prepared from 1,1-dimethylhydrazine (120 mg, 2 mmol), 5,5-
dimethyl-1,3-cyclohexanedione (280 mg, 2 mmol) and acrolein 
(134 mg, 2.4 mmol).  
Reaction time: 15 h for the first step and 40 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 7:1, v/v). 
Yield: 273 mg (78%). Yellow viscous liquid. 
 
Data of 28: 
Elemental analysis calcd (%) for C11H13NO: C 75.40, H 7.48, N 7.99; found: 
C75.43, H 7.59, N 8.07. 
IR (NaCl) ν 1692 (C=O), 1584 (C=N) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.14 (s, 6H, 2xCH3), 2.58 (s, 2H, CH2-6), 3.07 (s, 
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CH3
O
N
O
1
2
3
4 5
6
7
8
4a
8a
228 9. Experimental section 
 
 
2H, CH2-8), 7.32 (dd, J = 4.8, 7.85 Hz, 1H, CH-3), 8.29 (dd, J = 1.7, 7.85 Hz, 1H, 
CH-4), 8.73 (dd, J = 1.7, 4.8 Hz, 1H, CH-2) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 198.5 (C=O), 162.7 (C-8a), 154.3 (CH-2), 135.0 
(CH-4), 127.6 (C-4a), 122.6 (CH-3), 52.5 (CH2-6), 46.8 (CH2-8), 33.4 (C-7), 28.7 
(2xCH3) ppm. 
      
6,7,8,9-Tetrahydrocyclohepta[b]pyridin-5-one (29) 
Prepared from 1,1-dimethylhydrazine (120 mg, 2 mmol), 1,3-
cycloheptanedione (252 mg, 2 mmol) and acrolein (134 mg, 2.4 
mmol).  
Reaction time: 15 h for the first step and 20 h for the second step.  
Purification: n-hexane:ethyl acetate (from 15:1 to 7:1, v/v). 
Yield: 245 mg (76%). Yellow viscous liquid. 
 
Data of 29: 
Elemental analysis calcd (%) for C10H11NO: C 74.51, H 6.88, N 8.69; found: C 
74.34, H 7.01, N 8.57. 
IR (NaCl) ν 1680 (C=O), 1580 (C=N) cm-1; 
1H-NMR (CDCl3, 250 MHz) δ 1.87-2.04 (m, 4H, CH2-7 and CH2-8), 2.79-2.84 
(m, 2H, CH2-6), 3.20 (t, J = 5.8 Hz, 2H, CH2-9), 7.28 (dd, J = 4.83, 7.75 Hz, 1H, 
CH-3), 8.03 (dd, J = 1.8, 7.75 Hz, 1H, CH-4), 8.62 (dd, J = 1.8, 4.83 Hz, 1H, CH-
2) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 204.9 (C=O), 161.5 (C-9a), 152.2 (CH-2), 137.1 
(CH-4), 134.3 (C-4a), 122.3 (CH-3), 41.2 (CH2-6), 36.2 (CH2-9), 24.4 (CH2-8), 
21.8 (CH2-7) ppm. 
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9.2.6 Synthesis of benzo[f]quinolone (30) 
 
 
 
To a stirred solution of 1,1-dimethylhydrazine (1 equiv, 3 mmol) and β-tetralone 
(1 equiv, 3 mmol) in ethanol (3 mL) was added InCl3 (10 mol%), and stirring was 
continued for 30 min at room temperature. Acrolein (1.2 equiv, 3.6 mmol) was 
then added and stirring was continued under the same conditions for 4 hours. 
After completion of the reaction (checked by NMR), the mixture was diluted with 
CH2Cl2 (20 mL), washed with water followed by brine, dried over anhydrous 
Na2SO4, and the solvent was evaporated under reduced pressure.  
The residue containing the tetrahydropyridine derivative was then dissolved in 
toluene (10 mL), Palladium on Carbon 10 wt % loading (20% wt/crude) was 
added and the resulting mixture was heated under reflux for 16 hours. After this 
time, the mixture was diluted with CH2Cl2 (20 mL) and filtered through Celite, 
which was then washed repeatedly with additional CH2Cl2 in 5 mL portions. The 
combined organic layers were concentrated to dryness and the residue was 
purified by silica gel column chromatography using a petroleum ether-ethyl 
acetate mixture (7:1, v/v) as eluent to give a mixture of 5,6-
dihydrobenzo[f]quinoline and benzo[f]quinoline in a ratio of 2:1 (2,15mmol,	  72% 
yield).  
The mixture (1 eq, 2.15 mmol) was then dissolved in toluene (7 mL), DDQ (1.2 
eq, 2.6 mmol) was added and the solution was refluxed for 6 hours. The resulting 
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dark brown colored mixture was then poured into hexanes (20 mL) to precipitate 
out the hydroquinone by-product. The residue was then chromatographed on silica 
gel, eluting with a 5:1 petroleum ether-ethyl acetate mixture to yield 280 mg of 30 
as a white solid (73% yield for this step; the overall yield for the whole process is 
53%). 
 
Data of 30 
Mp: 92-93 °C. 
Elemental analysis calcd (%) for C13H9N: C 87.12, H 5.06, N 7.82; found: C 
86.91, H 5.30, N 7.81. 
IR (NaCl) ν 1571 (C=N) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 7.59-7.64 (m, 1H, ArH), 7.67-7.79 (m, 2H, ArH), 
7.99 (dd, J = 1.75, 7.6 Hz, 1H, ArH), 8.04 (s, 2H, ArH), 8.69 (dd, J = 1.65, 9.1 
Hz, 1H, ArH), 9.00 (s, 1H, ArH), 9.01-9.03 (m, 1H, ArH) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 148.7 (CH-3), 147.2 (C-4a), 130.7 (C-6a*), 129.9 
(CHAr), 129.7 (CHAr), 128.6 (C-10a*), 127.7 (CHAr), 127.2 (CHAr), 126.3 
(CHAr), 126.1 (CHAr), 124.4 (C-10b), 121.6 (CHAr), 120.3 (CH) ppm. 
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9.3 MULTICOMPONENT SYNTHESIS OF 4,6-DIARYL-1,4-
DIHYDROPYRIDINE DERIVATIVES 
9.3.1 Synthesis of chalcones 31-47. General procedure 
 
 
 
Cpd. R1 R2 R3 Cpd. R1 R2 R3 
31 C6H5 H 4-MeC6H4 40 4-ClC6H4 H 3-MeOC6H4 
32 4-MeC6H4 H C6H5 41 4-ClC6H4 H 2-NO2C6H4 
33 4-MeC6H4 H 4-MeC6H4 42 C6H5 H 4-NO2C6H4 
34 4-MeC6H4 H 4-BrC6H4 43 2-NO2C6H4 H 4-MeC6H4 
35 4-MeC6H4 H 2-NO2C6H4 44 C6H5 H 2-thienyl 
36 C6H5 H 4-MeOC6H4 45 4-MeC6H4 H 2-thienyl 
37 4-MeOC6H4 H 4-MeOC6H4 46 2-furyl H 4-MeC6H4 
38 4-ClC6H4 H C6H5 47 C6H5 CH3 C6H5 
39 4-ClC6H4 H 4-ClC6H4     
 
To a stirred solution of the appropriate aromatic ketone (1 equiv, 10 mmol) and 
aromatic aldehyde (1.05 equiv, 10.5 mmol) derivatives in ethanol (20 mL) at 
room temperature, is slowly added a solution of NaOH (1.2 equiv, 12 mmol) in a 
mixture of ethanol:water (1:1, 18 mL + 18 mL). The resulting mixture is stirred 
vigorously at the same temperature for the time period specified in the compound 
data sheet. After completion of the reaction (checked by TLC), the mixture was 
poured into ice-water (50 mL) and the precipitate formed was collected by 
filtration and washed with cold water. In case of an oily product, the reaction 
mixture was extracted with CH2Cl2 (3x25 mL); the organic phase was collected, 
washed with brine and dried over anhydrous Na2SO4, and then, the solvent was 
evaporated under reduced pressure. 
The crude residue was crystallized from EtOH or purified by silica gel column 
chromatography using n-hexane:ethyl acetate mixtures as eluents to give pure 
R1
O
R3R1
O
R2
H R3
O
+
NaOH
EtOH:H2O, rt R2
31-47
232 9. Experimental section 
 
 
compounds (31-47).  
 
Data of compounds 31-47, and the experimental conditions employed for their 
synthesis are indicated below. 
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1-Phenyl-3-(4-methylphenyl)prop-2-en-1-one (31) 
Prepared from acetophenone (1.201 g, 10 mmol), 4-
methylbenzaldehyde (1.261 g, 10.5 mmol) and sodium 
hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 1.890 g (85%). Pale yellow solid. 
 
Data of 31: 
IR (NaCl) ν 1657 (C=O), 983 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.43 (s, 3H, C-4’CH3), 7.27 (d, J = 8 Hz, 2H, CH-
3’ and CH-5’), 7.50-7.65 (m, 6H, CH-α, CH-3, CH-4, CH-5, CH-2’ and CH-6’), 
7.83 (d, J = 15.7 Hz, 1H, CH-β), 8.05 (dt, J = 1.6, 7.8 Hz, 2H, CH-2 and CH-6) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 191.1 (C=O), 145.4 (CH-β), 141.5 (C-1*), 138.8 
(C-4’*), 133.1 (CHAr), 132.5 (C-1’), 130.1 (2xCHAr), 129.0 (2xCHAr), 128.92 
(2xCHAr), 128.90 (2xCHAr), 121.5 (CH-α), 22.0 (C-4’CH3) ppm. 
These data are consistent with those described in the literature.280 
      
3-Phenyl-1-(4-methylphenyl)prop-2-en-1-one (32) 
Prepared from 4’-methylacetophenone (1.342 g, 10 
mmol), benzaldehyde (1.114 g, 10.5 mmol) and sodium 
hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 1.845 g (83%). Yellow solid. 
 
Data of 32: 
IR (NaCl) ν 1662 (C=O), 979 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.47 (s, 3H, C-4CH3), 7.35 (d, J = 8 Hz, 2H, CH-3 
                                                
280 Rocchi, D.; González, J. F.; Menéndez, J. C. Molecules 2014, 19, 7317-7326. 
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and CH-5), 7.42-7.46 (m, 3H, CH-3’, CH-4’ and CH-5’), 7.57 (d, J = 15.7 Hz, 
1H, CH-α), 7.66-7.70 (m, 2H, CH-2’ and CH-6’), 7.85 (d, J = 15.7 Hz, 1H, CH-
β), 7.97 (d, J = 8 Hz, 2H, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 190.5 (C=O), 144.8 (CH-β), 144.1 (C-4), 136.0 (C-
1’*), 135.4 (C-1*), 130.9 (CH-4’), 129.8 (2xCHAr), 129.4 (2xCHAr), 129.1 
(2xCHAr), 128.8 (2xCHAr), 122.5 (CH-α), 22.1 (C-4CH3) ppm. 
These data are consistent with those described in the literature.280 
      
1,3-Bis(4-methylphenyl)prop-2-en-1-one (33) 
Prepared from 4’-methylacetophenone (1.342 g, 10 
mmol), 4-methylbenzaldehyde (1.261 g, 10.5 mmol) 
and sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 1.915 g (81%). Yellow solid. 
 
Data of 33: 
IR (NaCl) ν 1654 (C=O), 992 (CH-α=CH-β) cm-1 
1H-NMR (CDCl3, 250 MHz) δ 2.43 (s, 3H, C-4’CH3*), 2.47 (s, 3H, C-4CH3*), 
7.25 (d, J = 8 Hz, 2H, CH-3’ and CH-5’), 7.34 (d, J = 8 Hz, 2H, CH-3 and CH-5), 
7.50-7.59 (m, 3H, CH-α, CH-2’ and CH-6’), 7.83 (d, J = 15.7 Hz, 1H, CH-β), 
7.97 (d, J = 8 Hz, 2H, 2H, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 190.5 (C=O), 144.9 (CH-β), 143.9 (C-4*), 141.4 
(C-4’*), 136.2 (C-1*), 132.7 (C-1’*), 130.1 (2xCHAr), 129.7 (2xCHAr), 129.0 
(2xCHAr), 128.9 (2xCHAr), 121.5 (CH-α), 22.1 (C-4CH3*), 22.0 (C-4’CH3*) 
ppm. 
These data are consistent with those described in the literature.280 
      
3-(4-Bromophenyl)-1-(4-methylphenyl)prop-2-en-1-one (34) 
Prepared from 4’-methylacetophenone (1.342 g, 10 mmol), 4-bromobenzaldehyde 
(1.943 g, 10.5 mmol) and sodium hydroxide (0.480 g, 12 mmol).  
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Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 2.680 g (89%). Yellow solid. 
 
Data of 34: 
IR (NaCl) ν 1659 (C=O), 1072 (C-Br), 984 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.47 (s, 3H, C-4CH3), 7.34 (d, J = 8 Hz, 2H, CH-3 
and CH-5), 7.52-7.60 (m, 5H, CH-α, CH-2’, CH-3’, CH-5’ and CH-6’), 7.77 (d, J 
= 15.7 Hz, 1H, CH-β), 7.97 (d, J = 8 Hz, 2H, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 190.1 (C=O), 144.3 (C-4), 143.3 (CH-β), 135.8 (C-
1*), 134.3 (C-1’*), 132.6 (2xCHAr), 130.2 (2xCHAr), 129.8 (2xCHAr), 129.1 
(2xCHAr), 125.1 (C-4’), 122.9 (CH-α), 22.1 (C-4CH3) ppm. 
These data are consistent with those described in the literature.280 
      
3-(2-Nitrophenyl)-1-(4-methylphenyl)prop-2-en-1-one (35) 
Prepared from 4’-methylacetophenone (1.342 g, 10 
mmol), 2-nitrobenzaldehyde (1.587 g, 10.5 mmol) and 
sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 24 h. 
Purification: Crystallization from EtOH. 
Yield: 1.975 g (74%). Yellow solid. 
 
Data of 35: 
IR (NaCl) ν 1663 (C=O), 1521 (NO2), 1342 (NO2), 972 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.48 (s, 3H, C-4CH3), 7.35 (d, J = 15.7 Hz, 1H, 
CH-α), 7.35 (d, J = 8.3 Hz, 2H, CH-3 and CH-5), 7.56-7.63 (m, 1H, CH-5’), 7.69-
7.79 (m, 2H, CH-4’ and CH-6’), 7.97 (d, J = 8.3 Hz, 2H, CH-2 and CH-6), 8.09 
(d, J = 1.1	  Hz, 1H, CH-3’), 8.15 (d, J = 15.7 Hz, 1H, CH-β) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 190.4 (C=O), 149.1 (C-2’), 144.5 (C-4), 140.1 
(CH-β), 135.3 (C-1), 133.9 (CH-5’), 131.8 (C-1’), 130.7 (CH-4’*), 129.8 
(2xCHAr), 129.7 (CH-6’*), 129.4 (2xCHAr), 127.8 (CH-3’), 125.4 (CH-α), 22.1 
(C-4CH3) ppm. 
These data are consistent with those described in the literature.280 
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3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one (36) 
Prepared from acetophenone (1.201 g, 10 mmol), 4-
methoxybenzaldehyde (1.430 g, 10.5 mmol) and 
sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 2.050 g (86%). Yellow solid. 
 
Data of 36: 
IR (NaCl) ν 1656 (C=O), 983 (CH-α=CH-β) cm-1 
1H-NMR (CDCl3, 250 MHz) δ 3.89 (s, 3H, C-4’OCH3), 6.98 (d, J = 8.7 Hz, 2H, 
CH-3’ and CH-5’), 7.45 (d, J = 15.7 Hz, 1H, CH-α), 7.50-7.66 (m, 5H, CH-3, 
CH-4, CH-5, CH-2’ and CH-6’), 7.83 (d, J = 15.7 Hz, 1H, CH-β), 8.03-8.06 (m, 
2H, CH-2 and CH-6) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 191.0 (C=O), 162.1 (C-4’), 145.2 (CH-β), 138.9 
(C-1), 133.0 (C-1’), 130.7 (2xCHAr), 129.0 (2xCHAr), 128.8 (2xCHAr), 128.0 
(CHAr), 120.2 (CH-α), 114.8 (2xCHAr), 55.8 (C-4’OCH3) ppm. 
These data are consistent with those described in the literature.280 
      
1,3-Bis(4-methoxyphenyl)prop-2-en-1-one (37) 
Prepared from 4’-methoxyacetophenone (1.502 g, 
10 mmol), 4-methoxybenzaldehyde (1.430 g, 10.5 
mmol) and sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 1.960 g (73%). solid. 
 
Data of 37: 
IR (NaCl) ν 1654 (C=O), 980 (CH-α=CH-β) cm-1 
1H-NMR (CDCl3, 250 MHz) δ 3.83 (s, 3H, C-4OCH3*), 3.87 (s, 3H, C-
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4’OCH3*), 6.87-7.03 (m, 4H, CH-3, CH-5, CH-3’ and CH-5’), 7.42 (d, J = 15.6 
Hz, 1H, CH-α), 7.59 (d, J = 8.8 Hz, 2H, CH-2’ and CH-6’), 7.78 (d, J = 15.6 Hz, 
1H, CH-β), 8.03 (d, J = 8.9 Hz, 2H, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 188.8 (C=O), 163.6 (C-4’), 161.6 (C-4), 143.9 
(CH-β), 131.4 (C-1), 130.8 (2xCHAr), 130.1 (2xCHAr), 127.9 (C-1’), 119.6 (CH-
α), 114.4 (2xCHAr), 113.9 (2xCHAr), 55.6 (C-4OCH3*), 55.5 (C-4’OCH3*) ppm. 
These data are consistent with those described in the literature.280 
      
1-(4-Chlorophenyl)-3-phenylprop-2-en-1-one (38) 
Prepared from 4’-chloroacetophenone (1.546 g, 10 
mmol), benzaldehyde (1.114 g, 10.5 mmol) and sodium 
hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 2.255 g (93%). Yellow solid. 
 
Data of 38: 
IR (NaCl) ν 1661 (C=O), 1090 (C-Cl), 983 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 7.42-7.55 (m, 6H, CH-α, CH-2’, CH-3’, CH-4’, 
CH-5’ and CH-6’), 7.64-7.69 (m, 2H, CH-3 and CH-5), 7.85 (d, J = 15.7 Hz, 1H, 
CH-β), 8.00 (dt, J = 2.35, 8.7 Hz, 2H, CH-2 and CH-6) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 189.6 (C=O), 145.8 (CH-β), 139.6 (C-4), 136.9 (C-
1*), 135.1 (C-1’*), 131.2 (CHAr), 130.3 (2xCHAr), 129.44 (2xCHAr), 
129.37(2xCHAr), 128.9 (2xCHAr), 121.9 (CH-α) ppm. 
These data are consistent with those described in the literature.280 
      
1,3-Bis(4-chlorophenyl)prop-2-en-1-one (39) 
Prepared from 4’-chloroacetophenone (1.546 g, 10 
mmol), 4-chlorobenzaldehyde (1.476 g, 10.5 mmol) and 
sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
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Purification: Crystallization from EtOH. 
Yield: 2.630 g (95%). Yellow solid. 
 
Data of 39: 
IR (NaCl) ν 1653 (C=O), 1090 (C-Cl), 982 (CH-α=CH-β) cm-1 
1H-NMR (CDCl3, 250 MHz) δ 7.40-7.52 (m, 5H, CH-α, CH-2’, CH-3’, CH-5’ 
and CH-6’), 7.61 (d, J = 8.4 Hz, 2H, CH-3 and CH-5), 7.79 (d, J = 15.7 Hz, 1H, 
CH-β), 7.99 (d, J = 8.4 Hz, 2H, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 189.3 (C=O), 144.2 (CH-β), 143.3 (C-4), 137.1 (C-
1*), 136.7 (C-4’*), 133.6 (C-1’), 130.3 (2xCHAr), 130.1 (2xCHAr), 129.7 
(2xCHAr), 129.4 (2xCHAr), 122.2 (CH-α) ppm. 
These data are consistent with those described in the literature.281 
      
1-(4-Chlorophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one (40) 
Prepared from 4’-chloroacetophenone (1.546 g, 10 
mmol), 3-methoxybenzaldehyde (1.430 g, 10.5 
mmol) and sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 2.155 g (79%). Pale yellow solid. 
 
Data of 40: 
IR (NaCl) ν 1663 (C=O), 1091 (C-Cl), 982 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 3.89 (s, 3H, C-3’OCH3), 7.01 (dd, J = 1.7, 8 Hz, 
1H, CH-4’), 7.17-7.26 (m, 2H, CH-2’ and CH-6’), 7.35-7.54 (m, 4H, CH-α, CH-
3, CH-5 and CH-5’), 7.81 (d, J = 15.7 Hz, 1H, CH-β), 8.00 (dt, J = 1.85, 8 Hz, 
2H, CH-2 and CH-6);  
13C-NMR (CDCl3, 63 MHz) δ 189.6 (C=O), 160.4 (C-3’), 145.7 (CH-β), 139.7 
(C-4), 136.9 (C-1*), 136.4 (C-1’*), 130.4 (CH-5’), 130.3 (2xCHAr), 129.4 
(2xCHAr), 122.2 (CH-6’*), 121.6 (CH-α*), 116.9 (CH-4’), 113.9 (CH-2’), 55.8 
(C-3’OCH3) ppm. 
                                                
281 Miura, Y.; Kitagishi, Y.; Ueno, S. Bull. Chem. Soc. Jpn. 1994, 67, 3282-3288. 
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These data are consistent with those described in the literature.280 
      
1-(4-Chlorophenyl)-3-(2-nitrophenyl)prop-2-en-1-one (41) 
Prepared from 4’-chloroacetophenone (1.546 g, 10 
mmol), 2-nitrobenzaldehyde (1.587 g, 10.5 mmol) and 
sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 24 h. 
Purification: Crystallization from EtOH. 
Yield: 1.755 g (61%). Grey solid. 
 
Data of 41: 
IR (NaCl) ν 1667 (C=O), 1517 (NO2), 1340 (NO2), 1090 (C-Cl) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 7.30 (d, J = 15.7 Hz, 1H, CH-α), 7.52 (dt, J = 
1.75, 8.5 Hz, 2H, CH-3 and CH-5), 7.58-7.65 (m, 1H, CH-5’), 7.69-7.79 (m, 2H, 
CH-4’ and CH-6’), 8.00 (dt, J = 1.75, 8.5 Hz, 2H, CH-2 and CH-6), 8.11 (d, J = 
1.1 Hz, 1H, CH-3’), 8.17 (d, J = 15.7 Hz, 1H, CH-β) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 189.7 (C=O), 148.9 (C-2’), 141.1 (CH-β), 140.1 
(C-4), 136.1 (C-1), 134.1 (CH-5’), 131.6 (C-1’), 130.9 (CH-4’*), 130.6 
(2xCHAr), 129.7(CH-6’*), 129.5 (2xCHAr), 127.2 (CH-3’), 125.5 (CH-α) ppm. 
These data are consistent with those described in the literature.280 
      
3-(4-Nitrophenyl)-1-phenylprop-2-en-1-one (42) 
Prepared from acetophenone (1.201 g, 10 mmol), 4-
nitrobenzaldehyde (1.587 g, 10.5 mmol) and sodium 
hydroxide (0.480 g, 12 mmol). 
Purification: Crystallization from EtOH. 
Yield: 1.340 g (53%). Pale yellow solid. 
 
Data of 42: 
IR (NaCl) ν 1665 (C=O), 1518 (NO2), 1338 (NO2) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ, 7.48-7.57 (m, 2H, CH-3 and CH-5), 7.59-7.70 (m, 
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2H, CH-α and CH-4) 7.75-7.88 (m, 3H, CH-β, CH-2’ and CH-6’), 8.04 (dd, J = 
1.3, 8.3 Hz, 2H, CH-2 and CH-6), 8.28 (d, J = 8.9 Hz, 2H, CH-3’ and CH-5’) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 189.7 (C=O), 141.6 (CH-β), 141.1 (C-4’), 137.6 
(C-1’), 133.5 (CHAr), 129.0 (2xCHAr), 128.9 (2xCHAr), 128.7 (2xCHAr), 125.8 
(CH-α), 128.7 (2xCHAr) ppm. C-1 is missing 
These data are consistent with those described in the literature.280 
      
3-(4-Methylphenyl)-1-(2-nitrophenyl)prop-2-en-1-one (43) 
Prepared from 2’-nitroacetophenone (1.615 g, 10 mmol), 
4-methylbenzaldehyde (1.261 g, 10.5 mmol) and sodium 
hydroxide (0.480 g, 12 mmol). 
Reaction time: 24 h. 
Purification: Crystallization from EtOH. 
Yield: 2.272 g (85%). Pale yellow solid. 
 
Data of 43: 
IR (NaCl) ν 1663 (C=O), 1522 (NO2), 1360 (NO2), 972 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.40 (s, 3H, C-4’CH3), 7.00 (d, J = 16.2 Hz, 1H, 
CH-α), 7.21-7.27 (m, 3H, CH-β, CH-3’ and CH-5’), 7.43 (d, J = 8.1 Hz, 2H, CH-
2’ and CH-6’), 7.54 (dd, J = 1.5, 7.5 Hz, 1H, CH-6), 7.69 (dt, J = 1.5, 7.5 Hz, 1H, 
CH-5), 7.80 (dt, J = 1.1, 7.5 Hz, 1H, CH-4), 8.22 (dd, J = 1.1, 8.1 Hz, 1H, CH-3) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 193.5 (C=O), 147.0 (CH-β), 142.2 (C-2), 136.8 (C-
4’), 134.5 (CH-5), 131.6 (C-1), 131.0 (CH-4*), 130.2 (2xCHAr), 129.3 (CH-6*), 
129.0 (2xCHAr), 125.7 (CH-3), 125.0 (CH-α), 22.1 (C-4’CH3) ppm. 
      
1-Phenyl-3-(thiophen-2-yl)prop-2-en-1-one (44) 
Prepared from acetophenone (1.201 g, 10 mmol), thiophene-
2-carbaldehyde (1.178 g, 10.5 mmol) and sodium hydroxide 
(0.480 g, 12 mmol).  
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Reaction time: 15 h. 
Purification: n-hexane:ethyl acetate (from 20:1 to 10:1, v/v). 
Yield: 1.415 g (66%). Pale brown solid. 
 
Data of 44: 
IR (NaCl) ν 1652 (C=O), 975 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 7.13 (dd, J = 3.7, 5.0 Hz, 1H, CH-4’), 7.34–7.40 
(m, 2H, CH-α and CH-3’), 7.46 (d, J = 5.0 Hz, 1H, CH-5’), 7.50-7.65 (m, 3H, 
CH-3, CH-4 and CH-5), 7.95-8.07 (m, 3H, CH-β, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 190.4 (C=O), 140.8 (C-2’), 138.5 (C-1), 137.7 
(CH-β), 133.2 (CH-4*), 132.6 (CH-5’*), 129.3 (CH-3’), 129.1 (2xCHAr), 128.8 
(2xCHAr), 128.8 (CH-4’), 120.5 (CH-α) ppm. 
These data are consistent with those described in the literature.280 
      
1-(4-Methylphenyl)-3-(thiophen-2-yl)prop-2-en-1-one (45) 
Prepared from 4’-methylacetophenone (1.342 g, 10 
mmol), thiophene-2-	  carbaldehyde (1.178 g, 10.5 mmol) 
and sodium hydroxide (0.480 g, 12 mmol). 
Reaction time: 15 h. 
Purification: n-hexane:ethyl acetate (from 20:1 to 10:1, v/v). 
Yield: 1.415 g (62%). Yellow solid. 
 
Data of 45: 
IR (NaCl) ν 1655 (C=O), 961 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.47 (s, 3H, C-4CH3), 7.12 (dd, J = 3.7, 5.0 Hz, 
1H, CH-4’), 7.32–7.40 (m, 4H, CH-α, CH-3’, CH-3 and CH-5), 7.45 (d, J = 5.0 
Hz, 1H, CH-5’), 7.94-8.00 (m, 3H, CH-β, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 189.8 (C=O), 144.1 (C-4), 140.9 (C-2’), 137.2 
(CH-β), 135.9 (C-1), 132.4 (CH-5’), 129.8 (2xCHAr), 129.1 (CH-3’), 129.0 
(2xCHAr), 128.8 (CH-4’), 121.2 (CH-α), 22.1 (C-4CH3)ppm. 
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These data are consistent with those described in the literature.282 
      
1-(Furan-2-yl)-3-(4-methylphenyl)prop-2-en-1-one (46) 
Prepared from 2-acetylfuran (1.101 g, 10 mmol), 4-
methylbenzaldehyde (1.261 g, 10.5 mmol) and sodium 
hydroxide (0.480 g, 12 mmol). 
Reaction time: 24 h. 
Purification: Crystallization from EtOH. 
Yield: 1.485 g (70%). Pale yellow solid. 
 
Data of 46: 
IR (NaCl) ν 1649 (C=O), 979 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.43 (s, 3H, C-4’CH3), 6.62 (dd, J = 1.6, 3.6 Hz, 
1H, CH-4), 7.26 (d, J = 8.1 Hz, 2H, CH-3’ and CH-5’), 7.35 (dd, J = 0.7, 3.6 Hz, 
1H, CH-3), 7.44 (d, J = 15.7 Hz, 1H, CH-α), 7.59 (d, J = 8.1 Hz, 2H, CH-2’ and 
CH-6’), 7.68 (dd, J = 0.7, 1.6 Hz, 1H, CH-5), 7.90 (d, J = 15.7 Hz, 1H, CH-β) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 178.6 (C=O), 154.2 (C-2), 146.9 (CH-5*), 144.5 
(CH-β*), 141.6 (C-4’), 132.4 (C-1’), 130.1 (2xCHAr), 129.0 (2xCHAr), 120.5 
(CH-α), 117.8 (CH-3), 112.9 (CH-4), 22.0 (C-4’CH3) ppm. 
These data are consistent with those described in the literature.282 
      
2-Methyl-1,3-diphenylprop-2-en-1-one (47) 
Prepared from propiophenone (1.342 g, 10 mmol), 
benzaldehyde (1.592 g, 15 mmol) and sodium hydroxide 
(0.600 g, 15 mmol). 
Reaction time: 24 h. 
Purification: n-hexane:ethyl acetate (from 30:1 to 20:1, v/v). 
Yield: 1.445 g (65%). Pale yellow liquid. 
 
                                                
282 Musumarra, G.; Ballistreri, F. P. Organic Magnetic Resonance 1980, 14, 384-391. 
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Data of 47: 
IR (NaCl) ν 1641 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.30 (d, J = 1.4 Hz, 3H, C-αCH3), 7.21-7.22 (m, 
1H, CH-β), 7.33-7.61 (m, 8H, CH-β, CH-3, CH-4, CH-5 and CβArH), 7.76-7.81 
(m, 2H, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 200.0 (C=O), 142.7 (CH-β), 138.9 (C-1*), 137.3 
(C-1’*), 136.2 (C-α*), 132.1 (CH-4), 130.1 (2xCHAr), 129.9 (2xCHAr), 129.0 
(CH-4’), 128.9 (2xCHAr), 128.6 (2xCHAr), 14.9 (C-αCH3) ppm. 
These data are consistent with those described in the literature.283 
      
  
                                                
283 Lu, S.-M.; Bolm, C. Angew. Chem., Int. Ed. 2008, 47, 8920–8923. 
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9.3.2 Synthesis of chalcones 48 and 49. General procedure 
 
 
 
Compound R 
48 H 
49 CH3 
 
To a stirred solution of acetophenone (1 equiv, 5.0 mmol) in methanol (30 mL) 
was slowly added an aqueous solution of sodium hydroxide (60%, 25 mL). After 
cooling the solution to room temperature, cinnamaldehyde, or its methyl 
derivative, (1.1 equiv, 5.5 mmol) was added and the mixture was stirred at the 
same temperature for 20 h. After completion of the reaction (checked by TLC), 
the mixture was poured into ice-water (50 mL) and 2N hydrochloric acid was 
added to adjust pH to ca. 5. The obtained solid was removed by filtration, 
dissolved in dichloromethane (100 mL) and washed with an aqueous solution of 
sodium hydrogen carbonate (5%, 2x50 mL). The organic layer was collected, 
dried over anhydrous sodium sulfate and the solution evaporated to dryness. The 
residue was purified by silica gel column chromatography with dichloromethane 
as eluent. 
 
Data of compounds 48 and 49 and the experimental conditions employed for their 
synthesis are indicated below. 
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1,5-Diphenylpenta-2,4-dien-1-one (48) 
 Prepared from acetophenone (600 mg, 5 mmol) and 
cinnamaldehyde (727 mg, 5.5 mmol). 
Reaction time: 20 h. 
Purification: dichloromethane. 
Yield: 915 mg (78%). Yellow solid. 
 
Data of 48: 
IR (NaCl) ν 1650 (C=O), 994 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 7.05-7.16 (m, 3H, CH-α, CH-γ and CH-δ), 7.29-
7.44 (m, 3H, CH-3’, CH-4’ and CH-5’), 7.49-7.70 (m, 6H, CH-β, CH-3, CH-4, 
CH-5, CH-2’ and CH-6’), 8.02 (d, J = 7.65 Hz, 2H, CH-2 and CH-6) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 190.9 (C=O), 145.3 (CH-β), 142.4 (CH-δ), 138.6 
(C-1), 136.5 (C-1’), 133.1 (CH-4), 129.7 (CH-4’), 129.3 (2xCHAr), 129.0 
(2xCHAr), 128.9 (2xCHAr), 127.7 (2xCHAr), 127.4 (CH-γ), 125.8 (CH-α) ppm. 
These data are consistent with those described in the literature.284 
      
4-Methyl-1,5-diphenylpenta-2,4-dien-1-one (49) 
Prepared from acetophenone (600 mg, 5 mmol) and 2-
methyl-3-phenylacrylaldehyde (804 mg, 5.5 mmol). 
Reaction time: 20 h. 
Purification: dichloromethane. 
Yield: 931 mg (75%). Yellow solid. 
 
Data of 49: 
IR (NaCl) ν 1653 (C=O), 978 (CH-α=CH-β) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.47 (d, J = 1.1 Hz, 3H, C-γCH3), 7.01 (bs, 1H, 
CH-δ),	  7.09 (d, J = 15.3 Hz, 1H, CH-α), 7.31-7.36 (m, 1H, CH-4’), 7.39-7.43 (m, 
4H, CH-2’, CH-3’, CH-5’ and CH-6’), 7.47-7.63 (m, 3H, CH-3, CH-4 and CH-5), 
7.68 (d, J = 15.4 Hz, 1H, CH-β), 8.01-8.04 (m, 2H, CH-2 and CH-6) ppm. 
                                                
284 Pinto, D. C. G. A.; Silva, A. M. S.; Levai, A.; Cavaleiro, J. A. S.; Patonay, T.; Elguero, J. Eur. J. 
Org. Chem. 2000, 2593–2599. 
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13C-NMR (CDCl3, 63 MHz) δ 191.3 (C=O), 150.7 (CH-β), 141.0 (CH-δ), 138.9 
(C-1), 137.2 (C-1’), 135.1 (C-γ), 133.0 (CH-4), 130.0 (2xCHAr), 129.0 
(2xCHAr), 128.9 (2xCHAr), 128.8 (2xCHAr), 128.3 (CH-4’), 121.9 (CH-α) 14.4 
(C-γCH3) ppm. 
These data are consistent with those described in the literature.284 
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9.3.3 Synthesis of 1,4-dihydropyridine derivatives 50-70. General 
procedure 
 
 
 
Cmpd. R1 R2 R3 R4 
50 CH3 OEt C6H5 C6H5 
51 C2H5 OEt C6H5 C6H5 
52 C3H7 OEt C6H5 C6H5 
53 CH3 StBu C6H5 C6H5 
54 CH3 CH3 C6H5 C6H5 
55 CH3 OEt C6H5 4-ClC6H4 
56 CH3 OEt 4-ClC6H4 4-ClC6H4 
57 CH3 OEt 4-MeOC6H4 C6H5 
58 CH3 StBu 4-MeOC6H4 C6H5 
59 CH3 OEt 3-MeOC6H4 4-ClC6H4 
60 CH3 StBu 4- BrC6H4 4-MeC6H4 
61 CH3 StBu 4-MeC6H4 C6H5 
62 CH3 StBu 4-MeC6H4 4-MeC6H4 
63 CH3 OEt 4-MeC6H4 C6H5 
64 CH3 OAllyl C6H5 4-ClC6H4 
65 CH3 OEt 4-NO2C6H4 C6H5 
66 CH3 OEt 2-NO2C6H4 4-MeC6H4 
67 CH3 OEt 2-NO2C6H4 4-ClC6H4 
68 CH3 OEt 2-Thienyl 4-MeC6H4 
69 CH3 OEt 4-MeC6H4 2-Furyl 
70 CH3 StBu  
C6H5 
 
To a stirred solution of 1,3-diphenyl-2-propen-1-one derivatives (1 equiv, 2 
mmol), 1,3-dicarbonyl compounds (1.1 equiv, 2.2 mmol) and ammonium acetate 
(3 equiv, 6 mmol) in ethanol (2 mL) was added ceric ammonium nitrate (CAN, 10 
R1
R2
O
R3
R4 O
O
NH4AcO
CAN (10 mol%)
EtOH, reflux, 8 h NH
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mol%) and the resulting mixture was heated under reflux for 4 hours. After this 
time, ammonium acetate (1.5 equiv, 3 mmol) was again added and stirring was 
continued under the same conditions for additional 4 hours. After this time, the 
mixture was allowed to cool to room temperature, diluted with CH2Cl2 (20 mL) 
and washed with water to remove CAN and the excess of ammonium acetate. The 
organic layer is then washed with brine and dried over anhydrous Na2SO4, and the 
solvent was evaporated under reduced pressure. 
The crude residue was crystallized from EtOH or purified by silica gel column 
chromatography using n-hexane: ethyl acetate mixtures as eluent to give pure 
compounds (50-70). 
 
Data of compounds 50-70, and the experimental conditions employed for their 
syntheses are indicated below. 
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Ethyl 2-methyl-4,6-diphenyl-1,4-dihydropyridine-3-carboxylate (50) 
 Prepared from 1,3-diphenyl-2-propen-1-one (416 mg, 2 
mmol), ethyl acetoacetate (286 mg, 2.2 mmol) and 
ammonium acetate (462 mg, 6 mmol + 231 mg, 3 mmol).  
Purification: Crystallization from EtOH. 
Yield: 574 mg (95%). Yellow solid. 
 
Data of 50: 
Mp: 244-246 °C 
Elemental analysis calcd (%) for C21H21NO2: C 78.97, H 6.63, N 4.39; found: C 
78.87, H 6.71, N 4.42. 
IR (NaCl) ν 1717 (C=O), 1220 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.56 (s, 3H, 
C-2CH3), 4.17 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.84 (d, J = 5.5 Hz, 1H, CH-4), 
5.34 (dd, J = 1.8, 5.5 Hz, 1H, CH-5), 5.73 (bs, 1H, NH), 7.30-7.33 (m, 1H, ArH), 
7.38-7.52 (m, 9H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.84 (C=O), 149.28 (C-2*), 147.29 (C-1’*), 
136.34 (C-6*), 134.73 (C-1”*), 129.20 (2xCHAr), 128.91 (CHAr), 128.64 
(2xCHAr), 128.20 (2xCHAr), 126.47 (CHAr), 125.50 (2xCHAr), 105.52 (CH-5), 
99.50 (C-3), 59.69 (OCH2CH3), 41.36 (CH-4), 21.12 (C-2CH3), 14.68 
(OCH2CH3) ppm. 
      
Ethyl 2-ethyl-4,6-diphenyl-1,4-dihydropyridine-3-carboxylate (51) 
Prepared from 1,3-diphenyl-2-propen-1-one (416 mg, 2 
mmol), ethyl 3-oxopentanoate (317 mg, 2.2 mmol) and 
ammonium acetate (462 mg, 6 mmol + 231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, v/v). 
Yield: 613 mg (92%). White solid. 
 
Data of 51: 
Mp: 143-145 °C 
Elemental analysis calcd (%) for C22H23NO2: C 79.25, H 6.95, N 4.20; found: C 
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78.94, H 6.88, N 4.40. 
IR (NaCl) ν 1666 (C=O), 1217 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.28 (t, J = 7.2 Hz, 3H, CH2CH3), 1.44 (t, J = 7.5 
Hz, 3H, OCH2CH3), 2.97 (dq, J = 4.3, 7.2 Hz, 2H, CH2CH3), 4.17 (dq, J = 0.6, 
7.5 Hz, 2H, OCH2CH3), 4.84 (d, J = 5.6 Hz, 1H, CH-4), 5.33 (dd, J = 1.9, 5.6 Hz, 
1H, CH-5), 5.79 (bs, 1H, NH), 7.23-7.33 (m, 1H, ArH), 7.38-7.57 (m, 9H, ArH) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.34 (C=O), 152.73 (C-2*), 149.37 (C-1’*), 
136.43 (C-6*), 134.63 (C-1”*), 129.22 (2xCHAr), 128.91 (CHAr), 128.63 
(2xCHAr), 128.12 (2xCHAr), 126.43 (CHAr), 125.47 (2xCHAr), 105.40 (CH-5), 
98.59 (C-3), 59.65 (OCH2CH3), 41.36 (CH-4), 27.43 (CH2CH3), 14.61 
(OCH2CH3), 13.51 (CH2CH3) ppm. 
      
Ethyl 4,6-diphenyl-2-propyl-1,4-dihydropyridine-3-carboxylate (52) 
Prepared from 1,3-diphenyl-2-propen-1-one (416 mg, 2 
mmol), ethyl butyrylacetate (345 mg, 2.2 mmol) and 
ammonium acetate (462 mg, 6 mmol + 231 mg, 3 mmol). 
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, v/v). 
Yield: 562 mg (81%). Yellow paste. 
 
Data of 52: 
Elemental analysis calcd (%) for C23H25NO2: C 79.51, H 7.25, N 4.03; found: C 
79.21, H 6.93, N 3.94. 
IR (NaCl) ν 3363 (N-H), 1724 (C=O), 1216 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.08 (t, J = 7.3 Hz, 3H, CH2CH2CH3), 1.17 (t, J = 
7.1 Hz, 3H, OCH2CH3), 1.69-1.84 (m, 2H, CH2CH2CH3) 2.69-2.90 (m, 2H, 
CH2CH2CH3), 4.06 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.72-4.75 (d, J = 5.6 Hz, 1H, 
CH-4), 5.20-5.23 (dd, J = 1.9, 5.6 Hz, 1H, CH-5), 5.68 (bs, 1H, NH), 7.15-7.43 
(m, 10H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.47 (C=O), 151.61 (C-2*), 149.43 (C-1’*), 
136.43(C-6*), 134.63 (C-1”*), 129.21 (2xCHAr), 128.90 (CHAr), 128.65 
(2xCHAr), 128.15 (2xCHAr), 126.44 (CHAr), 125.52 (2xCHAr), 105.37 (CH-5), 
98.98 (C-3), 59.68 (OCH2CH3), 41.43 (CH-4), 36.11 (CH2CH2CH3), 22.70 
N
H
OEt
O
CH3
9. Experimental section	   251 
 
 
(CH2CH2CH3), 14.64 (OCH2CH3*), 14.60 (CH2CH2CH3*) ppm. 
      
S-tert-butyl 2-methyl-4,6-diphenyl-1,4-dihydropyridine-3-carbothioate (53) 
Prepared from 1,3-diphenyl-2-propen-1-one (416 mg, 2 
mmol), S-tert-butyl 3-oxobutanethioate (383 mg, 2.2 
mmol) and ammonium acetate (462 mg, 6 mmol + 231 
mg, 3 mmol). 
Purification: crystallization from EtOH. 
Yield: 718 mg (99%). Yellow solid. 
 
Data of 53: 
Mp: 158-160 °C 
Elemental analysis calcd (%) for C23H25NOS: C 75.99, H 6.93, N 3.85, S 8.82; 
found: C 75.86, H 6.74, N 4.05, S 8.57. 
IR (NaCl) ν 1630 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.44 (s, 9H, SC(CH3)3), 2.45 (s, 3H, C-2CH3), 
4.87 (d, J = 6 Hz, 1H, CH-4), 5.30 (dd, J = 1.9, 6 Hz, 1H, CH-5), 5.68 (bs, 1H, 
NH), 7.20-7.24 (m, 1H, ArH), 7.31-7.40 (m, 9H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 193.12 (C=O), 147.94 (C-2*), 144.72 (C-1’*), 
136.06 (C-6*), 134.53 (C-1”*), 129.20 (2xCHAr), 128.96 (CHAr), 128.79 
(2xCHAr), 127.87 (2xCHAr), 126.59 (CHAr), 125.51 (2xCHAr), 108.04 (C-3), 
105.63 (CH-5), 47.59 (SC(CH3)3), 41.44 (CH-4), 30.53 (SC(CH3)3), 21.66 (C-
2CH3) ppm. 
      
1-(2-Methyl-4,6-diphenyl-1,4-dihydropyridin-3-yl)ethanone (54) 
Prepared from 1,3-diphenyl-2-propen-1-one (416 mg, 2 
mmol), acetylacetone (220 mg, 2.2 mmol) and ammonium 
acetate (462 mg, 6 mmol + 231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 10:1, v/v). 
Yield: 324 mg (56%). Yellow solid. 
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Data of 54: 
Mp: 153-155 °C 
Elemental analysis calcd (%) for C20H19NO: C 83.01, H 6.62, N 4.84; found: C 
82.83, H 6.45, N 4.98. 
IR (NaCl) ν 1637 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.07 (s, 3H, COCH3), 2.48 (s, 3H, C-2CH3), 4.74 
(d, J = 5.6 Hz, 1H, CH-4), 5.30 (dd, J = 1.9, 5.6 Hz, 1H, CH-5), 5.70 (bs, 1H, 
NH), 7.19-7.25 (m, 1H, ArH), 7.30-7.40 (m, 9H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 199.25 (C=O), 148.33 (C-2*), 147.26 (C-1’*), 
135.99 (C-6*), 134.08 (C-1”*), 129.21 (2xCHAr), 129.17 (2xCHAr), 129.01 
(CHAr), 127.74 (2xCHAr), 126.81 (CHAr), 125.44 (2xCHAr), 107.83 (C-3), 
106.36 (CH-5), 42.52 (CH-4), 29.94 (COCH3), 22.21 (C-2CH3) ppm. 
      
Ethyl 6-(4-chlorophenyl)-2-methyl-4-phenyl-1,4-dihydropyridine-3-
carboxylate (55) 
Prepared from 1-(4-chlorophenyl)-3-phenylprop-2-en-1-
one (487 mg, 2 mmol), ethyl acetoacetate (286 mg, 2.2 
mmol) and ammonium acetate (462 mg, 6 mmol + 231 mg, 
3 mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 7:1, v/v). 
Yield: 500 mg (71%). Yellow solid. 
 
Data of 55: 
Mp: > 250 °C 
Elemental analysis calcd (%) for C21H20ClNO2: C 71.28, H 5.70, N 3.96; found: 
C 70.91, H 5.68, N 4.00. 
IR (NaCl) ν 1722 (C=O), 1223 (C-O), 1097 (C-Cl) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.16 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.44 (s, 3H, 
C-2CH3), 4.05 (dq, J = 1.6, 7.1 Hz, 2H, OCH2CH3), 4.71 (d, J = 5.5 Hz, 1H, CH-
4), 5.19 (dd, J = 1.8, 5.5 Hz, 1H, CH-5), 5.52 (bs, 1H, NH), 7.16-7.22 (m, 1H, 
ArH), 7.27-7.36 (m, 8H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.69 (C=O), 149.01 (C-2*), 147.03 (C-1’*), 
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134.79 (C-6*), 134.66 (C-1”*), 133.75 (C-4”*), 129.36 (2xCHAr), 128.67 
(2xCHAr), 128.14 (2xCHAr), 126.81 (2xCHAr), 126.54 (CHAr), 106.03 (CH-5), 
99.73 (C-3), 59.74 (OCH2CH3), 41.33 (CH-4), 21.09 (C-2CH3), 14.63 
(OCH2CH3) ppm. 
      
Ethyl 4,6-bis(4-chlorophenyl)-2-methyl-1,4-dihydropyridine-3-carboxylate 
(56) 
Prepared from 1,3-bis(4-chlorophenyl)prop-2-en-1-one 
(554 mg, 2 mmol), ethyl acetoacetate (286 mg, 2.2 mmol) 
and ammonium acetate (462 mg, 6 mmol + 231 mg, 3 
mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 7:1, v/v). 
Yield: 666 mg (86%). Yellow solid. 
 
Data of 56: 
Mp: > 250 °C 
Elemental analysis calcd (%) for C21H19Cl2NO2: C 64.96, H 4.93, N 3.61; found: 
C 64.78, H 4.84, N 3.43. 
IR (NaCl) ν 3348 (N-H), 1724 (C=O), 1231 (C-O), 1091 (C-Cl) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.17 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.44 (s, 3H, 
C-2CH3), 4.05 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.69 (d, J = 5.5 Hz, 1H, CH-4), 
5.15 (dd, J = 1.88, 5.5 Hz, 1H, CH-5), 5.57 (bs, 1H, NH), 7.26 (s, 4H, ArH), 7.35 
(s, 4H, ArH)	  ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.51 (C=O), 147.55 (C-2*), 147.27 (C-1’*), 
134.83 (C-6*), 134.59 (C-1”*), 134.02 (C-4”*), 132.15 (C-4’*), 129.49 
(2xCHAr), 129.41 (2xCHAr), 128.77 (2xCHAr), 126.85 (2xCHAr), 105.48 (CH-
5), 99.39 (C-3), 59.85 (OCH2CH3), 40.85 (CH-4), 21.11 (C-2CH3), 14.67 
(OCH2CH3) ppm. 
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Ethyl 4-(4-methoxyphenyl)-2-methyl-6-phenyl-1,4-dihydropyridine-3-
carboxylate (57) 
Prepared from 3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one 
(476 mg, 2 mmol), ethyl acetoacetate (286 mg, 2.2 mmol) and 
ammonium acetate (462 mg, 6 mmol + 231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 12:1 to 5:1, v/v). 
Yield: 510 mg (73%). Yellow solid. 
 
Data of 57: 
Mp: 220-222 °C 
Elemental analysis calcd (%) for C22H23NO3: C 75.62, H 6.63, N 4.01; found: C 
75.42, H 6.48, N 4.00. 
IR (NaCl) ν 3375 (N-H), 1722 (C=O), 1250 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.20 (t, J = 7.12 Hz, 3H, OCH2CH3), 2.43 (s, 3H, 
C-2CH3), 3.80 (s, 3H, OCH3), 4.08 (q, J = 7.12 Hz, 2H, OCH2CH3), 4.67 (d, J = 
5.5 Hz, 1H, CH-4), 5.21 (dd, J = 1.62, 5.5 Hz, 1H, CH-5), 5.60 (bs, 1H, NH), 6.84 
(d, J = 8.7 Hz, 2H, CH-3’ and CH-5’), 7.27 (d, J = 8.7 Hz, 2H, CH-2’ and CH-6’), 
7.35-7.46 (m, 5H, C-6ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.91 (C=O), 158.31 (C-4’), 146.93 (C-2*), 
141.80 (C-1”*), 136.37 (C-1’*), 134.59 (C-6*), 129.20 (4xCHAr), 128.87 
(CHAr), 125.47 (2xCHAr), 113.96 (2xCHAr), 105.62 (CH-5), 99.82 (C-3), 59.69 
(OCH2CH3), 55.64 (C-4’OCH3), 40.35 (CH-4), 21.15 (C-2CH3), 14.74 
(OCH2CH3) ppm. 
      
S-tert-Butyl 4-(4-methoxyphenyl)-2-methyl-6-phenyl-1,4-dihydropyridine-
3-carbothioate (58) 
Prepared from 3-(4-methoxyphenyl)-1-phenylprop-2-en-
1-one (476 mg, 2 mmol), S-tert-butyl 3-oxobutanethioate 
(383 mg, 2.2 mmol) and ammonium acetate (462 mg, 6 
mmol + 231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 12:1 to 5:1, 
v/v). 
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Yield: 542 mg (69%). Yellow solid. 
 
Data of 58: 
Mp: 138-140 °C 
Elemental analysis calcd (%) for C24H27NO2S: C 73.25, H 6.92, N 3.56, S 8.15; 
found: C 73.11, H 6.75, N 3.73, S 7.91. 
IR (NaCl) ν 1634 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.56 (s, 9H, SC(CH3)3), 2.55 (s, 3H, C-2CH3), 
3.92 (s, 3H, OCH3), 4.92 (d, J = 6.0 Hz, 1H, CH-4), 5.40 (dd, J = 1.6, 6.0 Hz, 1H, 
CH-5), 5.78 (bs, 1H, NH), 6.97 (d, J = 8.6 Hz, 2H, CH-3’ and CH-5’), 7.38 (d, J = 
8.6 Hz, 2H, CH-2’ and CH-6’), 7.49-7.51 (m, 5H, C-6ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 193.19 (C=O), 158.40 (C-4’), 144.44 (C-2*), 
140.52 (C-1”*), 136.12 (C-6*), 134.32 (C-1’*), 129.20 (2xCHAr), 128.91 
(CHAr), 128.88 (2xCHAr), 125.50 (2xCHAr), 114.14 (2xCHAr), 108.39 (C-3), 
105.83 (CH-5), 55.60 (C-4’OCH3), 47.56 (SC(CH3)3), 40.51 (CH-4), 30.56 
(SC(CH3)3), 21.65 (C-2CH3) ppm. 
      
Ethyl 6-(4-chlorophenyl)-4-(3-methoxyphenyl)-2-methyl-1,4-
dihydropyridine-3-carboxylate (59) 
Prepared from 1-(4-chlorophenyl)-3-(3-methoxyphenyl) 
prop-2-en-1-one (545 mg, 2 mmol), ethyl acetoacetate (286 
mg, 2.2 mmol) and ammonium acetate (462 mg, 6 mmol + 
231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 12:1 to 5:1, v/v). 
Yield: 575 mg (75%). Yellow syrup. 
 
Data of 59: 
Elemental analysis calcd (%) for C22H22ClNO3: C 68.83, H 5.78, N 3.65; found: 
C 68.59, H 5.67, N 3.72. 
IR (NaCl) ν 3356 (N-H), 1724 (C=O), 1224 (C-O), 1093 (C-Cl) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.17 (t, J = 7.12 Hz, 3H, OCH2CH3), 2.44 (s, 3H, 
C-2CH3), 3.81 (s, 3H, OCH3), 4.08 (q, J = 7.12 Hz, 2H, OCH2CH3), 4.69 (d, J = 
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5.5 Hz, 1H, CH-4), 5.19 (dd, J = 1.2, 5.5 Hz, 1H, CH-5), 5.54 (bs, 1H, NH), 6.72-
6.77 (dd, J = 2.5, 8.1 Hz, 1H, CH-6’), 6.89-6.96 (m, 2H, CH-2’ and CH-4’) 7.23 
(t, J = 7.8 Hz, 1H, CH-5’), 7.35 (s, 4H, C-6ArH) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 168.65 (C=O), 160.05 (C-3’), 150.70 (C-1’*), 
147.06 (C-2*), 134.77 (C-6*), 134.68 (C-1”*), 133.81 (C-4”*), 129.58 (CHAr), 
129.36 (2xCHAr), 126.82 (2xCHAr), 120.61 (CHAr), 114.26 (CHAr), 111.39 
(CHAr), 105.89 (CH-5), 99.56 (C-3), 59.76 (OCH2CH3), 55.54 (C-3’OCH3), 
41.32 (CH-4), 21.12 (C-2CH3), 14.68 (OCH2CH3) ppm. 
      
S-tert-Butyl 4-(4-bromophenyl)-2-methyl-6-(4-methylphenyl)-1,4-
dihydropyridine-3-carbothioate (60) 
Prepared from 3-(4-bromophenyl)-1-(4-
methylphenyl)prop-2-en-1-one (602 mg, 2 mmol), S-
tert-butyl 3-oxobutanethioate (383 mg, 2.2 mmol) 
and ammonium acetate (462 mg, 6 mmol + 231 mg, 3 
mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, 
v/v). 
Yield: 610 mg (67%). Light yellow solid. 
 
Data of 60: 
Mp: 164-166 °C 
Elemental analysis calcd (%) for C24H26BrNOS: C 63.15, H 5.74, N 3.07, S 7.03; 
found: C 62.98, H 5.78, N 3.36, S 6.99. 
IR (NaCl) ν 3299 (N-H), 1612 (C=O), 1088 (C-Br) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.56 (s, 9H, SC(CH3)3), 2.49 (s, 3H, ArCH3*), 
2.55 (s, 3H, C-2CH3*), 4.93 (d, J = 5.9 Hz, 1H, CH-4), 5.32 (dd, J = 1.6, 5.9 Hz, 
1H, CH-5), 5.79 (bs, 1H, NH), 7.28-7.40 (m, 6H, ArH), 7.54 (d, J = 8.3 Hz, 2H, 
CH-3’ and CH-5’) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 192.50 (C=O), 146.77 (C-2*), 144.71 (C-1’*), 
138.82 (C-6*), 134.41 (C-4”*), 132.68 (C-1”*), 131.55 (2xCHAr), 129.61 
(2xCHAr), 129.32 (2xCHAr), 125.10 (2xCHAr), 120.03 (C-4’), 107.28 (C-3), 
104.03 (CH-5), 47.45 (SC(CH3)3), 40.65 (CH-4), 30.22 (SC(CH3)3), 21.42 (C-
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4”CH3*), 21.31 (C-2CH3*) ppm. 
      
S-tert-Butyl 2-methyl-4-(4-methylphenyl)-6-phenyl-1,4-dihydropyridine-3-
carbothioate (61) 
Prepared from 3-(4-methylphenyl)-1-phenylprop-2-en-1-
one (444 mg, 2 mmol), S-tert-butyl 3-oxobutanethioate 
(383 mg, 2.2 mmol) and ammonium acetate (462 mg, 6 
mmol + 231 mg, 3 mmol).  
Purification: crystallization from EtOH. 
Yield: 745 mg (99%). Yellow solid. 
 
Data of 61: 
Mp: 172-174 °C 
Elemental analysis calcd (%) for C24H27NOS: C 76.35, H 7.21, N 3.71, S 8.49; 
found: C 75.92, H 7.10, N 4.01, S 8.11. 
IR (NaCl) ν 3279 (N-H), 1612 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.45 (s, 9H, SC(CH3)3), 2.34 (s, 3H, ArCH3*), 
2.44 (s,	  3H, C-2CH3*), 4.82 (d, J = 6.1 Hz, 1H, CH-4), 5.31 (dd, J = 1.8, 6.1 Hz, 
1H, CH-5), 5.68 (bs, 1H, NH), 7.12 (d, J = 8.0 Hz, 2H, CH-3’ and CH-5’), 7.25 
(d, J = 8.0 Hz, 2H, CH-2’ and CH-6’), 7.33-7.39 (m, 5H C-6ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 193.13 (C=O), 145.10 (C-2*), 144.76 (C-1’*), 
136.10 (C-6*), 136.07 (C-1”*), 134.45 (C-4’*), 129.54 (2xCHAr), 129.19 
(2xCHAr), 128.92 (CHAr), 127.73 (2xCHAr), 125.52 (2xCHAr), 108.12 (C-3), 
105.82 (CH-5), 47.58 (SC(CH3)3), 40.90 (CH-4), 30.57 (SC(CH3)3), 21.71 (C-
4’CH3*), 21.54 (C-2CH3*) ppm. 
      
S-tert-Butyl 2-methyl-4,6-bis(4-methylphenyl)-1,4-dihydropyridine-3-
carbothioate (62) 
Prepared from 1,3-bis(4-methylphenyl)prop-2-en-1-one (472 mg, 2 mmol), S-tert-
butyl 3-oxobutanethioate (383 mg, 2.2 mmol) and ammonium acetate (462 mg, 6 
mmol + 231 mg, 3 mmol).  
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Purification: crystallization from EtOH. 
Yield: 760 mg (97%). Yellow solid. 
 
Data of 62: 
Mp: 169-171 °C 
Elemental analysis calcd (%) for C25H29NOS: C 
76.68, H 7.46, N 3.58, S 8.19; found: C 76.57, H 
7.36, N 3.79, S 8.13. 
IR (NaCl) ν 1614 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.46 (s, 9H, SC(CH3)3), 2.35 (s, 3H, C-4’CH3*), 
2.38 (s, 3H, C-4”CH3*), 2.44 (s, 3H, C-2CH3*), 4.82 (d, J = 6.1 Hz, 1H, CH-4), 
5.27 (dd, J = 1.7, 6.1 Hz, 1H, CH-5), 5.67 (bs, 1H, NH), 7.04-7.38 (m, 8H, ArH) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 193.11 (C=O), 145.21 (C-2*), 144.79 (C-1’*), 
138.85 (C-6*), 136.01 (C-4’*), 134.33 (C-4”*), 133.24 (C-1”*), 129.83 
(2xCHAr), 129.51 (2xCHAr), 127.73 (2xCHAr), 125.39 (2xCHAr), 108.08 (C-3), 
105.15 (CH-5),	  47.54 (SC(CH3)3), 40.85 (CH-4), 30.58 (SC(CH3)3), 21.74 (C-
4’CH3*), 21.60 (C-4”CH3*), 21.54 (C-2CH3*) ppm. 
      
Ethyl 2-methyl-4-(4-methylphenyl)-6-phenyl-1,4-dihydropyridine-3-
carboxylate (63) 
Prepared from 3-(4-methylphenyl)-1-phenylprop-2-en-1-one 
(444 mg, 2 mmol), ethyl acetoacetate (286 mg, 2.2 mmol) 
and ammonium acetate (462 mg, 6 mmol + 231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, v/v). 
Yield: 625 mg (94%). Yellow solid. 
 
Data of 63: 
Mp: 233-235 °C 
Elemental analysis calcd (%) for C22H23NO2: C 79.25, H 6.95, N 4.20; found: C 
79.01, H 6.89, N 4.14. 
IR (NaCl) ν 1723 (C=O), 1235 (C-O) cm-1; 
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1H-NMR (CDCl3, 250 MHz) δ 1.31 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.45 (s, 3H, 
C-4’CH3*), 2.55 (s, 3H, C-2CH3*), 4.19 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.81 (d, 
J = 5.5 Hz, 1H, CH-4), 5.34 (dd, J = 1.9-5.5 Hz, 1H, CH-5), 5.75 (bs, 1H, NH), 
7.24 (d, J = 8.0 Hz, 2H, CH-3’ and CH-5’), 7.38 (d, J =8.0 Hz, 2H, CH-2’ and 
CH-6’), 7.45-7.57 (m, 5H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.84 (C=O), 147.01 (C-2*), 146.36 (C-1’*), 
136.38 (C-6*), 135.91 (C-1”*), 134.64 (C-4’*), 129.32 (2xCHAr), 129.17 
(2xCHAr), 128.84 (CHAr), 128.08 (2xCHAr), 125.46 (2xCHAr), 105.61 (CH-5), 
99.72 (C-3), 59.67 (OCH2CH3), 40.80 (CH-4), 21.47 (C-4’CH3*), 21.15 (C-
2CH3*), 14.70 (OCH2CH3) ppm. 
      
Allyl 6-(4-chlorophenyl)-2-methyl-4-phenyl-1,4-dihydropyridine-3-
carboxylate (64) 
Prepared from 1-(4-chlorophenyl)-3-phenylprop-2-en-
1-one (487 mg, 2 mmol), allyl acetoacetate (313 mg, 
2.2 mmol) and ammonium acetate (462 mg, 6 mmol + 
231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, 
v/v). 
Yield: 568 mg (78%). Orange syrup. 
 
Data of 64: 
Elemental analysis calcd (%) for C22H20ClNO2: C 72.22, H 5.51, N 3.83; found: 
C 71.97, H 5.43, N 4.00. 
IR (NaCl) ν 1675 (C=O), 1219 (C-O), 1091 (C-Cl) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 2.45 (s, 3H, C-2CH3), 4.52 (dd, J = 0.85, 5.3 Hz, 
2H, OCH2CH=CH2), 4.74 (d, J = 5.58 Hz, 1H, CH-4), 5.10-5.23 (m, 3H, CH-5, 
OCH2CH=CH2), 5.60 (bs, 1H, NH) 5.76-5.93 (m, 1H, OCH2CH=CH2), 7.17-7.24 
(m, 1H, ArH), 7.28-7.38 (m, 8H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 165.86 (C=O), 146.44 (C-2*), 145.26 (C-1’*), 
132.28 (C-6*), 132.25 (C-1”*), 131.26 (C-4”*), 130.95 (OCH2CH=CH2), 126.92 
(2xCHAr), 126.32 (2xCHAr), 125.66 (2xCHAr), 124.41 (2xCHAr), 124.18 
(CHAr), 114.96 (OCH2CH=CH2), 103.75 (CH-5), 96.85 (C-3), 62.12 
N
H
O
O
Cl
CH3
1"
2"
3"
4"
5"
6"
260 9. Experimental section 
 
 
(OCH2CH=CH2), 38.81 (CH-4), 18.76 (C-2CH3) ppm. 
      
Ethyl 2-methyl-4-(4-nitrophenyl)-6-phenyl-1,4-dihydropyridine-3-
carboxylate (65) 
Prepared from 3-(4-nitrophenyl)-1-phenylprop-2-en-1-one 
(507 mg, 2 mmol), ethyl acetoacetate (286 mg, 2.2 mmol) and 
ammonium acetate (462 mg, 6 mmol + 231 mg, 3 mmol).  
Purification: Crystallization from EtOH. 
Yield: 700 mg (96%). Orange solid. 
 
Data of 65: 
Mp: 108-110 °C 
Elemental analysis calcd (%) for C21H20N2O4: C 69.22, H 5.53, N 7.69; found: C 
69.41, H 5.27, N 7.50. 
IR (NaCl) ν 3386 (N-H), 1723 (C=O), 1518 (NO2), 1220 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.17 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.48 (s, 3H, 
C-2CH3), 4.07 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.86 (d, J = 5.5 Hz, 1H CH-4), 
5.14 (dd, J = 1.88, 5.5 Hz, 1H, CH-5), 5.75 (bs, 1H, NH), 7.38-7.44 (m, 5H, C-
6ArH), 7.51 (d, J = 8.75 Hz, 2H, CH-2’ and CH-6’), 8.18 (d, J = 8.75 Hz, 2H, 
CH-3’ and CH-5’) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.25 (C=O), 156.40 (C-1’), 148.13 (C-2*), 
146.73 (C-4’*), 135.79 (C-6*), 135.68 (C-1”*), 129.36 (3xCHAr), 128.84 
(2xCHAr), 125.53 (2xCHAr), 124.16 (2xCHAr), 103.87 (CH-5), 98.46 (C-3), 
59.96 (OCH2CH3), 41.68 (C-4), 21.22 (C-2CH3), 14.69 (OCH2CH3) ppm. 
      
Ethyl 2-methyl-6-(4-methylphenyl)-4-(2-nitrophenyl) -1,4-dihydropyridine-
3-carboxylate (66) 
Prepared from 1-(4-methylphenyl)-3-(2-nitrophenyl)prop-2-en-1-one (534 mg, 2 
mmol), ethyl acetoacetate (286 mg, 2.2 mmol) and ammonium acetate (462 mg, 6 
mmol + 231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 12:1 to 5:1, v/v). 
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Yield: 590 mg (78%). Yellow syrup. 
 
Data of 66: 
Elemental analysis calcd (%) for C22H22N2O4: C 69.83, 
H 5.86, N 7.40; found: C 69.86, H 5.69, N 7.64. 
IR (NaCl) ν 3332 (N-H), 1674 (C=O), 1524 (NO2), 1221 
(C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 0.98 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.38 (s, 3H, 
C-4”CH3*), 2.49 (s, 3H, C-2CH3*), 3.92 (q, J = 7.1 Hz, 2H, OCH2CH3), 5.21 (d, 
J = 5.05 Hz, 1H, CH-4), 5.38 (dd, J = 1.8, 5.05 Hz, 1H, CH-5), 5.67 (bs, 1H, NH), 
7.19 (d, J = 7.95 Hz, 2H, CH-3” and CH-5”), 7.25-7.33 (m, 3H, CH-2”, CH-6” 
and CH-6’), 7.55 (dt, J = 1.0, 7.42 Hz, 1H, CH-4’), 7.66 (dd, J = 1.22, 7.87 Hz, 
1H, CH-5’), 7.74 (dd, J = 1.0, 8.08 Hz, 1H, CH-3’) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 167.97 (C=O), 148.92 (C-2*), 148.22 (C-1’*), 
144.08 (C-2’*), 139.15 (C-4”*), 135.09 (C-1”*), 133.50 (CHAr), 133.06 (C-6*), 
131.94 (CHAr), 129.89 (2xCHAr), 126.90 (CHAr), 125.28 (2xCHAr), 123.47 
(CHAr), 103.57 (CH-5), 98.47 (C-3), 59.70 (OCH2CH3), 37.14 (CH-4), 21.59 (C-
4”CH3*), 20.86 (C-2CH3*), 14.30 (OCH2CH3) ppm. 
      
Ethyl 6-(4-chlorophenyl)-2-methyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3-
carboxylate (67) 
Prepared from 1-(4-chlorophenyl)-3-(2-nitrophenyl) prop-
2-en-1-one (575 mg, 2 mmol), ethyl acetoacetate (286 mg, 
2.2 mmol) and ammonium acetate (462 mg, 6 mmol + 231 
mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 12:1 to 5:1, v/v). 
Yield: 495 mg (62%). Yellow syrup. 
 
Data of 67: 
Elemental analysis calcd (%) for C21H19ClN2O4: C 69.22, H 5.53, N 7.69; found: 
C 69.11, H 5.37, N 7.66. 
IR (NaCl) ν 3188 (N-H), 1721 (C=O), 1528 (NO2), 1269 (C-O), 1094 (C-Cl) cm-
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1. 
1H-NMR (CDCl3, 250 MHz) δ 0.97 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.49 (s, 3H, 
C-2CH3), 3.91 (q, J = 7.1 Hz, 2H, OCH2CH3), 5.21 (d, J = 5.1 Hz, 1H, CH-4), 
5.40 (dd, J = 1.7, 5.1 Hz, 1H, CH-5), 5.57 (bs, 1H, NH), 7.27-7.34 (m, 1H, CH-
6’), 7.36 (s,	  4H, C-6ArH), 7.53-7.66 (m, 2H, CH-4’ and CH-5’), 7.76 (dd, J = 1, 
8.2 Hz, 1H, CH-3’) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 167.80 (C=O), 148.73 (C-2*), 148.23 (C-2’*), 
143.68 (C-1’*), 134.96 (C-6*), 134.41 (C-1”*), 134.29 (C-4’*), 133.57 (CHAr), 
131.84 (CHAr), 129.42 (2xCHAr), 127.06 (CHAr), 126.81 (2xCHAr), 123.57 
(CHAr), 104.73 (CH-5), 98.74 (C-3), 59.81 (OCH2CH3), 37.16 (C-4), 20.83 (C-
2CH3), 14.27 (OCH2CH3) ppm. 
      
Ethyl 2-methyl-4-(thiophen-2-yl)-6-(4-methylphenyl)-1,4-dihydropyridine-
3-carboxylate (68) 
Prepared from 1-(4-methylphenyl)-3-(thiophen-2-yl)prop-
2-en-1-one (456 mg, 2 mmol), ethyl acetoacetate (286 mg, 
2.2 mmol) and ammonium acetate (462 mg, 6 mmol + 
231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, 
v/v). 
Yield: 387 mg (57%). Orange syrup. 
 
Data of 68: 
Elemental analysis calcd (%) for C20H21NO2S: C 70.77, H 6.24, N 4.13, S 9.45; 
found: C 70.76, H 6.06, N 4.25, S 9.46. 
IR (NaCl) ν 1718 (C=O), 1221 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.30 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.40 (s, 3H, 
C-4’CH3*), 2.41 (s, 3H, C-2CH3*), 4.18 (q, J = 7.1 Hz, 2H, OCH2CH3), 5.04 (d, 
J = 5.8 Hz, 1H, CH-4), 5.28 (dd, J = 1.8, 5.8 Hz, 1H, CH-5), 5.76 (bs, 1H, NH), 
6.92-6.95 (m, 2H, CH-3’ and CH-4’), 7.14 (dd, J = 1.6, 4.7 Hz, 1H, CH-5’), 7.22 
(d, J = 8.0 Hz, 2H, CH-3” and CH-5”), 7.36 (d, J = 8.0 Hz, 2H, CH-2” and CH-
6”) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 168.53 (C=O) 153.85 (C-2*), 147.11 (C-2’*), 
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139.10 (C-6*), 135.68 (C-4”*), 133.29 (C-1”*), 129.93 (2xCHAr), 126.95 (CH-
thienyl), 125.60 (2xCHAr), 123.92 (CH-thienyl), 123.29 (CH-thienyl), 103.30 
(CH-5),	  99.56 (C-3), 59.87 (OCH2CH3), 35.47 (CH-4), 21.62 (C-4CH3*), 21.16 
(C-2CH3*), 14.81 (OCH2CH3) ppm. 
      
Ethyl 6-(furan-2-yl)-2-methyl-4-(4-methylphenyl)-1,4-dihydropyridine-3-
carboxylate (69) 
Prepared from 1-(furan-2-yl)-3-(4-methylphenyl)prop-2-en-
1-one (424 mg, 2 mmol), ethyl acetoacetate (286 mg, 2.2 
mmol) and ammonium acetate (462 mg, 6 mmol + 231 mg, 3 
mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 8:1, v/v). 
Yield: 315 mg (49%). Yellow syrup. 
 
Data of 69: 
Elemental analysis calcd (%) for C20H21NO3: C 74.28, H 6.55, N 4.33; found: C 
73.99, H 6.37, N 4.22. 
IR (NaCl) ν 3348 (N-H), 1724 (C=O), 1268 (C-O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.18 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.32 (s, 3H, 
C-4’CH3*), 2.44 (s, 3H, C-2CH3*), 4.05 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.64 (d, 
J = 5.65 Hz, 1H, CH-4), 5.37 (dd, J = 1.58, 5.65 Hz, 1H, CH-5), 5.90 (bs, 1H, 
NH), 6.40-6.44 (m, 2H, CH-3” and CH-4”), 7.10 (d, J = 8.02 Hz, 2H, CH-3’ and 
CH-5’), 7.23 (d, J = 8.02 Hz, 2H, CH-2’ and CH-6’), 7.39-7.40 (m, 1H, CH-5”) 
ppm. 
13C-NMR (CDCl3, 63 MHz) δ 168.71 (C=O), 149.10 (C-2”*), 146.63 (C-2*), 
146.03 (C-1’*), 141.88 (CH-furanyl), 136.04 (C-4’), 129.36 (2xCHAr), 128.07 
(2xCHAr), 126.30 (C-6), 111.96 (CH-furanyl), 105.09 (CH-furanyl), 103.41 (CH-
5), 99.66 (C-3), 59.70 (OCH2CH3), 40.12 (CH-4), 21.48 (C-4’CH3*), 21.08 (C-
2CH3*), 14.67 (OCH2CH3) ppm. 
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S-tert-Butyl 2-methyl-6-phenyl-4-(1-phenylprop-1-en-2-yl)-1,4-
dihydropyridine-3-carbothioate (70) 
Prepared from 4-methyl-1,5-diphenylpenta-2,4-dien-1-one 
(497 mg, 2 mmol), S-tert-butyl 3-oxobutanethioate (383 
mg, 2.2 mmol) and ammonium acetate (462 mg, 6 mmol 
+ 231 mg, 3 mmol).  
Purification: n-hexane:ethyl acetate (from 15:1 to 10:1, 
v/v). 
Yield: 420 mg (52%). Yellow solid. 
 
Data of 70: 
Mp: 113-115 °C 
Elemental analysis calcd (%) for C26H29NOS: C 77.38, H 7.24, N 3.47, S 7.95; 
found: C 77.21, H 7.04, N 3.61, S 7.85. 
IR (NaCl) ν 3357 (N-H), 1633 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.5 (s, 9H, SC(CH3)3), 1.95 (d, J = 1.3 Hz, 3H, C-
αCH3), 2.39 (s, 3H, C-2CH3) 4.41 (d, J = 5.8 Hz, 1H, CH-4), 5.19 (dd, J = 1.9, 
5.8 Hz, 1H, CH-5), 5.55 (bs, 1H, NH), 6.40 (s, 1H, CH-β), 7.20-7.24 (m, 1H, 
ArH), 7.27-7.45 (m, 9H, ArH) ppm.  
13C-NMR (CDCl3, 63 MHz) δ 193.74 (C=O), 144.68 (C-2*), 142.62 (C-1”*), 
139.23 (C-6*), 136.28 (C-1’*), 135.75 (C-α*), 129.37 (2xCHAr), 129.25 
(2xCHAr), 128.96 (CHAr), 128.34 (2xCHAr), 126.25 (CHAr), 125.68 (CH-β), 
125.50 (2xCHAr), 106.88 (C-3), 103.78 (CH-5), 47.40 (SC(CH3)3), 45.76 (CH-4), 
30.64 (SC(CH3)3), 21.35 (C-2CH3), 15.67 (C-αCH3) ppm. 
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9.3.4 Synthesis of 1,4-dihydropyridine bicyclic derivatives 71 and 72. 
General procedure 
 
 
 
Compound R 
71 H 
72 CH3 
 
To a stirred solution of 1,3-diphenyl-2-propen-1-one (1 equiv, 2 mmol), 
cyclohexane-1,3-dione or its derivatives, (1.1 equiv, 2.2 mmol) and ammonium 
acetate (3 equiv, 6 mmol) in ethanol (2 mL) was added ceric ammonium nitrate 
(CAN, 10 mol%) and the resulting mixture was heated under reflux for 4 hours. 
After this time, ammonium acetate (1.5 equiv, 3 mmol) was again added and 
stirring was continued at the same conditions for additional 4 hours. After this 
time, the mixture was allowed to cool to room temperature, diluted with CH2Cl2 
(20 mL), and washed with water to remove CAN and the excess of ammonium 
acetate. The organic layer was then washed with brine and dried over anhydrous 
Na2SO4, and the solvent was evaporated under reduced pressure. 
The crude residue was crystallized from EtOH or purified by silica gel column 
chromatography using petroleum ether: ethyl acetate mixtures as eluent to give 
pure compounds 71 and 72. 
 
Data of compounds 71 and 72, and the experimental conditions employed for their 
synthesis are indicated below. 
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2,4-Diphenyl-4,6,7,8-tetrahydroquinolin-5(1H)-one (71) 
Prepared from 1,3-diphenyl-2-propen-1-one (416 mg, 2 mmol), 
1,3-cyclohexanedione (246 mg, 2.2 mmol) and ammonium 
acetate (462 mg, 6 mmol + 231 mg, 3 mmol). 
Purification: petroleum ether:ethyl acetate (from 8:1 to 3:1, 
v/v). 
Yield: 488 mg (81%). White solid. 
 
Data of 71: 
Mp: 208-210 °C 
Elemental analysis calcd (%) for C21H19NO: C 83.69 H 6.35, N 4.65; found: C 
83.45, H 6.01, N 4.51. 
IR (NaCl) ν 1584 (C=O) cm-1. 
1H-NMR (DMSO-d6, 250 MHz) δ 1.75-1.99 (m, 2H, CH2-7), 2.19-2.26 (m, 2H, 
CH2-8), 2.55-2.71 (m, 2H, CH2-6), 4.61 (d, J = 5.4 Hz, 1H, CH-4), 5.24 (dd, J = 
1.6, 5.4 Hz, 1H, CH-3), 7.08-7.51 (m, 10H, ArH), 8.71 (bs, 1H, NH) ppm. 
13C-NMR (DMSO-d6, 63 MHz) δ 194.66 (C=O), 154.65 (C-8a*), 148.66 (C-1’*), 
135.55 (C-2*), 134.85 (C-1”*), 128.81 (2xCHAr), 128.68 (CHAr), 128.46 
(2xCHAr), 127.67 (2xCHAr), 125.96 (CHAr), 125.91 (2xCHAr), 107.38 (C-4a), 
106.20 (CH-3), 37.28 (CH2-6), 37.24 (CH-4), 27.25 (CH2-8), 21.30 (CH2-7) ppm. 
      
7,7-Dimethyl-2,4-diphenyl-4,6,7,8-tetrahydroquinolin-5(1H)-one (72) 
Prepared from 1,3-diphenyl-2-propen-1-one (416 mg, 2 
mmol), 5,5-dimethyl-1,3-cyclohexanedione (308 mg, 2.2 
mmol) and ammonium acetate (462 mg, 6 mmol + 231 mg, 
3 mmol). 
Purification: petroleum ether:ethyl acetate (from 8:1 to 3:1, 
v/v). 
Yield: 545 mg (83%). Pale yellow solid. 
 
Data of 72: 
Mp: 204-206 °C 
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Elemental analysis calcd (%) for C23H23NO: C 83.85; H 7.04; N 4.25; found: C 
83.90, H 7.07, N 4.34. 
IR (NaCl) ν 1587 (C=O) cm-1. 
1H-NMR (CDCl3, 250 MHz) δ 1.05 (s, 3H, C-7CH3), 1.14 (s, 3H, C-7CH3), 2.16-
2.47 (m, 4H, CH2-6 and CH2-8), 4.78 (d, J = 5.2 Hz, 1H, CH-4), 5.33 (dd, J = 1.8, 
5.2 Hz, 1H, CH-3), 5.98 (bs, 1H, NH), 7.14-7.45 (m, 10H, ArH) ppm. 
13C-NMR (CDCl3, 63 MHz) δ 195.99 (C=O), 151.15 (C-8a*), 148.03 (C-1’*), 
136.19 (C-2*), 134.44 (C-1”*), 129.90 (CHAr), 129.27 (2xCHAr), 128.69 
(2xCHAr), 128.29 (2xCHAr), 126.47 (CHAr), 125.53 (2xCHAr), 108.86 (C-4a), 
107.55 (CH-3), 51.14 (CH2-6), 42.50 (CH2-8), 38.15 (CH-4), 32.94 (C-7), 29.83 
(C-7CH3*), 27.83 (C-7CH3*) ppm. 
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9.4 NICOTINAMIDE DERIVATIVES 
9.4.1) Synthesis of β-ketoamides 73-77. General procedure 
 
 
 
Compound Z 
73 NHc-Hex 
74 
 
75 
 
76 
 
77 NHC6H5 
 
A mixture of the appropriate amine (1 equiv, 5 mmol), 2,2,6-trimethyl-4H-1,3-
dioxin-4-one (1.3 equiv, 6.5 mmol) and anhydrous NaOAc (1 equiv, 5 mmol) in 
THF (1 mL) was heated under reflux for the time period specified in the 
compound data sheet. After completion of the reaction (checked by TLC), the 
mixture was allowed to cool to room temperature and diluted with Et2O (10 mL). 
The organic layer was washed with water and brine and dried over anhydrous 
Na2SO4 .The solvent was evaporated under reduced pressure and the crude 
residue was purified by silica gel column chromatography using petroleum 
ether:ethyl acetate mixtures as eluent to give pure compounds 73-77. 
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N-Cyclohexyl-3-oxobutanamide (73) 
Prepared from cyclohexanamine (496 mg, 5 mmol), 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (924 mg, 6.5 mmol) and 
sodium acetate (410 mg, 5 mmol).  
Reaction time: 24 h. 
Purification: petroleum ether:ethyl acetate (from 10:1 to 4:1, v/v). 
Yield: 870 mg (95%). Pale yellow solid. 
 
Data of 73: 
IR (KBr) ν 3296 (N-H), 1722 (C-3=O), 1644 (C-1=O), 1556 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.14–1.48 (m, 5H, CH2-γ, CH2-γ’ and CH-δax), 
1.61–1.78 (m, 3H, CH-βax, CH-β’ax and CH-δeq*), 1.90–1.94 (m, 2H, CH-βeq 
and CH-β’eq), 2.30 (s, 3H, CH3-4), 3.43 (s, 2H, CH2-2), 3.74–3.89 (m, 1H, CH-
α), 6.86 (bs, 1H, CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 205.39 (C-3=O), 164.82 (C-1=O), 50.21 (CH2-2), 
48.62 (CH-α), 33.25 (CH2-β and CH2-β’), 31.50 (CH3-4), 25.90 (CH2-δ), 25.12 
(CH2-γ and CH2-γ’) ppm. 
These data are consistent with those described in the literature.285 
      
1-(Piperidin-1-yl)butane-1,3-dione (74) 
Prepared from piperidine (426 mg, 5 mmol), 2,2,6-trimethyl-
4H-1,3-dioxin-4-one (924 mg, 6.5 mmol) and sodium acetate 
(410 mg, 5 mmol).  
Reaction time: 24 h. 
Purification: petroleum ether:ethyl acetate (from 12:1 to 7:1, v/v). 
Yield: 805 mg (95%). Yellow oil. 
 
Data of 74: 
IR (KBr) ν 1721 (C-3=O), 1639 (C-1=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.54–1.65 (m, 6H, CH2-β, CH2-β’ and CH2-γ), 
                                                
285 Sridharan, V.; Ruiz, M.; Menéndez, J.C. Synthesis 2010, 6, 1053-1057. 
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2.28 (s, 3H, CH3-4), 3.32–3.37 (m, 2H, CH-αax and CH-α’ax), 3.55 (s, 2H, CH2-
2), 3.55–3.59 (m, 2H, CH-αeq and CH-α’eq) ppm. 
13C NMR (63 MHz, CDCl3) δ 203.00 (C-3=O), 165.12 (C-1=O), 50.48 (CH2-2), 
47.82 (CH2-α*), 43.17 (CH2-α’*), 30.46 (CH3-4), 26.62 (CH2-β*), 25.79 (CH2-
β’*), 24.65 (CH2-γ) ppm. 
These data are consistent with those described in the literature.285 
      
1-Morpholinobutane-1,3-dione (75) 
Prepared from morpholine (436 mg, 5 mmol), 2,2,6-trimethyl-
4H-1,3-dioxin-4-one (924 mg, 6.5 mmol) and sodium acetate 
(410 mg, 5 mmol).  
Reaction time: 24 h. 
Purification: petroleum ether:ethyl acetate (from 10:1 to 7:1, v/v). 
Yield: 770 mg (90%). Pale yellow oil. 
 
Data of 75: 
IR (KBr) ν 1716 (C-3=O), 1629 (C-1=O), 1111 (C-O-C) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.26 (s, 3H, CH3-4), 3.38–3.42 (m, 2H, CH-αax 
and CH-α’ax), 3.56 (s, 2H, CH2-2), 3.62–3.68 (m, 6H, CH-αeq, CH-α’eq, CH2-β 
and CH2-β’) ppm. 
13C NMR (63 MHz, CDCl3) δ 202.61 (C-3=O), 165.45 (C-1=O), 67.08 (CH2-β*), 
66.96 (CH2-β’*), 50.17 (CH2-2), 47.17 (CH2-α*), 42.54 (CH2-α’*), 30.75 (CH3-4) 
ppm. 
These data are consistent with those described in the literature.286 
      
1-(4-Methylpiperazin-1-yl)butane-1,3-dione (76) 
Prepared from 1-methylpiperazine (501 mg, 5 mmol), 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (924 mg, 6.5 mmol) and 
sodium acetate (410 mg, 5 mmol).  
                                                
286 Bose, D. S.; Idrees, M.; Jakka, N. M.; Rao, J. V. J. Comb. Chem. 2010, 12, 100-110.  
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Purification: petroleum ether:ethyl acetate (from 10:1 to 4:1, v/v). 
Reaction time: 24 h. 
Yield: 653 mg (71%). Yellow oil. 
 
Data of 76: 
IR (KBr) ν 1719 (C-3=O), 1630 (C-1=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.18 (s, 3H, CH3-4), 2.22 (s, 3H, NCH3), 2.29–
2.33 (m, 4H, CH2-β and CH2-β’), 3.32–3.36 (m, 2H, CH-αax and CH-α’ax), 3.48 
(s, 2H, CH2-2), 3.54–3.58 (m, 2H, CH-αeq and CH-α’eq) ppm. 
13C NMR (63 MHz, CDCl3) δ 202.69 (C-3=O), 165.24 (C-1=O), 55.24 (CH2-β*), 
54.82 (CH2-β’*), 50.29 (CH2-2), 46.60 (CH2-α*), 46.27 (NCH3), 42.01 (CH2-α’*), 
30.58 (CH3-4) ppm. 
These data are consistent with those described in the literature.287 
      
3-Oxo-N-phenylbutanamide (77) 
Prepared from aniline (465 mg, 5 mmol), 2,2,6-trimethyl-
4H-1,3-dioxin-4-one (924 mg, 6.5 mmol) and sodium acetate 
(410 mg, 5 mmol).  
Reaction time: 24 h. 
Purification: petroleum ether:ethyl acetate (from 8:1 to 3:1, v/v). 
Yield: 850 mg (96%). White solid. 
 
Data of 77: 
IR (KBr) ν 3302 (N-H), 1710 (C-3=O), 1663 (C-1=O), 1549 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.36 (s, 3H, CH3-4), 3.60 (s, 2H, CH2-2), 7.15 (t, 
J=7.4 Hz, 1H, CH-4’), 7.36 (t, J=8.2 Hz, 2H, CH-3’ and CH-5’), 7.58 (d, J=7.7 
Hz, 2H, CH-2’ and CH-6’), 9.16 (bs, 1H, CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 205.80 (C-3=O), 163.90 (C-1=O), 137.87 (C-1’), 
129.43 (2xCHAr), 125.02 (CH-4’), 120.59 (2xCHAr), 50.07 (CH2-2), 31.75 
(CH3-4) ppm. 
                                                
287 Boido, A.; Novelli, F.; Savelli, F.; Sparatore, F.; Russo, S.; Filippelli, W.; Susanna, V.; Marmo, E. 
Farmaco 1989, 44, 279-301. 
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These data are consistent with those described in the literature.285 
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9.4.2 Synthesis of β-ketoamides 78-80. General procedure 
 
 
 
Compound R 
78 C2H5 
79 C3H7 
80 CH(CH3)2 
 
A solution of the appropriate β-ketoester (1 equiv, 5 mmol), aniline (1.1 equiv, 5.5 
mmol) and glacial acetic acid (0.1 mL) in toluene (15 mL) was heated under 
reflux with a Dean-Stark trap for the time period specified in the compound data 
sheet. After completion of the reaction (checked by TLC), the solvent was 
evaporated under reduced pressure and the crude residue was purified by silica gel 
column chromatography using petroleum ether:ethyl acetate mixtures as eluent to 
give pure compounds 78-80. 
 
  
R OEt
O O H2N AcOH cat.
PhCH3, reflux
+ R NH
O O
78-79
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3-Oxo-N-phenylpentanamide (78) 
Prepared from ethyl 3-oxopentanoate (720 mg, 5 mmol) 
and aniline (512 mg, 5.5 mmol). 
Reaction time: 7 h. 
Purification: petroleum ether:ethyl acetate (from 10:1 to 
5:1, v/v). 
Yield: 515 mg (54%). Pale yellow solid. 
 
Data of 78: 
IR (KBr) ν 3253 (N-H), 1712 (C-3=O), 1655 (C-1=O), 1594 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.15 (t, J=7.2, 3H, CH3-5), 2.65 (q, J=7.2, 2H, 
CH2-4), 3.60 (s, 2H, CH2-2), 7.14 (t, J=7.4 Hz, 1H, CH-4’), 7.35 (t, J=8.2 Hz, 2H, 
CH-3’ and CH-5’), 7.57 (d, J=7.7 Hz, 2H, CH-2’ and CH-6’), 9.21 (bs, 1H, 
CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 208.64 (C-3=O), 163.90 (C-1=O), 137.93 (C-1’), 
129.42 (2xCHAr), 124.94 (CH-4’), 120.51 (2xCHAr), 49.06 (CH2-2), 42.70 
(CH2-4), 7.80 (CH3-5) ppm. 
These data are consistent with those described in the literature.288 
      
3-Oxo-N-phenylhexanamide (79) 
Prepared from ethyl 3-oxohexanoate (791 mg, 5 mmol) 
and aniline (512 mg, 5.5 mmol). 
Reaction time: 10 h. 
Purification: petroleum ether:ethyl acetate (from 10:1 to 
5:1, v/v). 
Yield: 565 mg (55%). White solid. 
 
Data of 79: 
IR (KBr) ν 3285 (N-H), 1711 (C-3=O), 1655 (C-1=O), 1595 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 0.99 (t, J=7.4, 3H, CH3-6), 1.71 (sext, J=7.4, 2H, 
                                                
288 Steinhuebel, D.; Sun, Y.; Matsumura, K.; Sayo, N.; Saito T. J. Am. Chem. Soc. 2009, 131, 
11316-11317. 
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CH2-5), 2.61 (t, J=7.2, 2H, CH2-4), 3.60 (s, 2H, CH2-2), 7.15 (t, J=7.4 Hz, 1H, 
CH-4’), 7.36 (t, J=8.3 Hz, 2H, CH-3’ and CH-5’), 7.59 (d, J=8.2 Hz, 2H, CH-2’ 
and CH-6’), 9.21 (bs, 1H, CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 208.26 (C-3=O), 163.92 (C-1=O), 137.93 (C-1’), 
129.42 (2xCHAr), 124.94 (CH-4’), 120.53 (2xCHAr), 49.29 (CH2-2), 46.47 
(CH2-4), 17.25 (CH2-5), 13.95 (CH3-6) ppm. 
      
4-Methyl-3-oxo-N-phenylpentanamide (80) 
Prepared from ethyl 4-methyl-3-oxopentanoate (791 mg, 5 
mmol) and aniline (512 mg, 5.5 mmol). 
Reaction time: 7 h. 
Purification: petroleum ether:ethyl acetate (from 10:1 to 
5:1, v/v). 
Yield: 675 mg (66%). White solid. 
 
Data of 80: 
IR (KBr) ν 3297 (N-H), 1712 (C-3=O), 1656 (C-1=O), 1597 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.20 (d, J=6.9, 6H, CH(CH3)2), 2.77 (hept, 1H, 
CH(CH3)2), 3.64 (s, 2H, CH2-2), 7.13 (t, J=7.5 Hz, 1H, CH-4’), 7.35 (t, J=7.6 Hz, 
2H, CH-3’ and CH-5’), 7.58 (d, J=8.0 Hz, 2H, CH-2’ and CH-6’), 9.28 (bs, 1H, 
CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 212.00 (C-3=O), 164.08 (C-1=O), 137.95 (C-1’), 
129.41 (2xCHAr), 124.91 (CH-4’), 120.50 (2xCHAr), 47.29 (CH2-2), 42.70 
(CH(CH3)2), 18.15 (CH(CH3)2) ppm. 
These data are consistent with those described in the literature.288 
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9.4.3) Synthesis of tert-butyl 2,4-dioxopiperidine-1-carboxylate (81). 
 
 
 
To a solution of N-Boc-β-alanine (1 equiv, 20 mmol, 3.780 g), 2,2-dimethyl-1,3-
dioxane-4,6-dione (1.1 equiv, 22 mmol, 4.268 g), and DMAP (1.9 equiv, 38 
mmol, 4.636 g) in anhydrous CH2Cl2 (110 mL) at 0 °C was added EDCI (1.5 
equiv, 30 mmol, 5.751 g), and the resulting solution was stirred overnight at room 
temperature. The reaction mixture was washed (100 mL x 4) with 5% potassium 
bisulfate aqueous solution, the organic layer was dried over anhydrous sodium 
sulfate, filtered and concentrated, thereby affording crude tert-butyl [3-(2,2-
dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-3-oxopropyl]carbamate that was dissolved in 
100 mL of ethyl acetate and refluxed for 4 h. At the end of the reaction, the 
solvent was removed in vacuo and the residue was purified by chromatography on 
silica gel (eluent: chloroform:ethyl acetate 30:1), yielding 2.640 g (62%) of the 
desired product 81 as a pale yellow solid. 
 
Data of 81: 
IR (KBr) ν 1767 (C-4=O), 1732 (NC(O)O), 1671 (C-2=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.59 (s, 9H, C(CH3)3), 2.67 (t, J=6.1 Hz, 2H, CH2-
5), 3.55 (s, 2H, CH2-3), 4.15 (t, J=7 Hz, 2H, CH2-6) ppm. 
13C NMR (63 MHz, CDCl3) δ 202.73 (C-4=O), 165.88 (C-2=O), 151.58 
(NC(O)O), 84.61 (C(CH3)3), 52.67 (CH2-3), 41.11 (CH2-5), 38.62 (CH2-6), 28.34 
(C(CH3)3) ppm. 
These data are consistent with those described in the literature.289 
       
                                                
289 Vanotti, E.; Amici, R.; Bargiotti, A.; Berthelsen, J.; Bosotti, R.; Ciavolella, A.; Cirla, A.; Cristiani, 
C.; D’Alessio, R.; Forte, B.; Isacchi, A.; Martina, K.; Menichincheri, M.; Molinari, A.; Montagnoli, 
A.; Orsini, P.; Pillan, A.; Roletto, F.; Scolaro, A.; Tibolla, M.; Valsasina, B.; Varasi, M.; Volpi, D.; 
Santocanale, C. J. Med. Chem. 2008, 51, 487-501. 
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9.4.4 Synthesis of piperidine-2,4-dione (82). 
 
 
 
To a solution of tert-butyl 2,4-dioxopiperidine-1-carboxylate 81 (1 equiv, 6 mmol, 
1.278 g) in anhydrous CH2Cl2 (10 mL) at room temperature was added 
trifluoroacetic acid (10 mL), and the resulting mixture was stirred for 1 h at the 
same temperature. At the end of the reaction (as checked by TLC), the solvent and 
the trifluoroacetic acid were removed under reduced pressure and the residue was 
purified by column chromatography on silica gel (eluent: chloroform:ethyl acetate 
10:1), yielding 525 mg (93%) of the desired product 82 as a white solid. 
 
Data of 82: 
IR (KBr) ν 3185 (N-H), 1718 (C-4=O), 1648 (C-2=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.67 (t, J=6.2 Hz, 2H, CH2-5), 3.37 (s, 2H, CH2-
3), 3.58-3.64 (m, 2H, CH2-6), 6.85 (bs, 1H, CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 203.74 (C-4=O), 170.45 (C-2=O), 48.66 (CH2-3), 
38.52 (CH2-5), 37.52 (CH2-6) ppm. 
These data are consistent with those described in the literature.289 
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9.4.5 Synthesis of nicotinamide derivatives 83-103. General procedure 
 
 
 
Cmpd. R1 R2 R3 R4 Z 
83 C6H5 H C6H5 CH3 NH2 
84 4-MeC6H4 H C6H5 CH3 NH2 
85 4-MeC6H4 H 4-MeC6H4 CH3 NH2 
86 C6H5 H 4-MeOC6H4 CH3 NH2 
87 4-MeOC6H4 H 4-MeOC6H4 CH3 NH2 
88 4-ClC6H4 H 4-ClC6H4 CH3 NH2 
89 4-ClC6H4 H 2-NO2C6H4 CH3 NH2 
90 2-NO2C6H4 H 4-MeC6H4 CH3 NH2 
91a C6H5 CH3 C6H5 CH3 NH2 
92 4-MeC6H4 H 4-MeC6H4 CH3 NHc-Hex 
93 C6H5 H C6H5 CH3 NHPh 
94a,b C6H5 H C6H5 C2H5 NHPh 
95 C6H5 H C6H5 C3H7 NHPh 
96b C6H5 H C6H5 CH(CH3)2 NHPh 
97 C6H5 H C6H5 CH3  
98 C6H5 H C6H5 CH3  
99 C6H5 H C6H5 CH3  
100 C6H5 H 2-thienyl CH3 NH2 
101 4-MeC6H4 H 2-thienyl CH3 NH2 
102 C6H5 H 
 
CH3 NH2 
103 C6H5 H  CH3 NH2 
a experiments carried out with 1:2:3(+1 eq additional after 24 h) ratio of chalcone:β-
ketoamides:ammonium acetate 
b experiments carried out at 50°C 
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To a stirred solution of the suitable 1,3-diphenyl-2-propen-1-one derivatives (1 
equiv, 1 mmol), the appropriate primary or secondary β-ketoamide derivatives 
(1.1 equiv, 1.1 mmol) and ammonium acetate (3 equiv, 3 mmol) in ethanol (1 mL) 
was added ceric ammonium nitrate (CAN, 10 mol%), and the resulting mixture 
was heated under reflux for the time period specified in the compound data sheet. 
After completion of the reaction (checked by TLC), the mixture was poured into 
ice-water (15 mL) and the precipitate formed was collected by filtration and 
washed with cold water. 
 
For the derivatives 97-102 a different workup was carried on: after completion of 
the reaction (checked by TLC), the mixture was allowed to cool to room 
temperature, diluted with CH2Cl2 (15 mL) and washed with water to remove CAN 
and the excess of ammonium acetate. The organic layer was then washed with 
brine and dried over anhydrous Na2SO4 and the solvent was evaporated under 
reduced pressure. 
 
The crude residue was crystallized from EtOH or purified by silica gel column 
chromatography using chloroform:ethyl acetate or n-hexane:ethyl acetate 
mixtures as eluents to give pure compounds (83-103).  
 
Data of compounds 83-103 and the experimental conditions employed for their 
synthesis are indicated below. 
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2-Methyl-4,6-diphenylnicotinamide (83) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), acetoacetamide (111 mg, 1.1 mmol) and ammonium 
acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 265 mg (92%). White solid. 
 
Data of 83: 
Mp: 219-221 °C 
Elemental analysis calcd (%) for C19H16N2O: C 79.14, H 5.59, N 9.72; found: C 
78.93, H 5.53, N 9.51. 
IR (KBr) ν 3378 (N-H), 3204 (N-H), 1694 (C=O), 1651 (C=N), 1621 (N-C=O) 
cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.80 (s, 3H, C-2CH3), 5.40 (bs, 1H, CONH), 5.63 
(bs, 1H, CONH), 7.41-7.64 (m, 9H, ArH and CH-5), 8.05 (dd, J = 7.9, 1.6 Hz, 2H, 
CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, CDCl3) δ 170.84 (C=O), 157.40 (C-2*), 155.90 (C-6*), 
147.67 (C-4), 138.89 (C-1’*), 138.27 (C-1”*), 129.48 (CHAr), 129.01 (3xCHAr), 
128.96 (2xCHAr), 128.90 (C-3), 128.38 (2xCHAr), 127.28 (2xCHAr), 118.74 
(CH-5), 23.12 (C-2CH3) ppm. 
      
2-Methyl-6-(4-methylphenyl)-4-phenylnicotinamide (84) 
 Prepared from 1-(4-methylphenyl)-3-phenylprop-2-en-1-
one (222 mg, 1 mmol), acetoacetamide (111 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 286 mg (95%). White solid. 
 
Data of 84: 
Mp: 248-250 °C 
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Elemental analysis calcd (%) for C20H18N2O: C 79.44, H 6.00, N 9.26; found: C 
79.24, H 5.95, N 9.30. 
IR (KBr) ν 3380 (N-H), 3204 (N-H), 1692 (C=O), 1651 (C=N), 1621 (N-C=O) 
cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.38 (s, 3H, C-4”CH3), 2.60 (s, 3H, C-
2CH3), 7.31 (d, J = 7.8 Hz, 2H, CH-3” and CH-5”), 7.38-7.67 (m, 6H, ArH’ and 
CH-5), 7.71 (s, 1H, CONH), 7.87 (s, 1H, CONH), 8.06 (d, J = 7.8 Hz, 2H, CH-2” 
and CH-6”) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 169.82 (C=O), 154.89 (C-2*), 153.98 (C-6*), 
146.76 (C-4), 138.77 (C-1’*), 138.47 (C-1”*), 135.53 (C-4”), 130.79 (C-3), 
129.37 (2xCHAr), 128.39 (5xCHAr), 126.70 (2xCHAr), 117.70 (CH-5), 22.62 
(C-2CH3), 20.89 (C-4”CH3) ppm. 
      
4,6-Bis(4-methylphenyl)-2-methylnicotinamide (85) 
Prepared from 1,3-di-(4-methylphenyl)prop-2-en-1-one 
(236 mg, 1 mmol), acetoacetamide (111 mg, 1.1 mmol) 
and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 300 mg (95%). White solid. 
 
Data of 85: 
Mp: 247-249 °C 
Elemental analysis calcd (%) for C21H20N2O: C 79.72, H 6.37, N 8.85; found: C 
79.81, H 6.26, N 8.62. 
IR (KBr) ν 3289 (N-H), 3180 (N-H), 1652 (C=O), 1606 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 2.44 (s, 6H, 2xArCH3), 2.76 (s, 3H, C-2CH3), 
5.44 (bs, 1H, CONH), 5.69 (bs, 1H, CONH), 7.19-7.37 (m, 4H, CH-3’, CH-5’, 
CH-3” and CH-5”), 7.47 (d, J = 8.1 Hz, 2H, CH-2’ and CH-6’), 7.55 (s, 1H, CH-
5), 7.94 (d, J = 8.2 Hz, 2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, CDCl3) δ 171.19 (C=O), 157.28 (C-2*), 155.67 (C-6*), 
147.57 (C-4), 139.48 (C-1’*), 138.99 (C-1”*), 136.13 (C-4’*), 135.43 (C-4”*), 
129.66 (2xCHAr), 129.64 (2xCHAr), 128.61 (C-3), 128.25 (2xCHAr), 127.11 
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(2xCHAr), 118.35 (CH-5), 23.06 (C-2CH3), 21.45 (C-4’CH3*), 21.41 (C-
4”CH3*) ppm. 
      
4-(4-Methoxyphenyl)-2-methyl-6-phenylnicotinamide (86) 
Prepared from 3-(4-methoxyphenyl)-1-phenylprop-2-en-1-
one (238 mg, 1 mmol), acetoacetamide (111 mg, 1.1 mmol) 
and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 302 mg (95%). White solid. 
 
Data of 86: 
Mp: 233-235 °C 
Elemental analysis calcd (%) for C20H18N2O2: C 75.45, H 5.70, N 8.80; found: C 
75.11, H 5.64, N 8.71. 
IR (KBr) ν 3373 (N-H), 3195 (N-H), 1682 (C=O), 1651 (C=N), 1608 (N-C=O) 
cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.59 (s, 3H, C-2CH3), 3.82 (s, 3H, C-
4’OCH3), 7.05 (d, J = 8.7 Hz, 2H, CH-3’ and CH-5’), 7.40-7.63 (m, 6H, CH-5, 
CH-2’, CH-6’, CH-3”, CH4” and CH-5”), 7.72 (s, 1H, CONH), 7.88 (s, 1H, 
CONH), 8.14 (dd, J = 7.8, 1.5 Hz, 2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 170.05 (C=O), 159.57 (C-4’), 154.86 (C-2*), 
154.06 (C-6*), 146.38 (C-4), 138.42 (C-1”), 130.92 (C-1’*), 130.58 (C-3*), 
129.74 (2xCHAr), 129.13 (CHAr), 128.74 (2xCHAr), 126.80 (2xCHAr), 117.98 
(CH-5), 113.89 (2xCHAr), 55.26 (C-4’OCH3), 22.60 (C-2CH3) ppm. 
      
4,6-Bis(4-methoxyphenyl)-2-methylnicotinamide (87) 
Prepared from 1,3-di-(4-methoxyphenyl)prop-2-en-1-one (268 mg, 1 mmol),	  
acetoacetamide (111 mg, 1.1 mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: chloroform:ethyl acetate (5:1, v/v). 
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Yield: 254 mg (73%). Pale yellow solid. 
 
Data of 87: 
Mp: 239-241 °C 
Elemental analysis calcd (%) for C21H20N2O3: C 72.40, 
H 5.79, N 8.04; found: C 72.11, H 5.74 ,N 7.90. 
IR (KBr) ν 3363 (N-H), 3188 (N-H), 1683 (C=O), 1644 
(C=N), 1607 (N-C=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.57 (s, 3H, C-2CH3), 3.82 (s, 3H, C-
4’OCH3), 3.83 (s, 3H, C-4”OCH3), 7.04 (d, J=7.4 Hz, 4H, CH-3’, CH-5’, CH-3” 
and CH-5”), 7.53 (s, 1H, CH-5), 7.58 (d, J=8.6 Hz, 2H, CH-2’ and CH-6’), 7.65 
(s, 1H, CONH), 7.84 (s, 1H, CONH), 8.11 (d, J=8.6 Hz, 2H, CH-2” and CH-6”) 
ppm. 
13C NMR (63 MHz, DMSO-d6) δ 170.17 (C=O), 160.22 (C-4’*), 159.51 (C-4”*), 
154.58 (C-2*), 153.82 (C-6*), 146.32 (C-4), 130.87 (C-1’*), 130.73 (C-1”*), 
130.22 (C-3*), 129.70 (2xCHAr), 128.15 (2xCHAr), 117.04 (CH-5), 114.08 
(2xCHAr), 113.86 (2xCHAr), 55.27 (C-4’OCH3*), 55.25 (C-4”OCH3*), 22.62 
(C-2CH3) ppm. 
      
4,6-Bis(4-chlorophenyl)-2-methylnicotinamide (88) 
Prepared from 1,3-di-(4-chlorophenyl)prop-2-en-1-one 
(277 mg, 1 mmol), acetoacetamide (111 mg, 1.1 mmol) 
and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: Crystallization from EtOH. 
Yield: 338 mg (95%). White solid. 
 
Data of 88: 
Mp: 259-261 °C 
Elemental analysis calcd (%) for C19H14Cl2N2O: C 63.88, H 3.95, N 7.84; found: 
C 63.54, H 3.94 , N 7.88. 
IR (KBr) ν 3314 (N-H), 3157 (N-H), 1668 (C=O), 1600 (N-C=O), 1091 (C-Cl) 
cm-1. 
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1H NMR (250 MHz, DMSO-d6) δ = 2.61 (s, 3H, C-2CH3), 7.51-7.68 (m, 7H, CH-
5, CH-2’, CH-3’, CH-5’, CH-6’, CH-3” and CH-5”), 7.82 (s, 1H, CONH), 7.93 (s, 
1H, CONH), 8.21 (d, J=8.6 Hz, 2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 169.48 (C=O), 154.32 (C-2*), 153.72 (C-6*), 
145.73 (C-4), 137.03 (C-1’*), 136.95 (C-1”*), 134.16 (C-4’*), 133.53 (C-4”*), 
131.20 (C-3*), 130.30 (2xCHAr), 128.79 (2xCHAr), 128.62 (2xCHAr), 128.43 
(2xCHAr), 118.03 (CH-5), 22.57 (C-2CH3) ppm. 
      
6-(4-Chlorophenyl)-2-methyl-4-(2-nitrophenyl)nicotinamide (89) 
Prepared from 1-(4-chlorophenyl)-3-(2-nitrophenyl) prop-
2-en-1-one (277 mg, 1 mmol), acetoacetamide (111 mg, 
1.1 mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: chloroform:ethyl acetate (from 15:1 to 10:1, 
v/v). 
Yield: 312 mg (85%). Pale yellow solid. 
 
Data of 89: 
Mp: 228-230 °C 
Elemental analysis calcd (%) for C19H14ClN3O3: C 62.05, H 3.84, N 11.43; 
found: C 61.95 , H 3.87, N 11.24. 
IR (KBr) ν 3443 (N-H), 3122 (N-H), 1682 (C=O), 1652 (C=N), 1584 (N-C=O), 
1520 (NO2), 1094 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 2.78 (s, 3H, C-2CH3), 5.76 (bs, 1H, CONH), 
6.08 (bs, 1H, CONH), 7.29 (s, 1H, CH-5), 7.40-7.50 (m, 3H, CH-4’, CH-3” and 
CH-5”),	  7.58-7.78 (m, 2H, CH-2’ and CH-5’), 7.94 (d, J=8.5 Hz, 2H, CH-2” and 
CH-6”), 8.07 (d, J=7.3 Hz, 1H, CH-3’ and CH-5’) ppm. 
13C NMR (63 MHz, CDCl3) δ 169.60 (C=O), 156.09 (C-2*), 155.93 (C-6*), 
148.22 (C-4*), 144.54 (C-2’*), 136.74 (C-1”*), 135.86 (C-1’*), 133.58 (CHAr), 
133.11 (C-4”), 131.73 (CHAr), 129.90 (CHAr), 129.10 (2xCHAr), 128.94 (C-3), 
128.55 (2xCHAr), 124.57 (CHAr), 116.59 (CH-5), 23.04 (C-2CH3) ppm. 
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2-Methyl-4-(4-methylphenyl)-6-(2-nitrophenyl)nicotinamide (90) 
Prepared from 3-(4-methylphenyl)-1-(2-nitrophenyl)prop-2-
en-1-one (267 mg, 1 mmol), acetoacetamide (111 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 30 h. 
Purification: chloroform:ethyl acetate (5:1, v/v). 
Yield: 230 mg (66%). White solid. 
 
Data of 90: 
Mp: 214-216 °C 
Elemental analysis calcd (%) for C20H17N3O3: C 69.15, H 4.93, N 12.10; found: 
C 68.95, H 4.95, N 12.11. 
IR (KBr) ν 3370 (N-H), 3188 (N-H), 1667 (C=O), 1585 (N-C=O), 1538 (NO2) 
cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.39 (s, 3H, C-4’CH3), 2.49 (s, 3H, C-2CH3), 
7.31 (d, J=8.1 Hz, 2H, CH-3’ and CH-5’), 7.55 (d, J=8.1 Hz, 2H, CH-2’ and CH-
6’), 7.59 (s, 1H, CH-5), 7.64 (s, 1H, CONH), 7.66-7.75 (m, 1H, CH-4”), 7.76-7.85 
(m, 1H, CH-5”), 7.88-8.07 (m, 3H, CONH, CH-3” and CH-6”) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 169.49 (C=O), 154.03 (C-2*), 153.31 (C-6*), 
149.27 (C-4*), 146.82 (C-2”*), 138.19 (C-1’), 134.98 (C-4’*), 133.45 (C-1”*), 
132.67 (CHAr), 131.44 (C-3), 131.28 (CHAr), 129.91 (CHAr), 129.10 (2xCHAr), 
128.31 (2xCHAr), 124.29 (CHAr), 120.35 (CH-5), 22.20 (C-2CH3), 20.82 (C-
4’CH3) ppm. 
      
2,5-Dimethyl-4,6-diphenylnicotinamide (91) 
Prepared from 2-methyl-1,3-diphenylprop-2-en-1-one (222 
mg, 1 mmol), acetoacetamide (111 mg, 1.1 mmol) and 
ammonium acetate (231 mg, 3 mmol).  
Reaction time: 30 h. 
Purification: chloroform:ethyl acetate (5:1, v/v). 
Yield: 60 mg (20%). White solid. 
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Data of 91: 
Mp: 228-230 °C 
Elemental analysis calcd (%) for C20H18N2O: C 79.44, H 6.00, N 9.26; found: C 
79.25, H 6.07, N 9.16. 
IR (KBr) ν 3346 (N-H), 3175 (N-H), 1668 (C=O), 1652 (C=N), 1614 (N-C=O) 
cm-1. 
1H NMR (250 MHz, CDCl3) δ = 2.04 (s, 3H, C-5CH3), 2.69 (s, 3H, C-2CH3), 
5.37 (bs, 1H, CONH), 5.53 (bs, 1H, CONH), 7.38-7.58 (m, 8H, ArH), 7.32 (dd, 
J=7.5, 1.8 Hz, 2H, CH-2” and CH-6”), ppm. 
13C NMR (63 MHz, CDCl3) δ 170.45 (C=O), 159.43 (C-2*), 151.63 (C-6*), 
147.86 (C-4), 140.74 (C-1’*), 137.41 (C-1”*), 130.37 (C-5), 129.12 (2xCHAr), 
128.77 (2xCHAr), 128.64 (2xCHAr), 128.44 (2xCHAr), 128.34 (CHAr), 128.25 
(CHAr), 126.43 (C-3), 22.59 (C-2CH3), 17.84 (C-5CH3) ppm. 
      
N-Cyclohexyl-4,6-bis(4-methylphenyl)-2-methylnicotinamide (92) 
Prepared from 1,3-di-(4-methylphenyl)prop-2-en-1-
one (236 mg, 1 mmol), N-cyclohexyl-3-
oxobutanamide (202 mg, 1.1 mmol) and ammonium 
acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: n-hexane:ethyl acetate (from 20:1 to 
5:1, v/v) 
Yield: 330 mg (83%). Pale yellow solid. 
 
Data of 92: 
Mp: 214-216 °C 
Elemental analysis calcd (%) for C27H30N2O: C 81.37, H 7.59, N 7.03; found: C 
81.10,H 7.55, N 6.91. 
IR (KBr) ν 3230 (N-H), 1620 (C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 0.78-0.97 (m, 2H, CH-γax and CH-γ’ax), 1.03-
1.17 (m, 1H, CH-γeq*), 1.21-1.41 (m, 2H, CH-γ’eq* and CH-δax*), 1.47-1.74 (m, 
5H, CH-δeq*, CH2-β and CH2-β’), 2.43 (s, 6H, 2xArCH3), 2.73 (s, 3H, C-2CH3), 
3.74-3.94 (m, 1H, CH-α), 5.25 (d, J=8.5 Hz, 1H, CONH), 7.18-7.37 (m, 4H, CH-
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3’, CH-5’, CH-3” and CH-5”), 7.44 (d, J=8.1 Hz, 2H, CH-2’ and CH-6’), 7.54 (s, 
1H, CH-5), 7.93 (d, J=8.2 Hz, 2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, CDCl3) δ 167.98 (C=O), 157.07 (C-2*), 155.91 (C-6*), 
147.64 (C-4), 139.30 (C-1’*), 138.72 (C-1’*), 136.39 (C-4’*), 135.57 (C-4”*), 
129.78 (C-3), 129.62 (2xCHAr), 129.45 (2xCHAr), 128.27 (2xCHAr), 127.10 
(2xCHAr), 118.27 (CH-5), 48.24 (CH- α), 32.59 (CH2-β and CH2-β’), 25.49 
(CH2-δ), 24.67 (CH2-γ, CH2-γ’), 23.01 (C-2CH3), 21.45 (C-4’CH3*), 21.38 (C-
4”CH3*) ppm. 
      
2-Methyl-N,4,6-triphenylnicotinamide (93) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), 3-oxo-N-phenylbutanamide (195 mg, 1.1 mmol) 
and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 305 mg (84%). Pale yellow solid. 
 
Data of 93: 
Mp: 226-228 °C 
Elemental analysis calcd (%) for C25H20N2O: C 82.39, H 5.53, N 7.69; found: 
C82.14, H 5.61, N 7.57. 
IR (KBr) ν 3270 (N-H), 1649 (C=O), 1621 (C=N), 1546 (N-C=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.64 (s, 3H, C-2CH3), 7.08 (t, J=7.2 Hz, 1H, 
CH-δ), 7.30 (t, J=7.8 Hz, 2H, CH-γ and CH-γ’), 7.38-7.59 (m, 8H, C-4ArH, CH-
3”, CH-4” and CH-5”), 7.64 (d, J=6.5 Hz, 2H, CH-β and CH-β’), 7.86 (s, 1H, CH-
5), 8.20 (d, J=6.5 Hz, 2H, CH-2” and CH-6”), 10.50 (s, 1H, CONH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 166.38 (C=O), 155.63 (C-2*), 154.54 (C-6*), 
147.47 (C-4), 138.63 (C-1’*), 138.21 (C-1”*), 138.05 (C-α*), 130.58 (C-3), 
129.40 (CHAr), 128.83 (2xCHAr), 128.79 (2xCHAr), 128.61 (CHAr), 128.55 
(2xCHAr), 128.27 (2xCHAr), 126.96 (2xCHAr), 123.94 (CHAr), 119.70 
(2xCHAr), 118.28 (CH-5), 22.63 (C-2CH3) ppm. 
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2-Ethyl-N,4,6-triphenylnicotinamide (94) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), 3-oxo-N-phenylpentanamide (210 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 32 h. 
Purification: Crystallization from EtOH. 
Yield: 280 mg (74%). White solid. 
 
Data of 94: 
Mp: 233-235 °C 
Elemental analysis calcd (%) for C26H22N2O: C 82.51, H 5.86, N 7.40; found: C 
82.23, H 5.89, N 7.56. 
IR (KBr) ν 3265 (N-H), 1652 (C=O), 1538 (N-C=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 1.36 (t, J=7.5 Hz, 3H, C-2CH2CH3), 2.91 (q, 
J=7.5 Hz, 2H, C-2CH2CH3), 7.06 (t, J=7.3, 1H, CH-δ), 7.28 (t, J=7.8, 2H, CH-γ 
and CH-γ’), 7.36-7.58 (m, 8H, C-4ArH, CH-3”, CH-4” and CH-5”), 7.63 (dd, 
J=7.9, 1.5 Hz, 2H, CH-β and CH-β’), 7.85 (s, 1H, CH-5), 8.21 (dd, J=7.9, 1.5 Hz, 
2H, CH-2”	  and CH-6”), 10.46 (s, 1H, CONH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 166.34 (C=O), 159.00 (C-2*), 155.68 (C-6*), 
147.46 (C-4), 138.61 (C-1’*), 138.39 (C-1”*), 138.12 (C-α*), 130.20 (C-3), 
129.37 (CHAr), 128.84 (2xCHAr), 128.78 (2xCHAr), 128,56 (CHAr), 128.52 
(2xCHAr), 128.31 (2xCHAr), 126.95 (2xCHAr), 123.91 (CHAr), 119.69 
(2xCHAr), 118.26 (CH-5), 28.66 (C-2CH2CH3), 13.74 (C-2CH2CH3) ppm. 
      
N,4,6-Triphenyl-2-propylnicotinamide (95) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), 3-oxo-N-phenylhexanamide (226 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 320 mg (82%). White solid. 
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Data of 95: 
Mp: 231-233 °C 
Elemental analysis calcd (%) for C27H24N2O: C 82.62, H 6.16, N 7.14; found: C 
82.36, H 6.09, N 7.00. 
IR (KBr) ν 3230 (N-H), 1645 (C=O), 1621 (C=N), 1538 (N-C=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 0.97 (t, J=7.4 Hz, 3H, C-2CH2CH2CH3), 
1.76-1.96 (m, 2H, C-2CH2CH2CH3), 2.80-2.90 (m, 2H, C-2CH2CH2CH3), 7.06 (t, 
J=7.3 Hz, 1H, CH-δ), 7.28 (t, J=7.8 Hz, 2H, CH-γ and CH-γ’), 7.36-7.56 (m, 8H, 
C-4ArH, CH-3”, CH-4” and CH-5”), 7.63 (dd, J=7.9, 1.5 Hz, 2H, CH-β and CH-
β’), 7.84 (s, 1H, CH-5), 8.20 (dd, J=7.9, 1.4 Hz, 2H, CH-2” and CH-6”), 10.42 (s, 
1H, CONH) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 166.33 (C=O), 157.95 (C-2*), 155.56 (C-6*), 
147.46 (C-4), 138.59 (C-1’*), 138.38 (C-1”*), 138.15 (C-α*), 130.45 (C-3), 
129.36 (CHAr), 128.83 (2xCHAr), 128.78 (2xCHAr), 128.54 (CHAr), 
128.50(2xCHAr), 128.31 (2xCHAr), 126.94 (2xCHAr), 123.92 (CHAr), 119.74 
(2xCHAr), 118.22 (CH-5), 37.41 (CH-2CH2CH2CH3), 22.22 (CH-2CH2CH2CH3), 
14.18 (CH-2CH2CH2CH3) ppm. 
      
2-Isopropyl-N,4,6-triphenylnicotinamide (96) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), 4-methyl-3-oxo-N-phenylpentanamide (226 mg, 
1.1 mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: n-hexane:ethyl acetate (from 20:1 to 5:1, 
v/v). 
Yield: 290 mg (74%). White solid. 
 
Data of 96: 
Mp: 252-254 °C 
Elemental analysis calcd (%) for C27H24N2O: C 82.62, H 6.16, N 7.14; found: C 
82.41, H 6.22, N 7.05. 
IR (KBr) ν 3230 (N-H), 1646 (C=O), 1588 (N-C=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 1.36 (d, J=6.5 Hz, 6H, C-2CH(CH3)2), 3.11-
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3.36 (m, 1H, C-2CH(CH3)2), 7.05 (t, J=7.1 Hz, 1H, CH-δ), 7.27 (t, J=7.7 Hz, 2H, 
CH-γ and CH-γ’), 7.34-7.57 (m, 8H, C-4ArH, CH-3”, CH-4” and CH-5”), 7.64 
(d, J=6.7 Hz, 2H, CH-β and CH-β’), 7.83 (s, 1H, CH-5), 8.22 (d, J=6.8 Hz, 2H, 
CH-2” and CH-6”), 10.44 (s, 1H, CONH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 166.38 (C=O), 162.47 (C-2*), 155.60 (C-6*), 
147.37 (C-4), 138.58 (C-1’*), 138.51 (C-1”*), 138.20 (C-α*), 129.71 (C-3), 
129.32 (CHAr), 128.81 (2xCHAr), 128.72 (2xCHAr), 128.45 (3xCHAr), 128.31 
(2xCHAr), 126.85 (2xCHAr), 123.87 (CHAr), 119.67 (2xCHAr), 118.21 (CH-5), 
32.79 (CH-2CH(CH3)2), 22.66 (CH-2CH(CH3)2) ppm. 
      
(2-Methyl-4,6-diphenylpyridin-3-yl)(piperidin-1-yl)methanone (97) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), 1-(piperidin-1-yl)butane-1,3-dione (186 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: chloroform:ethyl acetate (from 20:1 to 15:1, 
v/v). 
Yield: 228 mg (64%). Pale yellow solid. 
 
Data of 97: 
Mp: 137-139 °C 
Elemental analysis calcd (%) for C24H24N2O: C 80.87, H 6.79, N 7.86; found: C 
80.58, H 6.70, N 7.59. 
IR (KBr) ν 1628 (C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 0.58-0.80 (m, 1H, CH-γax*), 1.14-1.35 (m, 2H, 
CH-βax*, CH-β’ax*), 1.35-1.60 (m, 3H, CH-βeq*, CH-β’eq* and CH-γeq*), 2.68 
(s, 3H, C-2CH3), 2.72-2.86 (m, 1H, CH-αax*), 2.92-3.07 (m, 1H, CH-α’ax*), 
3.42-3.58 (m, 1H, CH-αeq*), 3.58-3.74 (m, 1H, CH-α’eq*), 7.41-7.55 (m, 6H, C-
4ArH and CH-4”), 7.55-7.71 (m, 3H, CH-5, CH-3” and CH-5”), 7.96-8.15 (m, 
2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, CDCl3) δ 167.70 (C=O), 156.89 (C-2*), 155.32 (C-6*), 
146.90 (C-4), 139.09 (C-1’*), 138.19 (C-1”*), 129.18 (CHAr), 128.85 (3xCHAr), 
128.71 (2xCHAr), 128.67 (2xCHAr), 127.11 (2xCHAr), 118.20 (CH-5), 47.27 
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(CH2-α*), 42.10 (CH2-α’*), 25.85 (CH2-β*), 25.19 (CH2-β’*), 24.25 (CH2-γ), 
22.94 (C-2CH3) ppm. 
      
(2-Methyl-4,6-diphenylpyridin-3-yl)(morpholino)methanone (98) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), 1-morpholinobutane-1,3-dione (188 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: n-hexane:ethyl acetate (from 8:1 to 2:1, 
v/v). 
Yield: 285 mg (80%). Pale yellow solid. 
 
Data of 98: 
Mp: 132-134 °C 
Elemental analysis calcd (%) for C23H22N2O2: C 77.07, H 6.19, N 7.82; found: C 
76.91, H 6.24, N 7.80. 
IR (KBr) ν 1634 (C=O), 1113 (C-O-C) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 2.56-2.68 (m, 1H, CH-α’ax*), 2.70 (s, 3H, C-
2CH3), 2.75-2.91 (m, 1H, CH-αax*), 3.01-3.17 (m, 1H, CH-α’eq*), 3.22-3.41 (m, 
2H, CH-αeq* and CH-βax*), 3.49-3.80 (m, 3H, CH-βeq* and CH2-β’*), 7.45-7.62 
(m, 8H, C-4ArH, CH-3”, CH-4” and CH-5”), 7.64 (s, 1H, CH-5), 8.00-8.11 (m, 
2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, CDCl3) δ 168.09 (C=O), 157.41 (C-2*), 155.60 (C-6*), 
147.22 (C-4), 138.88 (C-1’*), 138.03 (C-1”*), 129.44 (CHAr), 129.25 (CHAr), 
129.00 (2xCHAr), 128.96 (2xCHAr), 128.65 (2xCHAr), 127.82 (C-3), 127.21 
(2xCHAr), 118.17 (CH-5), 66.39 (CH2-α*), 66.36 (CH2-α’*), 46.63 (CH2-β*), 
41.72 (CH2- β’*), 23.01 (C-2CH3) ppm. 
      
(2-Methyl-4,6-diphenylpyridin-3-yl)(4-methylpiperazin-1-yl)methanone 
(99) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 mmol), 1-(4-
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methylpiperazin-1-yl)butane-1,3-dione (202 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: n-hexane:ethyl acetate (from 8:1 to 
2:1, v/v). 
Yield: 248 mg (67%). Yellow solid. 
 
Data of 99: 
Mp: 132-134 °C 
Elemental analysis calcd (%) for C24H25N3O: C 77.60, H 6.78, N 11.31; found: C 
77.44, H 6.67, N 11.02. 
IR (KBr) ν 1620 (C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 1.37-1.52 (m, 1H, CH-βax*), 1.99-2.19 (m, 2H, 
CH-βeq* and CH-β’ax*), 2.15 (s, 3H, NCH3), 2.32-2.49 (m, 1H, CH-β’eq*), 2.69 
(s, 3H, C-2CH3), 2.75-2.91 (m, 1H, CH-αax*), 3.01-3.22 (m, 1H, CH-α’ax*), 
3.52-3.81 (m, 2H, CH-αeq* and CH-α’eq*), 7.45-7.61 (m, 8H, C-4ArH, CH-3”, 
CH-4” and CH-5”), 7.63 (s, 1H, CH-5), 8.06 (dd, J=8.0 Hz, 1.6, 2H, CH-2” and 
CH-6”) ppm. 
13C NMR (63 MHz, CDCl3) δ 167.99 (C=O), 157.27 (C-2*), 155.54 (C-6*), 
147.11 (C-4), 139.04 (C-1’*), 138.14 (C-1”*), 129.35 (CHAr), 129.01 (CHAr), 
128.94 (2xCHAr), 128.92 (2xCHAr), 128.71 (2xCHAr), 128.23 (C-3), 127.19 
(2xCHAr), 118.19 (CH-5), 54.56 (CH2-β*), 54.20 (CH2-β’*), 46.04 (CH2-α*), 
45.91 (N-CH3), 41.12 (CH2-α’*), 23.05 (C-2CH3) ppm. 
      
2-Methyl-6-phenyl-4-(thiophen-2-yl)nicotinamide (100) 
Prepared from 1-phenyl-3-(thiophen-2-yl)prop-2-en-1-one 
(214 mg, 1 mmol), acetoacetamide (111 mg, 1.1 mmol) and 
ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: chloroform:ethyl acetate (from 20:1 to 15:1, 
v/v). 
Yield: 205 mg (70%). Pale yellow solid. 
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Data of 100: 
Mp: 199-201 °C 
Elemental analysis calcd (%) for C17H14N2OS: C 69.36, H 4.79, N 9.52, S 10.89;	  
found: C 68.99, H 4.92, N 9.42, S 10.85. 
IR (KBr) ν 3310 (N-H), 3140 (N-H), 1652 (C=O), 1591 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 2.77 (s, 3H, C-2CH3), 5.71 (bs, 1H, CONH), 
5.86 (bs, 1H, CONH), 7.16 (dd, J=5.1, 3.7 Hz, 1H, CH-4’), 7.42-7.58 (m, 5H, 
CH-3’, CH-5’, CH-3”, CH-4” and CH-5”), 7.68 (s, 1H, CH-5), 8.03 (dd, J=8.0, 
1.7 Hz, 2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, CDCl3) δ 171.12 (C=O), 157.55 (C-2*), 155.83 (C-6*), 
139.95 (C-4), 138.92 (C-1”*), 138.69 (C-2’*), 129.55 (CHAr), 128.96 (2xCHAr), 
128.53 (CHAr), 128.33 (CHAr), 128.00 (C-3), 127.82 (CHAr), 127.25 (2xCHAr), 
118.15 (CH-5), 22.94 (C-2CH3) ppm. 
      
2-Methyl-6-(4-methylphenyl)-4-(thiophen-2-yl)nicotinamide (101) 
Prepared from 1-(4-methylphenyl)-3-(thiophen-2-yl)prop-
2-en-1-one (228 mg, 1 mmol), acetoacetamide (111 mg, 
1.1 mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: chloroform:ethyl acetate (from 20:1 to 15:1, 
v/v). 
Yield: 220 mg (72%). Pale yellow solid. 
 
Data of 101: 
Mp: 206-208 °C 
Elemental analysis calcd (%) for C18H16N2OS: C 70.10, H 5.23, N 9.08, S 10.40; 
found: C 69.88, H 5.30, N 8.98, S 10.33. 
IR (KBr) ν 3438 (N-H), 3278 (N-H), 1651 (C=O), 1585 (N-C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ = 2.45 (s, 3H, C-4”CH3), 2.76 (s, 3H, C-2CH3), 
5.73 (s, 1H, CONH), 5.79 (s, 1H, CONH), 7.16 (dd, J=5.1, 3.6 Hz, 1H, CH-4’), 
7.32 (d, J=8.2 Hz, 2H, CH-3” and CH-5”), 7.48 (dd, J=5.1, 0.9 Hz, 1H, CH-5’), 
7.53 (dd, J=3.6, 0.9 Hz, 1H, CH-3’), 7.65 (s, 1H, CH-5), 7.94 (d, J=8.2 Hz, 2H, 
CH-2” and	  CH-6”) ppm.  
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13C NMR (63 MHz, CDCl3) δ 171.12 (C=O), 157.51 (C-2*), 155.71 (C-6*), 
139.93 (C-4*), 139.70 (C-1”*), 139.02 (C-2’*), 135.83 (C-4”), 129.68 (2xCHAr), 
128.52 (CHAr), 128.29 (CHAr), 127.75 (CHAr), 127.13 (2xCHAr), 117.82 (CH-
5), 22.93 (C-2CH3), 21.48 (C-4”CH3) ppm. 
      
2-Methyl-6-phenyl-4-styrylnicotinamide (102) 
Prepared from 1,5-diphenylpenta-2,4-dien-1-one (234 mg, 1 
mmol), acetoacetamide (111 mg, 1.1 mmol) and ammonium 
acetate (231 mg, 3 mmol).  
Reaction time: 24 h. 
Purification: n-hexane:ethyl acetate (from 8:1 to 1:1, v/v). 
Yield: 231 mg (74%). Pale yellow solid. 
 
Data of 102: 
Mp: 199-201 °C 
Elemental analysis calcd (%) for C21H18N2O: C 80.23, H 5.77, N 8.91; found: C 
79.90 , H 5.79, N 8.82. 
IR (KBr) ν 3380 (N-H), 3180 (N-H), 1640 (C=O), 958 (CH-α=CH-β) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.56 (s, 3H, C-2CH3), 7.15 (d, J=16.3 Hz, 
1H, CH-α), 7.32-7.66 (m, 8H, C-4ArH, CH-3”, CH-4” and CH-5”), 7.72-7.91 (m, 
2H, CH-5 and CH-β), 8.09-8.27 (m, 4H, 2xCONH, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 169.71 (C=O), 154.84 (C-2*), 154.08 (C-6*), 
141.66 (C-4), 138.50 (C-1”*), 136.31 (C-1’*), 134.25 (CH-β), 130.90 (C-3), 
129.14 (CHAr), 129.07 (2xCHAr), 128.86 (CHAr), 128.71 (2xCHAr), 126.93 
(2xCHAr), 126.78 (2xCHAr), 123.41 (CH-α), 112.63 (CH-5), 22.55 (C-2CH3) 
ppm. 
      
2-Methyl-6-phenyl-4-(1-phenylprop-1-en-2-yl)nicotinamide (103) 
Prepared from 4-methyl-1,5-diphenylpenta-2,4-dien-1-one (248 mg, 1 mmol),	  
acetoacetamide (111 mg, 1.1 mmol) and ammonium acetate (231 mg, 3 mmol).  
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Reaction time: 24 h. 
Purification: n-hexane:ethyl acetate (from 8:1 to 1:1, v/v). 
Yield: 222 mg (68%). White solid. 
 
Data of 103: 
Mp: 186-188 °C 
Elemental analysis calcd (%) for C22H20N2O: C 80.46, H 
6.14, N 8.53; found: C 80.14, H 6.07, N 8.65. 
IR (KBr) ν 3398 (N-H), 3201 (N-H), 1689 (C=O), 1651 (C=N), 1620 (N-C=O) 
cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.25 (d, J=1.2 Hz, 3H, C-αCH3), 2.59 (s, 3H, 
C-2CH3), 6.65 (s, 1H, CH-β), 7.23-7.57 (m, 8H, C-4ArH, CH-3”, CH-4” and CH-
5”), 7.66 (s, 1H, CONH), 7.77 (s, 1H, CH-5), 7.92 (s, 1H, CONH), 8.14 (dd, 
J=8.0, 1.5 Hz, 2H, CH-2” and CH-6”) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 169.99 (C=O), 154.66 (C-2*), 154.06 (C-6*), 
150.97 (C-4), 138.36 (C-1”*), 137.02 (C-1’*), 135.46 (C-α), 130.57 (C-3), 129.87 
(CH-β), 129.13 (CHAr), 128.92 (2xCHAr), 128.74 (2xCHAr), 128.38 (2xCHAr), 
127.04 (CHAr), 126.73 (2xCHAr), 116.44 (CH-5), 22.72 (C-2CH3), 18.79 (C-
αCH3) ppm. 
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9.4.6 Robinson annulation products 104 and 105 
2-Oxo-4,6-diphenylcyclohex-3-enecarboxamide (104) 
Isolated from the reaction among 1,3-diphenyl-2-propen-1-
one, acetoacetamide and ammonium acetate. 
Pale yellow solid 
 
Data of 104: 
Mp: 176-177 °C 
IR (KBr) ν 3049 (N-H), 1679 (C-2=O), 1650 (C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 3.06 (dd, J=18.0, 9.0, 1H, one H of CH2-5), 3.33 
(dd, J=18.0, 5.0, 1H, one H of CH2-5), 3.62 (d, J=8.9, 1H, CH-1), 4.10 (td, J=8.8, 
5.2, 1H, CH-6), 5.43 (bs, 1H, CONH), 5.97 (bs, 1H, CONH), 6.60 (s, 1H, CH-3), 
7.41-7.32 (m, 5H, ArH), 7.52-7.42 (m, 3H, ArH), 7.59 (dd, J=6.7, 3.0, 2H, ArH) 
ppm. 
13C NMR (63 MHz, CDCl3) δ 196.08 (C-2=O), 170.89 (CONH2), 159.94 (C-4), 
142.38 (CAr), 138.21 (CAr), 130.99 (CHAr), 129.30 (2xCHAr), 129.21 
(2xCHAr), 127.87 (2xCHAr), 127.60 (CHAr), 126.71 (2xCHAr), 124.68 (CH-3), 
59.14 (CH-1), 42.82 (CH-6), 35.34 (CH2-5) ppm. 
These data are consistent with those described in the literature.290 
      
3-Methyl-2-oxo-N,4,6-triphenylcyclohex-3-enecarboxamide (105) 
Isolated from the reaction among 1,3-diphenyl-2-propen-
1-one, 3-oxo-N-phenylpentanamide and ammonium 
acetate. 
White solid 
 
Data of 105: 
Mp: 212-214 °C 
IR (KBr) ν 3380 (N-H), 3180 (N-H), 1640 (C=O) cm-1. 
                                                
290 Kato, T.; Noda, M. Chem. Pharm. Bull. 1975, 23, 2193-2200. 
O
O
NH21
23
4
5
6
O
O
N
H
CH3
1
23
4
5
6
9. Experimental section	   297 
 
 
1H NMR (250 MHz, DMSO-d6) δ 1.73 (s, 3H, C-3CH3) 2.76 (dd, J=18.3, 3.6 Hz, 
1H, one H of CH2-5), 2.97-3.18 (m, 1H, one H of CH2-5), 3.78-3.96 (m, 1H, CH-
6), 4.02 (d, J=13.2 Hz, 1H, CH-1), 7.01 (t, J=7.2 Hz, 1H, ArH), 7.14-7.35 (m, 5H, 
ArH), 7.35-7.53 (m, 9H, ArH), 10.04 (s, 1H, CONH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 196.12 (C-2=O), 167.90 (CONH), 156.34 (C-
4), 142.56 (CAr), 140.62 (CAr), 139.18 (CAr), 130.22 (C-3), 129.01 (2xCHAr), 
128.77 (2xCHAr), 128.69 (3xCHAr), 127.78 (2xCHAr), 127.73 (2xCHAr), 
127.15 (CHAr), 123.63 (CHAr), 119.37 (2xCHAr), 60.05 (CH-1), 42.99 (CH-6), 
40.25 (CH2-5), 13.29 (C-3CH3) ppm. 
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9.4.7 Synthesis of 1,4-dihydropyridine bicyclic derivatives 106-108. 
 
 
 
Compound R 
106 Boc 
107 H 
108 H 
 
The same procedure described above in section x.4.5 was employed for the 
synthesis of derivatives 106-108. 
 
Data of compounds 106-108, and the experimental conditions employed for their 
synthesis are indicated below. 
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tert-Butyl 5-oxo-2,4-diphenyl-1,4,5,6,7,8-hexahydro-1,6-naphthyridine-6-
carboxylate (106) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 
mg, 1 mmol), tert-butyl 2,4-dioxopiperidine-1-
carboxylate (234 mg, 1.1 mmol) and ammonium 
acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: Crystallization from EtOH. 
Yield: 280 mg (70%). White solid. 
 
Data of 106: 
Mp: 253-254 °C (dec.) 
Elemental analysis calcd (%) for C25H26N2O3: C 74.60, H 6.51, N 6.96; found: C 
74.70, H 6.42, N 7.08. 
IR (KBr) ν 3324 (N-H), 1748 (NC(O)O), 1656 (C-5=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.42 (s, 9H, OC(CH3)3), 2.57-2.82 (m, 2H, 
CH2-8), 3.39-3.56 (m, 1H, CH-7), 3.94-4.08 (m, 1H, CH-7), 4.63 (d, J=5.4 Hz, 
1H, CH-4), 5.21 (dd, J=5.3, 1.6 Hz, 1H, CH-3), 7.09-7.21 (m, 1H, CH-4’), 7.26-
7.31 (m, 4H, CH-2’, CH-3’, CH-5’ and CH-6’), 7.34-7.45 (m, 3H, CH-3”, CH-4” 
and CH-5”), 7.45-7.53 (m, 2H, CH-2” and CH-6”), 8.79 (s, 1H, NH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 164.56 (C-5=O), 152.59 (C-2*), 149.58 (C-
8a*), 148.25 (NC(O)O*), 134.99 (C-1’*), 134.20 (C-1”*), 128.51 (2xCHAr), 
128.42 (CHAr), 128.27 (2xCHAr), 127.41 (2xCHAr), 125.83 (CHAr), 125.51 
(2xCHAr), 105.17 (CH-3), 99.50 (C-4a), 80.85 (OC(CH3)3), 42.03 (CH2-7), 37.94 
(CH-4), 27.82 (OC(CH3)3), 26.35 (CH2-8) ppm. 
      
2,4-Diphenyl-4,6,7,8-tetrahydro-1,6-naphthyridin-5(1H)-one (107) 
Prepared from 1,3-diphenyl-2-propen-1-one (208 mg, 1 
mmol), piperidine-2,4-dione (124 mg, 1.1 mmol) and 
ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: chloroform:ethyl acetate (from 10:1 to 5:1, v/v). 
N
H
O
N
O
O
H3C
CH3
CH3
1
2
3
4 5 6
7
8
4a
8a
1'
2'
3'
4'
5'
6'
1"
2"
3"
4"
5"
6"
N
H
O
NH
1
2
3
4 5 6
7
8
4a
8a
1'
2'
3'
4'
5'
6'
1"
2"
3"
4"
5"
6"
300 9. Experimental section 
 
 
Yield: 222 mg (74%). Pale yellow solid. 
 
Data of 107: 
Mp: 267-269 °C 
Elemental analysis calcd (%) for C20H18N2O C 79.44, H 6.00, N 9.26; found: C 
79.54, H 5.80, N 8.99. 
IR (KBr) ν 3395 (N-H), 3227 (N-H), 1652 (C=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 2.50-2.59 (m, 2H, CH2-8), 3.09-3.29 (m, 2H, 
CH2-7), 4.61 (d, J=5.3 Hz, 1H, CH-4), 5.09 (dd, J=5.3, 1.6 Hz, 1H, CH-3), 6.77 
(s, 1H, CONH), 7.04-7.18 (m, 1H, CH-4’), 7.24-7.26 (m, 4H, CH-2’, CH-3’, CH-
5’ and CH-6’), 7.31-7.42 (m, 3H, CH-3”, CH-4” and CH-5”), 7.48 (dd, J=8.0, 1.7 
Hz, 2H, CH-2” and CH-6”), 8.27 (s, 1H, NH) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 168.11 (C=O), 148.97 (C-2*), 145.57 (C-8a*), 
135.58 (C-1’*), 135.01 (C-1”*), 128.46 (2xCHAr), 128.21 (CHAr), 128.13 
(2xCHAr), 127.45 (2xCHAr), 125.55 (CHAr), 125.46 (2xCHAr), 103.66 (CH-3), 
99.42 (C-4a), 37.83 (CH2-7), 37.45 (CH-4), 26.38 (CH2-8) ppm. 
      
2,4-Diphenyl-7,8-dihydro-1,6-naphthyridin-5(6H)-one (108) 
Isolated from the reaction between 1,3-diphenyl-2-propen-1-
one (208 mg, 1 mmol), piperidine-2,4-dione (124 mg, 1.1 
mmol) and ammonium acetate (231 mg, 3 mmol).  
Reaction time: 15 h. 
Purification: chloroform:ethyl acetate (from 10:1 to 5:1, v/v). 
Yield: 42 mg (14%). Pale yellow solid. 
 
Data of 108: 
Mp: 236-238 °C 
Elemental analysis calcd (%) for C20H16N2O: C 79.98, H 5.37, N 9.33; found: C 
79.95, H 5.54, N 9.14. 
IR (KBr) ν 1668 (C=O), 1652 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ = 3.13 (t, J=6.0, 2H, CH2-8), 3.43-3.57 (m, 2H, 
CH2-7), 7.40 (s, 5H, C-4ArH), 7.45-7.55 (m, 3H, CH-3”, CH-4” and CH-5”), 7.72 
(s, 1H, CH-3), 8.05 (s, 1H, CONH), 8.11-8.23 (m, 2H, CH-2” and CH-6”) ppm. 
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13C NMR (63 MHz, DMSO-d6) δ 163.54 (C=O), 160.78 (C-2*), 156.65 (C-8a*), 
151.33 (C-4*), 139.91 (C-1’), 137.67 (C-1”), 129.82 (CHAr), 128.84 (2xCHAr), 
128.50 (2xCHAr), 127.65 (3xCHAr), 127.14 (2xCHAr), 121.94 (C-4a), 121.17 
(CH-3), 37.90 (CH2-8), 32.72 (CH2-7) ppm. 
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9.5 FUSED PYRAZOLE DERIVATIVES 
9.5.1 Synthesis of 1,4-dihydropyrano[2,3-c]pyrazole derivatives 110-
129. General procedure 
 
 
 
Cmpd. Ar  Cmpd. Ar 
110 C6H5  120 2-MeC6H4 
111 2-ClC6H4  121 3-MeC6H4 
112 3-ClC6H4  122 4-MeC6H4 
113 4-ClC6H4  123 2-MeOC6H4 
114 2-BrC6H4  124 3-MeOC6H4 
115 4-BrC6H4  125 4-MeOC6H4 
116 4-FC6H4  126 3-pyridyl 
117 2-NO2C6H4  127 4-pyridyl 
118 3-NO2C6H4  128 2-furyl 
119 4-NO2C6H4  129 2-thienyl 
 
9.5.1.1 Synthesis of 5-methyl-1H-pyrazol-3(2H)-one (109) 
To a solution of ethyl acetoacetate (1.05 equiv, 10.5 mmol) in ethanol (15 mL) at 
0 °C was added dropwise hydrazine (1 equiv, 10 mmol). The mixture was allowed 
to warm to room temperature and then stirring was continued for 1 hour. After 
this time the solvent was removed in vacuum and the solid residue	  purified by 
crystallization and employed in the next step. 
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9.5.1.2 Synthesis of 1,4-dihydropyrano[2,3-c]pyrazole derivatives 110-129. 
A solution of pyrazolone derivative 109 (1 equiv, 1 mmol), malononitrile (1 
equiv, 1 mmol), the corresponding arylaldehyde (1 equiv, 1 mmol) and 
ammonium acetate (1 equiv, 1 mmol) in ethanol (2 mL) was heated under reflux 
for 5 hours. After this time the solvent was evaporated under reduced pressure and 
the crude residues were crystallized from EtOH or purified by silica gel column 
chromatography using dichloromethane:methanol as eluent to give pure 
compounds (110-129).  
 
Data of compounds 109-129 and the experimental conditions employed for their 
synthesis are indicated below. 
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5-Methyl-1H-pyrazol-3(2H)-one (109) 
Prepared from ethyl acetoacetate (1.366 g, 10.5 mmol) and hydrazine 
(0.501 g, 10 mmol). 
Reaction time: 1 h. 
Purification: Crystallization from EtOH. 
Yield: 0.970 g (99%). White solid. 
 
Data of 109: 
IR (neat) ν 1607 (C=O) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 2.08 (s, 3H, C-5CH3), 5.29 (s, 1H, CH-4), 
10.45 (bs, 2H, NHx2) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.81 (C=O), 139.35 (C-5), 88.91 (CH-4), 
11.22 (C-5CH3) ppm. 
These data are consistent with those described in the literature.291 
      
6-Amino-3-methyl-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (110) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), benzaldehyde (106 mg, 1 
mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 217 mg (86%). White solid. 
 
Data of 110: 
Mp: 249-250 °C (dec.) 
Elemental analysis calcd (%) for C14H12N4O: C 66.65, H 4.79, N 22.21; found: C 
66.43, H 4.82, N 22.08. 
HR-MS (ESI-Neg) m/z calcd for C14H11N4O [M-H]- 251.09383, found 
251.09420. 
                                                
291 Lehmann, F.; Holm, M.; Laufer, S. J. Comb. Chem., 2008, 10, 364-367. 
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IR (neat) ν 3368 (N-H), 3164 (N-H), 2191 (CN), 1647 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 4.59 (s, 1H, CH-4), 6.90 
(s, 2H, C-6NH2), 7.11-7.27 (m, 3H, CH-3’, CH-4’ and CH-5’), 7.27-7.38 (m, 2H, 
CH-2’ and CH-6’), 12.11 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.91 (C-6), 154.80 (C-7a), 144.50 (C-1’), 
135.61 (C-3), 128.49 (2xCHAr), 127.52 (2xCHAr), 126.79 (CHAr), 120.88 (CN), 
97.68 (C-3a), 57.15 (C-5), 36.25 (CH-4), 9.79 (C-3CH3) ppm. 
These data are consistent with those described in the literature.291 
      
6-Amino-4-(2-chlorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (111) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 2-chlorobenzaldehyde 
(141 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 243 mg (85%). White solid. 
 
Data of 111: 
Mp: 253-254 °C (dec.) 
Elemental analysis calcd (%) for C14H11ClN4O: C 58.65, H 3.87, N 19.54; found: 
C 58.26, H 3.91, N 19.44. 
IR (neat) ν 3385 (N-H), 3156 (N-H), 2187 (CN), 1650 (C=N), 1045 (C-Cl) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.76 (s, 3H, C-3CH3), 5.06 (s, 1H, CH-4), 6.96 
(s, 2H, C-6NH2), 7.11-7.37 (m, 3H, CH-4’, CH-5’ and CH-6’), 7.41 (d, J = 7.3 
Hz, 1H, CH-3’), 12.13 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.32 (C-6), 154.97 (C-7a), 140.96 (C-1’),	  
135.39 (C-3), 131.97 (C-2’), 130.76 (CHAr), 129.52 (CHAr), 128.64 (CHAr), 
127.81 (CHAr), 120.47 (CN), 96.87 (C-3a), 55.68 (C-5), 33.48 (CH-4), 9.57 (C-
3CH3) ppm. 
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6-Amino-4-(3-chlorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (112) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 3-chlorobenzaldehyde 
(141 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 220 mg (77%). Pale yellow solid. 
 
Data of 112: 
Mp: 205-206 °C (dec.) 
Elemental analysis calcd (%) for C14H11ClN4O: C 58.65, H 3.87, N 19.54; found: 
C 58.42, H 3.86, N 19.45. 
IR (neat) ν 3366 (N-H), 3175 (N-H), 2191 (CN), 1646 (C=N), 1070 (C-Cl) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.80 (s, 3H, C-3CH3), 4.66 (s, 1H, CH-4), 6.99 
(s, 2H, C-6NH2), 7.14 (d, J = 7.1 Hz, 1H, CH-4’), 7.20 (s, 1H, CH-2’), 7.25-7.45 
(m, 2H, CH-5’ and CH-6’), 12.18 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.06 (C-6), 154.73 (C-7a), 147.14 (C-1’), 
135.78 (C-3), 133.09 (C-3’), 130.55 (CHAr), 127.29 (CHAr), 126.90 (CHAr), 
126.37 (CHAr), 120.75 (CN), 97.07 (C-3a), 56.47 (C-5), 35.82 (CH-4), 9.83 (C-
3CH3) ppm. 
      
6-Amino-4-(4-chlorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (113) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 4-chlorobenzaldehyde 
(141 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 252 mg (88%). White solid. 
 
Data of 113: 
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Mp: 229-230 °C (dec.) 
Elemental analysis calcd (%) for C14H11ClN4O: C 58.65, H 3.87, N 19.54; found: 
C 58.55, H 3.88, N 19.55. 
IR (neat) ν 3404 (N-H), 3166 (N-H), 2185 (CN), 1649 (C=N), 1075 (C-Cl) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.79 (s, 3H, C-3CH3), 4.63 (s, 1H, CH-4), 6.94 
(s, 2H, C-6NH2), 7.19 (d, J = 8.4 Hz, 2H, CH-2’ and CH-6’), 7.38 (d, J = 8.4 Hz, 
2H, CH-3’ and CH-5’), 12.14 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.69 (C-6), 154.48 (C-7a), 143.29 (C-1’), 
135.46 (C-3), 131.01 (C-4’), 129.16 (2xCHAr), 128.25 (2xCHAr), 120.46 (CN), 
96.98 (C-3a), 56.50 (C-5), 35.33 (CH-4), 9.53 (C-3CH3) ppm. 
      
6-Amino-4-(2-bromophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (114) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 2-bromobenzaldehyde 
(185 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 271 mg (82%). White solid. 
 
Data of 114: 
Mp: 248-249 °C (dec.) 
Elemental analysis calcd (%) for C14H11BrN4O: C 50.77, H 3.35, N 16.92; found:	  
C 50.61, H 3.34, N 16.81. 
IR (neat) ν 3386 (N-H), 3142 (N-H), 2187 (CN), 1651 (C=N), 1047 (C-Br) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.76 (s, 3H, C-3CH3), 5.07 (s, 1H, CH-4), 6.97 
(s, 2H, C-6NH2), 7.07-7.27 (m, 2H, CH-5’ and CH-6’), 7.35 (t, J = 7.4 Hz, 1H, 
CH-4’), 7.58 (d, J = 7.7 Hz, 1H, CH-3’), 12.15 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.24 (C-6), 154.91 (C-7a), 142.60 (C-1’), 
135.42 (C-3), 132.66 (CHAr), 130.99 (CHAr), 128.95 (CHAr), 128.45 (CHAr), 
122.44 (C-2’), 120.38 (CN), 97.06 (C-3a), 55.92 (C-5), 35.86 (CH-4), 9.71 (C-
3CH3) ppm. 
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6-Amino-4-(4-bromophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (115) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 4-bromobenzaldehyde 
(185 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 305 mg (92%). Pale yellow solid. 
 
Data of 115: 
Mp: 232-233 °C (dec.) 
Elemental analysis calcd (%) for C14H11BrN4O: C 50.77, H 3.35, N 16.92; found: 
C 50.78, H 3.46, N 17.03. 
IR (neat) ν 3392 (N-H), 3177 (N-H), 2188 (CN), 1638 (C=N), 1073 (C-Br) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.79 (s, 3H, C-3CH3), 4.62 (s, 1H, CH-4), 6.95 
(s, 2H, C-6NH2), 7.14 (d, J = 8.4 Hz, 2H, CH-2’ and CH-6’), 7.51 (d, J = 8.4 Hz, 
2H, CH-3’ and CH-5’), 12.15 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.94 (C-6), 154.72 (C-7a), 143.95 (C-1’), 
135.70 (C-3), 131.41 (2xCHAr), 129.78 (2xCHAr), 120.70 (C-4’*), 119.78 
(CN*), 97.15 (C-3a), 56.64 (C-5), 35.63 (CH-4), 9.78 (C-3CH3) ppm. 
      
6-Amino-4-(4-fluorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (116) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 4-fluorobenzaldehyde 
(124 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: dichloromethane:methanol (from 100:0 to 96:4, 
v/v). 
Yield: 197 mg (73%). Pale yellow solid. 
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Data of 116: 
Mp: 223-224 °C (dec.) 
Elemental analysis calcd (%) for C14H11FN4O: C 62.22, H 4.10, N 20.73; found: 
C 62.26, H 4.15, N 20.62. 
IR (neat) ν 3220 (N-H), 3122 (N-H), 2193 (CN), 1642 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 4.63 (s, 1H, CH-4), 6.91 
(s, 2H, C-6NH2), 7.09-7.25 (m, 4H, CH-2’, CH-3’, CH-5’ and CH-6’), 12.13 (s, 
1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.97 (d, J = 242.4 Hz, C-4’), 160.86 (C-6), 
154.73 (C-7a), 140.71 (d, J = 3.0 Hz, C-1’), 135.66 (C-3), 129.38 (d, J = 8.2 Hz, 
2xCHAr), 120.77 (CN), 115.21 (d, J = 21.4 Hz, 2xCHAr), 97.52 (C-3a), 57.04 
(C-5), 35.44 (CH-4), 9.77 (C-3CH3) ppm. 
19F NMR (235 MHz, DMSO-d6) δ -116.64 (m) ppm. 
      
6-Amino-3-methyl-4-(2-nitrophenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (117) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 2-nitrobenzaldehyde 
(124 mg, 1 mmol) and ammonium	  acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 280 mg (94%). Pale yellow solid. 
 
Data of 117: 
Mp: 228-229 °C (dec.) 
Elemental analysis calcd (%) for C14H11N5O3: C 56.56, H 3.73, N 23.56; found: 
C 56.37, H 3.79, N 23.39. 
IR (neat) ν 3409 (N-H), 3159 (N-H), 2184 (CN), 1650 (C=N), 1593 (NO2), 1345 
(NO2) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.76 (s, 3H, C-3CH3), 5.09 (s, 1H, CH-4), 7.04 
(s, 2H, C-6NH2), 7.32 (dd, J = 7.8, 1.0 Hz, 1H, CH-6’), 7.49 (dt, J = 8.0, 1.0 Hz, 
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1H, CH-4’), 7.66 (dt, J = 7.6, 1.0 Hz, 1H, CH-5’), 7.85 (dd, J = 8.1, 1.0 Hz, 1H, 
CH-3’), 12.21 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.18 (C-6), 154.96 (C-7a), 149.15 (C-2’), 
137.62 (C-1’*), 135.72 (C-3*), 133.40 (CHAr), 131.29 (CHAr), 128.35 (CHAr), 
123.60 (CHAr), 120.26 (CN), 96.39 (C-3a), 55.99 (C-5), 31.39 (CH-4), 9.51 (C-
3CH3) ppm. 
      
6-Amino-3-methyl-4-(3-nitrophenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (118) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 3-nitrobenzaldehyde 
(124 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 270 mg (91%). Pale yellow solid. 
 
Data of 118: 
Mp: 226-227 °C (dec.) 
Elemental analysis calcd (%) for C14H11N5O3: C 56.56, H 3.73, N 23.56; found: 
C 56.15, H 3.80, N 23.27. 
IR (neat) ν 3412 (N-H), 3162 (N-H), 2193 (CN), 1644 (C=N), 1593 (NO2), 1345 
(NO2) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.80 (s, 3H, C-3CH3), 4.88 (s, 1H, CH-4), 7.06 
(s, 2H, C-6NH2), 7.59-7.72 (m, 2H, CH-5’ and CH-6’), 8.03 (s, 1H, CH-2’), 8.12 
(dt, J = 6.5, 2.4 Hz, 1H, CH-4’), 12.21 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.51 (C-6), 155.05 (C-7a), 148.23 (C-3’*), 
147.20 (C-1’*), 136.27 (C-3), 134.78 (CHAr), 130.64 (CHAr), 122.37 (CHAr), 
122.22 (CHAr), 120.91 (CN), 97.03 (C-3a), 56.44 (C-5), 35.98 (CH-4), 10.13 (C-
3CH3) ppm. 
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6-Amino-3-methyl-4-(4-nitrophenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (119) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 4-nitrobenzaldehyde 
(124 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 275 mg (93%). Pale yellow solid. 
 
Data of 119: 
Mp: 279-280 °C (dec.) 
Elemental analysis calcd (%) for C14H11N5O3: C 56.56, H 3.73, N 23.56; found: 
C 56.40, H 3.79, N 23.21. 
IR (neat) ν 3410 (N-H), 3219 (N-H), 2194 (CN), 1640 (C=N), 1511 (NO2), 1347 
(NO2) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.80 (s, 3H, C-3CH3), 4.83 (s, 1H, CH-4), 7.06 
(s, 2H, C-6NH2), 7.46 (d, J = 8.7 Hz, 2H, CH-2’ and CH-6’), 8.21 (d, J = 8.7 Hz, 
2H,	  CH-3’ and CH-5’), 12.21 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.18 (C-6), 154.70 (C-7a), 152.15 (C-4’), 
146.41 (C-1’), 135.92 (C-3), 128.88 (2xCHAr), 123.95 (2xCHAr), 120.55 (CN), 
96.59 (C-3a), 55.90 (C-5), 35.90 (CH-4), 9.78 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(2-methylphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (120) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 2-methylbenzaldehyde 
(120 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 235 mg (88%). Grey solid. 
 
Data of 120: 
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Mp: 241-242 °C (dec.) 
Elemental analysis calcd (%) for C15H14N4O: C 67.65, H 5.30, N 21.04; found: C 
67.51, H 5.31, N 20.99. 
IR (neat) ν 3362 (N-H), 3152 (N-H), 2191 (CN), 1650 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.68 (s, 3H, C-3CH3), 2.28 (s, 3H, C-2’CH3), 
4.84 (s, 1H, CH-4), 6.86 (s, 2H, C-6NH2), 6.96-7.01 (m, 1H, CH-6’), 7.09-7.18 
(m, 3H, CH-3’, CH-4’ and CH-5’), 12.09 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.80 (C-6), 155.11 (C-7a), 141.95 (C-1’), 
135.39 (C-2’*), 135.01 (C-3*), 130.54 (CHAr), 128.95 (CHAr), 126.64 (CHAr), 
126.39 (CHAr), 120.81 (CN), 97.58 (C-3a), 56.69 (C-5), 33.02 (CH-4), 18.99 (C-
2’CH3), 9.60 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(3-methylphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-
5-	  carbonitrile (121) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 3-methylbenzaldehyde 
(120 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 223 mg (84%). Pale yellow solid. 
 
Data of 121: 
Mp: 205-206 °C (dec.) 
Elemental analysis calcd (%) for C14H11ClN4O: C 58.65, H 3.87, N 19.54; found: 
C 58.42, H 3.86, N 19.45. 
IR (neat) ν 3366 (N-H), 3175 (N-H), 2191 (CN), 1646 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 2.27 (s, 3H, C-3’CH3), 
4.54 (s, 1H, CH-4), 6.87 (s, 2H, C-6NH2), 6.92-7.00 (m, 2H, CH-2’ and CH-6’), 
7.03 (d, J = 7.6 Hz, 1H, CH-4’), 7.20 (t, J = 7.8 Hz, 1H, CH-5’), 12.09 (s, 1H, 
NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.88 (C-6), 154.76 (C-7a), 144.47 (C-1’), 
137.53 (C-3’*), 135.58 (C-3*), 128.32 (CHAr), 127.92 (CHAr), 127.49 (CHAr), 
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124.72 (CHAr), 120.89 (CN), 97.70 (C-3a), 57.18 (C-5), 36.20 (CH-4), 21.12 (C-
3’CH3), 9.81 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(4-methylphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (122) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 mmol), 
malononitrile (66 mg, 1 mmol), 4-methylbenzaldehyde (120 mg, 
1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 1 h. 
Purification: Crystallization from EtOH. 
Yield: 215 mg (81%). White solid. 
 
Data of 122: 
Mp: 205-206 °C (dec.) 
Elemental analysis calcd (%) for C15H14N4O: C 67.65, H 5.30, N 21.04; found: C 
67.55, H 5.26, N 21.03. 
IR (neat) ν 3372 (N-H), 3184 (N-H), 2191 (CN), 1645 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 2.27 (s, 3H, C-4’CH3), 
4.54 (s, 1H, CH-4), 6.84 (s, 2H, C-6NH2), 7.04 (d, J = 7.8 Hz, 2H, CH-2’ and 
CH-6’), 7.12 (d, J = 7.8 Hz, 2H, CH-3’ and CH-5’), 12.08 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.78 (C-6), 154.77 (C-7a), 141.52 (C-1’), 
135.73 (C-4’*), 135.54 (C-3*), 129.02 (2xCHAr), 127.38 (2xCHAr), 120.85 
(CN), 97.74 (C-3a), 57.34 (C-5), 35.85 (CH-4), 20.66 (C-4’CH3), 9.78 (C-3CH3) 
ppm. 
      
6-Amino-4-(2-methoxyphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (123) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 mmol), malononitrile 
(66 mg, 1 mmol), 2-methoxybenzaldehyde (136 mg, 1 mmol) and ammonium 
acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
O
CN
NH2
N
N
H
H3C
CH3
5'
4'
6' 2'
3'
1'
314 9. Experimental section 
 
 
Purification: Crystallization from EtOH. 
Yield: 245 mg (87%). Grey solid. 
 
Data of 
Mp: 235-236 °C (dec.) 
Elemental analysis calcd (%) for C15H14N4O2: C 63.82, H 5.00, N 19.85; found: 
C 63.52, H 5.08, N 19.59. 
IR (neat) ν 3371 (N-H), 3151 (N-H), 2192 (CN), 1654 (C=N), 1256 (C-O-C) cm-
1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 3.78 (s, 3H, OCH3), 
4.96 (s, 1H, CH-4), 6.80 (s, 2H, C-6NH2), 6.89 (t, J = 7.3 Hz, 1H, CH-4’), 6.94-
7.04 (m, 2H,	  CH-3’ and CH-6’), 7.19 (t, J = 7.6 Hz, 1H, CH-5’), 12.00 (s, 1H, 
NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.51 (C-6), 156.36 (C-7a*), 155.09 (C-2’*), 
135.08 (C-3), 132.13 (C-1’), 128.65 (CHAr), 127.95 (CHAr), 120.96 (CN), 
120.84 (CHAr), 111.30 (CHAr), 97.85 (C-3a), 56.33 (C-2’OCH3), 55.59 (C-5), 
29.15 (CH-4), 9.55 (C-3CH3) ppm. 
      
6-Amino-4-(3-methoxyphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (124) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 3-
methoxybenzaldehyde (136 mg, 1 mmol) and ammonium 
acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: dichloromethane:methanol (from 100:0 to 95:5, v/v). 
Yield: 235 mg (83%). Pale yellow solid. 
 
Data of 124: 
Mp: 201-202 °C (dec.) 
Elemental analysis calcd (%) for C15H14N4O2: C 63.82, H 5.00, N 19.85; found: 
C 63.60, H 5.07, N 19.51. 
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IR (neat) ν 3383 (N-H), 3161 (N-H), 2184 (CN), 1641 (C=N), 1263 (C-O-C) cm-
1. 
1H NMR (250 MHz, DMSO-d6) δ 1.81 (s, 3H, C-3CH3), 3.72 (s, 3H, OCH3), 
4.57 (s, 1H, CH-4), 6.69-6.75 (m, 2H, CH-2’ and CH-6’), 6.80 (dd, J = 8.0, 1.8 
Hz, 1H, CH-4’), 6.88 (s, 2H, C-6NH2), 7.24 (t, J = 8.0 Hz, 1H, CH-5’), 12.10 (s, 
1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.93 (C-6), 159.24 (C-3’*), 154.76 (C-7a*), 
146.16 (C-1’), 135.62 (C-3), 129.62 (CHAr), 120.85 (CN), 119.70 (CHAr), 
113.51 (CHAr), 111.67 (CHAr), 97.50 (C-3a), 56.97 (C-5), 54.99 (C-3’OCH3), 
36.18 (CH-4), 9.84 (C-3CH3) ppm. 
      
6-Amino-4-(4-methoxyphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (125) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 mmol), malononitrile 
(66 mg, 1 mmol), 4-methoxybenzaldehyde (136 mg, 1 mmol) 
and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: dichloromethane:methanol (from 100:0 to 95:5, 
v/v). 
Yield: 200 mg (71%). Yellow solid. 
 
Data of 125: 
Mp: 202-203 °C (dec.) 
Elemental analysis calcd (%) for C15H14N4O2: C 63.82, H 5.00, N 19.85; found: 
C 63.73, H 4.98, N 19.62. 
IR (neat) ν 3231 (N-H), 3122 (N-H), 2190 (CN), 1639 (C=N), 1258 (C-O-C) cm-
1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 3.73 (s, 3H, OCH3), 
4.53 (s, 1H, CH-4), 6.83 (s, 2H, C-6NH2), 6.87 (d, J = 8.7 Hz, 2H, CH-3’ and 
CH-5’), 7.07 (d, J = 8.7 Hz, 2H, CH-2’ and CH-6’), 12.07 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.04 (C-6), 158.31 (C-4’*), 155.10 (C-7a*), 
136.85 (C-1’), 135.90 (C-3), 128.86 (2xCHAr), 121.22 (CN), 114.11 (2xCHAr), 
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98.24 (C-3a), 57.90 (C-5), 55.35 (C-4’OCH3), 35.78 (CH-4), 10.12 (C-3CH3) 
ppm. 
      
6-Amino-3-methyl-4-(pyridin-3-yl)-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (126) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 3-
pyridinecarboxaldehyde (107 mg, 1 mmol) and ammonium 
acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 215 mg (85%). Grey solid. 
 
Data of 126: 
Mp: 223-224 °C (dec.) 
Elemental analysis calcd (%) for C13H11N5O: C 61.65, H 4.38, N 27.65; found: C 
61.63, H 4.28, N 27.48. 
IR (neat) ν 3388 (N-H), 3165 (N-H), 2190 (CN), 1644 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 4.69 (s, 1H, CH-4), 7.01 
(s, 2H, C-6NH2), 7.35 (dd, J = 7.9, 4.8 Hz, 1H, CH-5’), 7.52 (dd, J = 7.9, 1.7 Hz, 
1H, CH-4’), 8.45 (s, 2H, CH-2’ and CH-6’), 12.19 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.11 (C-6), 154.78 (C-7a), 148.82 (CHAr), 
148.32 (CHAr), 139.78 (C-3’), 135.74 (C-3), 135.23 (CHAr), 123.95 (CHAr), 
120.71 (CN), 96.82 (C-3a), 56.23 (C-5), 33.68 (CH-4), 9.77 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(pyridin-4-yl)-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (127) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 4-
pyridinecarboxaldehyde (107 mg, 1 mmol) and ammonium 
acetate (77 mg, 1 mmol). 
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Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 212 mg (84%). White solid. 
 
Data of 127: 
Mp: 224-225 °C (dec.) 
Elemental analysis calcd (%) for C13H11N5O: C 61.65, H 4.38, N 27.65; found: C 
61.29, H 4.40, N 27.34. 
IR (neat) ν 3315 (N-H), 3025 (N-H), 2169 (CN), 1657 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.81 (s, 3H, C-3CH3), 4.66 (s, 1H, CH-4), 7.04 
(s,	  2H, C-6NH2), 7.19 (d, J = 5.8 Hz, 2H, CH-3’ and CH-5’), 8.51 (d, J = 5.8 Hz, 
2H, CH-2’ and CH-6’), 12.20 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.26 (C-6), 154.76 (C-7a), 152.86 (C-4’), 
149.95 (2xCHAr), 135.82 (C-3), 122.79 (2xCHAr), 120.55 (CN), 96.26 (C-3a), 
55.56 (C-5), 35.54 (CH-4), 9.76 (C-3CH3) ppm. 
      
6-Amino-4-(furan-2-yl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile (128) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 2-furancarboxaldehyde 
(96 mg, 1 mmol) and ammonium acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 200 mg (83%). Grey solid. 
 
Data of 128: 
Mp: > 300 °C (dec.) 
Elemental analysis calcd (%) for C12H10N4O2: C 59.50, H 4.16, N 23.13; found: 
C 59.31, H 4.20, N 22.67. 
IR (neat) ν 3345 (N-H), 3162 (N-H), 2185 (CN), 1647 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.97 (s, 3H, C-3CH3), 4.77 (s, 1H, CH-4), 6.17 
(d, J = 3.0 Hz, 1H, CH-3’), 6.37 (dd, J = 3.0, 1.9 Hz, 1H, CH-4’), 6.96 (s, 2H, C-
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6NH2), 7.53 (s, 1H, CH-5’), 12.16 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.51 (C-6), 155.74 (C-7a*), 154.84 (C-2’*), 
142.32 (CHAr), 135.87 (C-3), 120.65 (CN), 110.28 (CHAr), 105.68 (CHAr), 
95.14 (C-3a), 53.97 (C-5), 29.83 (CH-4), 9.62 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(thiophen-2-yl)-1,4-dihydropyrano[2,3-c]pyrazole-5-	  
carbonitrile (129) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 mmol), malononitrile 
(66 mg, 1 mmol), 2-thiophencarboxaldehyde (112 mg, 1 mmol) and ammonium 
acetate (77 mg, 1 mmol). 
Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 201 mg (78%). Pale yellow solid. 
 
Data of 129: 
Mp: 243-244 °C (dec.) 
Elemental analysis calcd (%) for C12H10N4OS: C 55.80, H 3.90, N 21.69, S 
12.41; found: C 55.45, H 3.82, N 21.46, S 12.27. 
IR (neat) ν 3339 (N-H), 3160 (N-H), 2189 (CN), 1646 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.91 (s, 3H, C-3CH3), 4.99 (s, 1H, CH-4), 
6.73-7.11 (m, 4H, CH-3’, CH-4’ and C-6NH2), 7.38 (d, J = 4.9 Hz, 1H, CH-5’), 
12.18 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 161.01 (C-6), 154.65 (C-7a), 150.15 (C-2’), 
136.39 (C-3), 126.88 (CHAr), 125.37 (CHAr), 124.74 (CHAr), 121.00 (CN), 
97.92 (C-3a), 57.89 (C-5), 31.75 (CH-4), 10.11 (C-3CH3) ppm. 
      
3-amino-1-(5-hydroxy-3-methyl-1H-pyrazol-4-yl)indolizine-2-carbonitrile 
(134) 
Isolated from the reaction between 5-methyl-1H-pyrazol-3(2H)-one (98 mg, 1 
mmol), malononitrile (66 mg, 1 mmol), 2-pyridinecarboxaldehyde (107 mg, 1 
mmol) and ammonium acetate (77 mg, 1 mmol). 
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Reaction time: 5 h. 
Purification: Crystallization from EtOH. 
Yield: 178 mg (70%). Yellow solid. 
 
Data of 134: 
Mp: °C (dec.) 
Elemental analysis calcd (%) for C13H11N5O: C 61.65, H 4.38, N 27.65; found: C 
61.58, H 4.50, N 27.48. 
IR (neat) ν 3340 (N-H), 3260 (N-H), 2205 (CN) cm-1. 
1H NMR (250 MHz, DMSO) δ 2.09 (s, 3H, C-3CH3), 6.16 (s, 2H, NH2), 6.36 – 
6.55 (m, 2H, CH-6’ and CH-7’), 6.94 (d, J = 8.9 Hz, 1H, CH-8’), 7.78 (d, J = 7.1 
Hz, 1H, CH-5’), 10.15 (bs, 1H, OH), 10.89 (bs, 1H, NH) ppm. 
13C NMR (63 MHz, DMSO) δ 159.56 (C-5), 138.05 (C-3*), 137.86 (C-8a’*), 
122.56 (C-3’), 120.98 (CH-5’*), 119.88 (CH-8’*), 117.80 (CN), 115.04 (CH-7’*), 
111.42 (CH-6’*), 103.15 (C-4), 94.88 (C-1’), 79.22 (C-2’), 11.18 (C-3CH3). 
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9.5.2 Synthesis of Knoevenagel adducts 130-131. General procedure 
 
 
Compound R 
130 H 
131 CH3 
 
To a mixture of malononitrile (1 equiv, 3 mmol), triethylamyne (1 equiv, 3 mmol) 
and magnesium bromide diethyl etherate (0.2 equiv, 0.6 mmol) in THF (5 mL), 
was added the appropriate benzaldehyde (1 equiv, 3 mmol) and the mixture was 
stirred at room temperature for 1 h, until the complete disappearance of the 
aldehyde (checked by TLC). The mixture was diluted with 20 mL of diethyl ether, 
the organic phase washed with water and filtered through a short Na2SO4 pad. The 
solvent was removed under reduced pressure and the products were recrystallized 
using hexane. 
 
Data of compounds 130 and 131 and the experimental conditions employed for 
their synthesis are indicated below. 
  
H
RCN
NC
130, 131
MgBr2.OEt2
Et3N
THF, rt, 1 hNC
CN
+ O
R
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2-Benzylidenemalononitrile (130) 
Prepared from malononitrile (198 mg, 3 mmol), benzaldehyde 
(318 mg, 3 mmol) and magnesium bromide diethyl etherate (155 
mg, 0.6 mmol). 
Yield: 440 mg (95%). Pale yellow solid. 
 
Data of 130: 
1H NMR (250 MHz, CDCl3) δ 7.49 – 7.71 (m, 3H, CH-3, CH-4 and CH-5), 7.79 
(s, 1H, CH-β), 7.86 – 7.97 (m, 2H, CH-2 and CH-6) ppm.  
13C NMR (63 MHz, CDCl3) δ 160.40 (CH-β), 135.09 (CH-4), 131.33 (2xCHAr), 
131.18 (C-1), 130.07 (2xCHAr), 114.14 (CN), 112.97 (CN), 83.27 (C-α) ppm. 
These data are consistent with those described in the literature.292 
      
2-(4-Methylbenzylidene)malononitrile (131) 
Prepared from malononitrile (198 mg, 3 mmol), 4-
methylbenzaldehyde (360 mg, 3 mmol) and magnesium 
bromide diethyl etherate (155 mg, 0.6 mmol). 
Yield: 470 mg (93%). Yellow solid.  
 
Data of 131: 
1H NMR (250 MHz, CDCl3) δ 2.46 (s, 3H, C-4CH3), 7.34 (d, J = 8.2 Hz, 2H, 
CH-3 and CH-5), 7.72 (s, 1H, CH-β), 7.81 (d, J = 8.3 Hz, 2H, CH-2 and CH-6) 
ppm.  
13C NMR (63 MHz, CDCl3) δ 160.23 (CH-β), 146.84 (C-4), 131.36 (2xCHAr), 
130.81 (2xCHAr), 128.87 (C-1), 114.46 (CN), 113.30 (CN), 81.59 (C-α), 22.46 
(C-4CH3) ppm. 
These data are consistent with those described in the literature.292 
      
  
                                                
292 Abaee, M. S.; Mojtahedi, M. M.; Zahedi, M. M.; Khanalizadeh, G. Arkivoc 2006, xv, 48-52. 
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9.5.3 Synthesis of the acyclic precursor of 1,4-dihydropyrano[2,3-
c]pyrazole 132-133. General procedure 
 
 
Compound R 
132 H 
133 CH3 
 
A solution of the suitable aromatic aldehyde (1 equiv, 3 mmol), 2-pyrazol in-5-
one (1 equiv, 3 mmol), malononitrile (1 equiv, 3 mmol) and sodium acetate (0.1 
equiv, 0.3 mmol) in EtOH (5 mL) was stirred at room temperature for 1 h. After 
the reaction was finished (as checked by TLC), the solution was filtered out to 
isolate the solid product, which was then rinsed with an ice-cold ethanol/water 
solution (9:1) and dried. 
 
Data of compounds 132 and 133 and the experimental conditions employed for 
their synthesis are indicated below. 
  
HN N
H
H3C
O CN
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++
HO
R
NaAcO
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2-((5-Hydroxy-3-methyl-1H-pyrazol-4-yl)(phenyl)methyl)malononitrile 
(132) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (294 mg, 3 
mmol), malononitrile (198 mg, 3 mmol), benzaldehyde (318 mg, 
3 mmol) and sodium acetate (25 mg, 0.3 mmol). 
Yield: 200 mg (80%). White solid. 
 
Data of 132: 
Mp: 243-244 °C (dec.) 
IR (neat) ν 3360 (N-H), 2191 (CN) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 2.08 (s, 3H, C-3CH3), 4.64 (d, J = 11.5 Hz, 1H, 
CH-α), 5.53 (d, J = 11.5 Hz, 1H, CH-β), 7.22 – 7.41 (m, 3H, CH-3’, CH-4’ and 
CH-5’), 7.48 (d, J = 7.0 Hz, 2H, CH-2’ and CH-6’), 10.81 (bs, 2H, NH and OH) 
ppm.  
13C NMR (63 MHz, DMSO-d6) δ 159.36 (C-5), 140.22 (C-1’*), 138.20 (C-3*), 
129.00 (2xCHAr), 128.02 (2xCHAr), 127.93 (CH-4’), 114.49 (CN), 98.94 (CN), 
41.66 (CH-β), 27.75 (CH-α), 10.10 (C-3CH3) ppm. 
These data are consistent with those described in the literature.293 
      
2-((5-Hydroxy-3-methyl-1H-pyrazol-4-yl)(4-methylphenyl)methyl) 
malononitrile (133) 
Prepared from 5-methyl-1H-pyrazol-3(2H)-one (294 mg, 3 
mmol), malononitrile (198 mg, 3 mmol), 4-methyl benzaldehyde 
(360 mg, 3 mmol) and sodium acetate (25 mg, 0.3 mmol). 
Yield: 240 mg (90%). White solid. 
 
Data of 133: 
Mp: 198-199 °C (dec.) 
IR (neat) ν 3354 (N-H), 2187 (CN) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 2.06 (s, 3H, C-3CH3), 2.26 (s, 3H, C-4’CH3), 
                                                
293 Elinson, M. N.; Naysbullin, R. F.; Nikishin, G. I. R. Chim. 2013, 16, 789-794.  
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4.58 (d, J = 11.4 Hz, 1H, CH-α), 5.48 (d, J = 11.4 Hz, 1H, CH-β), 7.14 (d, J = 7.9 
Hz, 2H, CH-3’ and CH-5’), 7.35 (d, J = 8.0 Hz, 2H, CH-2’ and CH-6’), 10.77 (bs, 
2H, NH and OH) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 159.35 (C-5), 138.13 (C-1’*), 137.22 (C-3*), 
137.12 (C-4’*), 129.52 (2xCHAr), 127.91 (2xCHAr), 114.51 (CN), 99.07 (CN), 
41.41 (CH-β), 27.81 (CH-α), 21.00 (C-4’CH3), 10.11 (C-3CH3) ppm. 
These data are consistent with those described in the literature.293 
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9.5.4 Synthesis of 4,7-dihydro-1H-pyrazolo[3,4-b]pyridine derivatives 
135-146. General procedure 
 
 
 
Cmpd. Ar  Cmpd. Ar 
135 C6H5  141 4-FC6H4 
136 2-ClC6H4  142 3-NO2C6H4 
137 3-ClC6H4  143 4-NO2C6H4 
138 4-ClC6H4  144 3-pyridyl 
139 2-BrC6H4  145 4-pyridyl 
140 4-BrC6H4  146 2-thienyl 
 
A solution of 3-methyl-1H-pyrazol-5-amine (1 equiv, 3 mmol), malononitrile (1 
equiv, 3 mmol), the corresponding arylaldehyde (1 equiv, 3 mmol) and 
ammonium acetate (1 equiv, 3 mmol) in ethanol (5 mL) was heated under reflux 
for 16 hours. After this time the solvent was evaporated under reduced pressure 
and the crude residues were crystallized from EtOH or purified by silica gel 
column chromatography using dichloromethane:methanol mixtures as eluent to 
give pure compounds 135-146. 
 
Data of compounds 135-146 and the experimental conditions employed for their 
synthesis are indicated below. 
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6-Amino-3-methyl-4-phenyl-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (135) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), benzaldehyde (318 mg, 3 
mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 330 mg (44%). White solid. 
 
Data of 135: 
Mp: > 300 °C (dec.) 
Elemental analysis calcd (%) for C14H13N5: C 66.92, H 5.21, N 27.87; found: C 
66.83, H 5.21, N 27.69. 
HR-MS (ESI-Neg) m/z calcd for C14H12N5 [M-H]- 250.10982, found 250.11047. 
IR (neat) ν 3401 (N-H), 3324 (N-H), 3225 (N-H), 2163 (CN), 1628 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.75 (s, 3H, C-3CH3), 4.61 (s, 1H, CH-4), 5.44 
(s, 2H, C-6NH2), 7.03-7.21 (m, 3H, CH-3’, CH-4’ and CH-5’), 7.21-7.39 (m, 2H, 
CH-2’ and CH-6’), 8.87 (s, 1H, NH-7), 11.69 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.38 (C-6), 146.87 (C-7a*), 146.17 (C-1’*), 
134.87 (C-3), 128.25 (2xCHAr), 127.32 (2xCHAr), 126.20 (CHAr), 123.30 (CN), 
100.53 (C-3a), 55.35 (C-5), 37.79 (CH-4), 9.51 (C-3CH3) ppm. 
      
6-Amino-4-(2-chlorophenyl)-3-methyl-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (136) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 2-chlorobenzaldehyde (422 mg, 
3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: dichloromethane:methanol (from 100:0 to 90:10, 
v/v). 
Yield: 290 mg (34%). White solid. 
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Data of 136: 
Mp: 267-268 °C (dec.) 
Elemental analysis calcd (%) for C14H12ClN5: C 58.85, H 4.23, N 24.51; found: 
C 58.76, H 4.13, N 24.38. 
IR (neat) ν 3406 (N-H), 3313 (N-H), 3212 (N-H), 2175 (CN), 1636 (C=N), 1045 
(C-Cl) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.73 (s, 3H, C-3CH3), 5.14 (s, 1H, CH-4), 5.48 
(s, 2H, C-6NH2), 7.11-7.32 (m, 3H, CH-4’, CH-5’ and CH-6’), 7.37 (dd, J = 7.7, 
1.2 Hz, 1H, CH-3’), 8.95 (s, 1H, NH-7), 11.72 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.70 (C-6), 146.38 (C-7a*), 143.60 (C-1’*), 
134.65 (C-3*), 131.19 (C-2’*), 130.92 (CHAr), 129.02 (CHAr), 127.96 (CHAr), 
127.68 (CHAr), 122.78 (CN), 99.92 (C-3a), 54.17 (C-5), 34.40 (CH-4), 9.27 (C-
3CH3) ppm. 
      
6-Amino-4-(3-chlorophenyl)-3-methyl-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (137) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 3-chlorobenzaldehyde (422 mg, 
3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: dichloromethane:methanol (from 100:0 to 90:10, 
v/v). 
Yield: 335 mg (39%). White solid. 
 
Data of 137: 
Mp: 281-282 °C (dec.) 
Elemental analysis calcd (%) for C14H12ClN5: C 58.85, H 4.23, N 24.51; found: 
C 58.62, H 4.24, N 24.39. 
IR (neat) ν 3398 (N-H), 3272 (N-H), 3194 (N-H), 2164 (CN), 1625 (C=N), 1074 
(C-Cl)  cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 4.67 (s, 1H, CH-4), 5.51 
(s, 2H, C-6NH2), 7.09-7.16 (m, 2H, CH-2’ and CH-6’), 7.21-7.27 (m, 1H, CH-4’), 
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7.32 (t, J = 7.9 Hz, 1H, CH-5’), 8.94 (s, 1H, NH-7), 11.76 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.51 (C-6), 149.48 (C-7a*), 146.15 (C-1’*), 
134.93 (C-3*), 132.90 (C-3’*), 130.24 (CHAr), 126.99 (CHAr), 126.26 (CHAr), 
126.05 (CHAr), 123.07 (CN), 99.92 (C-3a), 54.75 (C-5), 37.39 (CH-4), 9.46 (C-
3CH3) ppm. 
      
6-Amino-4-(4-chlorophenyl)-3-methyl-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (138) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 4-chlorobenzaldehyde (422 mg, 
3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 410 mg (48%). White solid. 
 
Data of 138: 
Mp: 297-298 °C (dec.) 
Elemental analysis calcd (%) for C14H12ClN5: C 58.85, H 4.23, N 24.51; found: 
C 58.81, H 4.12, N 24.58. 
IR (neat) ν 3211 (N-H), 3074 (N-H), 2167 (CN), 1627 (C=N), 1087 (C-Cl) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.76 (s, 3H, C-3CH3), 4.65 (s, 1H, CH-4), 5.48 
(s, 2H, C-6NH2), 7.15 (d, J = 8.4 Hz, 2H, CH-2’ and CH-6’), 7.34 (d, J = 8.4 Hz, 
2H, CH-3’ and CH-5’), 8.92 (s, 1H, NH-7), 11.73 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.39 (C-6), 146.15 (C-7a*), 145.86 (C-1’*), 
134.94 (C-3*), 130.66 (C-4’*), 129.16 (2xCHAr), 128.26 (2xCHAr), 123.12 
(CN),	  100.08 (C-3a), 54.99 (C-5), 37.14 (CH-4), 9.49 (C-3CH3) ppm. 
      
6-Amino-4-(2-bromophenyl)-3-methyl-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (139) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), malononitrile 
(198 mg, 3 mmol), 2-bromobenzaldehyde (555 mg, 3 mmol) and ammonium 
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acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 315 mg (32%). White solid. 
 
Data of 139: 
Mp: 236-237 °C (dec.) 
Elemental analysis calcd (%) for C14H12BrN5: C 50.93, H 3.66, N 21.21; found: 
C 50.77, H 3.66, N 21.08. 
IR (neat) ν 3339 (N-H), 3216 (N-H), 3055 (N-H), 2153 (CN), 1626 (C=N), 1023 
(C-Br) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.73 (s, 3H, C-3CH3), 5.13 (s, 1H, CH-4), 5.48 
(s, 2H, C-6NH2), 6.94-7.17 (m, 2H, CH-5’ and CH-6’), 7.32 (t, J = 7.0 Hz, 1H, 
CH-4’), 7.53 (d, J = 7.9 Hz, 1H, CH-3’), 8.95 (s, 1H, NH-7), 11.73 (s, 1H, NH-1) 
ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.60 (C-6), 146.31 (C-7a*), 145.33 (C-1’*), 
134.71 (C-3), 132.14 (CHAr), 131.18 (CHAr), 128.31 (2xCHAr), 122.67 (CN*), 
121.76 (C-2’*), 100.14 (C-3a), 54.47 (C-5), 36.98 (CH-4), 9.43 (C-3CH3) ppm. 
      
6-Amino-4-(4-bromophenyl)-3-methyl-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (140) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 4-bromobenzaldehyde (555 mg, 
3 mmol) and ammonium	  acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 505 mg (51%). White solid. 
 
Data of 140: 
Mp: > 300 °C (dec.) 
Elemental analysis calcd (%) for C14H12BrN5: C 50.93, H 3.66, N 21.21; found: 
C 50.78, H 3.46, N 21.22. 
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IR (neat) ν 3430 (N-H), 3214 (N-H), 3070 (N-H), 2161 (CN), 1626 (C=N), 1069 
(C-Br) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.76 (s, 3H, C-3CH3), 4.63 (s, 1H, CH-4), 5.48 
(s, 2H, C-6NH2), 7.09 (d, J = 8.2 Hz, 2H, CH-2’ and CH-6’), 7.47 (d, J = 8.2 Hz, 
2H, CH-3’ and CH-5’), 8.91 (s, 1H, NH-7), 11.73 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.40 (C-6), 146.28 (C-7a*), 146.16 (C-1’*), 
134.91 (C-3), 131.17 (2xCHAr), 129.56 (2xCHAr), 123.10 (CN*), 119.16 (C-
4’*), 100.02 (C-3a), 54.90 (C-5), 37.20 (CH-4), 9.47 (C-3CH3) ppm. 
      
6-Amino-4-(4-fluorophenyl)-3-methyl-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (141) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 4-fluorobenzaldehyde (372 mg, 
3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 290 mg (36%). White solid. 
 
Data of 141: 
Mp: > 300 °C (dec.) 
Elemental analysis calcd (%) for C14H12FN5: C 62.44, H 4.49, N 26.01; found: C 
62.31, H 4.48, N 25.94. 
IR (neat) ν 3464 (N-H), 3191 (N-H), 3140 (N-H), 2177 (CN), 1599 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.75 (s, 3H, C-3CH3), 4.65 (s, 1H, CH-4), 5.45 
(s, 2H, C-6NH2), 6.94-7.27 (m, 4H, CH-2’, CH-3’, CH-5’ and CH-6’), 8.89 (s, 
1H, NH-7), 11.71 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 160.68 (d, J = 241.5 Hz, C-4’), 153.30 (C-6), 
146.15 (C-7a), 143.08 (d, J = 2.9 Hz, C-1’), 134.85 (C-3), 129.05 (d, J = 8.1 Hz, 
2xCHAr), 123.17 (CN), 114.93 (d, J = 21.2 Hz, 2xCHAr), 100.39 (C-3a), 55.28 
(C-5), 36.99 (CH-4), 9.46 (C-3CH3) ppm. 
19F NMR (235 MHz, DMSO-d6) δ -117.52 (m) ppm. 
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6-Amino-3-methyl-4-(3-nitrophenyl)-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (142) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 3-nitrobenzaldehyde (453 mg, 
3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 355 mg (40%). Yellow solid. 
 
Data of 142: 
Mp: 249-250 °C (dec.) 
Elemental analysis calcd (%) for C14H12N6O2: C 56.75, H 4.08, N 28.36; found: 
C 56.77, H 4.01, N 28.17. 
IR (neat) ν 3357 (N-H), 3162 (N-H), 2161 (CN), 1644 (C=N), 1594 (NO2), 1340 
(NO2) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.77 (s, 3H, C-3CH3), 4.87 (s, 1H, CH-4), 5.58 
(s, 2H, C-6NH2), 7.56-7.67 (m, 2H, CH-5’ and CH-6’), 7.96 (s, 1H, CH-2’), 8.07 
(dt, J = 6.7, 2.2 Hz, 1H, CH-4’), 9.02 (s, 1H, NH-7), 11.80 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.67 (C-6*), 149.23 (C-3’*), 147.89 (C-7a*), 
146.17 (C-1’*), 135.16 (C-3), 134.17 (CHAr), 130.01 (CHAr), 122.98 (CN), 
121.58 (CHAr), 121.46 (CHAr), 99.56 (C-3a), 54.44 (C-5), 37.29 (CH-4), 9.48 
(C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(4-nitrophenyl)-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (143) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 4-nitrobenzaldehyde (453 mg, 3 
mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 310 mg (35%). Yellow solid. 
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Data of 143: 
Mp: > 300 °C (dec.) 
Elemental analysis calcd (%) for C14H12N6O2: C 56.75, H 4.08, N 28.36; found: 
C 56.74, H 4.01, N 28.17. 
IR (neat) ν 3440 (N-H), 3358 (N-H), 3220 (N-H), 2165 (CN), 1625 (C=N), 1597 
(NO2), 1350 (NO2) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.77 (s, 3H, C-3CH3), 4.83 (s, 1H, CH-4), 5.58 
(s, 2H, C-6NH2), 7.41 (d, J = 7.8 Hz, 2H, CH-2’ and CH-6’), 8.18 (d, J = 7.8 Hz, 
2H, CH-3’ and CH-5’), 9.02 (s, 1H, NH-7), 11.80 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 154.42 (C-6*), 153.66 (C-4’*), 146.16 (C-7a*), 
146.01 (C-1’*), 135.14 (C-3), 128.52 (2xCHAr), 123.82 (2xCHAr), 122.92 (CN), 
99.42 (C-3a), 54.18 (C-5), 37.52 (CH-4), 9.45 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(pyridin-3-yl)-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-
5-carbonitrile (144) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 3-pyridinecarboxaldehyde (321 
mg, 3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: Crystallization from EtOH. 
Yield: 370 mg (49%). White solid. 
 
Data of 144: 
Mp: 290-291 °C (dec.) 
Elemental analysis calcd (%) for C14H12N6: C 61.89, H 4.79, N 33.31; found: C 
61.72, H 4.81, N 32.97. 
IR (neat) ν 3389 (N-H), 3325 (N-H), 3191 (N-H), 2158 (CN), 1625 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.75 (s, 3H, C-3CH3), 4.70 (s, 1H, CH-4), 5.52 
(s, 2H, C-6NH2), 7.32 (dd, J = 7.8, 4.7 Hz, 1H, CH-2’), 7.48 (dt, J = 7.8, 1.8 Hz, 
1H, CH-6’), 8.40 (dd, J = 4.7, 1.8 Hz, 2H, CH-4’ and CH-5’), 8.95 (s, 1H, NH-7), 
11.76 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.56 (C-6), 148.50 (CHAr), 147.70 (CHAr), 
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146.17 (C-7a), 141.94 (C-3’), 134.97 (CHAr + C-3), 123.76 (CHAr), 123.05 
(CN), 99.65 (C-3a), 54.50 (C-5), 35.18 (CH-4), 9.44 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(pyridin-4-yl)-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-
5-carbonitrile (145) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 4-pyridinecarboxaldehyde (321 
mg, 3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: dichloromethane:methanol (from 100:0 to 85:15, 
v/v). 
Yield: 395 mg (52%). White solid. 
 
Data of 145: 
Mp: > 300 °C (dec.) 
Elemental analysis calcd (%) for C14H12N6: C 61.89, H 4.79, N 33.31; found: C 
61.83, H 4.71, N 33.10. 
IR (neat) ν 3456, (N-H), 3365 (N-H), 3189 (N-H), 2166 (CN), 1628 (C=N)  cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.78 (s, 3H, C-3CH3), 4.66 (s, 1H, CH-4), 5.55 
(s, 2H, C-6NH2), 7.13 (dd, J = 4.5, 1.5 Hz, 2H, CH-3’ and CH-5’), 8.47 (dd, J = 
4.5, 1.5 Hz, 2H, CH-2’ and CH-6’), 8.97 (s, 1H, NH-7), 11.78 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 154.93 (C-6*), 153.75 (C-4’*), 149.73 
(2xCHAr), 146.16 (C-7a), 135.08 (C-3), 122.92 (CN), 122.57 (2xCHAr), 99.08 
(C-3a), 53.81 (C-5), 37.10 (CH-4), 9.45 (C-3CH3) ppm. 
      
6-Amino-3-methyl-4-(thiophen-2-yl)-4,7-dihydro-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile (146) 
Prepared from 3-methyl-1H-pyrazol-5-amine (291 mg, 3 mmol), 
malononitrile (198 mg, 3 mmol), 2-thiophenecarboxaldehyde 
(336 mg, 3 mmol) and ammonium acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
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Purification: dichloromethane:methanol (from 100:0 to 90:10, v/v). 
Yield: 185 mg (24%). White solid. 
 
Data of 146: 
Mp: 275 -276 °C (dec.) 
Elemental analysis calcd (%) for C12H11N5S: C 56.01, H 4.31, N 27.22, S 12.46; 
found: C 56.06, H 4.24, N 27.04, S 12.35. 
IR (neat) ν 3390 (N-H), 3330 (N-H), 3061 (N-H), 2164 (CN), 1627 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.89 (s, 3H, C-3CH3), 5.00 (s, 1H, CH-4), 5.48 
(s, 2H, C-6NH2), 6.73-7.01 (m, 2H, CH-3’ and CH-4’), 7.31 (dd, J = 4.5, 1.7 Hz, 
1H,	  CH-5’), 8.93 (s, 1H, NH-7), 11.76 (s, 1H, NH-1) ppm.  
13C NMR (63 MHz, DMSO-d6) δ 153.21 (C-6*), 152.56 (C-2’*), 145.70 (C-7a), 
135.29 (C-3), 126.30 (CHAr), 124.39 (CHAr), 123.06 (CHAr + CN), 100.34 (C-
3a), 55.61 (C-5), 32.83 (CH-4), 9.50 (C-3CH3) ppm. 
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9.5.5 Formation of oxidized pyrazolo[3,4-b]pyridine derivatives 147-
149. 
 
 
 
Cmpd. Ar 
147 2-thienyl 
148 2-furyl 
149 4-MeOC6H4 
 
The same procedure described above in section x.5.4 was employed for the 
achievement of derivatives 147-149. 
 
Data of compounds 147-149, and the experimental conditions employed for their 
synthesis are indicated below. 
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6-Amino-3-methyl-4-(thiophen-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (147) 
Isolated from the reaction between 3-methyl-1H-pyrazol-5-
amine (291 mg, 3 mmol), malononitrile (198 mg, 3 mmol), 2-
thiophenecarboxaldehyde (336 mg, 3 mmol) and ammonium 
acetate (231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: dichloromethane:methanol (from 100:0 to 90:10, v/v). 
Yield: 105 mg (14%). Pale yellow solid. 
 
Data of 147: 
Mp: 250 -251 °C (dec.) 
Elemental analysis calcd (%) for C12H9N5S: C 56.45, H 3.55, N 27.43, S 12.56; 
found: C 56.31, H 3.58, N 27.19, S 12.32. 
IR (neat) ν 3388 (N-H), 3290 (N-H), 3060 (N-H), 2200 (CN), 1604 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.95 (s, 3H, C-3CH3), 6.96 (s, 2H, NH2), 7.27 
(dd, J = 5.0, 3.6 Hz, 1H, CH-4’), 7.40 (dd, J = 3.5, 1.1 Hz, 1H, CH-3’), 7.89 (dd, J 
= 5.0, 1.2 Hz, 1H, CH-5’), 12.90 (s, 1H, NH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 158.96 (C-7a*), 153.19 (C-6*), 144.56 (C-4*), 
142.18 (C-3*), 133.42 (C-2’), 129.91 (CHAr), 128.97 (CHAr), 127.58 (CHAr), 
116.83 (CN), 106.72 (C-3a), 87.88 (C-5), 14.30 (C-3CH3) ppm. 
      
6-Amino-4-(furan-2-yl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
(148) 
Isolated from the reaction between 3-methyl-1H-pyrazol-5-
amine (291 mg, 3 mmol), malononitrile (198 mg, 3 mmol), 2-
furancarboxaldehyde (288 mg, 3 mmol) and ammonium acetate 
(231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: dichloromethane:methanol (from 100:0 to 95:5, v/v). 
Yield: 60 mg (8%). Yellow solid. 
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Data of 148: 
Mp: 293 -294 °C (dec.) 
Elemental analysis calcd (%) for C12H9N5O: C 60.25, H 3.79, N 29.27; found: C 
60.02, H 3.90, N 29.09. 
IR (neat) ν 3374 (N-H), 3301 (N-H), 2201 (CN), 1600 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 2.23 (s, 3H, C-3CH3), 6.82 (dd, J = 3.3, 1.7 
Hz, 1H, CH-4’), 6.94 (s, 2H, NH2), 7.21 (d, J = 3.4 Hz, 1H, CH-3’), 8.07 (s, 1H, 
CH-5’), 12.89 (s, 1H, NH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 159.12 (C-7a*), 153.92 (C-6*), 146.40 (C-4*), 
145.48 (CHAr), 142.27 (C-3*), 138.60 (C-2’), 117.47 (CN), 114.60 (CHAr), 
112.38 (CHAr), 104.27 (C-3a), 83.94 (C-5), 15.34 (C-3CH3) ppm. 
      
6-amino-4-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carbonitrile (149) 
Isolated from the reaction between 3-methyl-1H-pyrazol-5-
amine (291 mg, 3 mmol), malononitrile (198 mg, 3 mmol), 4-
methoxybenzaldehyde (408 mg, 3 mmol) and ammonium acetate 
(231 mg, 3 mmol). 
Reaction time: 16 h. 
Purification: dichloromethane:methanol (from 100:0 to 95:5, 
v/v). 
Yield: 190 mg (23%). White solid. 
 
Data of 149: 
Mp: 267 -2698 °C (dec.) 
Elemental analysis calcd (%) for C15H13N5O: C 64.51, H 4.69, N 25.07; found: C 
64.34, H 4.77, N 24.81. 
IR (neat) ν 3368 (N-H), 3304 (N-H), 2203 (CN), 1602 (C=N) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.86 (s, 3H, C-3CH3), 3.85 (s, 3H, C-4’CH3), 
6.86 (s, 2H, NH2), 7.11 (d, J = 8.1 Hz, 2H, CH-3’ and CH-5’), 7.44 (d, J = 8.0 Hz, 
2H,	  CH-2’ and CH-6’), 12.81 (s, 1H, NH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 160.09 (C-4’*), 159.05 (C-7a*), 153.28 (C-6*), 
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151.95 (C-4*), 142.30 (C-3), 130.28 (2xCHAr), 126.54 (C-1’), 117.30 (CN), 
113.73 (2xCHAr), 106.29 (C-3a), 86.88 (C-5), 55.26 (C-4’OCH3), 14.61 (C-
3CH3). 
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9.6 AZA-ANALOGUE OF CGP-37157 AND HYBRYDS WITH 
NIMODIPINE AND LIPOIC ACID 
9.6.1 Synthesis of the aza-analogue of CGP-37157  
9.6.1.1) Synthesis of 2-(((2-amino-5-chlorophenyl)(2-chlorophenyl) 
methylene)amino) ethanol (150) 
 
 
 
In a sealed reaction tube were stirred 2-amino-2′,5-dichlorobenzophenone (2.661 
g, 10 mmol) and ethanolamine (7.5 mL, 125 mmol) at 140 °C for 20 hours. The 
mixture was cooled to room temperature and diluted with CH2Cl2. The CH2Cl2 
solution was washed with water, dried over anhydrous magnesium sulfate, 
filtered, and concentrated under vacuum. The crude product was purified using 
flash chromatography on silica gel (chloroform:ethyl acetate 5:1) to give 150 as a 
yellow solid (2.440 g, 79%). 
 
Data of 150: 
Mp 121-122 °C 
IR (neat) ν 3212 (N-H), 1612 (C=N), 1054 (C-Cl) cm-1. 
1H-NMR (250 MHz, CDCl3) δ 3.29-3.49 (m, 2H, CH2-β), 3.82-3.99 (m, 2H, CH2-
α), 6.57-6.81 (m, 2H, CH-3 and CH-6), 7.04-7.18 (m, 2H, CH-4 and CH-5’), 
7.36-7.45 (m, 2H, CH-3’ and CH-4’), 7.47-7.56 (m, 1H, CH-6’) ppm. 
13C NMR (63 MHz, CDCl3) δ 170.00 (C=N), 148.05 (C-2), 135.79 (C-1’*), 
131.77 (C-2’*), 131.58 (CHAr), 131.23 (CHAr), 130.55 (CHAr), 130.36 (CHAr), 
129.25(CHAr), 127.77 (CHAr), 120.56 (C-5*), 119.82 (C-1*), 118.31 (CHAr), 
63.49 (CH2-α), 56.13 (CH2-β) ppm. 
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9.6.1.2 Synthesis of 2-(((2-amino-5-chlorophenyl)(2-chlorophenyl) 
methyl)amino) ethanol (151) 
 
 
 
To a stirred solution of 150 (2.169 g 7.0 mmol) in 55 mL of MeOH/AcOH (100/1) 
at 0 °C was added NaBH3(CN) (2.199 g, 35.0 mmol). The mixture was stirred for 
18 hours and allowed to warm to room temperature. The reaction mixture was 
diluted with CH2Cl2, washed with water, dried over anhydrous magnesium 
sulfate, filtered, and concentrated to give pure 151 as a light yellow solid (2.178 g, 
100%). 
 
Data of 151: 
Mp: 99-100 °C 
IR (neat) ν 3233 (N-H), 1034 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.58-2.98 (m, 2H, CH2-β), 3.30 (bs, 4H, C-2NH2, 
C-ωNH, CH2-αOH), 3.72 (t, J = 5.1 Hz, 2H, CH2-α), 5.26 (s, 1H, CH-ω), 6.60 (d, 
J = 8.4 Hz, 1H, CH-3), 6.98 (d, J = 2.3 Hz, 1H, CH-6), 7.04 (dd, J = 8.4, 2.3 Hz, 
1H, CH-4), 7.19-7.32 (m, 2H, CH-4’ and CH-5’), 7.34-7.46 (m, 2H, CH-3’ and 
CH-6’) ppm. 
13C NMR (63 MHz, CDCl3) δ 144.71 (C-2), 138.36 (C-1’*), 134.34 (C-2’*), 
130.38 (CHAr), 129.68 (CHAr), 129.35 (CHAr), 128.84 (CHAr), 128.51 (CHAr), 
127.73 (CHAr), 127.28 (C-5*), 123.30 (C-1*), 118.13 (CHAr), 62.14 (CH2-α), 
60.80 (CH-	  ω), 50.05 (CH2-β) ppm. 
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9.6.1.3 Synthesis of 2-(7-chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-
tetrahydro-1H-benzo[e][1,4]diazepin-4-yl)ethyl 2-bromoacetate (152) 
 
 
 
To a stirred solution of 151 (2.116 g, 6.8 mmol) in 35 mL of CH2Cl2 at 0 °C was 
added bromoacetyl bromide (1.48 mL, 17.0 mmol), and stirring was continued at 
0 °C for 1 hour and then at room temperature for 16 hours. DIEA (17.4 mL, 100.0 
mmol) was added, and the mixture was stirred at 50 °C for 5 h. The mixture was 
cooled to room temperature and diluted with CH2Cl2; the CH2Cl2 solution was 
washed with water and dried over anhydrous magnesium sulfate. After filtration, 
the filtrate was concentrated to dryness, and the crude product was purified using 
silica gel column chromatography (hexane:ethyl acetate 100/0 to 60/40) to give 
152 as a white solid (1.894 g, 59%). 
 
Data of 152: 
Mp: 148-149 °C 
Elemental analysis calcd (%) for C19H17BrCl2N2O3: C 48.33, H 3.63, N 5.93; 
found: C 47.91, H 3.48, N 6.06. 
IR (neat) ν 2948 (N-H), 1733 (C-1”=O), 1664 (C-2=O), 1025 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.84-3.00 (m, 1H, one H of CH2-β), 3.00-3.15 (m, 
1H, one H of CH2-β), 3.47 (d, J = 15.5 Hz, 1H, one H of CH2-3), 3.58 (d, J = 15.5 
Hz, 1H, one H of CH2-3), 3.85 (s, 2H, CH2-2), 4.14-4.29 (m, 1H, one H of CH2-
α), 4.33-4.49 (m, 1H, one H of CH2-α), 5.31 (s, 1H, CH-5), 7.05 (d, J = 8.5 Hz, 
1H,	  CH-9), 7.25 (dd, J = 8.3, 2.2 Hz, 1H, CH-8), 7.45-7.29 (m, 4H, CH-6, CH-4’, 
CH-5’ and CH-6’), 7.60 (dd, J = 7.3, 1.5 Hz, 1H, CH-3’), 9.12 (s, 1H, CONH) 
ppm. 
13C NMR (63 MHz, CDCl3) δ 172.39 (C-2=O), 167.45 (C-1”=O), 137.26 (C-1’*), 
137.02 (C-5a*), 134.90 (C-9a), 132.78 (C-6’*), 131.14 (CHAr), 130.93 (C-7*), 
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130.68 (CHAr), 130.50 (CHAr), 129.93 (CHAr), 129.34 (CHAr), 127.52 (CHAr), 
122.56 (CHAr), 65.45 (CH-5), 64.17 (CH2-α), 53.23 (CH2-β), 52.30 (CH2-3), 
26.18 (CH2-2”) ppm. 
      
9.6.1.4 Synthesis of 7-chloro-5-(2-chlorophenyl)-4-(2-hydroxyethyl)-4,5-
dihydro-1H-benzo[e][1,4]diazepin-2(3H)-one (153) 
 
 
 
To a solution of 152 (1.794 g, 3.8 mmol) in 15 mL of EtOH/MeOH (2:1) at room 
temperature was added a 2N KOH aqueous solution (0.853 g, 15.2 mmol in 7.6 
mL of water) and the mixture was stirred at room temperature for 2h. At the end 
of the reaction (as monitored by TLC) 2N HCl aqueous solution was added to 
neutralize the reaction and then the crude was extracted with CH2Cl2 (3x30 mL); 
the organic layers were washed with brine, dried over anhydrous magnesium 
sulfate, filtered, and concentrated to give pure 153 as a white solid (1.334 g, 
100%). 
 
Data of 153: 
Mp: 157-158 °C 
Elemental analysis calcd (%) for C17H16Cl2N2O2: C 58.13, H 4.59, N 7.98; 
found: C 58.05, H 4.60, N 8.05. 
IR (neat) ν 3390 (O-H), 2927 (N-H), 1672 (C-2=O), 1038 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.47-2.53 (m, 1H, OH), 2.80-3.02 (m, 2H, CH2-β), 
3.53 (s, 2H, CH2-3), 3.62-3.83 (m, 2H, CH2-α), 5.40 (s, 1H, CH-5), 6.82 (d, J = 
2.2 Hz, 1H, CH-6), 7.00 (d, J = 8.5 Hz, 1H, CH-8), 7.18-7.36 (m, 4H, CH-9, CH-
4’, CH-5’ and CH-6’), 7.45 (dd, J = 5.9, 3.4 Hz, 1H, CH-3’), 8.61 (s, 1H, CONH) 
ppm. 
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13C NMR (63 MHz, CDCl3) δ 173.87 (CONH), 137.37 (C-1’*), 136.21 (C-5a*), 
134.67 (C-9a), 131.69 (C-2’*), 131.40 (CHAr), 131.01 (CHAr), 130.93 (CHAr), 
130.33 (C-7*), 130.02 (CHAr), 129.43 (CHAr), 127.66 (CHAr), 122.33 (CHAr), 
66.09 (CH-5), 59.13 (CH2-α), 55.40 (CH2-β), 52.82 (CH2-3) ppm. 
      
9.6.2 Synthesis of the hybrid 153-nimodipine via a multicomponent 
process 
9.6.2.1 Synthesis of 2-(7-chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-
tetrahydro-1H-benzo[e][1,4] diazepin-4-yl)ethyl 3-oxobutanoate (154) 
 
 
 
A mixture of methyl acetoacetate (0.332 g, 2.85 mmol), 153 (1.053 g, 3 mmol) 
and Amberlyst-15 (10% by weight of β-ketoester, 0.033g) in toluene (10 mL) was 
heated to 110 °C in a flask provided with a distillation condenser (Dean-Stark) to 
remove MeOH. After completion of the reaction (as monitored by TLC), the 
catalyst was filtered off and the filtrate concentrated and purified using silica gel 
column chromatography (dichlorometane:ethyl acetate from 100:0 to 75:25) to 
give 154 as a light brown solid (0.640 g, 49%). 
 
Data of 154: 
Mp 68-69 °C 
Elemental analysis calcd (%) for C21H20Cl2N2O4: C 57.94, H 4.63, N 6.44; 
found: C 57.82, H 4.78, N 6.33. 
IR (neat) ν 2918 (N-H), 1712 (C-3”=O), 1665 (C-2=O), 1034 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) δ 2.27 (s, 3H, CH3-4”), 2.80-2.96 (m, 1H, one H of 
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CH2-β), 2.97-3.11 (m, 1H, one H of CH2-β), 3.36-3.67 (m, 4H, CH2-3 and CH2-
2”), 4.12-4.28 (m, 1H, one H of CH2-α), 4.28-4.42 (m, 1H, one H of CH2-α), 5.29 
(s, 1H, CH-5), 6.61 (d, J = 2.3 Hz, 1H, CH-6), 6.98 (d, J = 8.5 Hz, 1H, CH-8), 
7.18-7.47 (m, 4H, CH-9, CH-4’, CH-5’ and CH-6’), 7.54 (dd, J = 7.2, 2.2 Hz, 1H, 
CH-3’), 8.38 (s, 1H, CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 200.88 (C-3”=O), 172.62 (C-2=O), 167.38 (C-
1”=O), 137.35 (C-1’*), 136.93 (C-5a*), 134.86 (C-9a), 132.80 (C-2’*), 131.10 
(CHAr), 130.86 (C-7*), 130.67 (CHAr), 130.50 (CHAr), 129.89 (CHAr), 129.29 
(CHAr), 127.49 (CHAr), 122.55 (CHAr), 65.42 (CH-5), 63.33 (CH2-α), 53.24 
(CH2-β), 52.34 (CH2-3), 50.35 (CH2-2”), 30.66 (CH3-4”) ppm. 
      
9.6.2.2 Synthesis of isopropyl 2-(3-nitrobenzylidene)-3-oxobutanoate (155) 
 
 
 
A solution of 3-nitrobenzaldehyde (1.511 g, 10 mmol), isopropyl acetoacetate 
(1.442 g, 10 mmol), 0.5 mL of glacial AcOH, 0.1 mL of piperidine and benzene 
(5 mL) was refluxed for 15 hours, using a Dean-Stark trap to remove water as it 
was generated. The dark yellow solution was cooled to room temperature and 
solidification occurred. Filtration followed by washing with a mixture of 
petroleum ether and ethyl ether afforded 155 as a yellow solid (2.240 g, 81%). 
 
Data of 155: 
Mp: 94-95 °C 
IR (neat) ν 1715 (C-3=O), 1662 (C-1=O), 1530 (NO2), 1349 (NO2), 1096 (C-Cl) 
cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.30 (d, J = 6.3 Hz, 6H, OCH(CH3)2), 2.44 (s, 3H, 
CH3-4), 5.28 (hept, J = 6.3 Hz, 1H, OCH(CH3)2), 7.54-7.64 (m, 2H, CH-5’ and 
CH3
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CH-6’), 7.77 (d, J = 7.8 Hz, 1H, CH-4’), 8.26 (ddd, J = 8.2, 2.1, 0.9 Hz, 1H, CH-
2’), 8.35 (t, J = 1.7 Hz, 1H, CH-α) ppm. 
13C NMR (63 MHz, CDCl3) δ 194.33 (C-3=O), 166.88 (C-1=O), 148.82 (C-3’), 
137.95 (CH-α), 137.50 (C-1’), 135.65 (CHAr), 135.25 (C-2), 130.28 (CHAr), 
125.21 (CHAr), 124.13 (CHAr), 70.70 (OCH(CH3)2), 27.34 (CH3-4), 21.93 
(OCH(CH3)2) ppm. 
These data are consistent with those described in the literature.294 
      
9.6.2.3 Synthesis of 3-(2-(7-chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-
tetrahydro-1H-benzo[e][1,4]diazepin-4-yl)ethyl) 5-isopropyl 2,6-dimethyl-4-
(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (156) 
 
 
 
A solution of 154 (192 mg, 0.44 mmol) and ammonium acetate (68 mg, 0.88 
mmol) in ethanol (2 mL) was stirred for 30 min at room temperature; 155 (122	  
mg, 0.44 mmol) was then added and the mixture was heated under reflux and 
stirred for 15 hours. After this time, the mixture was diluted with CH2Cl2 (20 mL), 
washed with water followed by brine, and dried over anhydrous magnesium 
sulfate. Evaporation of the solvent under reduced pressure left a crude that was 
purified using silica gel column chromatography (dichlorometane:ethyl acetate 
from 100:0 to 90:10) to give 156 as a light yellow solid (218 mg, 72%). 
 
Data of 156: 
Mp: 149-150°C 
                                                
294 Kobayashy, T.; Inoue, T.; Nishino, S.; Fujihara, Y.; Oizumi, K.; Kimura, T. Chem. Pharm. Bull. 
1995, 43, 797-817 
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Elemental analysis calcd (%) for C35H34Cl2N4O7: C 60.61, H 4.94, N 8.08; 
found: C 60.21, H 4.94, N 8.10. 
IR (neat) ν 1675 (C=O), 1526 (NO2), 1348 (NO2), 1101 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) 2 isomers δ 1.06 (d, J = 6.2 Hz, 3H, OCH(CH3)2 one 
isomer), 1.07 (d, J = 6.2 Hz, 3H, OCH(CH3)2 one isomer), 1.22 (d, J = 6.0 Hz, 
3H, OCH(CH3)2 one isomer), 1.24 (d, J = 5.8 Hz, 3H, OCH(CH3)2  one isomer), 
2.32 (s, 6H, C-6CH3 two isomers), 2.37 (s, 3H, C-2CH3 one isomer) 2.38 (s, 3H, 
C-2CH3 one isomer), 2.77-3.04 (m, 4H, CH2-β, two isomers), 3.35-3.56 (m, 4H, 
CH2-3’ two isomers), 4.06-4.14 (m, 2H, CH2-α one isomer), 4.23-4.39 (m, 2H, 
CH2-α one isomer), 4.89-5.00 (m, 2H, OCH(CH3)2 two isomers), 5.06 (s, 1H, CH-
4 one isomer), 5.12 (s, 1H, CH-4 one isomer), 5.16 (s, 1H, CH-5’ one isomer), 
5.28 (s, 1H, CH-5’ one isomer), 5.73 (bs, 2H, NH-1 two isomers), 6.43 (d, J = 2.0 
Hz, 1H, NH-1’ one isomer), 6.62 (d, J = 2.1 Hz, 1H, NH-1’ one isomer), 6.94 (d, 
J = 5.5 Hz, 1H, ArH one isomer), 6.98 (d, J = 5.5 Hz, 1H, ArH one isomer), 7.16-
7.39 (m, 11H, ArH two isomers), 7.52-7.55 (m, 1H, ArH one isomer), 7.64 (d, J = 
7.5 Hz, 2H, ArH two isomers), 7.92-7.97 (m, 2H, ArH two isomers), 8.23-8.04 
(m, 4H, ArH two isomers) ppm. 
13C NMR (63 MHz, CDCl3) 2 isomers δ 172.35 (C-2’=O one isomer), 171.83 (C-
2’=O one isomer), 167.26 (C-5C=O* one isomer), 167.22 (C-5C=O* one 
isomer), 166.96 (C-3C=O* one isomer), 166.91 (C-3C=O* one isomer), 150.28 
(C-6* one isomer), 150.22 (C-6* one isomer), 148.53 (C-2* one isomer), 148.47 
(C-2* one isomer), 145.64 (CNO2* one isomer), 145.45 (CNO2* one isomer),	  
144.84 (CAr* one isomer), 144.78 (CAr* one isomer), 137.46 (C-1”* one 
isomer), 137.30 (C-1”* one isomer), 137.02 (C-5a* one isomer), 136.82 (C-5a* 
one isomer), 135.01 (CHAr one isomers), 134.95 (CHAr one isomer), 134.82 (C-
9a* one isomer), 134.81 (C-9a* one isomer), 133.01 (C-2”’* one isomer), 132.75 
(C-2”* one isomer), 131.05 (CHAr one isomer), 130.96 (C-7 one isomer), 130.77 
(CHAr + C-7 one isomer), 130.64 (CHAr one isomer), 130.55 (CHAr one 
isomer), 130.50 (CHAr one isomer), 130.33 (CHAr one isomer), 129.75 (CHAr 
one isomer), 129.67 (CHAr one isomer), 129.22 (CHAr one isomer), 128.99 
(CHAr one isomer), 128.94 (CHAr one isomer), 127.50 (CHAr one isomer), 
127.30 (CHAr one isomer), 123.59 (CHAr one isomer), 123.53 (CHAr one 
isomer), 122.46 (CHAr two isomers), 121.76 (CHAr two isomers), 104.24 (C-5 
two isomers), 103.47 (C-3 one isomer), 103.29 (C-3 one isomer), 67.84 
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(OCH(CH3)2 two isomers), 65.35 (CH-5’ one isomer), 65.07 (CH-5’ one isomer), 
61.74 (CH2-α one isomer), 61.15 (CH2-α one isomer), 53.30 (CH2-β one isomer), 
52.68 (CH2-β one isomer), 52.48 (CH2-3’ two isomers), 40.41 (CH-4 one isomer), 
40.33 (CH-4 one isomer), 22.52 (C-6CH3 two isomers OCH(CH3)2 one isomer), 
22.19 (C-2CH3 one isomer), 20.37 (OCH(CH3)2 one isomer), 20.21 (OCH(CH3)2 
one isomer), 20.04 (OCH(CH3)2 two isomer) ppm. 
      
9.6.3 Linear synthesis of the hybrid 153-nimodipine 
9.6.3.1 Synthesis of 3-allyl 5-isopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate (157) 
 
 
 
A solution of allyl acetoacetate (0.710 g, 5.0 mmol) and ammonium acetate 
(0.578 g, 7.5 mmol) in ethanol (5 mL) was stirred for 30 min at room temperature; 
155 (1.385 g, 5.0 mmol) was then added and the mixture was heated under reflux 
and stirred for 8 hours. After completion of the reaction (checked by TLC), the 
mixture was diluted with CH2Cl2 (20 mL), washed with water followed by brine, 
and dried over anhydrous magnesium sulfate. Evaporation of the solvent under 
reduced pressure left a crude that was purified using silica gel column 
chromatography (n-hexane:ethyl acetate from 100:0 to 70:30) to give 157 as a 
yellow solid (1.420 g, 71%). 
 
Data of 157: 
Mp: 89-90 °C 
Elemental analysis calcd (%) for C21H24N2O6: C 62.99, H 6.04, N 7.00; found: C 
63.18, H 6.10, N 6.81. 
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IR (neat) ν 1692 (C=O), 1651 (C=O), 1623 (C=CH2), 1522 (NO2), 1346 (NO2) 
cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.09 (d, J = 6.2 Hz, 3H, OCH(CH3)2), 1.26 (d, J = 
6.2 Hz, 3H, OCH(CH3)2), 2.36 (s, 3H, C-2CH3*), 2.37 (s, 3H, C-6CH3*), 4.45-
4.68 (m, 2H, OCH2CH=CH2), 4.88-5.01 (m, 1H, OCH(CH3)2), 5.03-5.24 (m, 3H, 
OCH2CH=CH2, CH-4, NH), 5.67-5.97 (m, 2H, OCH2CH=CH2), 7.36 (t, J = 7.8 
Hz, 1H, CH-5’), 7.64 (dt, J = 7.8, 1.0 Hz, 1H, CH-6’), 8.00 (ddd, J = 7.8, 2.0, 1.0 
Hz, 1H, CH-4’), 8.12 (t, J = 2.0 Hz, 1H, CH-2’) ppm. 
13C NMR (63 MHz, CDCl3) two isomers δ 167.27, 167.18 (C-5C=O*), 167.14, 
167.04, (C-3C=O*), 150.58, 150.35 (C-2*), 148.48, 148.36 (C-6*), 145.88, 
145.83 (C-1’), 145.10, 145.06 (C-3’), 135.12, 135.03 (CHAr), 132.85, 132.81 
(OCH2CH=CH2), 129.00, 128.92 (CHAr), 123.73, 123.59 (CHAr), 121.72, 
121.63 (CHAr), 118.34, 118.18 (OCH2CH=CH2), 104.06, 103.88 (C-3*), 103.38, 
103.21 (C-5*), 67.79, 67.74 (OCH(CH3)2), 65.20, 65.13 (OCH2CH=CH2), 40.55, 
40.36 (CH-4), 22.50 (C-2CH3*), 22.20 (C-6CH3*), 20.02, 19.96, 19.90, 19.84 
(OCH(CH3)2) ppm. 
      
9.6.3.2 Synthesis of 5-(isopropoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-
1,4-dihydropyridine-3-carboxylic acid (158) 
 
 
 
A solution of 157 (1.128 g, 2.82 mmol) and morpholine (2.46 mL, 28.2 mmol) in 
THF (15 mL) was degassed under Ar for 10 min. Pd(PPh3)4 (0.163 g, 0.14 mmol) 
was added and the solution was stirred at room temperature for 3 hours. The 
reaction was diluted with AcOEt, washed with 1M HCl and brine, dried over 
anhydrous magnesium sulfate, filtered and concentrated in vacuo. The crude was 
purified using silica gel column chromatography (dichlorometane:ethyl acetate 
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from 100:0 to 85:15) to give 158 as a light yellow solid (0.630 g, 62%). 
 
Data of 158: 
Mp: 179-180 °C 
IR (neat) ν 3358 (N-H), 1650 (C=O), 1531 (NO2), 1347 (NO2) cm-1. 
1H NMR (250 MHz, DMSO-d6) δ 1.03 (d, J = 6.2 Hz, 3H, OCH(CH3)2), 1.19 (d, 
J = 6.2 Hz, 3H, OCH(CH3)2), 2.26 (s, 3H, C-2CH3*), 2.27 (s, 3H, C-6CH3*), 4.82 
(hept, J = 6.2 Hz, 1H, OCH(CH3)2), 4.94 (s, 1H, CH-4), 7.50-7.64 (m, 2H, CH-5’ 
and CH-6’), 7.93– 8.05 (m, 2H, CH-2’ and CH-4’), 8.89 (s, 1H, NH), 11.81 (bs, 
1H, COOH) ppm. 
13C NMR (63 MHz, DMSO-d6) δ 168.79 (C-3C=O), 166.42 (C-5C=O), 150.75 
(C-2*), 147.72 (C-6*), 146.75 (C-1’*), 146.16 (C-3’*), 134.63 (CHAr), 129.93 
(CHAr), 122.26 (CHAr), 121.35 (CHAr), 101.96 (C-3*), 101.41 (C-5*), 66.59 
(OCH(CH3)2), 39.70 (CH-4), 22.23 (C-2CH3*), 21.89 (C-6CH3*), 18.58 
(OCH(CH3)2) ppm. 
These data are consistent with those described in the literature.295 
      
9.6.3.3 Synthesis of 2-cyanoethyl 3-oxobutanoate (159) 
 
 
 
A mixture of 3-hydroxypropanenitrile (1.065 g, 15 mmol), 2,2,6-trimethyl-4H-
1,3-dioxin-4-one (2.772 g, 19.5 mmol) and anhydrous NaOAc (1.230 g, 15 mmol) 
in THF (10 mL) is heated under reflux for 24 hours. After completion of the 
reaction, the mixture is cooled, diluted with Et2O and the solution is washed with 
water, brine, dried over anhydrous magnesium sulfate, filtered and concentrated in 
vacuo. The crude was purified using silica gel column chromatography 
(petroleum ether:ethyl acetate from 95:5 to 50:50) to give 159 as a colorless liquid 
                                                
295 Ogawa, T.; Hatayama, K.; Maeda, H.; Kita, Y. Chem. Pharm. Bull. 1994, 42, 1579-1589. 
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(1.191 g, 51%). 
 
Data of 159: 
IR (neat) ν 2249 (CN), 1664 (C=O) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.95 (d, J = 0.4 Hz, 3H enol, CH3-4), 2.25 (s, 3H 
keto, CH3-4), 2.72 (t, J = 6.3 Hz, 2H keto+enol, CH2-β), 3.51 (s, 2H keto, CH2-2), 
4.32 (t, J = 6.3 Hz, 2H keto+enol, CH2-α), 5.02 (d, J = 0.6 Hz, 1H enol, C=CH), 
11.76 (s, 1H enol, C(OH)) ppm. 
13C NMR (63 MHz, CDCl3) δ 200.41 (keto, C-3=O), 177.38 (enol, C(OH)), 
172.11 (enol, C-1=O), 166.95 (keto, C-1=O), 117.13 (keto+enol, CN), 89.46 
(enol, C=CH), 59.80 (keto, CH2-α), 58.58 (enol, CH2-α), 49.96 (keto, CH2-3), 
30.68 (keto+enol, CH3-4) 18.48 (enol, CH2-β), 18.31 (keto, CH2-β) ppm. 
These data are consistent with those described in the literature.296 
      
9.6.3.4 Synthesis of 3-(2-cyanoethyl) 5-isopropyl 2,6-dimethyl-4-(3-
nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (160) 
 
 
 
A solution of 2-cyanoethyl 3-oxobutanoate (1.085 g, 7.0 mmol) and ammonium 
acetate (0.809 g, 10.5 mmol) in ethanol (7.5 mL) was stirred for 30 min at room 
temperature; 155 (1.939 g, 7.0 mmol) was then added and the mixture was heated 
under reflux and stirred for 6 hours. After completion of the reaction (checked by 
TLC), the mixture was diluted with CH2Cl2 (20 mL), washed with water followed 
by brine, dried over anhydrous magnesium sulfate and the solvent was finally 
                                                
296 Dollé, F.; Hinnen, F.; Valette, H.; Fuseau, C.; Duval, R.; Péglion, J.-L.; Crouzel, C. Bioorg. Med. 
Chem. 1997, 5, 749-764. 
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evaporated under reduced pressure. The crude was purified using silica gel 
column chromatography (n-hexane:ethyl acetate from 100:0 to 85:15) to give 160 
as a yellow solid (1.450 g, 50%). 
 
Data of 160: 
Mp: 129-130 °C; 
IR (neat) ν 3366 (N-H), 2279 (CN), 1691 (C=O), 1523 (NO2), 1347 (NO2) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.11 (d, J = 6.2 Hz, 3H, OCH(CH3)2), 1.26 (d, J = 
6.2 Hz, 3H, OCH(CH3)2), 2.37 (s, 3H, C-2CH3*), 2.39 (s, 3H, C-6CH3*), 2.65 (t, 
J = 6.1 Hz, 2H, CH2-β), 4.25 (td, J = 6.2, 2.2 Hz, 2H, CH2-α), 4.95 (hept, J = 6.3 
Hz, 1H, OCH(CH3)2), 5.08 (s, 1H, CH-4), 5.82 (s, 1H, NH), 7.40 (t, J = 8.0 Hz, 
1H, CH-5’), 7.67 (dd, J = 8.0, 1.1 Hz, 1H, CH-6’), 8.01 (ddd, J = 8.0, 2.2, 1.1 Hz, 
1H, CH-4’),	  8.12 (d, J = 2.2 Hz, 1H, CH-2’) ppm. 
13C NMR (63 MHz, CDCl3) δ 166.79 (C-3C=O*), 166.73 (C-5C=O*), 150.07 
(C-2*), 148.61 (C-6*), 147.09 (C-1’*), 144.64 (C-3’*), 135.00 (CHAr), 129.18 
(CHAr), 123.49 (CHAr), 121.90 (CHAr), 117.49 (CN), 104.59 (C-3*), 102.27 (C-
5*), 67.95 (OCH(CH3)2), 58.76 (CH2-α), 40.27 (CH-4), 22.50 (C-2CH3*), 22.18 
(C-6CH3*), 20.38 and 19.78 (OCH(CH3)2), 18.55 (CH2-β) ppm. 
These data are consistent with those described in the literature.297 
      
9.6.3.5 Synthesis of 5-(isopropoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-
1,4-dihydropyridine-3-carboxylic acid (158) 
 
 
 
Sodium sulfide hydrate (0.195 g, 2.5 mmol) was added to a CH2Cl2/MeOH (8/4 
                                                
297 Ogawa, T.; Nakazato, A.; Tsuchida, K.; Hatayama, K. Chem. Pharm. Bull. 1993, 41, 108-116. 
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mL) solution of 160 (1.033 g, 2.5 mmol) and the reaction was stirred at room 
temperature for 5 hours. The reaction mixture was diluted with water and 
extracted with CH2Cl2. The aqueous layer was acidified with 1N HCl and the 
formed precipitate was filtered off and recrystallized from EtOH to give 158 as a 
light yellow solid (0.638 g, 71%). 
 
Data of 158 are identical to those described in Section 9.6.3.2  
      
9.6.3.6 Synthesis of 3-(2-(7-chloro-5-(2-chlorophenyl)-2-oxo-2,3-dihydro-
1H-	   benzo[e] [1,4]diazepin-4(5H)-yl)ethyl) 5-isopropyl 2,6-dimethyl-4-(3-
nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (156) 
 
 
 
Step I: 
Compound 153 (173 mg, 0.49 mmol) was dissolved in anhydrous CH2Cl2 (1 mL) 
at room temperature; triethylamine (0.10 mL, 0.73 mmol) was added and the 
contents were cooled to 10 °C under Ar atmosphere. TMSiCl (74 mg, 0.68 mmol) 
was slowly added to the reaction mass, while maintaining the temperature 
between 10-15 °C. The mass temperature is raised to room temperature and stirred 
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for 3 hours at this temperature to give the silyl derivative. 
 
Step II: 
Compound 158 (169 mg, 0.47 mmol) was suspended in anhydrous CH2Cl2 (3 
mL); anhydrous DMF (0.5 mL) was added and then the mixture was cooled to -10 
°C under Ar atmosphere. Thionyl chloride (0.05 mL, 0.70 mL) was slowly added 
to the reaction mass at -10 °C and maintained at the same temperature	  for 1 hour 
to obtain the acetyl chloride derivative. 
 
Step III: 
The reaction mass obtained in the step I was slowly added to the solution obtained 
in step II. The mass temperature was slowly raised to room temperature and 
stirring continued for 5 hours at the same temperature. Then the reaction mixture 
was cooled to 5 °C, water was added and stirring continued for 15 min. The 
resulting organic layer was washed with 20% w/w NaCl solution, dried over 
anhydrous magnesium sulfate and the solvent was evaporated under reduced 
pressure. The crude was purified using silica gel column chromatography (n-
hexane:ethyl acetate from 90:10 to 40:60) to give 156 as a light yellow solid (176 
mg, 54%). 
 
Data of 156 were identical to those described above in Section 9.6.2.3 
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9.6.4 Synthesis of the hybrid 153-Lipoic acid 
9.6.4.1 Synthesis of 2-(7-chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-
tetrahydro-1H-benzo[e][1,4]diazepin-4-yl)ethyl 5-(1,2-dithiolan-3-
yl)pentanoate (161 and 162) 
 
 
 
Under argon flow, 153 (70 mg, 0.2 mmol) was dissolved in anhydrous 
dichloromethane (3 mL), and α-lipoic acid (racemic mixture or (R)-(+)-	  
enantiomer) (50 mg, 0.24 mmol) and DMAP (73 mg, 0.6 mmol) were then added 
at room temperature. After cooling at 0 °C, a solution of EDCI (46 mg, 0.24 
mmol) in anhydrous dichloromethane (2 mL) was added dropwise to the solution; 
the reaction was allowed to warm slowly to room temperature and kept at this 
condition for 16 hours. At the end of reaction, as monitored by TLC, the reaction 
mixture was diluted with dichloromethane, washed with water followed by brine 
solution, dried over Na2SO4 and evaporated under reduced pressure. The crude 
was purified using silica gel column chromatography (n-hexane:ethyl acetate from 
100:0 to 60:40) to give 161 or 162 as pale yellow viscous oils (87 mg, 74%). 
 
Data of 161: 
Elemental analysis calcd (%) for C25H28Cl2N2O3S2: C 55.65, H 5.23, N 5.19, S 
11.89; found: C 55.47, H 5.08, N 5.16, S 11.75. 
IR (neat) ν 2923 (N-H), 1729 (C-1=O), 1664 (C-2’=O), 1070 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.38-1.54 (m, 2H, CH2-4), 1.56-1.77 (m, 4H, CH2-
3 and CH2-5), 1.83-1.96 (m, 1H, one H of CH2-4”), 2.32 (t, J = 7.2 Hz, 2H, CH2-
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2), 2.38-2.51 (m, 1H, one H of CH2-4”), 2.78-2.93 (m, 1H, CH-3”), 2.97-3.26 (m, 
3H, one H of CH2-β and CH2-5”), 3.39-3.64 (m, 3H, CH2-3’ and one H of CH2-β), 
4.07-4.22 (m, 1H, one H of CH2-α), 4.22-4.35 (m, 1H, one H of CH2-α), 5.30 (s, 
1H, CH-5’), 6.61 (d, J = 2.3 Hz, 1H, ArH), 7.02 (d, J = 8.5 Hz, 1H, ArH), 7.24 
(dd, J = 8.1, 2.0 Hz, 1H, ArH), 7.29-7.47 (m, 3H, ArH), 7.50-7.62 (m, 1H, ArH), 
8.83 (s, 1H, CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 173.70 (CONH), 172.62 (C-1=O), 137.44 (CAr*), 
137.03 (C-5a’*), 134.89 (C-9a’*), 132.89 (CCl*), 131.13 (CHAr), 130.81 (C-7’*), 
130.66 (CHAr), 130.47 (CHAr), 129.85 (CHAr), 129.26 (CHAr), 127.42 (CHAr), 
122.52 (CHAr), 65.40 (CH-5’), 62.38 (CH2-α), 56.74 (CH-3”), 53.33 (CH2-β), 
52.51 (CH2-3’), 40.65 (CH2-4”), 38.91 (CH2-5”), 35.02 (CH2-5), 34.42 (CH2-2), 
29.22 (CH2-3), 24.99 (CH2-4) ppm. 
      
 
Data of 162: 
Elemental analysis calcd (%) for C25H28Cl2N2O3S2: C 55.65, H 5.23, N 5.19, S 
11.89; found: C 55.55, H 5.24, N 5.11, S 11.92. 
IR (neat) ν 2920 (N-H), 1728 (C-1=O), 1664 (C-2’=O), 1070 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3) δ 1.38-1.53 (m, 2H, CH2-4), 1.57-1.78 (m, 4H, CH2-
3 and CH2-5), 1.80-1.98 (m, 1H, one H of CH2-4”), 2.32 (t, J = 7.2 Hz, 2H, CH2-
2), 2.38-2.51 (m, 1H, one H of CH2-4”), 2.77-2.96 (m, 1H, CH-3”), 2.96-3.28 (m, 
3H, one H of CH2-β, CH2-5”), 3.40-3.66 (m, 3H, CH2-3’, one H of CH2-β), 4.07-
4. 22 (m, 1H, one H of CH2-α), 4.22-4.39 (m, 1H, one H of CH2-α), 5.30 (s, 1H, 
CH-5’), 6.61 (d, J = 2.3 Hz, 1H, ArH), 7.01 (d, J = 8.5 Hz, 1H, ArH), 7.24 (dd, J 
= 8.0, 1.9 Hz, 1H, ArH), 7.29-7.46 (m, 3H, ArH), 7.53-7.63 (m, 1H, ArH), 8.66 
(s, 1H, CONH) ppm. 
13C NMR (63 MHz, CDCl3) δ 173.69 (CONH), 172.20 (C-1=O), 137.41 (CAr*), 
136.95 (C-5a’*), 134.89 (C-9a’*), 132.96 (CCl*), 131.10 (CHAr), 130.89 (C-7’*), 
130.66 (CHAr), 130.50 (CHAr), 129.86 (CHAr), 129.26 (CHAr), 127.43 (CHAr), 
122.46 (CHAr), 65.37 (CH-5’), 62.38 (CH2-α), 56.75 (CH-3”), 53.27 (CH2-β), 
52.51 (CH2-3’), 40.64 (CH2-4”), 38.91 (CH2-5”), 35.02 (CH2-5), 34.41 (CH2-2), 
29.22 (CH2-3), 24.98 (CH2-4) ppm. 
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9.7 SULFONAMIDE AS DIRECTING GROUP FOR THE C-H BOND 
FUNCTIONALIZATION 
9.7.1 Synthesis of the starting benzenesulfonamides. 
9.7.1.1 Synthesis of N-isopropyl-4-methylbenzenesulfonamide (163) 
 
 
 
p-Toluenesulfonyl chloride (1.906 g, 10 mmol) was dissolved in Et2O (20 mL) 
and treated with isopropylamine (0.90 mL, 11 mmol) and Et3N (1.53 mL, 11 
mmol) at 0 ︎ C, and the mixture was stirred at room temperature for 4 h. After 
removal of the solvent in vacuo, the residue was purified by silica gel packed 
flash column chromatography (eluent: EtOAc:hexane from 25:75 to 50:50) to 
afford 163 as a colorless solid (1.795 g, 84%). 
 
Data of 163: 
1H NMR (300 MHz, CDCl3) δ 1.05 (d, J = 6.5 Hz, 6H, CH(CH3)2), 2.40 (s, 3H, 
ArCH3), 3.33-3.51 (m, 1H, CH(CH3)2), 4.57 (d, J = 7.4 Hz, 1H, SO2NH), 7.27 (d, 
J = 7.9 Hz, 2H, CH-3 and CH-5), 7.72-7.78 (m, 2H, CH-2 and CH-6) ppm. 
13C NMR (126 MHz, CDCl3) δ 143.07 (C-1), 138.06 (C-4), 129.55 (2xCHAr), 
126.94 (2xCHAr), 46.02 (CH(CH3)2), 23.74 (CH(CH3)2), 21.51 (C-4CH3) ppm. 
These data are consistent with those described in the literature.298 
      
  
                                                
298 Hamura, S.; Oda, T.; Shimizu, Y.; Matsubara, K.; Nagashima, H. J. Chem. Soc., Dalton Trans. 
2002, 1521-1527. 
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9.7.1.2 Synthesis of 2,4-dimethylbenzenesulfonyl chloride (164) 
 
 
 
To a solution of 2,4-dimethylbenzenesulfonic acid (1.862 g, 10 mmol) and 
triethylamine (1.012 g, 10 mmol) in 20 mL of acetone was added cyanuric 
chloride (1.844 g, 10 mmol) and the mixture was heated under reflux for 20 hours. 
After cooling to room temperature the solution was filtered through a celite pad; 
solvent was removed in vacuo and the crude mixture was purified by silica gel 
packed flash column chromatography (eluent: EtOAc:hexane from 0:100 to 3:97) 
to afford 164 as a colorless liquid (1.705 g, 83%). 
 
Data of 164: 
MS (EI) m/z (relative intensity) 204 (30) [M+], 169 (52), 151 (13), 105 (100), 103 
(25), 79 (33), 51 (13). 
HR-MS (EI) m/z calcd for C8H9ClO2S 204.0012, found 204.0012. 
IR (neat) ν 1364 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ 2.43 (s, 3H, C-4CH3), 2.74 (s, 3H, C-2CH3), 7.16-
7.24 (m, 2H, CH-3 and CH-5), 7.93 (d, J = 8.1 Hz, 1H, CH-6).  
13C NMR (126 MHz, CDCl3) δ 146.5 (C-4), 140.2 (C-1), 137.8 (C-2), 134.0 (CH-
3), 128.9 (CH-6*), 127.3 (CH-5*), 21.4 (C-2CH3), 20.1 (C-4CH3).  
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9.7.1.3 Synthesis of benzenesulfoanilides 165-167. General procedure 
 
 
 
Compound R 
165 4-CH3 
166 2,4-diCH3 
167 3-CH3 
 
To a solution of benzenesulfonyl chloride (10.0 mmol, 1 equiv) in pyridine (30 
mL) was added DMAP (5.0 mmol, 0.5 equiv). After the mixture was stirred for 15 
min at room temperature, 2,3,4,5,6-pentafluoroaniline (11.0 mmol, 1.1 equiv) was 
added, and then the mixture was stirred overnight at 80 °C. After removing the 
solvent (pyridine) in vacuo, the residue was dissolved in dichloromethane (100 
mL) and washed with H2O (3x30 mL) and brine (20 mL) successively. The 
combined organic layer was dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The residue was purified by a silica gel packed flash 
chromatography column (eluent: EtOAc/hexane) to afford benzenesulfonamides 
165-167. 
 
Data of compounds 165-167 and the experimental conditions employed for their 
synthesis are indicated below. 
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4-Methyl-N-(pentafluorophenyl)benzenesulfonamide (165) 
Prepared from 4-methylbenzenesulfonyl chloride (2.86 g, 
15.0 mmol), 2,3,4,5,6-pentafluoroaniline (3.02 g, 16.5 
mmol) and DMAP (0.92 g, 7.5 mmol) in pyridine (50 
mL). 
Purification: n-hexane: ethyl acetate (from 95:5 to 80:20, 
v/v). 
Yield: 1.92 g (38%). White solid. 
 
Data of 165: 
Mp: 151-152 °C  
MS (EI) m/z (relative intensity) 337 (23) [M+], 182 (7), 155 (89), 91 (100), 65 
(29).  
HR-MS (ESI) calcd for C13H8F5NO2S+Na+ [M+Na]+ 360.0088, found 360.0088. 
IR (neat) ν 3267 (N-H), 1344 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ 2.46 (s, 3H, C-4CH3), 6.37 (s, 1H, NH), 7.32 (d, J 
= 8.2 Hz, 2H CH-3 and CH-5), 7.73 (d, J = 8.0 Hz, 2H, CH-2 and CH-6) ppm. 
13C NMR (126 MHz, CDCl3) δ 144.8 (C-1), 144.1 (dm, J = 250 Hz, C-4’), 140.7 
(dm, J = 262 Hz, C-3’ and C-5’), 137.6 (dm, J = 250 Hz, C-2’ and C-4’), 135.8 
(C-4), 129.8 (2xCHAr), 127.3 (2xCHAr), 111.3 (m, C-1’), 21.7 (C-4CH3) ppm. 
19F NMR (282 MHz, CDCl3) δ -145.0 (m, 2F), -154.05 (t, J = 21.6 Hz, 1F), -
161.5 (m, 2F) ppm. 
      
2,4-Dimethyl-N-(pentafluorophenyl)benzenesulfonamide (166) 
Prepared from 2,4-dimethylbenzenesulfonyl chloride 
(1.64 g, 8.0 mmol), 2,3,4,5,6-pentafluoroaniline (1.61 g, 
8.8 mmol) and DMAP (0.49 g, 4.0 mmol) in pyridine (25 
mL).  
Purification: n-hexane: ethyl acetate (from 100:0 to 
90:10, v/v). 
Yield: 1.090 g (39%). White solid. 
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Data of 166: 
Mp: 156-157 °C  
MS (EI) m/z (relative intensity) 351 (12) [M+], 182 (6), 169 (50), 155 (10), 105 
(100), 77 (22).  
HR-MS (EI) m/z calcd for C14H10F5NO2S 351.0352, found 351.0354. 
IR (neat) ν 3249 (N-H), 1326 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ 2.38 (s, 3H, C-4CH3), 2.67 (s, 3H, C-2CH3), 6.34 
(s, 1H, NH), 7.07 (d, J = 8.2 Hz, 1H, CH-5), 7.15 (s, 1H, CH-3), 7.72 (d, J = 8.1 
Hz, 1H, CH-6) ppm. 
13C NMR (126 MHz, CDCl3) δ 144.7 (C-1), 143.9 (dm, J = 250 Hz, C-4’), 140.5 
(dm, J = 262 Hz, C-3’ and C-5’), 137.5 (dm, J = 250 Hz, C-2’ and C-6’), 137.4 
(C-2), 136.5 (C-4), 133.9 (CHAr), 129.7 (CHAr), 126.7 (CHAr), 111.3 (m, C-1’), 
21.4 (C-2CH3), 20.4 (C-4CH3) ppm.  
19F NMR (282 MHz, CDCl3) δ -145.1 (m, 2F), -154.48 (t, J = 21.6 Hz, 1F), -
161.4 (m, 2F) ppm. 
      
3-Methyl-N-(pentafluorophenyl)benzenesulfonamide (167) 
Prepared from 3-methylbenzenesulfonyl chloride (2.86 g, 
15.0 mmol), 2,3,4,5,6-pentafluoroaniline (3.02 g, 16.5 
mmol) and DMAP (0.92 g, 7.5 mmol) in pyridine (50 
mL). 
Purification: n-hexane: ethyl acetate (from 95:5 to 80:20, 
v/v). 
Yield: 2.010 g (40%). White solid. 
 
Data of 167: 
Mp: 156-157 °C  
MS (EI) m/z (relative intensity) 337 (18) [M+], 182 (5), 155 (51), 91 (100), 65 
(24).  
HR-MS (EI) m/z calcd for C13H8F5NO2S  337.0196,  found 337.0202. 
IR (neat) ν 3239 (N-H), 1350 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ 2.41 (s, 3H, C-3CH3), 6.44 (s, 1H, NH), 7.35-7.46 
(m, 2H, CH-4 and CH-5), 7.61 (d, J = 7.4 Hz, 1H, CH-6), 7.66 (s, 1H, CH-2) 
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ppm. 
13C NMR (126 MHz, CDCl3) δ 144.1 (dm, J = 250 Hz, C-4’), 140.6 (dm, J = 262 
Hz, C-3’ and C-5’), 139.5 (C-1), 138.6 (C-3), 137.6 (dm, J = 250 Hz, C-2’ and C-
6’), 134.5 (CHAr), 129.0 (CHAr), 127.4 (CHAr), 124.3 (CHAr), 111.2 (m, C-1’), 
21.4 (CH3) ppm. 
19F NMR (282 MHz, CDCl3) δ -145.4 (m, 2F), -153.96 (t, J = 21.6 Hz, 1F), -
161.7 (m, 2F) ppm. 
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9.7.2 Ruthenium-catalyzed oxidative alkenylation of 
benzenesulfonamides. General procedure 
 
 
 
Compound R 
168 4-CH3 
169 4-CH3 
170 3-CH3 
171 3-CH3 
 
A mixture of N-(pentafluorophenyl)benzenesulfonamide (0.25 mmol, 1.0 equiv.), 
ethyl acrylate (0.75 mmol, 3.0 equiv.), [RuCl2(p-cymene)]2 (5 mol%), and 
Cu(OAc)2·H2O (0.50 mmol, 2.0 equiv.) in H2O (2.0 mL) and DMF (0.2 mL) was 
stirred at 120 °C under N2 for 16 hours. After cooling to ambient temperature, the 
reaction was quenched with a mixture of sat. aq. NH4Cl/NH3 (1:1, 15 mL) and 
extracted with CH2Cl2 (3 x 25 mL). The combined organic phase was washed 
with brine (50 mL) and dried over anhydrous Na2SO4. After filtration and 
evaporation of the solvents in vacuo, the crude product was purified by column 
chromatography on silica gel to give pure compounds 167-169. 
 
Data of compounds 167-169 and the experimental conditions employed for their 
synthesis are indicated below. 
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Ethyl 2-(5-methyl-1,1-dioxido-2-(pentafluorophenyl)-2,3-dihydrobenzo[d] 
isothiazol-3-yl)acetate (168) 
Prepared from 4-methyl-N-(pentafluorophenyl) 
benzenesulfonamide (83.4 mg, 0.25 mmol) and ethyl 
acrylate (75.0 mg, 0.75 mmol), [RuCl2(p-cymene)]2 (7.7 
mg, 5 mol %), and Cu(OAc)2·H2O (99.8 mg, 0.50 mmol) 
in H2O (2.0 mL) and DMF (0.2 mL).  
Purification: n-hexane: ethyl acetate (from 95:5 to 70:30, v/v). 
Yield: 13 mg (12%). Colorless solid. 
 
Data of 168: 
Mp: 109-111 °C  
MS (EI) m/z (relative intensity) 436 (5) [M+H]+, 371 (31), 348 (100), 342 (30) 
297 (32), 284 (70), 234 (27), 166 (14).  
HR-MS (ESI) calcd for C18H15F5NO4S [M+H]+ 436.0636, found 436.0634. 
IR (neat) ν 1734 (C=O), 1305 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ 1.21 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.50 (s, 3H, 
C-5CH3), 2.88-2.97 (m, 2H, CH2-2’), 4.08 (q, J = 7.1 Hz, 2H, OCH2CH3), 5.30-
5.37 (m, 1H, CH-3), 7.21-7.27 (m, 1H, CH-4), 7.42 (d, J = 8.0 Hz, 1H, CH-6), 
7.74 (d, J = 8.0 Hz, 1H, CH-7) ppm.  
13C NMR (126 MHz, CDCl3) δ 169.8 (C-1’=O), 144.8 (C-3a), 142.1 (dm, J = 262 
Hz, C-3’ and C-5’), 137.8 (dm, J = 250 Hz, C-2’ and C-6’), 136.6 (C-5), 131.3 
(C-7a), 130.8 (CHAr), 124.2 (CHAr), 121.4 (CHAr), 111.3 (m, C-1’), 61.4 
(OCH2CH3), 60.3 (CH-3), 41.2 (CH2-2’), 22.0 (C-5CH3), 14.0 (OCH2CH3) ppm. 
C-4” is missing. 
19F NMR (282 MHz, CDCl3) δ -141.72 (bs, 1F), -142.82 (bs, 1F), -151.1 (tt, J = 
21.5, 2.5 Hz, 1F), -(161.0-161.8) (m, 2F) ppm. 
      
Ethyl 3-(5-methyl-2-(N-(pentafluorophenyl)sulfamoyl)phenyl)acrylate (169) 
Prepared from 4-methyl-N-(pentafluorophenyl) benzenesulfonamide (83.4 mg, 
0.25 mmol) and ethyl acrylate (75.0 mg, 0.75 mmol), [RuCl2(p-cymene)]2 (7.7	  
mg, 5 mol %), and Cu(OAc)2·H2O (99.8 mg, 0.50 mmol) in H2O (2.0 mL) and 
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DMF (0.2 mL).  
Purification: n-hexane: ethyl acetate (from 95:5 to 70:30, 
v/v). 
Yield: 50 mg (46%). Colorless solid. 
 
Data of 169: 
Mp: 149-151 °C  
MS (EI) m/z (relative intensity) 435 (3) [M+], 390 (13), 362 (10), 253 (55), 225 
(20), 181 (100), 155 (13), 115 (44).  
HR-MS (EI) m/z calcd for C18H14F5NO4S 435.0564, found 435.0562. 
IR (neat) ν 3155 (N-H), 1692 (C=O), 1345 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ 1.33 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.46 (s, 3H, 
C-5CH3), 4.25 (q, J = 7.1 Hz, 2H, OCH2CH3), 6.35 (d, J = 15.8 Hz, 1H, CH-2’), 
6.98 (s, 1H, NH), 7.28 (dd, J = 8.1, 1.0 Hz, 1H, CH-4), 7.47 (d, J = 1.0 Hz, 1H, 
CH-6), 7.85 (d, J = 8.1 Hz, 1H, CH-3), 8.41 (d, J = 15.8 Hz, 1H, CH-3’) ppm.  
13C NMR (126 MHz, CDCl3) δ 166.1 (C-1’=O), 144.8 (C-5), 144.3 (dm, J = 250 
Hz, C-4’), 140.7 (dm, J = 262 Hz, C-3’ and C-5’), 140.4 (CH-3’), 137.6 (dm, J = 
250 Hz, C-2’ and C-6’), 134.6 (C-2*), 134.1 (C-1*), 130.2 (CH), 129.8 (CH), 
129.4 (CH), 123.1 (CH-2’), 111.0 (m, C-1’), 61.1 (OCH2CH3), 21.6 (C-5CH3), 
14.2 (OCH2CH3) ppm.  
19F NMR (282 MHz, CDCl3) δ -144.7 (m, 2F), -154.1 (t, J = 21.5 Hz, 1F), -161.7 
(m, 2F) ppm. 
      
Ethyl 2-(6-methyl-1,1-dioxido-2-(perfluorophenyl)-2,3-dihydrobenzo[d] 
isothiazol-3-yl)acetate (170) 
Prepared from 3-methyl-N-(pentafluorophenyl) 
benzenesulfonamide (83.4 mg, 0.25 mmol) and ethyl 
acrylate (75.0 mg, 0.75 mmol), [RuCl2(p-cymene)]2 (7.7 
mg, 5 mol %), and Cu(OAc)2·H2O (99.8 mg, 0.50	  mmol) 
in H2O (2.0 mL) and DMF (0.2 mL).  
Purification: n-hexane: ethyl acetate (from 95:5 to 70:30, v/v). 
Yield: 23 mg (21%). Colorless solid. 
 
O2
S
H3C
N
H
F
F
F
F
F
COOEt
1'
2'
1
2
3
5
6
4
3'
N
O2
S
F F
F
F
EtOOC
F
H3C
1'
7
2'
1
2
34
5
6 7a
3a
1"
2"
4"
5"6"
3"
9. Experimental section	   365 
 
 
Data of 170: 
Mp: 116-117 °C  
MS (EI) m/z (relative intensity) 436 (5) [M+H]+, 371 (25), 348 (100), 297 (30), 
284 (80), 234 (35), 166 (10).  
HR-MS (ESI) calcd for C18H18F5N2O4S [M+NH4]+ 453.0902, found 453.0910. 
IR (neat) ν 1730 (C=O), 1316 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ 1.22 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.49 (s, 3H, 
C-6CH3), 2.91-2.95 (m, 2H, CH2-2’), 4.08 (q, J = 7.1 Hz, 2H, OCH2CH3), 5.30-
5.38 (m, 1H, CH-3), 7.34 (d, J = 8.1 Hz, 1H, CH-5), 7.51 (d, J = 8.0 Hz, 1H, CH-
4), 7.66 (s, 1H, CH-7) ppm.  
13C NMR (126 MHz, CDCl3) δ 169.8 (C-1’=O), 142.1 (dm, J = 262 Hz, C-3’ and 
C-5’), 140.7 (C-3a), 137.7 (dm, J = 250 Hz, C-2’ and C-6’), 134.7 (CHAr), 134.0 
(C-6*), 133.6 (C-7a*), 123.7 (CHAr), 121.6 (CHAr), 111.2 (m, C-1”), 61.4 
(OCH2CH3), 60.3 (CH-3), 41.2 (CH2-2’), 21.4 (C-6CH3), 14.0 (OCH2CH3) ppm. 
C-4’ is missing. 
19F NMR (282 MHz, CDCl3) δ -141.75 (bs, 1F), -142.9 (bs, 1F), -151.0 (tt, J = 
21.5, 2.6 Hz, 1F), -(160.8-161.6) (m, 2F) ppm. 
      
Ethyl 3-(4-methyl-2-(N-(pentafluorophenyl)sulfamoyl)phenyl)acrylate (171) 
Prepared from 3-methyl-N-(pentafluorophenyl) 
benzenesulfonamide (83.4 mg, 0.25 mmol) and ethyl 
acrylate (75.0 mg, 0.75 mmol), [RuCl2(p-cymene)]2 (7.7 
mg, 5 mol %), and Cu(OAc)2·H2O (99.8 mg, 0.50 mmol) 
in H2O (2.0 mL) and DMF (0.2 mL).  
Purification: n-hexane: ethyl acetate (from 95:5 to 70:30, v/v). 
Yield: 55 mg (51%). Colorless solid. 
 
Data of 171: 
Mp: 140-142 °C  
MS (EI) m/z (relative intensity) 435 (2) [M+], 390 (13), 362 (10), 253 (64), 225 
(26), 181 (100), 161 (15), 115 (50).  
HR-MS (EI) m/z calcd for C18H14F5NO4S 435.0564, found 435.0556. 
IR (neat) ν 3138 (N-H), 1692 (C=O), 1349 (SO2) cm-1. 
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1H NMR (300 MHz, CDCl3) δ 1.33 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.42 (s, 3H, 
C-4CH3), 4.24 (q, J = 7.1 Hz, 2H, OCH2CH3), 6.34 (d, J = 15.8 Hz, 1H, CH-2’), 
7.17 (s, 1H, NH), 7.44 (dd, J = 7.9, 1.0 Hz, 1H, CH-5), 7.59 (d, J = 7.9 Hz, 1H, 
CH-6), 7.80 (d, J = 1.0 Hz, 1H, CH-3), 8.40 (d, J = 15.8 Hz, 1H, CH-3’) ppm. 
13C NMR (126 MHz, CDCl3) δ 166.3 (C-1’=O), 144.3 (dm, J = 250 Hz, C-4’), 
140.8 (dm, J = 262 Hz, C-3’ and C-5’), 140.5 (C-4), 140.1 (CH-3’), 137.6 (dm, J 
= 250 Hz, C-2’ and C-6’), 137.3 (C-2), 134.4 (CHAr), 131.1 (C-1), 130.0 (CHAr), 
128.6 (CHAr), 122.3 (CH-2’), 111.0 (m, C-1’), 61.1 (OCH2CH3), 21.3 (C-5CH3), 
14.2 (OCH2CH3) ppm. 
19F NMR (282 MHz, CDCl3) δ -144.7 (m, 2F), -154.0 (t, J = 21.6 Hz, 1F), -161.5 
(m, 2F) ppm. 
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9.7.3 Synthesis of N,3-dimethyl-N-(pentafluorophenyl) 
benzenesulfonamide (172) 
 
 
 
In a 25-mL two-neck round bottom flask under nitrogen, a solution of 3-methyl-
N-(pentafluorophenyl)benzenesulfonamide 167 (270 mg, 0.8 mmol) in 1 mL of 
anhydrous DMF was added to a solution of NaH (35 mg, 1.44 mmol) in 1 mL of 
anhydrous DMF. The mixture was stirred at room temperature for 15 min and 
then methyl iodide (136 mg, 0.96 mmol) was added dropwise, and the mixture 
was stirred at the same temperature for additional 2 hour. Reaction mixture was 
quenched by addition of H2O (15 mL) and the organic layer was extracted with 
EtOAc (3x20 mL), washed with brine (20 mL) and dried over anhydrous Na2SO4. 
After filtration and evaporation of the solvents in vacuo, the crude product was 
purified by column chromatography on silica gel (n-hexane:ethyl acetate from 
100:0 to 90:10) to yield 172 (248 mg, 88%) as a white solid. 
 
Data of 172: 
Mp: 129-130 °C 
MS (EI) m/z (relative intensity) 351 (21) [M+], 249 (3), 196 (12), 155 (38), 91 
(100), 65 (20), 58 (16), 43 (61).  
HR-MS (EI) m/z calcd for C14H10F5NO2S 351.0352, found 351.0346. 
IR (neat) ν 1349 (SO2) cm-1. 
1H NMR (300 MHz, CDCl3) δ), 2.45 (s, 3H, C-3CH3), 3.18 (s, 3H, NCH3), 7.39-
7.49 (m, 2H, CH-2 and CH-4) 7.58-7.65 (m, 2H, CH-5 and CH-6) ppm. 
13C NMR (126 MHz, CDCl3) δ 145.9  (dm, J = 250 Hz, C-4’), 141.4 (dm, J = 250 
Hz, C-3’ and C-5’), 139.4 (C-1), 137.7 (dm, J = 250 Hz, C-2’ and C-6’), 137.5 
(C-3), 134.2 (CHAr), 129.0 (CHAr), 127.8 (CHAr), 124.7 (CHAr), 116.1 (m, C-
1’), 37.6 (NCH3), 21.4 (C-3CH3) ppm.  
19F NMR (282 MHz, CDCl3) δ -142.8 (m, 2F), -152. 8 (tt, J = 21.6, 2.1 Hz, 1F), -
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161.6 (m, 2F) ppm. 
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1. The indium trichloride-catalysed four-component reaction between b-
dicarbonyl compounds, dimethylhydrazine, acroleins and ethanol affords 6-
ethoxy-1,4,5,6-tetrahydropyridine derivatives. This transformation was telescoped 
with a double elimination reaction, without the need for any intermediate 
purification stage, to yield a process that affords 2,3-disubstituted pyridines and 
which could also be adapted to the preparation of several types of fused pyridines. 
 
 
 
2.  The three-component reaction between b-dicarbonyl compounds, 
chalcones and ammonium acetate in refluxing ethanol, in the presence of a 
catalytic amount of cerium(IV) ammonium nitrate, affords 4,6-diaryl-1,4-	  
dihydropyridines. These compounds showed improved selectivity towards Cav1.3 
neuronal calcium channels with regard to previously known dihydropyridines and 
behave as neuroprotective agents against ischemic injury. 
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3. The three-component reaction summarized in Conclusion 2 was applied to 
the synthesis of nicotinamides from b-ketoamides, chalcones and ammonium 
acetate under similar conditions (CAN as catalyst in refluxing ethanol). In this 
case, the reaction directly afforded aromatic compounds via a 3CR-air oxidation 
sequence. 
 
 
  
4. The synthesis of fused dihydropyridines and their oxygen heteroanalogues 
was achieved via Hantzsch-like three-component reactions between malononitrile, 
aromatic aldehydes and the suitable (lactam or aminine) C5-functionalized 
pyrazoles. These compounds are currently being studied as anti-Alzheimer agents 
via inhibition of GSK3β. 
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5. Hybrid structures related to nimodipine and CGP-37157 were designed as 
potential anti-Alzheimer compounds aimed at stabilizing neuronal and 
mitochondrial calcium cycling by a multitarget approach. These compounds were 
prepared via a modified Hantzsch dihydropyridine synthesis. Hybrids of a CGP-
37157 aza analogue and lipoic acid, a well-known antioxidant able to cross the 
blood-brain barrier, were also synthesized. These compounds are currently being 
studied as anti-Alzheimer agents. 
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6. During a stay at the group of Professor Lutz Ackermann at Goettingen 
University as part of the requirements for the European Mention to the Ph. D. 
title, a Ru(II)-catalyzed oxidative C-H alkenylation of arylsulfonamides was 
developed. 
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